GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: January 12, 2004, 13:56:44 ; Search time 0.001 Seconds
(without alignments)
6.672 Million cell updates/sec

Title: us-09-925-139-3
Perfect score: 139
Sequence: 1 ggatggggcttgtagcagaa.....ctatcctaaaggcccactgg 139

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 2 seqs, 24 residues

Total number of hits satisfying chosen parameters: 4

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 4 summaries

Database : rst.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		8.8	6.3	12	1	BH169696	ACCESSION:BH169696
2		8.4	6.0	12	1	BQ587766	ACCESSION:BQ587766
c	3	7.2	5.2	12	1	BQ587766	ACCESSION:BQ587766
c	4	6.2	4.5	12	1	BH169696	ACCESSION:BH169696

ALIGNMENTS

RESULT 1
BH169696
LOCUS BH169696 12 bp DNA linear GSS 03-OCT-2001
DEFINITION SALK_001766 Arabidopsis thaliana TDNA insertion lines Arabidopsis thaliana genomic clone SALK_001766, genomic survey sequence.
ACCESSION BH169696
VERSION BH169696.1 GI:15905071
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids ; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1 (bases 1 to 12)
AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab ,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P. , Zimmerman,J. and Ecker,J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
JOURNAL Unpublished
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGnAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of TDNA.
Class: TDNA tagged.
FEATURES Location/Qualifiers
source 1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_001766"
/clone_lib="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html"
BASE COUNT 3 a 5 c 2 g 2 t

Query Match 6.3%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 0;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1733 TGGCTCCCAACT 1744
              |||| || ||||
Db          1 TGGCCCCAAACT 12
```

RESULT 2
BQ587766
LOCUS BQ587766 12 bp mRNA linear EST 06-DEC-2002
DEFINITION E012340-024-010-M01-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone 024-010-M01 5-PRIME, mRNA sequence.
ACCESSION BQ587766
VERSION BQ587766.1 GI:26117348
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 12)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 12 Std Error: 0.00
Plate: 10 row: M column: 01
Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES Location/Qualifiers
source 1. .12
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:185095"
/db_xref="taxon:161934"
/clone="024-010-M01"
/tissue_type="leaf"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-leaf"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;

cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project , local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database:http://gabi.rzpd.de"

```
BASE COUNT        0 a      7 c      0 g      5 t

  Query Match             6.0%;  Score 8.4;  DB 1;  Length 12;
  Best Local Similarity   90.0%;  Pred. No. 0;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1683 TGTCTCCTCC 1692
              | ||||||||
Db          2 TCTCTCCTCC 11
```

```
RESULT 3
BQ587766/c
LOCUS       BQ587766                 12 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012340-024-010-M01-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone
            024-010-M01 5-PRIME, mRNA sequence.
ACCESSION   BQ587766
VERSION     BQ587766.1  GI:26117348
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 12   Std Error: 0.00
            Plate: 10  row: M  column: 01
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding line
                     )"
                     /db_xref="GABI:185095"
                     /db_xref="taxon:161934"
                     /clone="024-010-M01"
                     /tissue_type="leaf"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-leaf"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
                     Sequencing granted in the context of the GABI-Beet project
                     , local PI: Dr. Katharina Schneider, coordinator: Prof.
                     Christian Jung; Sequence submission managed by
                     RZPD/GABI-Primary database:http://gabi.rzpd.de"
BASE COUNT        0 a      7 c      0 g      5 t
```

```
  Query Match             5.2%;  Score 7.2;  DB 1;  Length 12;
  Best Local Similarity   75.0%;  Pred. No. 0;
  Matches    9;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1713 AGGAGTACGGAG 1724
              ||||| |  |||
Db         12 AGGAGGAGAGAG 1
```

```
RESULT 4
BH169696/c
LOCUS       BH169696                 12 bp    DNA     linear   GSS 03-OCT-2001
DEFINITION  SALK_001766 Arabidopsis thaliana TDNA insertion lines Arabidopsis
            thaliana genomic clone SALK_001766, genomic survey sequence.
ACCESSION   BH169696
VERSION     BH169696.1  GI:15905071
KEYWORDS    GSS.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids
            ; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab
            ,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.
            , Zimmerman,J. and Ecker,J.R.
  TITLE     A Sequence-Indexed Library of Insertion Mutations in the
            Arabidopsis Genome
  JOURNAL   Unpublished
COMMENT     Contact: Joseph R. Ecker
            Salk Institute Genomic Analysis Laboratory (SIGnAL)
            The Salk Institute for Biological Studies
            10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
            Tel: 858 453 4100 x1752
            Fax: 858 558 6379
            Email: ecker@salk.edu
            This is single pass sequence recovered from the left border of
            TDNA.
            Class: TDNA tagged.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /strain="Columbia 0"
                     /db_xref="taxon:3702"
                     /clone="SALK_001766"
                     /clone_lib="Arabidopsis thaliana TDNA insertion lines"
                     /note="PCR was performed on Arabidopsis thaliana lines
                     each of which contains  one or more TDNA insertion
                     elements. The resultant fragment for each  line was
                     directly sequenced to determine the genomic sequence at
                     the  site of insertion. Details of the protocols used can
                     be found at  http://signal.salk.edu/tdna_protocols.html"
BASE COUNT        3 a      5 c      2 g      2 t
```

```
  Query Match             4.5%;  Score 6.2;  DB 1;  Length 12;
  Best Local Similarity   72.7%;  Pred. No. 0;
  Matches    8;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1729 AGATTGGCTCC 1739
              || ||||  ||
Db         12 AGTTTGGGGCC 2
```

```
Search completed: January 12, 2004, 13:56:45
Job time : 0.001 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: January 12, 2004, 13:54:43 ; Search time 0.001 Seconds
(without alignments)
800.084 Million cell updates/sec

Title: us-09-925-139-3
Perfect score: 139
Sequence: 1 ggatggggcttgtagcagaa.....ctatcctaaaggcccactgg 139

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 198 seqs, 2878 residues

Total number of hits satisfying chosen parameters: 396

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 225 summaries

Database : rni.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	18	12.9	18	1	US-08-363-240A-1125	Sequence 1125, Ap
	2	16.2	11.7	22	1	US-08-927-219-102	Sequence 102, App
	3	15	10.8	15	1	US-08-363-240A-240	Sequence 240, App
	4	15	10.8	15	1	US-08-363-240A-241	Sequence 241, App
	5	15	10.8	15	1	US-08-363-240A-242	Sequence 242, App
	6	15	10.8	15	1	US-08-363-240A-243	Sequence 243, App
	7	15	10.8	15	1	US-08-363-240A-244	Sequence 244, App
	8	15	10.8	15	1	US-08-363-240A-245	Sequence 245, App
	9	15	10.8	15	1	US-08-363-240A-246	Sequence 246, App
	10	15	10.8	15	1	US-08-363-240A-247	Sequence 247, App
	11	15	10.8	15	1	US-08-363-240A-248	Sequence 248, App
	12	15	10.8	15	1	US-08-363-240A-249	Sequence 249, App
	13	15	10.8	15	1	US-08-363-240A-250	Sequence 250, App
	14	15	10.8	15	1	US-08-363-240A-251	Sequence 251, App
	15	15	10.8	15	1	US-08-363-240A-252	Sequence 252, App
	16	15	10.8	15	1	US-08-363-240A-253	Sequence 253, App
	17	15	10.8	15	1	US-08-363-240A-254	Sequence 254, App
	18	15	10.8	15	1	US-08-363-240A-255	Sequence 255, App
	19	15	10.8	15	1	US-08-363-240A-256	Sequence 256, App
c	20	14.2	10.2	20	1	US-08-227-370-2	Sequence 2, Appli
c	21	14.2	10.2	20	1	US-08-486-962-4	Sequence 4, Appli
c	22	14.2	10.2	20	1	US-08-458-347-1	Sequence 1, Appli
c	23	14.2	10.2	20	1	US-08-975-522A-5	Sequence 5, Appli
c	24	14.2	10.2	20	1	US-09-103-875-123	Sequence 123, App
c	25	14.2	10.2	20	1	US-09-798-096-16	Sequence 16, Appl
	26	14.2	10.2	20	1	US-08-754-477A-109	Sequence 109, App
c	27	14.2	10.2	20	1	PCT-US94-06284-2	Sequence 2, Appli
c	28	13.2	9.5	18	1	US-08-802-547-12	Sequence 12, Appl
c	29	13.2	9.5	18	1	US-08-712-357-12	Sequence 12, Appl
	30	13.2	9.5	18	1	US-09-255-912-28	Sequence 28, Appl
	31	13.2	9.5	18	1	US-09-280-409-75	Sequence 75, Appl
c	32	13.2	9.5	18	1	US-09-723-534-10	Sequence 10, Appl
c	33	13.2	9.5	18	1	US-09-721-822A-116	Sequence 116, App
c	34	13.2	9.5	18	1	US-09-077-619-15	Sequence 15, Appl
	35	13	9.4	15	1	US-08-363-240A-758	Sequence 758, App
	36	13	9.4	15	1	US-08-363-240A-759	Sequence 759, App
c	37	12.8	9.2	17	1	US-08-486-962-12	Sequence 12, Appl
c	38	12.8	9.2	17	1	US-08-584-040-7909	Sequence 7909, Ap
c	39	12.8	9.2	17	1	US-09-371-772B-3692	Sequence 3692, Ap
c	40	12.8	9.2	17	1	PCT-US94-06284-12	Sequence 12, Appl
c	41	12.8	9.2	18	1	US-08-486-962-15	Sequence 15, Appl
	42	12.8	9.2	18	1	US-08-671-975A-7	Sequence 7, Appli
	43	12.8	9.2	18	1	US-09-280-409-109	Sequence 109, App
	44	12.8	9.2	18	1	US-09-280-409-142	Sequence 142, App
c	45	12.8	9.2	18	1	PCT-US94-06284-15	Sequence 15, Appl
	46	12.4	8.9	15	1	US-07-912-900-11	Sequence 11, Appl
	47	12.4	8.9	15	1	US-08-285-309-11	Sequence 11, Appl
	48	12.4	8.9	15	1	US-08-502-046-11	Sequence 11, Appl
c	49	12.4	8.9	16	1	US-07-696-793A-22	Sequence 22, Appl
c	50	12.4	8.9	16	1	US-07-977-694-22	Sequence 22, Appl
c	51	12.4	8.9	16	1	US-08-255-264-24	Sequence 24, Appl
c	52	12.4	8.9	16	1	US-08-161-674B-20	Sequence 20, Appl
c	53	12.4	8.9	16	1	US-09-371-772B-5908	Sequence 5908, Ap
c	54	12.4	8.9	17	1	US-07-696-793A-20	Sequence 20, Appl
c	55	12.4	8.9	17	1	US-07-977-694-20	Sequence 20, Appl
c	56	12.4	8.9	17	1	US-09-371-772B-4993	Sequence 4993, Ap
	57	12.2	8.8	17	1	US-08-373-124A-1709	Sequence 1709, Ap
	58	12.2	8.8	17	1	US-08-435-628-1709	Sequence 1709, Ap
	59	12.2	8.8	17	1	US-08-292-492D-6	Sequence 6, Appli
c	60	12.2	8.8	18	1	US-09-280-409-142	Sequence 142, App
	61	12	8.6	16	1	US-09-586-376-5	Sequence 5, Appli
c	62	11.8	8.5	15	1	US-08-310-501-4	Sequence 4, Appli
c	63	11.8	8.5	15	1	US-08-469-177-4	Sequence 4, Appli
c	64	11.8	8.5	15	1	US-08-484-551-1	Sequence 1, Appli
c	65	11.8	8.5	15	1	US-08-484-551-5	Sequence 5, Appli
c	66	11.8	8.5	15	1	US-08-486-962-18	Sequence 18, Appl
	67	11.8	8.5	15	1	US-08-913-833-5	Sequence 5, Appli
	68	11.8	8.5	15	1	US-09-580-794C-5	Sequence 5, Appli
c	69	11.8	8.5	15	1	US-09-813-781-48	Sequence 48, Appl
c	70	11.8	8.5	16	1	US-08-486-962-14	Sequence 14, Appl
c	71	11.8	8.5	16	1	US-08-975-522A-6	Sequence 6, Appli
c	72	11.4	8.2	13	1	US-08-544-381B-27	Sequence 27, Appl
c	73	11.4	8.2	13	1	US-08-778-794A-85	Sequence 85, Appl
c	74	11.4	8.2	13	1	US-09-922-445-17	Sequence 17, Appl
	75	11.4	8.2	13	1	US-09-922-445-27	Sequence 27, Appl
	76	11.4	8.2	14	1	US-08-913-833-9	Sequence 9, Appli
	77	11.4	8.2	14	1	US-09-580-794C-9	Sequence 9, Appli
c	78	11.4	8.2	15	1	US-08-111-076-17	Sequence 17, Appl
c	79	11.4	8.2	15	1	US-08-398-305-17	Sequence 17, Appl
	80	11.4	8.2	15	1	US-08-182-968A-452	Sequence 452, App
c	81	11.4	8.2	15	1	US-08-705-225-17	Sequence 17, Appl
	82	11.4	8.2	15	1	US-08-513-841-16	Sequence 16, Appl
	83	11.4	8.2	15	1	US-08-696-834-17	Sequence 17, Appl
	84	11.4	8.2	15	1	US-08-942-673-16	Sequence 16, Appl
	85	11.4	8.2	15	1	US-08-774-306A-452	Sequence 452, App
	86	11.4	8.2	15	1	US-09-064-156A-452	Sequence 452, App
	87	11.4	8.2	15	1	US-09-118-317-16	Sequence 16, Appl
c	88	11.4	8.2	16	1	US-07-696-793A-18	Sequence 18, Appl
c	89	11.4	8.2	16	1	US-07-977-694-18	Sequence 18, Appl
	90	11.4	8.2	16	1	US-08-303-004-32	Sequence 32, Appl
c	91	11.2	8.1	16	1	US-07-696-793A-7	Sequence 7, Appli
c	92	11.2	8.1	16	1	US-07-696-793A-9	Sequence 9, Appli
c	93	11.2	8.1	16	1	US-07-977-694-7	Sequence 7, Appli
c	94	11.2	8.1	16	1	US-07-977-694-9	Sequence 9, Appli
c	95	11.2	8.1	16	1	US-08-872-917-11	Sequence 11, Appl
c	96	11.2	8.1	16	1	US-09-371-772B-5657	Sequence 5657, Ap
c	97	11.2	8.1	16	1	US-09-371-772B-5658	Sequence 5658, Ap
c	98	11.2	8.1	16	1	US-09-371-772B-5954	Sequence 5954, Ap
c	99	11.2	8.1	18	1	US-09-280-409-75	Sequence 75, Appl
	100	11	7.9	15	1	US-09-081-646-218	Sequence 218, App
	101	11	7.9	15	1	US-09-081-646-855	Sequence 855, App
	102	10.8	7.8	14	1	US-08-173-489C-179	Sequence 179, App
	103	10.8	7.8	14	1	US-08-913-833-4	Sequence 4, Appli
	104	10.8	7.8	14	1	US-09-580-794C-4	Sequence 4, Appli
	105	10.8	7.8	15	1	US-07-998-973A-18	Sequence 18, Appl
c	106	10.8	7.8	15	1	US-08-479-248-1	Sequence 1, Appli

	107	10.8	7.8	15	1	US-08-479-248-2	Sequence 2, Appli
	108	10.8	7.8	15	1	US-08-462-305-8	Sequence 8, Appli
C	109	10.8	7.8	15	1	US-08-363-240A-602	Sequence 602, App
C	110	10.8	7.8	15	1	US-08-363-240A-603	Sequence 603, App
C	111	10.8	7.8	15	1	US-08-311-486C-598	Sequence 598, App
C	112	10.8	7.8	15	1	US-08-311-486C-599	Sequence 599, App
	113	10.8	7.8	15	1	US-08-613-417A-8	Sequence 8, Appli
	114	10.8	7.8	15	1	US-08-585-684B-2047	Sequence 2047, Ap
	115	10.8	7.8	15	1	US-08-452-800-18	Sequence 18, Appl
	116	10.8	7.8	15	1	US-08-594-452-8	Sequence 8, Appli
	117	10.8	7.8	15	1	US-08-578-686C-7	Sequence 7, Appli
	118	10.8	7.8	15	1	US-09-094-405-8	Sequence 8, Appli
	119	10.8	7.8	15	1	US-09-258-408-8	Sequence 8, Appli
	120	10.8	7.8	15	1	US-09-196-132-8	Sequence 8, Appli
	121	10.8	7.8	15	1	US-09-144-112-7	Sequence 7, Appli
	122	10.8	7.8	15	1	US-09-038-073-2047	Sequence 2047, Ap
	123	10.8	7.8	15	1	US-08-410-390-3	Sequence 3, Appli
	124	10.8	7.8	15	1	US-08-895-981-8	Sequence 8, Appli
	125	10.8	7.8	15	1	US-08-337-120A-8	Sequence 8, Appli
	126	10.8	7.8	15	1	US-09-643-233-7	Sequence 7, Appli
	127	10.8	7.8	15	1	PCT-US92-11353-18	Sequence 18, Appl
C	128	10.8	7.8	18	1	US-09-280-409-109	Sequence 109, App
C	129	10.4	7.5	14	1	US-08-985-162-1849	Sequence 1849, Ap
C	130	10.4	7.5	14	1	US-08-535-249-90	Sequence 90, Appl
C	131	10.2	7.3	15	1	US-08-363-240A-242	Sequence 242, App
C	132	10	7.2	10	1	US-08-171-718-43	Sequence 43, Appl
C	133	10	7.2	10	1	US-08-388-353-425	Sequence 425, App
C	134	10	7.2	10	1	US-08-388-353-501	Sequence 501, App
C	135	10	7.2	10	1	US-08-388-353-502	Sequence 502, App
C	136	10	7.2	10	1	US-08-488-551B-425	Sequence 425, App
C	137	10	7.2	10	1	US-08-488-551B-501	Sequence 501, App
C	138	10	7.2	10	1	US-08-488-551B-502	Sequence 502, App
C	139	10	7.2	10	1	US-08-488-551B-819	Sequence 819, App
C	140	10	7.2	10	1	US-08-488-551B-820	Sequence 820, App
C	141	10	7.2	10	1	US-08-478-087-43	Sequence 43, Appl
	142	10	7.2	12	1	US-08-173-489C-255	Sequence 255, App
	143	10	7.2	12	1	US-08-889-502-3	Sequence 3, Appli
	144	10	7.2	12	1	US-08-889-502-16	Sequence 16, Appl
C	145	10	7.2	12	1	US-08-192-943-11	Sequence 11, Appl
C	146	10	7.2	14	1	US-08-434-503-10	Sequence 10, Appl
	147	10	7.2	20	1	US-08-227-370-2	Sequence 2, Appli
	148	10	7.2	20	1	US-08-486-962-4	Sequence 4, Appli
	149	10	7.2	20	1	US-08-458-347-1	Sequence 1, Appli
	150	10	7.2	20	1	US-08-975-522A-5	Sequence 5, Appli
	151	10	7.2	20	1	PCT-US94-06284-2	Sequence 2, Appli
C	152	9.8	7.1	13	1	US-08-544-381B-19	Sequence 19, Appl
C	153	9.8	7.1	13	1	US-08-544-381B-23	Sequence 23, Appl
C	154	9.8	7.1	13	1	US-08-544-381B-24	Sequence 24, Appl
C	155	9.8	7.1	13	1	US-08-544-381B-26	Sequence 26, Appl
C	156	9.8	7.1	13	1	US-08-544-381B-28	Sequence 28, Appl
C	157	9.8	7.1	13	1	US-08-544-381B-29	Sequence 29, Appl
C	158	9.8	7.1	13	1	US-08-778-794A-77	Sequence 77, Appl
C	159	9.8	7.1	13	1	US-08-778-794A-81	Sequence 81, Appl
C	160	9.8	7.1	13	1	US-08-778-794A-84	Sequence 84, Appl
C	161	9.8	7.1	13	1	US-08-778-794A-86	Sequence 86, Appl
C	162	9.8	7.1	13	1	US-08-778-794A-87	Sequence 87, Appl
C	163	9.8	7.1	13	1	US-09-922-445-16	Sequence 16, Appl
	164	9.8	7.1	13	1	US-09-922-445-26	Sequence 26, Appl
	165	9.8	7.1	14	1	US-08-913-833-8	Sequence 8, Appli
	166	9.8	7.1	14	1	US-09-580-794C-8	Sequence 8, Appli
C	167	9.8	7.1	14	1	US-09-328-174A-40	Sequence 40, Appl
	168	9.8	7.1	14	1	US-09-230-652-23	Sequence 23, Appl
C	169	9.6	6.9	13	1	US-08-544-381B-13	Sequence 13, Appl
C	170	9.6	6.9	13	1	US-08-778-794A-71	Sequence 71, Appl
C	171	9.6	6.9	13	1	US-08-778-794A-95	Sequence 95, Appl
	172	9.6	6.9	16	1	US-07-696-793A-9	Sequence 9, Appli
	173	9.6	6.9	16	1	US-07-977-694-9	Sequence 9, Appli
	174	9.6	6.9	16	1	US-09-371-772B-5954	Sequence 5954, Ap
C	175	9.6	6.9	20	1	US-08-754-477A-109	Sequence 109, App
	176	9.4	6.8	11	1	US-08-757-024-530	Sequence 530, App
C	177	9.4	6.8	11	1	US-09-617-548-12	Sequence 12, Appl
	178	9.4	6.8	11	1	US-09-249-155A-43	Sequence 43, Appl
	179	9.4	6.8	11	1	US-09-249-155A-181	Sequence 181, App
C	180	9.4	6.8	11	1	PCT-US94-08023-37	Sequence 37, Appl
	181	9.4	6.8	12	1	US-08-192-300-5	Sequence 5, Appli
C	182	9.4	6.8	12	1	US-08-221-816B-27	Sequence 27, Appl
	183	9.4	6.8	12	1	US-08-441-887A-338	Sequence 338, App
	184	9.4	6.8	12	1	US-08-441-887A-339	Sequence 339, App
	185	9.4	6.8	12	1	US-08-757-024-501	Sequence 501, App
	186	9.4	6.8	12	1	US-08-757-024-529	Sequence 529, App
	187	9.4	6.8	12	1	US-07-794-396-6	Sequence 6, Appli
C	188	9.4	6.8	12	1	US-08-959-853-8	Sequence 8, Appli
	189	9.4	6.8	12	1	US-08-713-742-8	Sequence 8, Appli
	190	9.4	6.8	12	1	US-08-211-882-5	Sequence 5, Appli
	191	9.4	6.8	12	1	US-08-211-882-9	Sequence 9, Appli
	192	9.4	6.8	12	1	US-09-372-856-8	Sequence 8, Appli
C	193	9.4	6.8	12	1	US-09-281-418-20	Sequence 20, Appl
C	194	9.4	6.8	12	1	US-09-281-418-74	Sequence 74, Appl
	195	9.4	6.8	12	1	US-09-688-394-8	Sequence 8, Appli
	196	9.4	6.8	12	1	US-09-633-659-5	Sequence 5, Appli
	197	9.4	6.8	12	1	US-09-633-659-9	Sequence 9, Appli
C	198	9.4	6.8	12	1	US-10-112-547-27	Sequence 27, Appl
	199	9.4	6.8	12	1	5240847-3	Patent No. 5240847
C	200	9.4	6.8	12	1	5427911-12	Patent No. 5427911
	201	9.4	6.8	12	1	5427911-14	Patent No. 5427911
	202	9.4	6.8	13	1	US-08-123-449A-17	Sequence 17, Appl
	203	9.4	6.8	13	1	US-08-458-050-17	Sequence 17, Appl
C	204	9.4	6.8	13	1	US-08-667-023-3	Sequence 3, Appli
C	205	9.4	6.8	13	1	US-08-671-975A-17	Sequence 17, Appl
	206	9.4	6.8	13	1	US-08-757-024-471	Sequence 471, App
	207	9.4	6.8	13	1	US-08-757-024-500	Sequence 500, App
	208	9.4	6.8	13	1	US-08-757-024-528	Sequence 528, App
	209	9.4	6.8	13	1	US-08-950-196-17	Sequence 17, Appl
C	210	9.4	6.8	13	1	US-09-474-432B-120	Sequence 120, App
	211	9.4	6.8	13	1	US-09-216-584-18	Sequence 18, Appl
	212	9.4	6.8	20	1	US-09-798-096-16	Sequence 16, Appl
	213	9.2	6.6	17	1	US-08-584-040-7909	Sequence 7909, Ap
	214	9.2	6.6	17	1	US-09-371-772B-3692	Sequence 3692, Ap
C	215	9	6.5	11	1	US-09-249-155A-43	Sequence 43, Appl
C	216	9	6.5	11	1	US-09-249-155A-181	Sequence 181, App
C	217	8.8	6.3	15	1	US-08-363-240A-249	Sequence 249, App
	218	8.6	6.2	16	1	US-07-696-793A-7	Sequence 7, Appli
	219	8.6	6.2	16	1	US-07-977-694-7	Sequence 7, Appli
	220	8.6	6.2	17	1	US-08-486-962-12	Sequence 12, Appl
	221	8.6	6.2	17	1	PCT-US94-06284-12	Sequence 12, Appl
	222	8.6	6.2	18	1	US-08-486-962-15	Sequence 15, Appl
	223	8.6	6.2	18	1	PCT-US94-06284-15	Sequence 15, Appl
	224	8.4	6.0	12	1	US-09-281-418-74	Sequence 74, Appl
	225	8.4	6.0	14	1	US-08-434-503-10	Sequence 10, Appl

ALIGNMENTS

```
RESULT 1
US-08-363-240A-1125
; Sequence 1125, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
```

```
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1125:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-1125

  Query Match             12.9%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1;
  Matches   15;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1663 GCTCACAGCTGGAACCCT 1680
              ||:||||||:|||||||:
Db          1 GCUCACAGCUGGAACCCU 18


RESULT 2
US-08-927-219-102
; Sequence 102, Application US/08927219
; Patent No. 6187533
;  GENERAL INFORMATION:
;    APPLICANT:  Bell, Graeme I.
;    APPLICANT:  Yamagata, Kazuya
;    APPLICANT:  Oda, Naohisha
;    APPLICANT:  Kaisaki, Pamela J.
;    APPLICANT:  Furuta, Hiroto
;    APPLICANT:  Horikawa, Yukio
;    APPLICANT:  Menzel, Stephen
;    TITLE OF INVENTION:  MUTATIONS IN THE DIABETES SUSCEPTIBILITY
;    TITLE OF INVENTION:  GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA, HNF-1BETA
;    TITLE OF INVENTION:  AND HNF-4ALPHA
;    NUMBER OF SEQUENCES:  147
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/927,219
;      FILING DATE:  Concurrently Herewith
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/029,679
;      FILING DATE:  30-OCT-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/028,056
;      FILING DATE:  02-OCT-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/025,719
;      FILING DATE:  10-SEP-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wilson, Mark B.
;      REGISTRATION NUMBER:  37,259
;      REFERENCE/DOCKET NUMBER:  ARCD:272
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/418-3000
;      TELEFAX:  512/474-7577
;  INFORMATION FOR SEQ ID NO:  102:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-927-219-102

  Query Match             11.7%;  Score 16.2;  DB 1;  Length 22;
  Best Local Similarity   85.7%;  Pred. No. 9.3;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAGCTGGAACC 1678
              ||||| |||||||| |||||
Db          2 ACCAGACTCACAGCCTGAACC 22


RESULT 3
US-08-363-240A-240
; Sequence 240, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  240:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-240

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1634 TGGGGCTTGTAGCAG 1648
              :|||||::|:|||||
Db          1 UGGGGCUUGUAGCAG 15


RESULT 4
US-08-363-240A-241
; Sequence 241, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  241:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-241

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 7.2;
  Matches   12;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1637 GGCTTGTAGCAGAAG 1651
              |||:|:|||||||||
Db          1 GGCUUGUAGCAGAAG 15


RESULT 5
US-08-363-240A-242
; Sequence 242, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  242:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-242

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 7.2;
  Matches   13;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACAGCTG 1673
              ||||||:||||||:|
Db          1 CCAGGCUCACAGCUG 15


RESULT 6
US-08-363-240A-243
; Sequence 243, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
```

```
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  243:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-243

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 7.2;
  Matches   10;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1679 CTGGTGTCTCCTCCA 1693
              |:||:|:|:||:|||
Db          1 CUGGUGUCUCCUCCA 15


RESULT 7
US-08-363-240A-244
; Sequence 244, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  244:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-244

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1681 GGTGTCTCCTCCAGC 1695
              ||:|:|:||:|||||
Db          1 GGUGUCUCCUCCAGC 15


RESULT 8
US-08-363-240A-245
; Sequence 245, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
```

```
;       TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  245:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-363-240A-245

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1684 GTCTCCTCCAGCGTG 1698
              |:|:||:||||||:|
Db          1 GUCUCCUCCAGCGUG 15


RESULT 9
US-08-363-240A-246
; Sequence 246, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  246:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-246

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 7.2;
  Matches   10;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1700 TGGAAGTTGGGTTAG 1714
              :|||||::|||::||
Db          1 UGGAAGUUGGGUUAG 15


RESULT 10
US-08-363-240A-247
; Sequence 247, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  247:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-247

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 7.2;
  Matches   10;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGAGTA 1719
              |::|||::|||||:|
Db          1 GUUGGGUUAGGAGUA 15


RESULT 11
US-08-363-240A-248
; Sequence 248, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
```

```
;     TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;     TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;     TITLE OF INVENTION:  OF VASCULAR DISEASES
;     NUMBER OF SEQUENCES:  1243
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/363,240A
;       FILING DATE:  December 23, 1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  210/096
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  248:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-363-240A-248

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 7.2;
  Matches   10;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAGTAC 1720
              ::|||::|||||:||
Db          1 UUGGGUUAGGAGUAC 15


RESULT 12
US-08-363-240A-249
; Sequence 249, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  249:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-249

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 7.2;
  Matches   12;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1712 TAGGAGTACGGAGAT 1726
              :|||||:|||||||:
Db          1 UAGGAGUACGGAGAU 15


RESULT 13
US-08-363-240A-250
; Sequence 250, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
```

```
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  250:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-363-240A-250

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCTCCC 1740
              :|||||::|||:|||
Db          1 UGGAGAUUGGCUCCC 15


RESULT 14
US-08-363-240A-251
; Sequence 251, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  251:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-251

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1731 ATTGGCTCCCAACTC 1745
              |::|||:||||||:|
Db          1 AUUGGCUCCCAACUC 15


RESULT 15
US-08-363-240A-252
; Sequence 252, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  252:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-252

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 7.2;
  Matches   12;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCCCTA 1752
              ||||||:||:|||:|
Db          1 CCCAACUCCUCCCUA 15


RESULT 16
US-08-363-240A-253
; Sequence 253, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
```

```
;     APPLICANT:  Bisgaier, Charles
;     APPLICANT:  Pape, Michael
;     TITLE OF INVENTION:  METHOD AND REAGENT FOR
;     TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;     TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;     TITLE OF INVENTION:  OF VASCULAR DISEASES
;     NUMBER OF SEQUENCES:  1243
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/363,240A
;       FILING DATE:  December 23, 1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  210/096
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  253:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-363-240A-253

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTATCC 1755
              |||:||:|||:|:||
Db          1 AACUCCUCCCUAUCC 15


RESULT 17
US-08-363-240A-254
; Sequence 254, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  254:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-254

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 CCTCCCTATCCTAAA 1759
              ||:|||:|:||:|||
Db          1 CCUCCCUAUCCUAAA 15


RESULT 18
US-08-363-240A-255
; Sequence 255, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
```

```
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  210/096
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  255:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-363-240A-255

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 7.2;
  Matches   11;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAAAGG 1761
              :|||:|:||:|||||
Db          1 UCCCUAUCCUAAAGG 15


RESULT 19
US-08-363-240A-256
; Sequence 256, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  256:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-363-240A-256

  Query Match             10.8%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 7.2;
  Matches   12;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1750 CTATCCTAAAGGCCC 1764
              |:|:||:||||||||
Db          1 CUAUCCUAAAGGCCC 15


RESULT 20
US-08-227-370-2/c
; Sequence 2, Application US/08227370
; Patent No. 5559207
;  GENERAL INFORMATION:
;    APPLICANT:  Sessler, Jonathan L.
;    APPLICANT:  Smith, Daniel A.
;    APPLICANT:  Miller, Richard
;    APPLICANT:  Ross, Kevin
;    APPLICANT:  Wright, Meredith
;    APPLICANT:  Hemmi, Gregory W.
;    APPLICANT:  Dow, William C.
;    APPLICANT:  Kral, Vladimir
;    APPLICANT:  Iverson, Brent
;    APPLICANT:  Magda, Darren
;    TITLE OF INVENTION:  Texaphyrin Metal Complex Mediated Ester
;    TITLE OF INVENTION:  Hydrolysis
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/227,370
;      FILING DATE:  14-APR-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTSB:562
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/320-7200
;      TELEFAX:  512/474-7577
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-227-370-2

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 22;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAGCTG 1673
              | |||| |||||||| ||
Db         19 AACACCCGGCTCACAGATG 1


RESULT 21
US-08-486-962-4/c
; Sequence 4, Application US/08486962
; Patent No. 5763172
```

```
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    APPLICANT:  Wright, Meredith
;    APPLICANT:  Ross, Kevin L.
;    APPLICANT:  Miller, Richard A.
;    APPLICANT:  Dow, William C.
;    APPLICANT:  Kral, Vladimir A.
;    APPLICANT:  Smith, Daniel A.
;    TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94086-4521
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,962
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 774-0330
;      TELEFAX:  (408) 774-0340
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-486-962-4

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 22;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAGCTG 1673
                | |||| ||||||||| ||
Db         19 AACACCCGGCTCACAGATG 1


RESULT 22
US-08-458-347-1/c
; Sequence 1, Application US/08458347
; Patent No. 5798491
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    TITLE OF INVENTION:  Multi-Mechanistic Chemical Cleavage Using Certain
;    TITLE OF INVENTION:  Metal Complexes
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Ave.
;      CITY:  Sunnyvale
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94086-4593
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/458,347
;      FILING DATE:  Concurrently herewith
;      CLASSIFICATION:  204
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:048
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  408/774-0330
;      TELEFAX:  408/774-0340
;      TELEX:  N/A
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-458-347-1

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 22;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAGCTG 1673
                | |||| ||||||||| ||
Db         19 AACACCCGGCTCACAGATG 1


RESULT 23
US-08-975-522A-5/c
; Sequence 5, Application US/08975522A
; Patent No. 6022959
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Crofts, Shaun P.
;    APPLICANT:  Wright, Meredith
;    TITLE OF INVENTION:  NUCLEIC ACIDS INTERNALLY-
;    TITLE OF INVENTION:  DERIVATIZED WITH A TEXAPHYRIN
;    TITLE OF INVENTION:  METAL COMPLEX AND USES THEREOF
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94085
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Patentin Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/975,522A
;      FILING DATE:  No. 6022959ember 20, 1997
;      CLASSIFICATION:  536
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 499-6200
;      TELEFAX:  (512)  499-6290
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-975-522A-5

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
```

Best Local Similarity 84.2%; Pred. No. 22;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1655 AGCACCAGGCTCACAGCTG 1673
              | |||| ||||||||| ||
Db         19 AACACCCGGCTCACAGATG 1
```

RESULT 24
US-09-103-875-123/c
; Sequence 123, Application US/09103875A
; Patent No. 6221849
; GENERAL INFORMATION:
; APPLICANT: Szyf, Moshe
; APPLICANT: Bigey, Pascal
; APPLICANT: Ramchandani, Shyam
; TITLE OF INVENTION: DNA METHYLTRANSFERASE GENOMIC SEQUENCES AND ANTISENSE
; TITLE OF INVENTION: OLIGONUCLEOTIDES
; FILE REFERENCE: 106101.194
; CURRENT APPLICATION NUMBER: US/09/103,875A
; CURRENT FILING DATE: 1998-06-24
; EARLIER APPLICATION NUMBER: 60/069,865
; EARLIER FILING DATE: 1997-12-17
; EARLIER APPLICATION NUMBER: 08/866,340
; EARLIER FILING DATE: 1997-05-30
; NUMBER OF SEQ ID NOS: 138
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 123
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide
US-09-103-875-123

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 22;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1681 GGTGTCTCCTCCAGCGTGG 1699
              || |||| |||| ||||||
Db         20 GGGGTCTGCTCCTGCGTGG 2
```

RESULT 25
US-09-798-096-16/c
; Sequence 16, Application US/09798096
; Patent No. 6399378
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RECQL2 EXPRESSION
; FILE REFERENCE: RTS-0207
; CURRENT APPLICATION NUMBER: US/09/798,096
; CURRENT FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-798-096-16

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 22;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1662 GGCTCACAGCTGGAACCCT 1680
              |||||||| ||| || |||
Db         20 GGCTCACACCTGTAATCCT 2
```

RESULT 26
US-08-754-477A-109
; Sequence 109, Application US/08754477A
; Patent No. 6518411
; GENERAL INFORMATION:
; APPLICANT: Murray, Jeffrey
; APPLICANT: Semina, Elena
; TITLE OF INVENTION: RIEG COMPOSITIONS AND THERAPEUTIC
; TITLE OF INVENTION: AND DIAGNOSTIC USES THEREFOR
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/754,477A
; FILING DATE: 22-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: UIA-022.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 109:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-754-477A-109

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 22;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1733 TGGCTCCCAACTCCTCCCT 1751
              || ||||||| ||||| ||
Db          2 TGTCTCCCAATTCCTCACT 20
```

RESULT 27
PCT-US94-06284-2/c
; Sequence 2, Application PC/TUS9406284
; GENERAL INFORMATION:
; APPLICANT:
; APPLICANT: NAME: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
; APPLICANT: SYSTEM
; APPLICANT: STREET: 201 West 7th Street
; APPLICANT: CITY: Austin
; APPLICANT: STATE: Texas
; APPLICANT: COUNTRY: United States of America
; APPLICANT: POSTAL CODE: 78701
; APPLICANT: TELEPHONE NO: (512)499-4462
; APPLICANT: TELEFAX: (512)499-4523
; APPLICANT: STREET: 995 East Arques Ave.
; APPLICANT: CITY: Sunnyvale
; APPLICANT: STATE: California
; APPLICANT: COUNTRY: United States of America
; APPLICANT: POSTAL CODE: 94086-4593
; APPLICANT: TELEPHONE NO: (408)774-0330
; APPLICANT: TELEFAX: (408)774-0340
; TITLE OF INVENTION: TEXAPHYRIN METAL COMPLEX

```
;    TITLE OF INVENTION:  MEDIATED ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/06284
;      FILING DATE:  CONCURRENTLY HEREWITH
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  USSN 08/075,123
;      FILING DATE:  09 JUNE 1993 (09.06.93)
;      CLASSIFICATION:
;      APPLICATION NUMBER:  USSN 08/227,370
;      FILING DATE:  14 APRIL 1994 (14.04.94)
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PARKER, DAVID L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTFB570P--
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/320-7200
;      TELEFAX:  713/789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US94-06284-2

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 22;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAGCTG 1673
                | |||| ||||||||| ||
Db         19 AACACCCGGCTCACAGATG 1


RESULT 28
US-08-802-547-12/c
; Sequence 12, Application US/08802547
; Patent No. 5780611
;  GENERAL INFORMATION:
;    APPLICANT:  Guntaka, Ramareddy V.
;    APPLICANT:  Weber, Karl T.
;    APPLICANT:  Kovacs, Attilla
;    APPLICANT:  Kandala, Jagannadhachari
;    TITLE OF INVENTION:  OLIGOMERS WHICH INHIBIT EXPRESSION OF
;    TITLE OF INVENTION:  COLLAGEN GENES
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hovey, Williams, Timmons & Collins
;      STREET:  2405 Grand Boulevard, Suite 400
;      CITY:  Kansas City
;      STATE:  MO
;      COUNTRY:  USA
;      ZIP:  64108
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/802,547
;      FILING DATE:
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Collins, John M.
;      REGISTRATION NUMBER:  26,262
;      REFERENCE/DOCKET NUMBER:  24129-B
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  816-474-9050
;      TELEFAX:  816-474-9057
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
;    POSITION IN GENOME:
;      UNITS:  bp
US-08-802-547-12

  Query Match             9.5%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCTCCCTAT 1753
                |||||  |||||||| |
Db         18 CTCCCCCCTCCTCCCTTT 1


RESULT 29
US-08-712-357-12/c
; Sequence 12, Application US/08712357
; Patent No. 5808037
;  GENERAL INFORMATION:
;    APPLICANT:  Guntaka, Ramareddy V.
;    APPLICANT:  Weber, Karl T.
;    APPLICANT:  Kovacs, Attila
;    APPLICANT:  Kandala, Jagannadhachari
;    TITLE OF INVENTION:  OLIGOMERS WHICH INHIBIT
;    TITLE OF INVENTION:  EXPRESSION OF COLLAGEN GENES
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hovey, Williams, Timmons & Collins
;      STREET:  2405 Grand Boulevard, Suite 400
;      CITY:  Kansas City
;      STATE:  Missouri
;      COUNTRY:  U.S.A.
;      ZIP:  64108
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/712,357
;      FILING DATE:
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Collins, John M.
;      REGISTRATION NUMBER:  26262
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (816) 474-9050
;      TELEFAX:  (816) 474-9057
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
;    POSITION IN GENOME:
;      UNITS:  bp
US-08-712-357-12

  Query Match             9.5%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCTCCCTAT 1753
              ||||| |||||||||  |
Db         18 CTCCCCCCTCCTCCCTTT 1


RESULT 30
US-09-255-912-28
; Sequence 28, Application US/09255912
; Patent No. 6037142
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD2 EXPRESSION
;  FILE REFERENCE: RTS-0044
;  CURRENT APPLICATION NUMBER: US/09/255,912
;  CURRENT FILING DATE: 1999-02-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 28
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-255-912-28

  Query Match             9.5%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGGTTAGGA 1716
              | |||||||  |||||||
Db          1 GCGGAAGTTCTGTTAGGA 18


RESULT 31
US-09-280-409-75
; Sequence 75, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Bert W. O'Malley
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
;  FILE REFERENCE: RTS-0048
;  CURRENT APPLICATION NUMBER: US/09/280,409
;  CURRENT FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 75
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-75

  Query Match             9.5%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              | ||||||| |||||| |
Db          1 CTGCTGGAAGCCTGGTAT 18


RESULT 32
US-09-723-534-10/c
; Sequence 10, Application US/09723534
; Patent No. 6294382
; GENERAL INFORMATION:
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:  ANTISENSE MODULATION OF SRC-1 EXPRESSION
;  FILE REFERENCE:  RTS-0225
;  CURRENT APPLICATION NUMBER: US/09/723,534
;  CURRENT FILING DATE:  2000-11-27
;  NUMBER OF SEQ ID NOS:  49
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-723-534-10

  Query Match             9.5%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1691 CCAGCGTGGTGGAAGTTG 1708
              |||| |||||||||| | |
Db         18 CCAGTGTGGTGGAATTCG 1


RESULT 33
US-09-721-822A-116/c
; Sequence 116, Application US/09721822A
; Patent No. 6306606
; GENERAL INFORMATION:
;  APPLICANT: Michael J. Weber
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MP-1 EXPRESSION
;  FILE REFERENCE: RTS-0142
;  CURRENT APPLICATION NUMBER: US/09/721,822A
;  CURRENT FILING DATE:  2000-11-22
;  NUMBER OF SEQ ID NOS: 135
; SEQ ID NO 116
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-721-822A-116

  Query Match             9.5%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1664 CTCACAGCTGGAACCCTG 1681
              ||||| || | |||||||
Db         18 CTCACTGCAGCAACCCTG 1


RESULT 34
US-09-077-619-15/c
; Sequence 15, Application US/09077619
; Patent No. 6500614
; GENERAL INFORMATION:
;  APPLICANT: ARGUELLO, Rafael
;  APPLICANT:  AVAKIAN, Hovanes
;  APPLICANT:  MADRIGAL, Alejandro
;  TITLE OF INVENTION: METHOD FOR IDENTIFYING AN UNKNOWN ALLELE
;  FILE REFERENCE: 028979/0104
;  CURRENT APPLICATION NUMBER: US/09/077,619
```

; CURRENT FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/GB96/02959
; PRIOR FILING DATE: 1996-11-29
; PRIOR APPLICATION NUMBER: GB 9524381.2
; PRIOR FILING DATE: 1995-11-29
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-077-619-15

Query Match 9.5%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 30;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1732 TTGGCTCCCAACTCCTCC 1749
| ||||| ||||| ||||
Db 18 TAGGCTCTCAACTGCTCC 1

RESULT 35
US-08-363-240A-758
; Sequence 758, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 758:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-758

Query Match 9.4%; Score 13; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 22;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1733 TGGCTCCCAACTC 1745
:|||:||||||:|
Db 3 UGGCUCCCAACUC 15

RESULT 36
US-08-363-240A-759
; Sequence 759, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 759:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-759

Query Match 9.4%; Score 13; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 22;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1733 TGGCTCCCAACTC 1745
:|||:||||||:|
Db 3 UGGCUCCCAACUC 15

RESULT 37
US-08-486-962-12/c
; Sequence 12, Application US/08486962
; Patent No. 5763172
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren

```
;    APPLICANT:  Sessler, Jonathan L.
;    APPLICANT:  Wright, Meredith
;    APPLICANT:  Ross, Kevin L.
;    APPLICANT:  Miller, Richard A.
;    APPLICANT:  Dow, William C.
;    APPLICANT:  Kral, Vladimir A.
;    APPLICANT:  Smith, Daniel A.
;    TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94086-4521
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,962
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 774-0330
;      TELEFAX:  (408) 774-0340
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-486-962-12

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 32;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAG 1670
             | |||| ||||||||
Db         16 AACACCCGGCTCACAG 1


RESULT 38
US-08-584-040-7909/c
; Sequence 7909, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7909:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7909

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 32;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1646 CAGAAGGCAAGCACCA 1661
              |||||| ||||| |||
Db         17 CAGAAGCCAAGCGCCA 2


RESULT 39
US-09-371-772B-3692/c
; Sequence 3692, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3692
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3692

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 32;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1646 CAGAAGGCAAGCACCA 1661
              |||||| ||||| |||
Db         17 CAGAAGCCAAGCGCCA 2
```

```
RESULT 40
PCT-US94-06284-12/c
; Sequence 12, Application PC/TUS9406284
;  GENERAL INFORMATION:
;     APPLICANT:
;     APPLICANT:  NAME:      BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
;     APPLICANT:  SYSTEM
;     APPLICANT:  STREET:    201 West 7th Street
;     APPLICANT:  CITY:      Austin
;     APPLICANT:  STATE:     Texas
;     APPLICANT:  COUNTRY:   United States of America
;     APPLICANT:  POSTAL CODE:  78701
;     APPLICANT:  TELEPHONE NO: (512)499-4462
;     APPLICANT:  TELEFAX:   (512)499-4523
;     APPLICANT:  STREET:    995 East Arques Ave.
;     APPLICANT:  CITY:      Sunnyvale
;     APPLICANT:  STATE:     California
;     APPLICANT:  COUNTRY:   United States of America
;     APPLICANT:  POSTAL CODE:  94086-4593
;     APPLICANT:  TELEPHONE NO: (408)774-0330
;     APPLICANT:  TELEFAX:   (408)774-0340
;     TITLE OF INVENTION:  TEXAPHYRIN METAL COMPLEX
;     TITLE OF INVENTION:  MEDIATED ESTER HYDROLYSIS
;     NUMBER OF SEQUENCES:  16
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Arnold, White & Durkee
;       STREET:  P.O. Box 4433
;       CITY:  Houston
;       STATE:  Texas
;       COUNTRY:  USA
;       ZIP:  77210
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US94/06284
;       FILING DATE:  CONCURRENTLY HEREWITH
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  USSN 08/075,123
;       FILING DATE:  09 JUNE 1993 (09.06.93)
;       CLASSIFICATION:
;       APPLICATION NUMBER:  USSN 08/227,370
;       FILING DATE:  14 APRIL 1994 (14.04.94)
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  PARKER, DAVID L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTFB570P--
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  512/320-7200
;       TELEFAX:  713/789-2679
;       TELEX:  79-0924
;   INFORMATION FOR SEQ ID NO:  12:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
PCT-US94-06284-12

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 32;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAG 1670
              | |||| |||||||||
Db         16 AACACCCGGCTCACAG 1
```

```
RESULT 41
US-08-486-962-15/c
; Sequence 15, Application US/08486962
; Patent No. 5763172
;  GENERAL INFORMATION:
;     APPLICANT:  Magda, Darren
;     APPLICANT:  Sessler, Jonathan L.
;     APPLICANT:  Wright, Meredith
;     APPLICANT:  Ross, Kevin L.
;     APPLICANT:  Miller, Richard A.
;     APPLICANT:  Dow, William C.
;     APPLICANT:  Kral, Vladimir A.
;     APPLICANT:  Smith, Daniel A.
;     TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;     NUMBER OF SEQUENCES:  18
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Pharmacyclics, Inc.
;       STREET:  995 E. Arques Avenue
;       CITY:  Sunnyvale
;       STATE:  California
;       COUNTRY:  USA
;       ZIP:  94086-4521
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/486,962
;       FILING DATE:  07-JUN-1995
;       CLASSIFICATION:  530
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Larson, Jacqueline S.
;       REGISTRATION NUMBER:  30,279
;       REFERENCE/DOCKET NUMBER:  PHAY:053
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (408) 774-0330
;       TELEFAX:  (408) 774-0340
;   INFORMATION FOR SEQ ID NO:  15:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc = "DNA"
US-08-486-962-15

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 37;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAG 1670
              | |||| |||||||||
Db         17 AACACCCGGCTCACAG 2
```

```
RESULT 42
US-08-671-975A-7
; Sequence 7, Application US/08671975A
; Patent No. 5830656
;  GENERAL INFORMATION:
;     APPLICANT:  Milo, George
;     TITLE OF INVENTION:  CATR GENE
;     NUMBER OF SEQUENCES:  20
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  CALFEE, HALTER & GRISWOLD
;       STREET:  800 SUPERIOR AVENUE, SUITE 1400
;       CITY:  CLEVELAND
;       STATE:  OHIO
;       COUNTRY:  USA
;       ZIP:  44114
```

```
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/671,975A
;       FILING DATE:
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  GOLRICK, MARY E
;       REGISTRATION NUMBER:  34,829
;       REFERENCE/DOCKET NUMBER:  22727/00134
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (216) 622-8200
;       TELEFAX:  (216) 241-0816
;   INFORMATION FOR SEQ ID NO:  7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
US-08-671-975A-7

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 37;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1691 CCAGCGTGGTGGAAGT 1706
                |||| |||||||||  |
Db          2 CCAGTGTGGTGGAATT 17


RESULT 43
US-09-280-409-109
; Sequence 109, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Bert W. O'Malley
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
;  FILE REFERENCE: RTS-0048
;  CURRENT APPLICATION NUMBER: US/09/280,409
;  CURRENT FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 109
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-109

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 37;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1670 GCTGGAACCCTGGTGT 1685
                |||||||  ||||||  |
Db          2 GCTGGAAGCCTGGTAT 17


RESULT 44
US-09-280-409-142
; Sequence 142, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Bert W. O'Malley
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
;  FILE REFERENCE: RTS-0048
;  CURRENT APPLICATION NUMBER: US/09/280,409
;  CURRENT FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 142
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-142

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 37;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGT 1683
                |  |||||||  ||||||
Db          2 CTGCTGGAAGCCTGGT 17


RESULT 45
PCT-US94-06284-15/c
; Sequence 15, Application PC/TUS9406284
;  GENERAL INFORMATION:
;    APPLICANT:
;    APPLICANT:  NAME:     BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
;    APPLICANT:  SYSTEM
;    APPLICANT:  STREET:   201 West 7th Street
;    APPLICANT:  CITY:     Austin
;    APPLICANT:  STATE:    Texas
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  78701
;    APPLICANT:  TELEPHONE NO: (512)499-4462
;    APPLICANT:  TELEFAX:  (512)499-4523
;    APPLICANT:  STREET:   995 East Arques Ave.
;    APPLICANT:  CITY:     Sunnyvale
;    APPLICANT:  STATE:    California
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  94086-4593
;    APPLICANT:  TELEPHONE NO: (408)774-0330
;    APPLICANT:  TELEFAX:  (408)774-0340
;    TITLE OF INVENTION:  TEXAPHYRIN METAL COMPLEX
;    TITLE OF INVENTION:  MEDIATED ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/06284
;      FILING DATE:  CONCURRENTLY HEREWITH
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  USSN 08/075,123
;      FILING DATE:  09 JUNE 1993 (09.06.93)
;      CLASSIFICATION:
;      APPLICATION NUMBER:  USSN 08/227,370
;      FILING DATE:  14 APRIL 1994 (14.04.94)
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PARKER, DAVID L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTFB570P--
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/320-7200
;      TELEFAX:  713/789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US94-06284-15

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 37;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACAG 1670
              | |||| |||||||||
Db         17 AACACCCGGCTCACAG 2


RESULT 46
US-07-912-900-11
; Sequence 11, Application US/07912900
; Patent No. 5349125
;  GENERAL INFORMATION:
;    APPLICANT:  Holton, Timothy A.
;    APPLICANT:  Cornish, Edwina C.
;    APPLICANT:  Kovacic, Filippa
;    APPLICANT:  Tanaka, Yoshikazu
;    APPLICANT:  Lester, Diane R.
;    TITLE OF INVENTION:  GENETIC SEQUENCES ENCODING FLAVONOID
;    TITLE OF INVENTION:  PATHWAY ENZYMES AND USES THEREFOR
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/912,900
;      FILING DATE:  19920713
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  8633
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-912-900-11

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 30;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1683 TGTCTCCTCCAGCG 1696
              |||||||||||| |
Db          2 TGTCTCCTCCAGTG 15


RESULT 47
US-08-285-309-11
; Sequence 11, Application US/08285309
; Patent No. 5569832
;  GENERAL INFORMATION:
;    APPLICANT:  Holton, Timothy A.
;    APPLICANT:  Cornish, Edwina C.
;    APPLICANT:  Kovacic, Filippa
;    APPLICANT:  Tanaka, Yoshikazu
;    APPLICANT:  Lester, Diane R.
;    TITLE OF INVENTION:  GENETIC SEQUENCES ENCODING A 3,5'-
;    TITLE OF INVENTION:  HYDROXYLASE AND USES
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/285,309
;      FILING DATE:  03-AUG-1994
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  8633Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-285-309-11

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 30;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1683 TGTCTCCTCCAGCG 1696
              |||||||||||| |
Db          2 TGTCTCCTCCAGTG 15


RESULT 48
US-08-502-046-11
; Sequence 11, Application US/08502046
; Patent No. 5861487
;  GENERAL INFORMATION:
;    APPLICANT:  Holton, Timothy A.
;    APPLICANT:  Cornish, Edwina C.
;    APPLICANT:  Kovacic, Filippa
;    APPLICANT:  Tanaka, Yoshikazu
;    APPLICANT:  Lester, Diane R.
;    TITLE OF INVENTION:  GENETIC SEQUENCES ENCODING A 3,5'-
;    TITLE OF INVENTION:  HYDROXYLASE AND USES
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/502,046
;      FILING DATE:  14-JUL-1995
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/285,309
;      FILING DATE:  03-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  8633Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-502-046-11

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 30;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1683 TGTCTCCTCCAGCG 1696
              ||||||||||||| |
Db          2 TGTCTCCTCCAGTG 15


RESULT 49
US-07-696-793A-22/c
; Sequence 22, Application US/07696793A
; Patent No. 5220004
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cetus Corporation
;      STREET:  1400 Fifty-Third Street
;      CITY:  Emeryville
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  94608
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/696,793A
;      FILING DATE:  19910507
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kevin R. Kaster
;      REGISTRATION NUMBER:  32704
;      REFERENCE/DOCKET NUMBER:  2598
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 420-3444
;      TELEFAX:  (415) 658-5239
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-696-793A-22

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 35;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1698 GGTGGAAGTTGGGT 1711
              |||||||| |||||
Db         16 GGTGGAAGCTGGGT 3


RESULT 50
US-07-977-694-22/c
; Sequence 22, Application US/07977694
; Patent No. 5273883
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110-1199
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/977,694
;      FILING DATE:  19921117
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stacey R. Sias, Ph.D.
;      REGISTRATION NUMBER:  32,630
;      REFERENCE/DOCKET NUMBER:  8733
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2863
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-977-694-22

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 35;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1698 GGTGGAAGTTGGGT 1711
              ||||||| |||||
Db         16 GGTGGAAGCTGGGT 3


RESULT 51
US-08-255-264-24/c
; Sequence 24, Application US/08255264
; Patent No. 5643724
;  GENERAL INFORMATION:
;    APPLICANT:  Fildes, Nicola J.
;    APPLICANT:  Reynolds, Rebecca L.
;    TITLE OF INVENTION:  Methods and Reagents for Glycophorin A
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/255,264
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry Ph.D., Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8865
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-255-264-24

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 35;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1698 GGTGGAAGTTGGGT 1711
              ||||||| |||||
Db         16 GGTGGAAGCTGGGT 3


RESULT 52
US-08-161-674B-20/c
; Sequence 20, Application US/08161674B
; Patent No. 6180766
; GENERAL INFORMATION:
;  APPLICANT:  Schinazi, Raymond F.
;  APPLICANT:  Fulcrand-El Kattan, Geraldine
;  APPLICANT:  Lesnikowski, Zibigniew J.
;  TITLE OF INVENTION:  Nucleosides and Oligonucleotides Containing Boron
;  TITLE OF INVENTION:  Clusters
;  FILE REFERENCE:  18085.105068
;  CURRENT APPLICATION NUMBER: US/08/161,674B
;  CURRENT FILING DATE:  1993-12-02
;  NUMBER OF SEQ ID NOS:  22
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Human immunodeficiency virus type 1
US-08-161-674B-20

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 35;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1677 CCCTGGTGTCTCCT 1690
              ||||||||||||| |
Db         16 CCCTGGTGTCTCAT 3


RESULT 53
US-09-371-772B-5908/c
; Sequence 5908, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5908
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5908

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 35;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1663 GCTCACAGCTGGAA 1676
              || |||||||||||
Db         16 GCCCACAGCTGGAA 3


RESULT 54
US-07-696-793A-20/c
; Sequence 20, Application US/07696793A
; Patent No. 5220004
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cetus Corporation
;      STREET:  1400 Fifty-Third Street
;      CITY:  Emeryville
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  94608
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
```

```
;       APPLICATION NUMBER:  US/07/696,793A
;       FILING DATE:  19910507
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Kevin R. Kaster
;       REGISTRATION NUMBER:  32704
;       REFERENCE/DOCKET NUMBER:  2598
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 420-3444
;       TELEFAX:  (415) 658-5239
;   INFORMATION FOR SEQ ID NO:  20:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  Other nucleic acid
US-07-696-793A-20

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1698 GGTGGAAGTTGGGT 1711
              ||||||| |||||
Db         17 GGTGGAAGCTGGGT 4


RESULT 55
US-07-977-694-20/c
; Sequence 20, Application US/07977694
; Patent No. 5273883
;  GENERAL INFORMATION:
;     APPLICANT:  Saiki, Randall K.
;     APPLICANT:  Nasarabadi, Shanavaz L.
;     TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;     TITLE OF INVENTION:  Typing
;     NUMBER OF SEQUENCES:  58
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Hoffmann-La Roche Inc.
;       STREET:  340 Kingsland Street
;       CITY:  Nutley
;       STATE:  New Jersey
;       COUNTRY:  U.S.A.
;       ZIP:  07110-1199
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;       COMPUTER:  Apple Macintosh
;       OPERATING SYSTEM:  Macintosh 6.0.5
;       SOFTWARE:  WordPerfect
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/977,694
;       FILING DATE:  19921117
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Stacey R. Sias, Ph.D.
;       REGISTRATION NUMBER:  32,630
;       REFERENCE/DOCKET NUMBER:  8733
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (510) 814-2863
;       TELEFAX:  (510) 814-2977
;   INFORMATION FOR SEQ ID NO:  20:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  Other nucleic acid
US-07-977-694-20

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1698 GGTGGAAGTTGGGT 1711
              ||||||| |||||
Db         17 GGTGGAAGCTGGGT 4


RESULT 56
US-09-371-772B-4993/c
; Sequence 4993, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4993
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4993

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1663 GCTCACAGCTGGAA 1676
              || ||||||||||||
Db         15 GCCCACAGCTGGAA 2


RESULT 57
US-08-373-124A-1709
; Sequence 1709, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;     APPLICANT:  Stinchcomb, Dan T.
;     APPLICANT:  Draper, Kenneth
;     APPLICANT:  McSwiggen, James
;     APPLICANT:  Jarvis, Thale
;     TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;     TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;     TITLE OF INVENTION:  CANCER USING RIBOZYMES
;     NUMBER OF SEQUENCES:  2627
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
```

```
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/373,124A
;       FILING DATE:  January 13, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1709:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-1709

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 44;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1665 TCACAGCTGGAACCCTG 1681
              :| ||||: |||| |:|
Db          1 UCUCAGCUCGAACUCUG 17


RESULT 58
US-08-435-628-1709
; Sequence 1709, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;     APPLICANT:  Stinchcomb, Dan T.
;     APPLICANT:  Draper, Kenneth
;     APPLICANT:  McSwiggen, James
;     APPLICANT:  Jarvis, Thale
;     TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;     TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;     TITLE OF INVENTION:  CANCER USING RIBOZYMES
;     NUMBER OF SEQUENCES:  2627
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/435,628
;       FILING DATE:  05-MAY-1995
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/373,124
;       FILING DATE:  January 13, 1995
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1709:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-628-1709

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 44;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1665 TCACAGCTGGAACCCTG 1681
              :| ||||: |||| |:|
Db          1 UCUCAGCUCGAACUCUG 17


RESULT 59
US-08-292-492D-6
; Sequence 6, Application US/08292492D
; Patent No. 6328971
;   GENERAL INFORMATION:
;       APPLICANT: van der Bruggen, Pierre; Szikora, Jean-
;                  Pierre; Coulie, Pierre; Wildman, Claude; Bol,
;                  Pascale;
;                  Boon-Falleur, Thierry
;       TITLE OF INVENTION: METHOD FOR IDENTIFYING
;                           INDIVIDUALS
;                           SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE
;                           ABNORMAL CELLS PRESENT COMPLEXES OF HLA-Cw*1601/MAGE-1
;       NUMBER OF SEQUENCES: 17
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fulbright & Jaworski LLP
;            STREET: 666 Fifth Avenue
;            CITY: New York City
;            STATE: New York
;            COUNTRY: USA
;            ZIP: 10103
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
;            COMPUTER: IBM PS/2
;            OPERATING SYSTEM: PC-DOS
;            SOFTWARE: Wordperfect
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/08/292,492D
;            FILING DATE: 18-Aug-1994
;            CLASSIFICATION: 435
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/195,186
;            FILING DATE: 14-FEB-1994
;            APPLICATION NUMBER: 08/008,446
;            FILING DATE: 22-JANUARY-1993
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Hanson, No. 6328971man D.
;            REGISTRATION NUMBER: 30,946
;            REFERENCE/DOCKET NUMBER: LUD 5361.1
;       TELECOMMUNICATION INFORMATION:
```

```
;             TELEPHONE: (212) 318-3100
;             TELEFAX: (212) 318-3400
;    INFORMATION FOR SEQ ID NO: 6:
;         SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-08-292-492D-6

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1653 CAAGCACCAGGCTCACA 1669
              ||||| |||||| || |
Db          1 CAAGCGCCAGGCACAGA 17


RESULT 60
US-09-280-409-142/c
; Sequence 142, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Bert W. O'Malley
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
;  FILE REFERENCE: RTS-0048
;  CURRENT APPLICATION NUMBER: US/09/280,409
;  CURRENT FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 142
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-142

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 50;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAGCTGG 1674
              |||||||  |||| ||
Db         17 ACCAGGCTTCCAGCAGG 1


RESULT 61
US-09-586-376-5
; Sequence 5, Application US/09586376
; Patent No. 6492115
; GENERAL INFORMATION:
;  APPLICANT:  Guida, Marco
;  APPLICANT:  Hall, Jeff
;  TITLE OF INVENTION:  GENETIC TYPING OF THE HUMAN CYTOCHROME P450 2A6 GENE
;  TITLE OF INVENTION:  AND RELATED MATERIALS AND METHODS
;  FILE REFERENCE:  4389-20
;  CURRENT APPLICATION NUMBER: US/09/586,376
;  CURRENT FILING DATE:  2000-06-02
;  NUMBER OF SEQ ID NOS:  29
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-586-376-5

  Query Match             8.6%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1634 TGGGGCTTGTAG 1645
              ||||||||||||
Db          1 TGGGGCTTGTAG 12


RESULT 62
US-08-310-501-4/c
; Sequence 4, Application US/08310501
; Patent No. 5567687
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    APPLICANT:  Iverson, Brent
;    APPLICANT:  Jansen, Petra I.
;    APPLICANT:  Wright, Meredith
;    APPLICANT:  Mody, Tarak D.
;    APPLICANT:  Hemmi, Gregory W.
;    TITLE OF INVENTION:  Texaphyrins and Uses Thereof
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  US
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/310,501
;      FILING DATE:  Concurrently herewith
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/112,872
;      FILING DATE:  25-AUG-1993
;      APPLICATION NUMBER:  PCT/US94/06284
;      FILING DATE:  09-JUN-1994
;      APPLICATION NUMBER:  US 07/822,964
;      FILING DATE:  21-JAN-1992
;      APPLICATION NUMBER:  US 08/227,370
;      FILING DATE:  14-APR-1994
;      APPLICATION NUMBER:  US 08/075,123
;      FILING DATE:  09-JUN-1993
;      APPLICATION NUMBER:  US 07/822,964
;      FILING DATE:  21-JAN-1992
;      APPLICATION NUMBER:  US 07/771,393
;      FILING DATE:  30-SEP-1991
;      APPLICATION NUMBER:  US 07/539,975
;      FILING DATE:  18-JUN-1990
;      APPLICATION NUMBER:  PCT/US90/01208
;      FILING DATE:  06-MAR-1990
;      APPLICATION NUMBER:  US 07/320,293
;      FILING DATE:  06-MAR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  PHAY:034/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/418-3000
;      TELEFAX:  512/474-7577
;      TELEX:  n/a
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
US-08-310-501-4
```

```
  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACAGCTG 1673
              || |||||||| ||
Db         15 CCCGGCTCACAGATG 1


RESULT 63
US-08-469-177-4/c
; Sequence 4, Application US/08469177
; Patent No. 5607924
;  GENERAL INFORMATION:
;    APPLICANT:  MAGDA, Darren
;    APPLICANT:  SESSLER, Jonathan L.
;    APPLICANT:  IVERSON, Brent L.
;    APPLICANT:  SANSOM, Petra I.
;    APPLICANT:  WRIGHT, Meredith
;    TITLE OF INVENTION:  DNA PHOTOCLEAVAGE USING TEXAPHYRINS
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 East Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94086
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/469,177
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:057
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 774-3363
;      TELEFAX:  (408) 774-0340
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "RNA"
US-08-469-177-4

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACAGCTG 1673
              || |||||||| ||
Db         15 CCCGGCTCACAGATG 1


RESULT 64
US-08-484-551-1/c
; Sequence 1, Application US/08484551
; Patent No. 5714328
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    TITLE OF INVENTION:  RNA PHOTOCLEAVAGE USING TEXAPHYRINS
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  United States of America
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,551
;      FILING DATE:  Concurrently herewith
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  PHAY:047/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (512) 747-7577
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-484-551-1

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACAGCTG 1673
              || |||||||| ||
Db         15 CCCGGCTCACAGATG 1


RESULT 65
US-08-484-551-5/c
; Sequence 5, Application US/08484551
; Patent No. 5714328
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    TITLE OF INVENTION:  RNA PHOTOCLEAVAGE USING TEXAPHYRINS
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  United States of America
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,551
;      FILING DATE:  Concurrently herewith
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  PHAY:047/PAR
;    TELECOMMUNICATION INFORMATION:
```

```
;       TELEPHONE:  (512) 418-3000
;       TELEFAX:  (512) 747-7577
;       TELEX:  79-0924
;   INFORMATION FOR SEQ ID NO:  5:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc = "RNA"
US-08-484-551-5

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACAGCTG 1673
              || |||||||||  ||
Db         15 CCCGGCTCACAGATG 1


RESULT 66
US-08-486-962-18/c
; Sequence 18, Application US/08486962
; Patent No. 5763172
;  GENERAL INFORMATION:
;     APPLICANT:  Magda, Darren
;     APPLICANT:  Sessler, Jonathan L.
;     APPLICANT:  Wright, Meredith
;     APPLICANT:  Ross, Kevin L.
;     APPLICANT:  Miller, Richard A.
;     APPLICANT:  Dow, William C.
;     APPLICANT:  Kral, Vladimir A.
;     APPLICANT:  Smith, Daniel A.
;     TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;     NUMBER OF SEQUENCES:  18
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Pharmacyclics, Inc.
;       STREET:  995 E. Arques Avenue
;       CITY:  Sunnyvale
;       STATE:  California
;       COUNTRY:  USA
;       ZIP:  94086-4521
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/486,962
;       FILING DATE:  07-JUN-1995
;       CLASSIFICATION:  530
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Larson, Jacqueline S.
;       REGISTRATION NUMBER:  30,279
;       REFERENCE/DOCKET NUMBER:  PHAY:053
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (408) 774-0330
;       TELEFAX:  (408) 774-0340
;   INFORMATION FOR SEQ ID NO:  18:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc = "DNA"
US-08-486-962-18

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACAGCTG 1673
              || |||||||||  ||
Db         15 CCCGGCTCACAGATG 1


RESULT 67
US-08-913-833-5
; Sequence 5, Application US/08913833
; Patent No. 6087093
;  GENERAL INFORMATION:
;     APPLICANT:  STUYVER, LIEVEN
;     APPLICANT:  LOUWAGIE, JOOST
;     APPLICANT:  ROSSAU, RUDI
;     TITLE OF INVENTION:  METHOD FOR DETECTION OF DRUG-INDUCED
;     TITLE OF INVENTION:  MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;     NUMBER OF SEQUENCES:  164
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  ARNOLD, WHITE & DURKEE
;       STREET:  P.O. BOX 4433
;       CITY:  HOUSTON
;       STATE:  TEXAS
;       COUNTRY:  USA
;       ZIP:  77210-4433
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  Microsoft Word 6.0 / ASCII text output
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/913,833
;       FILING DATE:  15 Sep 1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/EP97/00211
;       FILING DATE:  17 Jan 1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  EP 96870005.4
;       FILING DATE:  26 Jan 1996
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  EP 96870081.5
;       FILING DATE:  25 Jun 1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  KAMMERER, PATRICIA A.
;       REGISTRATION NUMBER:  29,775
;       REFERENCE/DOCKET NUMBER:  INNS:008
;   INFORMATION FOR SEQ ID NO:  5:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
US-08-913-833-5

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 GTACGGAGATGGAGA 1731
              |||| ||||||||  |
Db          1 GTACAGAGATGGAAA 15


RESULT 68
US-09-580-794C-5
; Sequence 5, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
;  APPLICANT: Stuyver, Lieven
;  APPLICANT:  Louwagie, Joost
;  APPLICANT:  Rossau, Rudi
```

```
;  TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
;  TITLE OF INVENTION:  TRANSCRIPTASE GENE
;  FILE REFERENCE: INNS008--2
;  CURRENT APPLICATION NUMBER: US/09/580,794C
;  CURRENT FILING DATE:  2000-05-30
;  PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
;  PRIOR FILING DATE: 1997-09-15
;  PRIOR APPLICATION NUMBER: PCT/EP 97/00211
;  PRIOR FILING DATE: 1997-01-17
;  PRIOR APPLICATION NUMBER: EP 96870005.4
;  PRIOR FILING DATE: 1996-01-26
;  PRIOR APPLICATION NUMBER: EP 96870081.5
;  PRIOR FILING DATE: 1996-06-25
;  NUMBER OF SEQ ID NOS: 164
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Primer
US-09-580-794C-5

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 GTACGGAGATGGAGA 1731
             |||| |||||||| |
Db          1 GTACAGAGATGGAAA 15


RESULT 69
US-09-813-781-48/c
; Sequence 48, Application US/09813781
; Patent No. 6405989
; GENERAL INFORMATION:
;  APPLICANT: WEIDANZ, JON A.
;  APPLICANT:  CARD, KIMBERLYN F.
;  APPLICANT:  WONG, HING C.
;  TITLE OF INVENTION: FUSION PROTEINS COMPRISING BACTERIOPHAGE COAT PROTEIN
;  TITLE OF INVENTION:  AND A SINGLE-CHAIN T-CELL RECEPTOR
;  FILE REFERENCE: 46745(1758)
;  CURRENT APPLICATION NUMBER: US/09/813,781
;  CURRENT FILING DATE:  2001-03-22
;  NUMBER OF SEQ ID NOS: 130
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 48
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-813-781-48

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 GCACCAGGCTCACAG 1670
             | ||||| |||||||
Db         15 GAACCAGACTCACAG 1


RESULT 70
US-08-486-962-14/c
; Sequence 14, Application US/08486962
; Patent No. 5763172
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    APPLICANT:  Wright, Meredith
;    APPLICANT:  Ross, Kevin L.
;    APPLICANT:  Miller, Richard A.
;    APPLICANT:  Dow, William C.
;    APPLICANT:  Kral, Vladimir A.
;    APPLICANT:  Smith, Daniel A.
;    TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94086-4521
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,962
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 774-0330
;      TELEFAX:  (408) 774-0340
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-486-962-14

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACA 1669
             | |||| ||||||||
Db         15 AACACCCGGCTCACA 1


RESULT 71
US-08-975-522A-6/c
; Sequence 6, Application US/08975522A
; Patent No. 6022959
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Crofts, Shaun P.
;    APPLICANT:  Wright, Meredith
;    TITLE OF INVENTION:  NUCLEIC ACIDS INTERNALLY-
;    TITLE OF INVENTION:  DERIVATIZED WITH A TEXAPHYRIN
;    TITLE OF INVENTION:  METAL COMPLEX AND USES THEREOF
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94085
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Patentin Release #1.0, Version #1.30
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/975,522A
;      FILING DATE:  No. 6022959ember 20, 1997
;      CLASSIFICATION:  536
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 499-6200
;      TELEFAX:  (512)  499-6290
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-975-522A-6

  Query Match             8.5%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCACA 1669
              | |||| ||||||||
Db         15 AACACCCGGCTCACA 1


RESULT 72
US-08-544-381B-27/c
; Sequence 27, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  27:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-27

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 37;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||||||||||
Db         13 AGGGCAAGCACCA 1


RESULT 73
US-08-778-794A-85/c
; Sequence 85, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
```

```
;       TELEFAX:  (415) 576-0200
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  85:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-778-794A-85

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 37;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||||||||||
Db         13 AGGGCAAGCACCA 1


RESULT 74
US-09-922-445-17/c
; Sequence 17, Application US/09922445
; Patent No. 6528268
; GENERAL INFORMATION:
;  APPLICANT: Andersson, Maria K.
;  APPLICANT:  Berglund, Lars G. T.
;  APPLICANT:  Reneland, Rikard  H.
;  APPLICANT:  Adam, Gail I. R.
;  TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
;  FILE REFERENCE: GG126US
;  CURRENT APPLICATION NUMBER: US/09/922,445
;  CURRENT FILING DATE:  2001-08-03
;  NUMBER OF SEQ ID NOS: 51
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: synthetic
US-09-922-445-17

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 37;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1662 GGCTCACAGCTGG 1674
              |||||||| ||||
Db         13 GGCTCACATCTGG 1


RESULT 75
US-09-922-445-27
; Sequence 27, Application US/09922445
; Patent No. 6528268
; GENERAL INFORMATION:
;  APPLICANT: Andersson, Maria K.
;  APPLICANT:  Berglund, Lars G. T.
;  APPLICANT:  Reneland, Rikard  H.
;  APPLICANT:  Adam, Gail I. R.
;  TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
;  FILE REFERENCE: GG126US
;  CURRENT APPLICATION NUMBER: US/09/922,445
;  CURRENT FILING DATE:  2001-08-03
;  NUMBER OF SEQ ID NOS: 51
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: synthetic
US-09-922-445-27

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 37;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1662 GGCTCACAGCTGG 1674
              |||||||| ||||
Db          1 GGCTCACATCTGG 13


RESULT 76
US-08-913-833-9
; Sequence 9, Application US/08913833
; Patent No. 6087093
;  GENERAL INFORMATION:
;    APPLICANT:  STUYVER, LIEVEN
;    APPLICANT:  LOUWAGIE, JOOST
;    APPLICANT:  ROSSAU, RUDI
;    TITLE OF INVENTION:  METHOD FOR DETECTION OF DRUG-INDUCED
;    TITLE OF INVENTION:  MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;    NUMBER OF SEQUENCES:  164
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ARNOLD, WHITE & DURKEE
;      STREET:  P.O. BOX 4433
;      CITY:  HOUSTON
;      STATE:  TEXAS
;      COUNTRY:  USA
;      ZIP:  77210-4433
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Microsoft Word 6.0 / ASCII text output
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/913,833
;      FILING DATE:  15 Sep 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/EP97/00211
;      FILING DATE:  17 Jan 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 96870005.4
;      FILING DATE:  26 Jan 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 96870081.5
;      FILING DATE:  25 Jun 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KAMMERER, PATRICIA A.
;      REGISTRATION NUMBER:  29,775
;      REFERENCE/DOCKET NUMBER:  INNS:008
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-913-833-9

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 44;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1717 GTACGGAGATGGA 1729
              |||| ||||||||
Db          1 GTACAGAGATGGA 13


RESULT 77
US-09-580-794C-9
; Sequence 9, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
;  APPLICANT: Stuyver, Lieven
;  APPLICANT:  Louwagie, Joost
```

```
;  APPLICANT:  Rossau, Rudi
;  TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
;  TITLE OF INVENTION:  TRANSCRIPTASE GENE
;  FILE REFERENCE: INNS008--2
;  CURRENT APPLICATION NUMBER: US/09/580,794C
;  CURRENT FILING DATE:  2000-05-30
;  PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
;  PRIOR FILING DATE: 1997-09-15
;  PRIOR APPLICATION NUMBER: PCT/EP 97/00211
;  PRIOR FILING DATE: 1997-01-17
;  PRIOR APPLICATION NUMBER: EP 96870005.4
;  PRIOR FILING DATE: 1996-01-26
;  PRIOR APPLICATION NUMBER: EP 96870081.5
;  PRIOR FILING DATE: 1996-06-25
;  NUMBER OF SEQ ID NOS: 164
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Primer
US-09-580-794C-9

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 44;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1717 GTACGGAGATGGA 1729
              |||| ||||||||
Db          1 GTACAGAGATGGA 13


RESULT 78
US-08-111-076-17/c
; Sequence 17, Application 08/111076
; Patent No. 5470723
;  GENERAL INFORMATION:
;    APPLICANT:  Walker, George T.
;    APPLICANT:  Nadeau, James G.
;    APPLICANT:  Nycz, Colleen M.
;    APPLICANT:  Spears, Patricia A.
;    APPLICANT:  Shank, Daryl S.
;    APPLICANT:  Schram, James L.
;    APPLICANT:  Jurgensen, Stewart R.
;    TITLE OF INVENTION:  DETECTION OF MYCOBACTERIA BY MULTIPLEX
;    TITLE OF INVENTION:  NUCLEIC ACID AMPLIFICATION
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick, Becton Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  US
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  08/111,076
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 073197
;      FILING DATE:  04-JUN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 058648
;      FILING DATE:  05-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fugit, Donna R.
;      REGISTRATION NUMBER:  32,135
;      REFERENCE/DOCKET NUMBER:  P-2894
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-847-7166
;      TELEFAX:  201-848-9228
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-111-076-17

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAG 1670
              |||| ||||||||
Db         14 ACCACGCTCACAG 2


RESULT 79
US-08-398-305-17/c
; Sequence 17, Application US/08398305
; Patent No. 5561044
;  GENERAL INFORMATION:
;    APPLICANT:  Walker, George T.
;    APPLICANT:  Nadeau, James G.
;    APPLICANT:  Nycz, Colleen M.
;    APPLICANT:  Spears, Patricia A.
;    APPLICANT:  Shank, Daryl S.
;    APPLICANT:  Schram, James L.
;    APPLICANT:  Jurgensen, Stewart R.
;    TITLE OF INVENTION:  DETECTION OF MYCOBACTERIA BY MULTIPLEX
;    TITLE OF INVENTION:  NUCLEIC ACID AMPLIFICATION
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick, Becton Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  US
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/398,305
;      FILING DATE:  03-MAR-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/111,076
;      FILING DATE:  24-AUG-1993
;      APPLICATION NUMBER:  US 073197
;      FILING DATE:  04-JUN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 058648
;      FILING DATE:  05-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fugit, Donna R.
;      REGISTRATION NUMBER:  32,135
;      REFERENCE/DOCKET NUMBER:  P-2894
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-847-7166
;      TELEFAX:  201-848-9228
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
```

```
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-398-305-17

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAG 1670
              |||| ||||||||
Db         14 ACCACGCTCACAG 2


RESULT 80
US-08-182-968A-452
; Sequence 452, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,968A
;      FILING DATE:  13-JANUARY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  205/277
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  452:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-968A-452

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   69.2%;  Pred. No. 51;
  Matches    9;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1686 CTCCTCCAGCGTG 1698
              |:||:||| ||:|
Db          3 CUCCUCCAACGUG 15


RESULT 81
US-08-705-225-17/c
; Sequence 17, Application US/08705225
; Patent No. 5736365
;  GENERAL INFORMATION:
;    APPLICANT:  Walker, George T.
;    APPLICANT:  Nadeau, James G.
;    APPLICANT:  Nycz, Colleen M.
;    APPLICANT:  Spears, Patricia A.
;    APPLICANT:  Shank, Daryl S.
;    APPLICANT:  Schram, James L.
;    APPLICANT:  Jurgensen, Stewart R.
;    TITLE OF INVENTION:  DETECTION OF MYCOBACTERIA BY MULTIPLEX
;    TITLE OF INVENTION:  NUCLEIC ACID AMPLIFICATION
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick, Becton Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  US
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/705,225
;      FILING DATE:  29-AUG-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/111,076
;      FILING DATE:  24-AUG-1993
;      APPLICATION NUMBER:  US 073197
;      FILING DATE:  04-JUN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 058648
;      FILING DATE:  05-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fugit, Donna R.
;      REGISTRATION NUMBER:  32,135
;      REFERENCE/DOCKET NUMBER:  P-2894
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-847-7166
;      TELEFAX:  201-848-9228
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-705-225-17

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAG 1670
              |||| ||||||||
Db         14 ACCACGCTCACAG 2


RESULT 82
US-08-513-841-16
; Sequence 16, Application US/08513841
; Patent No. 5753481
;  GENERAL INFORMATION:
;    APPLICANT:  Niwa, Mineo
;    APPLICANT:  Saito, Yoshimasa
;    APPLICANT:  Ishii, Yoshinori
;    APPLICANT:  Yoshida, Masaru
;    APPLICANT:  Suzuki, Hiromi
;    TITLE OF INVENTION:  No. 5753481el L-sorbose Dehydrogenase and No. 5753481el L-sorbc
;    TITLE OF INVENTION:  Dehydrogenase Obtained from Gluconobacter oxydans T-100
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
```

```
;       ADDRESSEE:  Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
;       STREET:  1755 Jefferson Davis Highway, Suite 400
;       CITY:  Arlington
;       STATE:  Virginia
;       COUNTRY:  USA
;       ZIP:  22202
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  MS-DOS Editor
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/513,841
;       FILING DATE:  01-NOV-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  UK 9304700.9
;       FILING DATE:  08-MAR-1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  JP 241851/1993
;       FILING DATE:  28-SEP-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  NORMAN F. OBLON
;       REGISTRATION NUMBER:  24,618
;       REFERENCE/DOCKET NUMBER:  18-909-0 PCT
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  703-413-3000
;       TELEFAX:  703-413-2220
;       TELEX:  248855 OPAT UR
;   INFORMATION FOR SEQ ID NO:  16:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid (synthetic DNA)
US-08-513-841-16

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1724 GATGGAGATTGGC 1736
              ||||||| ||||
Db          2 GATGGAGAATGGC 14


RESULT 83
US-08-696-834-17
; Sequence 17, Application US/08696834
; Patent No. 5834263
;  GENERAL INFORMATION:
;    APPLICANT:  Niwa, Mineo
;    APPLICANT:  Saito, Yoshimasa
;    APPLICANT:  Ishii, Yoshinori
;    APPLICANT:  Yoshida, Masaru
;    APPLICANT:  Hayashi, Hiromi
;    TITLE OF INVENTION:  Method for Producing 2-Keto-L-Gulonic Acid
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Oblon, Spivak, McClelland, Maier & Neustadt,
;      ADDRESSEE:  P.C.
;      STREET:  1755 Jefferson Davis Highway, Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette - 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/696,834
;      FILING DATE:  24-SEP-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 28612/1994
;      FILING DATE:  25-FEB-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:
;      REGISTRATION NUMBER:
;      REFERENCE/DOCKET NUMBER:
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 413-3000
;      TELEFAX:  (703) 413-2220
;      TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid (synthetic DNA)
US-08-696-834-17

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1724 GATGGAGATTGGC 1736
              ||||||| ||||
Db          2 GATGGAGAATGGC 14


RESULT 84
US-08-942-673-16
; Sequence 16, Application US/08942673
; Patent No. 5861292
;  GENERAL INFORMATION:
;    APPLICANT:  Niwa, Mineo
;    APPLICANT:  Saito, Yoshimasa
;    APPLICANT:  Ishii, Yoshinori
;    APPLICANT:  Yoshida, Masaru
;    APPLICANT:  Suzuki, Hiromi
;    TITLE OF INVENTION:  No. 5861292el L-sorbose Dehydrogenase and No. 5861292el
;    TITLE OF INVENTION:  L-sorbosone Dehydrogenase Obtained from Gluconobacter
;    TITLE OF INVENTION:  oxydans T-100
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
;      STREET:  1755 Jefferson Davis Highway, Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  MS-DOS Editor
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/942,673
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/513,841
;      FILING DATE:  01-NOV-1995
;      APPLICATION NUMBER:  UK 9304700.9
;      FILING DATE:  08-MAR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 241851/1993
;      FILING DATE:  28-SEP-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  NORMAN F. OBLON
;      REGISTRATION NUMBER:  24,618
```

; REFERENCE/DOCKET NUMBER: 18-909-0 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid (synthetic DNA)
US-08-942-673-16

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 51;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1724 GATGGAGATTGGC 1736
||||||| ||||
Db 2 GATGGAGAATGGC 14

RESULT 85
US-08-774-306A-452
; Sequence 452, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 452:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-306A-452

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 51;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTG 1698
|:||:||| ||:|
Db 3 CUCCUCCAACGUG 15

RESULT 86
US-09-064-156A-452
; Sequence 452, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 452:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-064-156A-452

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 51;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTG 1698
|:||:||| ||:|
Db 3 CUCCUCCAACGUG 15

RESULT 87
US-09-118-317-16
; Sequence 16, Application US/09118317
; Patent No. 6197562
; GENERAL INFORMATION:
; APPLICANT: Niwa, Mineo
; APPLICANT: Saito, Yoshimasa

```
;    APPLICANT:  Ishii, Yoshinori
;    APPLICANT:  Yoshida, Masaru
;    APPLICANT:  Suzuki, Hiromi
;    TITLE OF INVENTION:  No. 6197562el L-sorbose Dehydrogenase and No. 6197562el
;    TITLE OF INVENTION:  L-sorbosone Dehydrogenase Obtained from Gluconobacter
;    TITLE OF INVENTION:  oxydans T-100
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
;      STREET:  1755 Jefferson Davis Highway, Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  MS-DOS Editor
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/118,317
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/513,841
;      FILING DATE:  01-NOV-1995
;      APPLICATION NUMBER:  UK 9304700.9
;      FILING DATE:  08-MAR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 241851/1993
;      FILING DATE:  28-SEP-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  NORMAN F. OBLON
;      REGISTRATION NUMBER:  24,618
;      REFERENCE/DOCKET NUMBER:  18-909-0 PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-413-3000
;      TELEFAX:  703-413-2220
;      TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid (synthetic DNA)
US-09-118-317-16

  Query Match              8.2%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1724 GATGGAGATTGGC 1736
                ||||||| ||||
Db          2 GATGGAGAATGGC 14


RESULT 88
US-07-696-793A-18/c
; Sequence 18, Application US/07696793A
; Patent No. 5220004
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cetus Corporation
;      STREET:  1400 Fifty-Third Street
;      CITY:  Emeryville
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  94608
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/696,793A
;      FILING DATE:  19910507
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kevin R. Kaster
;      REGISTRATION NUMBER:  32704
;      REFERENCE/DOCKET NUMBER:  2598
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 420-3444
;      TELEFAX:  (415) 658-5239
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-696-793A-18

  Query Match              8.2%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGGT 1711
                ||||||| |||||
Db         16 GTGGAAGCTGGGT 4


RESULT 89
US-07-977-694-18/c
; Sequence 18, Application US/07977694
; Patent No. 5273883
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110-1199
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/977,694
;      FILING DATE:  19921117
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stacey R. Sias, Ph.D.
;      REGISTRATION NUMBER:  32,630
;      REFERENCE/DOCKET NUMBER:  8733
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2863
```

```
;       TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  18:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  Other nucleic acid
US-07-977-694-18

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGGT 1711
              ||||||| |||||
Db         16 GTGGAAGCTGGGT 4


RESULT 90
US-08-303-004-32
; Sequence 32, Application US/08303004
; Patent No. 5556955
;  GENERAL INFORMATION:
;     APPLICANT:  Vergnaud, Gilles
;     TITLE OF INVENTION:  Process for Detection of New Polymor-
;     TITLE OF INVENTION:  phic  Loci in an ADN Sequence, Nucleotide Sequences Forming
;     TITLE OF INVENTION:  Hybridisation Probes and Their Biological Applications
;     NUMBER OF SEQUENCES:  38
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Oliff & Berridge
;       STREET:  P.O. Box 19928
;       CITY:  Alexandria
;       STATE:  Virginia
;       COUNTRY:  U.S.A
;       ZIP:  22320
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/303,004
;       FILING DATE:
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/931,311B
;       FILING DATE:  19920818
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Berridge, William P.
;       REGISTRATION NUMBER:  30,024
;       REFERENCE/DOCKET NUMBER:  WPB 28264
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (703) 836-6400
;       TELEFAX:  (703) 836-2787
;       TELEX:  90-1799 PTO ALEX
;  INFORMATION FOR SEQ ID NO:  32:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
US-08-303-004-32

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1655 AGCACCAGGCTCA 1667
              || ||||||||||
Db          1 AGAACCAGGCTCA 13


RESULT 91
US-07-696-793A-7/c
; Sequence 7, Application US/07696793A
; Patent No. 5220004
;  GENERAL INFORMATION:
;     APPLICANT:  Saiki, Randall K.
;     APPLICANT:  Nasarabadi, Shanavaz L.
;     TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;     TITLE OF INVENTION:  Typing
;     NUMBER OF SEQUENCES:  58
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Cetus Corporation
;       STREET:  1400 Fifty-Third Street
;       CITY:  Emeryville
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  94608
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;       COMPUTER:  Apple Macintosh
;       OPERATING SYSTEM:  Macintosh 6.0.5
;       SOFTWARE:  WordPerfect
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/696,793A
;       FILING DATE:  19910507
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Kevin R. Kaster
;       REGISTRATION NUMBER:  32704
;       REFERENCE/DOCKET NUMBER:  2598
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 420-3444
;       TELEFAX:  (415) 658-5239
;  INFORMATION FOR SEQ ID NO:  7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  Other nucleic acid
US-07-696-793A-7

  Query Match             8.1%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 65;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1670 GCTGGAACCCTGGTGT 1685
              | ||||| | ||||||
Db         16 GGTGGAAGCTTGGTGT 1


RESULT 92
US-07-696-793A-9/c
; Sequence 9, Application US/07696793A
; Patent No. 5220004
;  GENERAL INFORMATION:
;     APPLICANT:  Saiki, Randall K.
;     APPLICANT:  Nasarabadi, Shanavaz L.
;     TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;     TITLE OF INVENTION:  Typing
;     NUMBER OF SEQUENCES:  58
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Cetus Corporation
;       STREET:  1400 Fifty-Third Street
;       CITY:  Emeryville
;       STATE:  California
;       COUNTRY:  U.S.A.
```

```
;       ZIP:  94608
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;       COMPUTER:  Apple Macintosh
;       OPERATING SYSTEM:  Macintosh 6.0.5
;       SOFTWARE:  WordPerfect
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/696,793A
;       FILING DATE:  19910507
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Kevin R. Kaster
;       REGISTRATION NUMBER:  32704
;       REFERENCE/DOCKET NUMBER:  2598
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 420-3444
;       TELEFAX:  (415) 658-5239
;   INFORMATION FOR SEQ ID NO:  9:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  Other nucleic acid
US-07-696-793A-9

  Query Match             8.1%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 65;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1669 AGCTGGAACCCTGGTG 1684
              || ||||| | |||||
Db         16 AGGTGGAAGCTTGGTG 1


RESULT 93
US-07-977-694-7/c
; Sequence 7, Application US/07977694
; Patent No. 5273883
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110-1199
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/977,694
;      FILING DATE:  19921117
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stacey R. Sias, Ph.D.
;      REGISTRATION NUMBER:  32,630
;      REFERENCE/DOCKET NUMBER:  8733
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2863
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-977-694-7

  Query Match             8.1%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 65;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1670 GCTGGAACCCTGGTGT 1685
              | ||||| | ||||||
Db         16 GGTGGAAGCTTGGTGT 1


RESULT 94
US-07-977-694-9/c
; Sequence 9, Application US/07977694
; Patent No. 5273883
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110-1199
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/977,694
;      FILING DATE:  19921117
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stacey R. Sias, Ph.D.
;      REGISTRATION NUMBER:  32,630
;      REFERENCE/DOCKET NUMBER:  8733
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2863
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-977-694-9

  Query Match             8.1%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 65;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1669 AGCTGGAACCCTGGTG 1684
              || ||||| | |||||
Db         16 AGGTGGAAGCTTGGTG 1
```

RESULT 95
US-08-872-917-11/c
; Sequence 11, Application US/08872917
; Patent No. 6096549
; GENERAL INFORMATION:
; APPLICANT: PELICIC, Vladimir
; APPLICANT: REYRAT, Jean-Marc
; APPLICANT: GICQUEL, Brigitte
; TITLE OF INVENTION: METHOD OF SELECTION OF ALLELIC EXCHANGE MUTANTS
; FILE REFERENCE: 03495.0148-01
; CURRENT APPLICATION NUMBER: US/08/872,917
; CURRENT FILING DATE: 1997-07-11
; EARLIER APPLICATION NUMBER: 08/661,658
; EARLIER FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Mycobacterium sp.
US-08-872-917-11

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 65;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1754 CCTAAAGGCCCACTGG 1769
||||| |||| | |||
Db 16 CCTAATGGCCTAATGG 1

RESULT 96
US-09-371-772B-5657/c
; Sequence 5657, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5657
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5657

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 65;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1666 CACAGCTGGAACCCTG 1681
|||||| ||| ||| |
Db 16 CACAGCAGGACCCCGG 1

RESULT 97
US-09-371-772B-5658/c
; Sequence 5658, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5658
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5658

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 65;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1663 GCTCACAGCTGGAACC 1678
|| |||||| ||| ||
Db 16 GCGCACAGCAGGACCC 1

RESULT 98
US-09-371-772B-5954/c
; Sequence 5954, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5954
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5954

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 65;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1661 AGGCTCACAGCTGGAA 1676
||| ||| |||||| |
Db 16 AGGGTCAGAGCTGGGA 1

RESULT 99
US-09-280-409-75/c
; Sequence 75, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsert
; APPLICANT: C. Frank Bennett

```
;  APPLICANT: Bert W. O'Malley
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
;  FILE REFERENCE: RTS-0048
;  CURRENT APPLICATION NUMBER: US/09/280,409
;  CURRENT FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 75
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-75

  Query Match             8.1%;  Score 11.2;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAGCTG 1673
              ||||||||  |||| |
Db         16 ACCAGGCTTCCAGCAG 1


RESULT 100
US-09-081-646-218
; Sequence 218, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 218
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-218

  Query Match             7.9%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1672 TGGAACCCTGG 1682
              ||||||||||
Db          3 TGGAACCCTGG 13


RESULT 101
US-09-081-646-855
; Sequence 855, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 855
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-855

  Query Match             7.9%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1672 TGGAACCCTGG 1682
              ||||||||||
Db          3 TGGAACCCTGG 13


RESULT 102
US-08-173-489C-179
; Sequence 179, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  179:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;      DESCRIPTION:  hepatitis B virus adw2 isolate,
;      DESCRIPTION:  nucleotides 727 to 740
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:
;      ORGANISM:  Hepatitis B virus
;      INDIVIDUAL ISOLATE:  adw2
;    PUBLICATION INFORMATION:
;      AUTHORS:  Valenzuela, P,  Quiroga, M,  Zaldivar, J,
;      AUTHORS:  Gray, P,  Ruter, W J.
;      TITLE:  The nucleotide sequence of
;      TITLE:  the Hepatitis B viral genome and the
;      TITLE:  identification of the major viral genes
;      JOURNAL:  In "Animal Virus Genetics", Fields, B N,
```

```
;       JOURNAL:  Jaenisch, R,  Fox C F eds
;       VOLUME:
;       PAGES:  57-70
;       DATE:  1980
;       RELEVANT RESIDUES IN SEQ ID NO:  179 :FROM 1 TO 14
US-08-173-489C-179

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 14;
  Best Local Similarity   85.7%;  Pred. No. 60;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATCCT 1756
              ||||| ||| ||||
Db          1 CTCCTTCCTTTCCT 14


RESULT 103
US-08-913-833-4
; Sequence 4, Application US/08913833
; Patent No. 6087093
;  GENERAL INFORMATION:
;    APPLICANT:  STUYVER, LIEVEN
;    APPLICANT:  LOUWAGIE, JOOST
;    APPLICANT:  ROSSAU, RUDI
;    TITLE OF INVENTION:  METHOD FOR DETECTION OF DRUG-INDUCED
;    TITLE OF INVENTION:  MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;    NUMBER OF SEQUENCES:  164
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ARNOLD, WHITE & DURKEE
;      STREET:  P.O. BOX 4433
;      CITY:  HOUSTON
;      STATE:  TEXAS
;      COUNTRY:  USA
;      ZIP:  77210-4433
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Microsoft Word 6.0 / ASCII text output
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/913,833
;      FILING DATE:  15 Sep 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/EP97/00211
;      FILING DATE:  17 Jan 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 96870005.4
;      FILING DATE:  26 Jan 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 96870081.5
;      FILING DATE:  25 Jun 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KAMMERER, PATRICIA A.
;      REGISTRATION NUMBER:  29,775
;      REFERENCE/DOCKET NUMBER:  INNS:008
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-913-833-4

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 14;
  Best Local Similarity   85.7%;  Pred. No. 60;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 TACGGAGATGGAGA 1731
              ||| |||||||| |
Db          1 TACAGAGATGGAAA 14


RESULT 104
US-09-580-794C-4
; Sequence 4, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
;  APPLICANT: Stuyver, Lieven
;  APPLICANT:  Louwagie, Joost
;  APPLICANT:  Rossau, Rudi
;  TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
;  TITLE OF INVENTION:  TRANSCRIPTASE GENE
;  FILE REFERENCE: INNS008--2
;  CURRENT APPLICATION NUMBER: US/09/580,794C
;  CURRENT FILING DATE:  2000-05-30
;  PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
;  PRIOR FILING DATE: 1997-09-15
;  PRIOR APPLICATION NUMBER: PCT/EP 97/00211
;  PRIOR FILING DATE: 1997-01-17
;  PRIOR APPLICATION NUMBER: EP 96870005.4
;  PRIOR FILING DATE: 1996-01-26
;  PRIOR APPLICATION NUMBER: EP 96870081.5
;  PRIOR FILING DATE: 1996-06-25
;  NUMBER OF SEQ ID NOS: 164
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Primer
US-09-580-794C-4

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 14;
  Best Local Similarity   85.7%;  Pred. No. 60;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 TACGGAGATGGAGA 1731
              ||| |||||||| |
Db          1 TACAGAGATGGAAA 14


RESULT 105
US-07-998-973A-18
; Sequence 18, Application US/07998973A
; Patent No. 5514579
;  GENERAL INFORMATION:
;    APPLICANT:  O'Hara, Patrick J
;    APPLICANT:  Grant, Francis J
;    APPLICANT:  Sheppard, Paul O
;    TITLE OF INVENTION:  NOVEL HUMAN TRANSGLUTAMINASES
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/998,973A
;      FILING DATE:  19921230
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/816,284
;      FILING DATE:  31-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parmelee, Steve W
```

```
;       REGISTRATION NUMBER:  31-990
;       REFERENCE/DOCKET NUMBER:  13952-13-1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  206-467-9600
;       TELEFAX:  206-623-6793
;   INFORMATION FOR SEQ ID NO:  18:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     IMMEDIATE SOURCE:
;       CLONE:  ZC4048
US-07-998-973A-18

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1663 GCTCACAGCTGGAA 1676
              || | |||||||||
Db          1 GCGCTCAGCTGGAA 14


RESULT 106
US-08-479-248-1/c
; Sequence 1, Application US/08479248
; Patent No. 5594121
;  GENERAL INFORMATION:
;    APPLICANT:  FROEHLER, BRIAN
;    APPLICANT:  MATTEUCCI, MARK
;    TITLE OF INVENTION:  ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX
;    TITLE OF INVENTION:  FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  GILEAD SCIENCES INC.
;      STREET:  353 Lakeside Drive
;      CITY:  Foster City
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/479,248
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MUENCHAU, DARYL
;      REGISTRATION NUMBER:  36,616
;      REFERENCE/DOCKET NUMBER:  160.1C
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 574-3000
;      TELEFAX:  (415) 573-4899
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-479-248-1

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATCCT 1756
              ||||||| | ||||
Db         14 CTCCTCCTTCTCCT 1


RESULT 107
US-08-479-248-2
; Sequence 2, Application US/08479248
; Patent No. 5594121
;  GENERAL INFORMATION:
;    APPLICANT:  FROEHLER, BRIAN
;    APPLICANT:  MATTEUCCI, MARK
;    TITLE OF INVENTION:  ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX
;    TITLE OF INVENTION:  FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  GILEAD SCIENCES INC.
;      STREET:  353 Lakeside Drive
;      CITY:  Foster City
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/479,248
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MUENCHAU, DARYL
;      REGISTRATION NUMBER:  36,616
;      REFERENCE/DOCKET NUMBER:  160.1C
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 574-3000
;      TELEFAX:  (415) 573-4899
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-479-248-2

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATCCT 1756
              ||||||| | ||||
Db         2 CTCCTCCTTCTCCT 15


RESULT 108
US-08-462-305-8
; Sequence 8, Application US/08462305
; Patent No. 5696248
;  GENERAL INFORMATION:
;    APPLICANT:  Peyman, Anuschirwan
;    APPLICANT:  Uhlmann, Eugen
;    APPLICANT:  Carolus, Carolin
;    TITLE OF INVENTION:  3'-Modified Oligonucleotide Derivatives
;    NUMBER OF SEQUENCES:  42
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoechst Marion Roussel, Inc.
;      STREET:  2110 E. Galbraith Road, P.O. Box 156300
;      CITY:  Cincinnati
;      STATE:  Ohio
;      COUNTRY:  USA
;      ZIP:  45215-6300
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/462,305
;      FILING DATE:  05-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Payne, T. Helen
;      REGISTRATION NUMBER:  36,889
;      REFERENCE/DOCKET NUMBER:  HOE94/F161K US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  513-948-7183
;      TELEFAX:  513-948-7960 or 4681
;      TELEX:  214320
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
US-08-462-305-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 109
US-08-363-240A-602/c
; Sequence 602, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  602:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-602

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGATTG 1734
              ||||||| || |||
Db         15 GGAGATGAAGTTTG 2


RESULT 110
US-08-363-240A-603/c
; Sequence 603, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  603:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-603

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGATTG 1734
              ||||||| || |||
Db         14 GGAGATGAAGTTTG 1
```

```
RESULT 111
US-08-311-486C-598/c
; Sequence 598, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  598:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-598

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGTACG 1721
             |||| ||||| |||
Db         15 GGGTGAGGAGCACG 2


RESULT 112
US-08-311-486C-599/c
; Sequence 599, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  599:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-599

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGTACG 1721
             |||| ||||| |||
Db         15 GGGTGAGGAGCACG 2


RESULT 113
US-08-613-417A-8
; Sequence 8, Application US/08613417A
; Patent No. 5874553
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Phosphonomonoester nucleic acids,
;    TITLE OF INVENTION:  process for their preparation, and their use
;    NUMBER OF SEQUENCES:  33
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0. Version #1.25 (EPO)
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/613,417A
;      FILING DATE:
;      CLASSIFICATION:  514
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  yes
;    FEATURE:
;      NAME/KEY:  exon
;      LOCATION:  1..15
US-08-613-417A-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              ||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 114
US-08-585-684B-2047
; Sequence 2047, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2047:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2047

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   57.1%;  Pred. No. 70;
  Matches    8;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1678 CCTGGTGTCTCCTC 1691
              ||:||: :| ||:|
Db          2 CCUGGUCUCACCUC 15


RESULT 115
US-08-452-800-18
; Sequence 18, Application US/08452800
; Patent No. 5952011
;  GENERAL INFORMATION:
;    APPLICANT:  O'Hara, Patrick J
;    APPLICANT:  Grant, Francis J
;    APPLICANT:  Sheppard, Paul O
;    TITLE OF INVENTION:  NOVEL HUMAN TRANSGLUTAMINASES
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/452,800
;      FILING DATE:  30-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/998,973
;      FILING DATE:  30-DEC-1992
;      APPLICATION NUMBER:  US 07/816,284
;      FILING DATE:  31-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parmelee, Steve W
;      REGISTRATION NUMBER:  31-990
;      REFERENCE/DOCKET NUMBER:  13952-13-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-467-9600
;      TELEFAX:  206-623-6793
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    IMMEDIATE SOURCE:
;      CLONE:  ZC4048
US-08-452-800-18

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1663 GCTCACAGCTGGAA 1676
              || | |||||||||
Db          1 GCGCTCAGCTGGAA 14


RESULT 116
US-08-594-452-8
; Sequence 8, Application US/08594452
; Patent No. 6013639
;  GENERAL INFORMATION:
;    APPLICANT:  PEYMAN, Anuschirwan
```

```
;    APPLICANT:  UHLMANN, Eugen
;    TITLE OF INVENTION:  G CAP-STABILIZED OLIGONUCLEOTIDES
;    NUMBER OF SEQUENCES:  105
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  3000 K Street, N.W., Suite 500
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20007-5109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/594,452
;      FILING DATE:  31-JAN-1996
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DE 195 02 912.7
;      FILING DATE:  31-JAN-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SANDERCOCK, Colin G.
;      REGISTRATION NUMBER:  31,298
;      REFERENCE/DOCKET NUMBER:  18748/264/HOCE
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)672-5300
;      TELEFAX:  (202)672-5399
;      TELEX:  904136
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-594-452-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 117
US-08-578-686C-7
; Sequence 7, Application US/08578686C
; Patent No. 6028182
;  GENERAL INFORMATION:
;    APPLICANT:  Uhlmann, Eugen
;    TITLE OF INVENTION:  Methylphosphonic Acid Ester, Process For
;    TITLE OF INVENTION:  Preparing The Same And Its Use
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner, L.L.P.
;      STREET:  1300 I. Street, N.W., Suite 700
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20005-3315
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/578,686C
;      FILING DATE:  January 2, 1996
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Johnson, Lori-Ann
;      REGISTRATION NUMBER:  34,498
;      REFERENCE/DOCKET NUMBER:  2481.1481-00000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-408-4000
;      TELEFAX:  202-408-4400
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-578-686C-7

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 118
US-09-094-405-8
; Sequence 8, Application US/09094405
; Patent No. 6066720
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Modified oligonucleotides, their preparation
;    TITLE OF INVENTION:  and use
;    NUMBER OF SEQUENCES:  30
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/094,405
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/940,196
;      FILING DATE:
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
;    ORIGINAL SOURCE:
;      ORGANISM:  human
;    FEATURE:
;      NAME/KEY:  exon
;      LOCATION:  1..15
;      OTHER INFORMATION:  /note= "c-Ha-ras"
US-09-094-405-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 119
```

```
US-09-258-408-8
; Sequence 8, Application US/09258408
; Patent No. 6121434
;  GENERAL INFORMATION:
;    APPLICANT:  PEYMAN, Anuschirwan
;    APPLICANT:  UHLMANN, Eugen
;    TITLE OF INVENTION:  G CAP-STABILIZED OLIGONUCLEOTIDES
;    NUMBER OF SEQUENCES:  105
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  3000 K Street, N.W., Suite 500
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20007-5109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/258,408
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/594,452
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SANDERCOCK, Colin G.
;      REGISTRATION NUMBER:  31,298
;      REFERENCE/DOCKET NUMBER:  18748/264/HOCE
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)672-5300
;      TELEFAX:  (202)672-5399
;      TELEX:  904136
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-258-408-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 120
US-09-196-132-8
; Sequence 8, Application US/09196132
; Patent No. 6127346
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Phosphonomonoester nucleic acids,
;    TITLE OF INVENTION:  process for their preparation, and their use
;    NUMBER OF SEQUENCES:  33
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/196,132
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/613,417
;      FILING DATE:
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  yes
;    FEATURE:
;      NAME/KEY:  exon
;      LOCATION:  1..15
US-09-196-132-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 121
US-09-144-112-7
; Sequence 7, Application US/09144112
; Patent No. 6150510
; GENERAL INFORMATION:
;  APPLICANT:  SEELA, Frank
;  APPLICANT:  THOMAS, Horst
;  TITLE OF INVENTION:  MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
;  TITLE OF INVENTION:  USE
;  FILE REFERENCE:  026083/0181
;  CURRENT APPLICATION NUMBER: US/09/144,112
;  CURRENT FILING DATE:  1998-08-31
;  PRIOR APPLICATION NUMBER:  DE P 44 38 918.3
;  PRIOR FILING DATE:  1994-11-04
;  NUMBER OF SEQ ID NOS:  53
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 7
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Antisense
;   OTHER INFORMATION: Oligonucleotide
US-09-144-112-7

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 122
US-09-038-073-2047
; Sequence 2047, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
```

```
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/038,073
;       FILING DATE:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/585,684
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/078
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2047:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-038-073-2047

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   57.1%;  Pred. No. 70;
  Matches    8;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1678 CCTGGTGTCTCCTC 1691
              ||:||: :| ||:|
Db          2 CCUGGUCUCACCUC 15


RESULT 123
US-08-410-390-3
; Sequence 3, Application US/08410390
; Patent No. 6214974
; GENERAL INFORMATION:
;  APPLICANT:  Rosenblum, Michael G.
;  APPLICANT:  Donato, Nicholas J.
;  TITLE OF INVENTION:  Avidin Biotin Immunoconjugates
;  FILE REFERENCE:  D5702C
;  CURRENT APPLICATION NUMBER: US/08/410,390
;  CURRENT FILING DATE:  1995-03-27
;  PRIOR APPLICATION NUMBER:  US 08/192,655
;  PRIOR FILING DATE:  1994-07-02
;  NUMBER OF SEQ ID NOS:  3
; SEQ ID NO 3
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense oligonucleotide sequence against
;   OTHER INFORMATION: 5' flanking sequence in c-HA-ras mRNA
US-08-410-390-3

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 124
US-08-895-981-8
; Sequence 8, Application US/08895981
; Patent No. 6326487
; GENERAL INFORMATION:
;   APPLICANT:  Peyman, Anuschirwan
;   APPLICANT:  Uhlmann, Eugen
;   APPLICANT:  Carolus, Carolin
;   TITLE OF INVENTION:  3'-Modified Oligonucleotide Derivatives
;   NUMBER OF SEQUENCES:  42
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Hoechst Marion Roussel, Inc.
;     STREET:  2110 E. Galbraith Road, P.O. Box 156300
;     CITY:  Cincinnati
;     STATE:  Ohio
;     COUNTRY:  USA
;     ZIP:  45215-6300
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/895,981
;     FILING DATE:
;     CLASSIFICATION:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/462,305
;     FILING DATE:  05-JUN-1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Payne, T. Helen
;     REGISTRATION NUMBER:  36,889
;     REFERENCE/DOCKET NUMBER:  HOE94/F161K US
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  513-948-7183
;     TELEFAX:  513-948-7960 or 4681
;     TELEX:  214320
;  INFORMATION FOR SEQ ID NO:  8:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  15 base pairs
;     TYPE:  nucleic acid
;     STRANDEDNESS:  single
;     TOPOLOGY:  linear
;   MOLECULE TYPE:  other nucleic acid
US-08-895-981-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 125
US-08-337-120A-8
; Sequence 8, Application US/08337120A
; Patent No. 6348312
;  GENERAL INFORMATION:
;    APPLICANT:  Peyman, Anuschirwan
;    APPLICANT:  Uhlmann, Eugen
;    APPLICANT:  Mag, Matthias
;    APPLICANT:  Kretzschmar, Gerhard
;    APPLICANT:  Helsberg, Matthias
;    APPLICANT:  Winkler, Irvin
;    TITLE OF INVENTION:  Stabilized Oligonucleotides And Their
;    TITLE OF INVENTION:  Use
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner, L.L.P.
;      STREET:  1300 I Street, N.W., Suite 700
;      CITY:  Washington
```

```
;       STATE:  D.C.
;       COUNTRY:  USA
;       ZIP:  20005-3315
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/337,120A
;       FILING DATE:  12-NOV-1994
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  DE P 43 38 704.7
;       FILING DATE:  12-NOV-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Einaudi, Carol P.
;       REGISTRATION NUMBER:  32,220
;       REFERENCE/DOCKET NUMBER:  02481.1409-00000
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (202)408-4000
;       TELEFAX:  (202)408-4400
;   INFORMATION FOR SEQ ID NO:  8:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-337-120A-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 126
US-09-643-233-7
; Sequence 7, Application US/09643233
; Patent No. 6479651
; GENERAL INFORMATION:
;  APPLICANT: SEELA, Frank
;  APPLICANT:  THOMAS, Horst
;  TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
;  TITLE OF INVENTION:  USE
;  FILE REFERENCE: 026083/0181
;  CURRENT APPLICATION NUMBER: US/09/643,233
;  CURRENT FILING DATE:  2000-08-22
;  PRIOR APPLICATION NUMBER: 09/144,112
;  PRIOR FILING DATE: 1998-08-31
;  NUMBER OF SEQ ID NOS: 53
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
;    LENGTH: 15
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Antisense
;    OTHER INFORMATION: Oligonucleotide
US-09-643-233-7

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 127
PCT-US92-11353-18
; Sequence 18, Application PC/TUS9211353
;  GENERAL INFORMATION:
;    APPLICANT:  O'Hara, Patrick J
;    APPLICANT:  Grant, Francis J
;    APPLICANT:  Sheppard, Paul O
;    TITLE OF INVENTION:  NOVEL HUMAN TRANSGLUTAMINASES
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/11353
;      FILING DATE:  19921230
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/816,284
;      FILING DATE:  31-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parmelee, Steve W
;      REGISTRATION NUMBER:  31-990
;      REFERENCE/DOCKET NUMBER:  13952-13-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-467-9600
;      TELEFAX:  206-623-6793
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    IMMEDIATE SOURCE:
;      CLONE:  ZC4048
PCT-US92-11353-18

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 70;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1663 GCTCACAGCTGGAA 1676
              || | |||||||||
Db          1 GCGCTCAGCTGGAA 14


RESULT 128
US-09-280-409-109/c
; Sequence 109, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Bert W. O'Malley
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
;  FILE REFERENCE: RTS-0048
;  CURRENT APPLICATION NUMBER: US/09/280,409
;  CURRENT FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 109
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-109

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 18;
  Best Local Similarity   85.7%;  Pred. No. 1e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAGC 1671
              ||||||||  ||||
Db         15 ACCAGGCTTCCAGC 2


RESULT 129
US-08-985-162-1849/c
; Sequence 1849, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1849:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-1849

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   91.7%;  Pred. No. 74;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1639 CTTGTAGCAGAA 1650
              |||| |||||||
Db         13 CTTGAAGCAGAA 2


RESULT 130
US-08-535-249-90/c
; Sequence 90, Application US/08535249
; Patent No. 6455689
;  GENERAL INFORMATION:
;    APPLICANT:  Schlingensiepen, Georg-Ferdinand
;    APPLICANT:  Brysch, Wolfgang
;    APPLICANT:  Schlingensiepen, Karl-Hermann
;    APPLICANT:  Schlingensiepen, Reimar
;    APPLICANT:  Bogdahn, Ulrich
;    TITLE OF INVENTION:  Antisense-oligonucleotides for the treatment of
;    TITLE OF INVENTION:  immuno-suppressive effect of transforming-growth-factor beta (T
;    NUMBER OF SEQUENCES:  137
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman & Stern
;      STREET:  400 Seventh St. N.W.
;      CITY:  Washington D.C
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/535,249
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93 107 089.0
;      FILING DATE:  30-APR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93 107 849.7
;      FILING DATE:  13-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Player, William E.
;      REGISTRATION NUMBER:  31,409
;      REFERENCE/DOCKET NUMBER:  10577/P58418
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-6666
;      TELEFAX:  (202) 393-5350
;      TELEX:  RCA 248593 IDEA UR
;  INFORMATION FOR SEQ ID NO:  90:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  YES
US-08-535-249-90

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   91.7%;  Pred. No. 74;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1644 AGCAGAAGGCAA 1655
              |||||||||| |
Db         14 AGCAGAAGGCGA 3


RESULT 131
US-08-363-240A-242/c
; Sequence 242, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
```

```
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  242:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-242

  Query Match             7.3%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 94;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGG 1682
              ||||||  | |||||
Db         15 CAGCTGTGAGCCTGG 1


RESULT 132
US-08-171-718-43/c
; Sequence 43, Application US/08171718
; Patent No. 5707863
;  GENERAL INFORMATION:
;    APPLICANT:  Trofatter, James A.
;    APPLICANT:  MacCollin, Mia M.
;    APPLICANT:  Gusella, James F.
;    TITLE OF INVENTION:  Tumor Suppressor Gene Merlin and Uses
;    TITLE OF INVENTION:  Thereof
;    NUMBER OF SEQUENCES:  120
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sterne, Kessler, Goldstein & Fox
;      STREET:  1100 New York Avenue, N.W., Suite 600
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20005-3934
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/171,718
;      FILING DATE:  22-DEC-1993
;      CLASSIFICATION:  436
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/108,808
;      FILING DATE:  19-AUG-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/022,034
;      FILING DATE:  25-FEB-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/026,063
;      FILING DATE:  04-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Brown, Anne
;      REGISTRATION NUMBER:  36,463
;      REFERENCE/DOCKET NUMBER:  0609.3850003
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 371-2600
;      TELEFAX:  (202) 371-2540
;  INFORMATION FOR SEQ ID NO:  43:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-171-718-43

  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCAC 1668
              ||||||||||
Db         10 CCAGGCTCAC 1


RESULT 133
US-08-388-353-425/c
; Sequence 425, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  425:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-425

  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 GCTTGTAGCA 1647
             ||||||||||
Db         10 GCTTGTAGCA 1


RESULT 134
US-08-388-353-501/c
; Sequence 501, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  501:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-501

  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1661 AGGCTCACAG 1670
             ||||||||||
Db         10 AGGCTCACAG 1


RESULT 135
US-08-388-353-502/c
; Sequence 502, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  502:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-502

  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1660 CAGGCTCACA 1669
             ||||||||||
Db         10 CAGGCTCACA 1


RESULT 136
US-08-488-551B-425/c
; Sequence 425, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  425:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-425

  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 GCTTGTAGCA 1647
              ||||||||||
Db         10 GCTTGTAGCA 1


RESULT 137
US-08-488-551B-501/c
; Sequence 501, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  501:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-501

  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1661 AGGCTCACAG 1670
              ||||||||||
Db         10 AGGCTCACAG 1


RESULT 138
US-08-488-551B-502/c
; Sequence 502, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  502:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-502
```

```
  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1660 CAGGCTCACA 1669
              ||||||||||
Db         10 CAGGCTCACA 1


RESULT 139
US-08-488-551B-819/c
; Sequence 819, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  819:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-819


  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1661 AGGCTCACAG 1670
              ||||||||||
Db         10 AGGCTCACAG 1


RESULT 140
US-08-488-551B-820/c
; Sequence 820, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  820:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-820


  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1660 CAGGCTCACA 1669
              ||||||||||
Db         10 CAGGCTCACA 1


RESULT 141
US-08-478-087-43/c
; Sequence 43, Application US/08478087
; Patent No. 6077685
;  GENERAL INFORMATION:
;    APPLICANT:  Trofatter, James A.
;    APPLICANT:  MacCollin, Mia M.
;    APPLICANT:  Gusella, James F.
;    TITLE OF INVENTION:  Tumor Suppressor Gene Merlin and Uses
;    TITLE OF INVENTION:  Thereof
;    NUMBER OF SEQUENCES:  120
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sterne, Kessler, Goldstein & Fox
;      STREET:  1100 New York Avenue, N.W., Suite 600
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
```

```
;       ZIP:  20005-3934
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/478,087
;       FILING DATE:  07-JUN-1995
;       CLASSIFICATION:  530
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/171,718
;       FILING DATE:  22-DEC-1993
;       APPLICATION NUMBER:  US 08/108,808
;       FILING DATE:  19-AUG-1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/022,034
;       FILING DATE:  25-FEB-1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/026,063
;       FILING DATE:  04-MAR-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Brown, Anne
;       REGISTRATION NUMBER:  36,463
;       REFERENCE/DOCKET NUMBER:  0609.3850003
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (202) 371-2600
;       TELEFAX:  (202) 371-2540
;   INFORMATION FOR SEQ ID NO:  43:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  10 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-478-087-43

  Query Match             7.2%;  Score 10;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCAC 1668
             ||||||||||
Db         10 CCAGGCTCAC 1


RESULT 142
US-08-173-489C-255
; Sequence 255, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  255:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;      DESCRIPTION:  23s rRNA gene from Micrococcus luteus
;      DESCRIPTION:  (Accession # X06484) nucleotides 2795 to 2806
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:
;      ORGANISM:  Micrococcus luteus
;      STRAIN:  dsm 20030
;    PUBLICATION INFORMATION:
;      AUTHORS:  Regensburger, A,  Ludwig, W,  Frank, R,
;      AUTHORS:  Bloecker, H,  Schleifer, K H.
;      TITLE:  Complete nucleotide sequence
;      TITLE:  of a 23S ribosomal RNA gene from Micrococcus
;      TITLE:  luteus
;      JOURNAL:  Nucleic Acids Research
;      VOLUME:  16
;      PAGES:  2344-2344
;      DATE:  1988
;      RELEVANT RESIDUES IN SEQ ID NO:  255 :FROM 1 TO 12
US-08-173-489C-255

  Query Match             7.2%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 65;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCT 1756
             ||||||||||
Db          1 TCCCTATCCT 10


RESULT 143
US-08-889-502-3
; Sequence 3, Application US/08889502
; Patent No. 6066726
;  GENERAL INFORMATION:
;    APPLICANT:  Farb, David H
;    APPLICANT:  Russek, Shelley J
;    TITLE OF INVENTION:  GENE THERAPY VECTOR WITH TISSUE
;    TITLE OF INVENTION:  SPECIFICITY
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kevin M. Farrell
;      STREET:  P.O. Box 999
;      CITY:  York Harbor
;      STATE:  ME
;      COUNTRY:  USA
;      ZIP:  03911
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/889,502
;      FILING DATE:  08-JUL-1997
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Farrell, Kevin M
;      REGISTRATION NUMBER:  35,505
```

```
;      REFERENCE/DOCKET NUMBER:  0146-2008
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (207) 363-0558
;      TELEFAX:  (207) 363-0528
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-889-502-3

  Query Match             7.2%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 65;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAG 1730
             ||||||||||
Db          2 GGAGATGGAG 11


RESULT 144
US-08-889-502-16
; Sequence 16, Application US/08889502
; Patent No. 6066726
;  GENERAL INFORMATION:
;    APPLICANT:  Farb, David H
;    APPLICANT:  Russek, Shelley J
;    TITLE OF INVENTION:  GENE THERAPY VECTOR WITH TISSUE
;    TITLE OF INVENTION:  SPECIFICITY
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kevin M. Farrell
;      STREET:  P.O. Box 999
;      CITY:  York Harbor
;      STATE:  ME
;      COUNTRY:  USA
;      ZIP:  03911
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/889,502
;      FILING DATE:  08-JUL-1997
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Farrell, Kevin M
;      REGISTRATION NUMBER:  35,505
;      REFERENCE/DOCKET NUMBER:  0146-2008
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (207) 363-0558
;      TELEFAX:  (207) 363-0528
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-889-502-16

  Query Match             7.2%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 65;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAG 1730
             ||||||||||
Db          2 GGAGATGGAG 11


RESULT 145
US-08-192-943-11/c
; Sequence 11, Application US/08192943
; Patent No. 6544755
;  GENERAL INFORMATION:
;    APPLICANT:  James D. Thompson
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  TREATMENT OF DISEASES CAUSED
;    TITLE OF INVENTION:  BY EXPRESSION OF THE c-MYC
;    TITLE OF INVENTION:  GENE
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/192,943
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/936,422
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/241
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-192-943-11

  Query Match             7.2%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 65;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1683 TGTCTCCTCC 1692
             ||||||||||
Db         11 TGTCTCCTCC 2


RESULT 146
US-08-434-503-10/c
; Sequence 10, Application US/08434503
; Patent No. 5616490
;  GENERAL INFORMATION:
;    APPLICANT:  Sean M. Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  TREATMENT OF INFLAMMATORY
;    TITLE OF INVENTION:  DISEASE
;    NUMBER OF SEQUENCES:  54
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
```

```
;       ZIP:  90017
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM MS-DOS (Version 5.0)
;       SOFTWARE:  WordPerfect (Version 5.1)
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/434,503
;       FILING DATE:  04-MAY-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/008,895
;       FILING DATE:  19-JAN-1993
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  200/276
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  10:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  14
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-434-503-10

  Query Match             7.2%;  Score 10;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 90;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1693 AGCGTGGTGG 1702
              ||||||||||
Db         10 AGCGTGGTGG 1


RESULT 147
US-08-227-370-2
; Sequence 2, Application US/08227370
; Patent No. 5559207
;  GENERAL INFORMATION:
;     APPLICANT:  Sessler, Jonathan L.
;     APPLICANT:  Smith, Daniel A.
;     APPLICANT:  Miller, Richard
;     APPLICANT:  Ross, Kevin
;     APPLICANT:  Wright, Meredith
;     APPLICANT:  Hemmi, Gregory W.
;     APPLICANT:  Dow, William C.
;     APPLICANT:  Kral, Vladimir
;     APPLICANT:  Iverson, Brent
;     APPLICANT:  Magda, Darren
;     TITLE OF INVENTION:  Texaphyrin Metal Complex Mediated Ester
;     TITLE OF INVENTION:  Hydrolysis
;     NUMBER OF SEQUENCES:  4
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Arnold, White & Durkee
;       STREET:  P.O. Box 4433
;       CITY:  Houston
;       STATE:  Texas
;       COUNTRY:  USA
;       ZIP:  77210
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/227,370
;       FILING DATE:  14-APR-1994
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Parker, David L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTSB:562
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  512/320-7200
;       TELEFAX:  512/474-7577
;   INFORMATION FOR SEQ ID NO:  2:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-227-370-2

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 1.6e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || ||| | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 148
US-08-486-962-4
; Sequence 4, Application US/08486962
; Patent No. 5763172
;  GENERAL INFORMATION:
;     APPLICANT:  Magda, Darren
;     APPLICANT:  Sessler, Jonathan L.
;     APPLICANT:  Wright, Meredith
;     APPLICANT:  Ross, Kevin L.
;     APPLICANT:  Miller, Richard A.
;     APPLICANT:  Dow, William C.
;     APPLICANT:  Kral, Vladimir A.
;     APPLICANT:  Smith, Daniel A.
;     TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;     NUMBER OF SEQUENCES:  18
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Pharmacyclics, Inc.
;       STREET:  995 E. Arques Avenue
;       CITY:  Sunnyvale
;       STATE:  California
;       COUNTRY:  USA
;       ZIP:  94086-4521
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/486,962
;       FILING DATE:  07-JUN-1995
;       CLASSIFICATION:  530
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Larson, Jacqueline S.
;       REGISTRATION NUMBER:  30,279
;       REFERENCE/DOCKET NUMBER:  PHAY:053
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (408) 774-0330
;       TELEFAX:  (408) 774-0340
;   INFORMATION FOR SEQ ID NO:  4:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc = "DNA"
US-08-486-962-4
```

```
  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 1.6e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 149
US-08-458-347-1
; Sequence 1, Application US/08458347
; Patent No. 5798491
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    TITLE OF INVENTION:  Multi-Mechanistic Chemical Cleavage Using Certain
;    TITLE OF INVENTION:  Metal Complexes
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Ave.
;      CITY:  Sunnyvale
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94086-4593
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/458,347
;      FILING DATE:  Concurrently herewith
;      CLASSIFICATION:  204
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:048
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  408/774-0330
;      TELEFAX:  408/774-0340
;      TELEX:  N/A
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-458-347-1

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 1.6e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 150
US-08-975-522A-5
; Sequence 5, Application US/08975522A
; Patent No. 6022959
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Crofts, Shaun P.
;    APPLICANT:  Wright, Meredith
;    TITLE OF INVENTION:  NUCLEIC ACIDS INTERNALLY-
;    TITLE OF INVENTION:  DERIVATIZED WITH A TEXAPHYRIN
;    TITLE OF INVENTION:  METAL COMPLEX AND USES THEREOF
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94085
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Patentin Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/975,522A
;      FILING DATE:  No. 6022959ember 20, 1997
;      CLASSIFICATION:  536
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 499-6200
;      TELEFAX:  (512)   499-6290
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-975-522A-5

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 1.6e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 151
PCT-US94-06284-2
; Sequence 2, Application PC/TUS9406284
;  GENERAL INFORMATION:
;    APPLICANT:
;    APPLICANT:  NAME:     BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
;    APPLICANT:  SYSTEM
;    APPLICANT:  STREET:   201 West 7th Street
;    APPLICANT:  CITY:     Austin
;    APPLICANT:  STATE:    Texas
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  78701
;    APPLICANT:  TELEPHONE NO: (512)499-4462
;    APPLICANT:  TELEFAX:  (512)499-4523
;    APPLICANT:  STREET:   995 East Arques Ave.
;    APPLICANT:  CITY:     Sunnyvale
;    APPLICANT:  STATE:    California
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  94086-4593
;    APPLICANT:  TELEPHONE NO: (408)774-0330
;    APPLICANT:  TELEFAX:  (408)774-0340
;    TITLE OF INVENTION:  TEXAPHYRIN METAL COMPLEX
;    TITLE OF INVENTION:  MEDIATED ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
```

```
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US94/06284
;       FILING DATE:  CONCURRENTLY HEREWITH
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  USSN 08/075,123
;       FILING DATE:  09 JUNE 1993 (09.06.93)
;       CLASSIFICATION:
;       APPLICATION NUMBER:  USSN 08/227,370
;       FILING DATE:  14 APRIL 1994 (14.04.94)
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  PARKER, DAVID L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTFB570P--
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  512/320-7200
;       TELEFAX:  713/789-2679
;       TELEX:  79-0924
;   INFORMATION FOR SEQ ID NO:  2:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
PCT-US94-06284-2

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 1.6e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 152
US-08-544-381B-19/c
; Sequence 19, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;     APPLICANT:  Cronin, Maureen T.
;     APPLICANT:  Miyada, Charles Garrett
;     APPLICANT:  Hubbell, Earl A.
;     APPLICANT:  Chee, Mark
;     APPLICANT:  Fodor, Stephen P.A.
;     APPLICANT:  Huang, Xiaohua C.
;     APPLICANT:  Lipshutz, Robert J.
;     APPLICANT:  Lobban, Peter E.
;     APPLICANT:  Morris, Macdonald S.
;     APPLICANT:  Sheldon, Edward L.
;     TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;     TITLE OF INVENTION:  Detecting Cystic Fibrosis
;     NUMBER OF SEQUENCES:  250
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Townsend and Townsend and Crew LLP
;       STREET:  Two Embarcadero Center, 8th Floor
;       CITY:  San Francisco
;       STATE:  California
;       COUNTRY:  USA
;       ZIP:  94111
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/544,381B
;       FILING DATE:  10-OCT-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/510,521
;       FILING DATE:  02-AUG-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US94/12305
;       FILING DATE:  26-OCT-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/284,064
;       FILING DATE:  02-AUG-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/143,312
;       FILING DATE:  26-OCT-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Liebeschuetz, Joe
;       REGISTRATION NUMBER:  37,505
;       REFERENCE/DOCKET NUMBER:  018547-004130US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-576-0200
;       TELEFAX:  415-576-0300
;   INFORMATION FOR SEQ ID NO:  19:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-19

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||| |||||||
Db         13 AGGGCGAGCACCA 1


RESULT 153
US-08-544-381B-23/c
; Sequence 23, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;     APPLICANT:  Cronin, Maureen T.
;     APPLICANT:  Miyada, Charles Garrett
;     APPLICANT:  Hubbell, Earl A.
;     APPLICANT:  Chee, Mark
;     APPLICANT:  Fodor, Stephen P.A.
;     APPLICANT:  Huang, Xiaohua C.
;     APPLICANT:  Lipshutz, Robert J.
;     APPLICANT:  Lobban, Peter E.
;     APPLICANT:  Morris, Macdonald S.
;     APPLICANT:  Sheldon, Edward L.
;     TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;     TITLE OF INVENTION:  Detecting Cystic Fibrosis
;     NUMBER OF SEQUENCES:  250
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Townsend and Townsend and Crew LLP
;       STREET:  Two Embarcadero Center, 8th Floor
;       CITY:  San Francisco
;       STATE:  California
;       COUNTRY:  USA
;       ZIP:  94111
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/544,381B
;       FILING DATE:  10-OCT-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/510,521
;       FILING DATE:  02-AUG-1995
;     PRIOR APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-23

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | |||| ||||||
Db         13 AGGGCACGCACCA 1


RESULT 154
US-08-544-381B-24/c
; Sequence 24, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-24

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | |||| ||||||
Db         13 AGGGCGAGCACCA 1


RESULT 155
US-08-544-381B-26/c
; Sequence 26, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
```

```
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  26:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-26

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||| |||||
Db         13 AGGGCAATCACCA 1


RESULT 156
US-08-544-381B-28/c
; Sequence 28, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-28

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||| |||||
Db         13 AGGGCAACCACCA 1


RESULT 157
US-08-544-381B-29/c
; Sequence 29, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
```

```
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Liebeschuetz, Joe
;       REGISTRATION NUMBER:  37,505
;       REFERENCE/DOCKET NUMBER:  018547-004130US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-576-0200
;       TELEFAX:  415-576-0300
;   INFORMATION FOR SEQ ID NO:  29:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-29

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||| |||||
Db         13 AGGGCAAACACCA 1


RESULT 158
US-08-778-794A-77/c
; Sequence 77, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0200
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  77:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-778-794A-77

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||| |||||||
Db         13 AGGGCGAGCACCA 1


RESULT 159
US-08-778-794A-81/c
; Sequence 81, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
```

```
;       TELEPHONE:  (415) 576-0200
;       TELEFAX:  (415) 576-0200
;       TELEX:
;  INFORMATION FOR SEQ ID NO:  81:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-778-794A-81

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||  ||||||
Db         13 AGGGCACGCACCA 1

RESULT 160
US-08-778-794A-84/c
; Sequence 84, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0200
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  84:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-778-794A-84

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||  ||||||
Db         13 AGGGCAATCACCA 1

RESULT 161
US-08-778-794A-86/c
; Sequence 86, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0200
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  86:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-778-794A-86

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
                | ||||| |||||
Db         13 AGGGCAACCACCA 1


RESULT 162
US-08-778-794A-87/c
; Sequence 87, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0200
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  87:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-778-794A-87

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
                | ||||| |||||
Db         13 AGGGCAAACACCA 1


RESULT 163
US-09-922-445-16/c
; Sequence 16, Application US/09922445
; Patent No. 6528268
; GENERAL INFORMATION:
;  APPLICANT: Andersson, Maria K.
;  APPLICANT:  Berglund, Lars G. T.
;  APPLICANT:  Reneland, Rikard  H.
;  APPLICANT:  Adam, Gail I. R.
;  TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
;  FILE REFERENCE: GG126US
;  CURRENT APPLICATION NUMBER: US/09/922,445
;  CURRENT FILING DATE:  2001-08-03
;  NUMBER OF SEQ ID NOS: 51
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: synthetic
US-09-922-445-16

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1662 GGCTCACAGCTGG 1674
                |||||| | ||||
Db         13 GGCTCAGATCTGG 1


RESULT 164
US-09-922-445-26
; Sequence 26, Application US/09922445
; Patent No. 6528268
; GENERAL INFORMATION:
;  APPLICANT: Andersson, Maria K.
;  APPLICANT:  Berglund, Lars G. T.
;  APPLICANT:  Reneland, Rikard  H.
;  APPLICANT:  Adam, Gail I. R.
;  TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
;  FILE REFERENCE: GG126US
;  CURRENT APPLICATION NUMBER: US/09/922,445
;  CURRENT FILING DATE:  2001-08-03
;  NUMBER OF SEQ ID NOS: 51
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: synthetic
US-09-922-445-26

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 85;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1662 GGCTCACAGCTGG 1674
                |||||| | ||||
Db          1 GGCTCAGATCTGG 13
```

```
RESULT 165
US-08-913-833-8
; Sequence 8, Application US/08913833
; Patent No. 6087093
;  GENERAL INFORMATION:
;     APPLICANT:  STUYVER, LIEVEN
;     APPLICANT:  LOUWAGIE, JOOST
;     APPLICANT:  ROSSAU, RUDI
;     TITLE OF INVENTION:  METHOD FOR DETECTION OF DRUG-INDUCED
;     TITLE OF INVENTION:  MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;     NUMBER OF SEQUENCES:  164
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  ARNOLD, WHITE & DURKEE
;       STREET:  P.O. BOX 4433
;       CITY:  HOUSTON
;       STATE:  TEXAS
;       COUNTRY:  USA
;       ZIP:  77210-4433
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  Microsoft Word 6.0 / ASCII text output
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/913,833
;       FILING DATE:  15 Sep 1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/EP97/00211
;       FILING DATE:  17 Jan 1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  EP 96870005.4
;       FILING DATE:  26 Jan 1996
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  EP 96870081.5
;       FILING DATE:  25 Jun 1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  KAMMERER, PATRICIA A.
;       REGISTRATION NUMBER:  29,775
;       REFERENCE/DOCKET NUMBER:  INNS:008
;   INFORMATION FOR SEQ ID NO:  8:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  14 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
US-08-913-833-8

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 14;
  Best Local Similarity   84.6%;  Pred. No. 99;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1719 ACGGAGATGGAGA 1731
              || |||||||| |
Db          1 ACAGAGATGGAAA 13


RESULT 166
US-09-580-794C-8
; Sequence 8, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
;  APPLICANT: Stuyver, Lieven
;  APPLICANT:  Louwagie, Joost
;  APPLICANT:  Rossau, Rudi
;  TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
;  TITLE OF INVENTION:  TRANSCRIPTASE GENE
;  FILE REFERENCE: INNS008--2
;  CURRENT APPLICATION NUMBER: US/09/580,794C
;  CURRENT FILING DATE:  2000-05-30
;  PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
;  PRIOR FILING DATE: 1997-09-15
;  PRIOR APPLICATION NUMBER: PCT/EP 97/00211
;  PRIOR FILING DATE: 1997-01-17
;  PRIOR APPLICATION NUMBER: EP 96870005.4
;  PRIOR FILING DATE: 1996-01-26
;  PRIOR APPLICATION NUMBER: EP 96870081.5
;  PRIOR FILING DATE: 1996-06-25
;  NUMBER OF SEQ ID NOS: 164
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Primer
US-09-580-794C-8

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 14;
  Best Local Similarity   84.6%;  Pred. No. 99;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1719 ACGGAGATGGAGA 1731
              || |||||||| |
Db          1 ACAGAGATGGAAA 13


RESULT 167
US-09-328-174A-40/c
; Sequence 40, Application US/09328174A
; Patent No. 6448003
; GENERAL INFORMATION:
;  APPLICANT:  Guida, Marco
;  APPLICANT:  Kurth, Janice
;  TITLE OF INVENTION:  Genotyping Human Phenol Sulfotransferase
;  TITLE OF INVENTION:  (STP2)
;  FILE REFERENCE:  4389-6 (formerly SEQ-16P)
;  CURRENT APPLICATION NUMBER: US/09/328,174A
;  CURRENT FILING DATE:  1999-06-08
;  PRIOR APPLICATION NUMBER:  09/328,174
;  PRIOR FILING DATE:  1999-06-08
;  NUMBER OF SEQ ID NOS:  110
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 40
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: H. sapiens
US-09-328-174A-40

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 14;
  Best Local Similarity   84.6%;  Pred. No. 99;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1641 TGTAGCAGAAGGC 1653
              ||| |||| ||||
Db         14 TGTGGCAGCAGGC 2


RESULT 168
US-09-230-652-23
; Sequence 23, Application US/09230652A
; Patent No. 6537775
; GENERAL INFORMATION:
;  APPLICANT: Tournier-Lasserve, Elisabeth
;  APPLICANT: Joutel, Anne
;  APPLICANT: Bousser, Marie-Germaine
;  APPLICANT: Bach, Jean-Francois
;  TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
;  TITLE OF INVENTION: THERAPEUTIC APPLICATION
;  FILE REFERENCE: 03715.0048-00000
;  CURRENT APPLICATION NUMBER: US/09/230,652A
;  CURRENT FILING DATE: 1999-05-17
```

```
;  EARLIER APPLICATION NUMBER: FR 96 09733
;  EARLIER FILING DATE: 1996-08-01
;  EARLIER APPLICATION NUMBER: FR 97 04680
;  EARLIER FILING DATE: 1997-04-16
;  EARLIER APPLICATION NUMBER: PCT/FR97/01433
;  EARLIER FILING DATE: 1997-07-31
;  NUMBER OF SEQ ID NOS: 163
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-230-652-23

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 14;
  Best Local Similarity   84.6%;  Pred. No. 99;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1666 CACAGCTGGAACC 1678
              ||||| ||| |||
Db          2 CACAGGTGGGACC 14


RESULT 169
US-08-544-381B-13/c
; Sequence 13, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-13

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 13;
  Best Local Similarity   69.2%;  Pred. No. 94;
  Matches    9;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | |||:: |||||
Db         13 AGGGCRMNCACCA 1


RESULT 170
US-08-778-794A-71/c
; Sequence 71, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
```

```
;       TELEPHONE:  (415) 576-0200
;       TELEFAX:  (415) 576-0200
;       TELEX:
;  INFORMATION FOR SEQ ID NO:  71:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-778-794A-71

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 13;
  Best Local Similarity   69.2%;  Pred. No. 94;
  Matches    9;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | |||:: |||||
Db         13 AGGGCRMNCACCA 1


RESULT 171
US-08-778-794A-95/c
; Sequence 95, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, MacDonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;    TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;    NUMBER OF SEQUENCES:  156
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/778,794A
;      FILING DATE:  03-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  WO PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;      APPLICATION NUMBER:  US 08/544,381
;      FILING DATE:  10-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-015700US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0200
;       TELEX:
;  INFORMATION FOR SEQ ID NO:  95:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-778-794A-95

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 13;
  Best Local Similarity   69.2%;  Pred. No. 94;
  Matches    9;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | |||:: |||||
Db         13 AGGGCRMNCACCA 1


RESULT 172
US-07-696-793A-9
; Sequence 9, Application US/07696793A
; Patent No. 5220004
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cetus Corporation
;      STREET:  1400 Fifty-Third Street
;      CITY:  Emeryville
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  94608
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/696,793A
;      FILING DATE:  19910507
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kevin R. Kaster
;      REGISTRATION NUMBER:  32704
;      REFERENCE/DOCKET NUMBER:  2598
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 420-3444
;      TELEFAX:  (415) 658-5239
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-696-793A-9

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 16;
  Best Local Similarity   75.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1657 CACCAGGCTCACAGCT 1672
              ||||| ||:  || ||
Db          1 CACCAAGCTTCCACCT 16
```

```
RESULT 173
US-07-977-694-9
; Sequence 9, Application US/07977694
; Patent No. 5273883
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110-1199
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/977,694
;      FILING DATE:  19921117
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stacey R. Sias, Ph.D.
;      REGISTRATION NUMBER:  32,630
;      REFERENCE/DOCKET NUMBER:  8733
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2863
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-977-694-9

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 16;
  Best Local Similarity   75.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1657 CACCAGGCTCACAGCT 1672
              ||||| ||| || ||
Db          1 CACCAAGCTTCCACCT 16


RESULT 174
US-09-371-772B-5954
; Sequence 5954, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5954
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5954

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 16;
  Best Local Similarity   56.2%;  Pred. No. 1.4e+02;
  Matches    9;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1665 TCACAGCTGGAACCCT 1680
              :| |||:   ||||:
Db          1 UCCCAGCUCUGACCCU 16


RESULT 175
US-08-754-477A-109/c
; Sequence 109, Application US/08754477A
; Patent No. 6518411
;  GENERAL INFORMATION:
;    APPLICANT:  Murray, Jeffrey
;    APPLICANT:  Semina, Elena
;    TITLE OF INVENTION:  RIEG COMPOSITIONS AND THERAPEUTIC
;    TITLE OF INVENTION:  AND DIAGNOSTIC USES THEREFOR
;    NUMBER OF SEQUENCES:  139
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  FOLEY, HOAG & ELIOT LLP
;      STREET:  One Post Office Square
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02109-2170
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/754,477A
;      FILING DATE:  22-NOV-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Arnold, Beth E.
;      REGISTRATION NUMBER:  35,430
;      REFERENCE/DOCKET NUMBER:  UIA-022.01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-832-1000
;      TELEFAX:  617-832-7000
;  INFORMATION FOR SEQ ID NO:  109:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-754-477A-109

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 1.9e+02;
  Matches   12;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACGGAGA 1725
              || |||| |  |||||
Db         19 GTGAGGAATTGGGAGA 4


RESULT 176
US-08-757-024-530
; Sequence 530, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
```

```
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  530:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  11 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-530

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 73;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 CGGAGATGGAG 1730
             | |||||||||
Db          1 CTGAGATGGAG 11


RESULT 177
US-09-617-548-12/c
; Sequence 12, Application US/09617548
; Patent No. 6476214
; GENERAL INFORMATION:
;  APPLICANT:  EAGLES, Peter Anthony Minter
;  APPLICANT:  ZHENG, Richard  Qihao
;  TITLE OF INVENTION:  INHIBITION OF CYTOKINE PRODUCTION
;  FILE REFERENCE:  N & V 604-557  BTG 137 766
;  CURRENT APPLICATION NUMBER: US/09/617,548
;  CURRENT FILING DATE:  2000-07-14
;  PRIOR APPLICATION NUMBER:  GB 9801391.5
;  PRIOR FILING DATE:  1998-01-22
;  PRIOR APPLICATION NUMBER:  GB 9824794.3
;  PRIOR FILING DATE:  1998-11-11
;  PRIOR APPLICATION NUMBER:  PCT/GB99/00179
;  PRIOR FILING DATE:  1999-01-20
;  NUMBER OF SEQ ID NOS:  15
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 12
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Human tumour necrosis factor alpha promoter
US-09-617-548-12

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 73;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1732 TTGGCTCCCAA 1742
             |||||| ||||
Db          11 TTGGCTTCCAA 1


RESULT 178
US-09-249-155A-43
; Sequence 43, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
;  APPLICANT:  Heber-Katz, Ellen
;  TITLE OF INVENTION:  Compositions and Methods for Wound
;  TITLE OF INVENTION:  Healing
;  FILE REFERENCE:  00486.78503
;  CURRENT APPLICATION NUMBER: US/09/249,155A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER:  US 60/074,737
;  PRIOR FILING DATE:  1998-02-13
;  PRIOR APPLICATION NUMBER:  US 60/097,937
;  PRIOR FILING DATE:  1998-08-26
;  PRIOR APPLICATION NUMBER:  US 60/102,051
;  PRIOR FILING DATE:  1998-09-28
;  NUMBER OF SEQ ID NOS:  346
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 43
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-09-249-155A-43

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 73;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1651 GGCAAGCACCA 1661
             ||||||| |||
Db          1 GGCAAGCCCCA 11


RESULT 179
US-09-249-155A-181
; Sequence 181, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
;  APPLICANT:  Heber-Katz, Ellen
;  TITLE OF INVENTION:  Compositions and Methods for Wound
;  TITLE OF INVENTION:  Healing
;  FILE REFERENCE:  00486.78503
;  CURRENT APPLICATION NUMBER: US/09/249,155A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER:  US 60/074,737
;  PRIOR FILING DATE:  1998-02-13
;  PRIOR APPLICATION NUMBER:  US 60/097,937
;  PRIOR FILING DATE:  1998-08-26
;  PRIOR APPLICATION NUMBER:  US 60/102,051
;  PRIOR FILING DATE:  1998-09-28
;  NUMBER OF SEQ ID NOS:  346
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 181
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-09-249-155A-181

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 73;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1651 GGCAAGCACCA 1661
             ||||||| |||
Db          1 GGCAAGCCCCA 11
```

```
RESULT 180
PCT-US94-08023-37/c
; Sequence 37, Application PC/TUS9408023
;  GENERAL INFORMATION:
;    APPLICANT:  de Kloet, Siwo R.
;    TITLE OF INVENTION:  Sex-Specific DNA Probe For Parrots,
;    TITLE OF INVENTION:  Methods And Kits
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Ruden, Barnett, McClosky, Smith, Schuster &
;      ADDRESSEE:  Russell, P.A.
;      STREET:  200 East Broward Boulevard
;      CITY:  Fort Lauderdale
;      STATE:  FL
;      COUNTRY:  USA
;      ZIP:  33301
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/08023
;      FILING DATE:  15-JUL-1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/093,198
;      FILING DATE:  15-JUL-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Manso, Peter J.
;      REGISTRATION NUMBER:  32,264
;      REFERENCE/DOCKET NUMBER:  FL20979-34
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  305-527-2498
;      TELEFAX:  305-764-4996
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  11 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US94-08023-37

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 73;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGT 1718
                ||||||||| |
Db         11 GGGTTAGGAAT 1


RESULT 181
US-08-192-300-5
; Sequence 5, Application US/08192300
; Patent No. 5580759
;  GENERAL INFORMATION:
;    APPLICANT:  Yang, Yih-Sheng
;    APPLICANT:  Tucker, Philip W.
;    APPLICANT:  Capra, J. Donald
;    TITLE OF INVENTION:  CONSTRUCTION OF RECOMBINANT DNA BY
;    TITLE OF INVENTION:  EXONUCLEASE RECESSION
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy Disk
;      COMPUTER:  IBM PC Compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII-DOS
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/192,300
;      FILING DATE:  February 3, 1994
;      CLASSIFICATION:  535
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Denise L. Mayfield
;      REGISTRATION NUMBER:  33,732
;      REFERENCE/DOCKET NUMBER:  UTSD:327
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 320-7200
;      TELEFAX:  (512) 474-7577
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  Nucleic acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    MOLECULE TYPE:  Oligonucleotide
US-08-192-300-5

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGT 1706
                ||||||||| |
Db          2 GTGGTGGAATT 12


RESULT 182
US-08-221-816B-27/c
; Sequence 27, Application US/08221816B
; Patent No. 5738985
;  GENERAL INFORMATION:
;    APPLICANT:  Miles, Vincent J.
;    APPLICANT:  Mathews, Michael B.
;    APPLICANT:  Katze, Michael G.
;    APPLICANT:  Witherell, Gary
;    APPLICANT:  Watson, Julia C.
;    TITLE OF INVENTION:  METHOD FOR SELECTIVE INACTIVATION
;    TITLE OF INVENTION:  OF VIRAL REPLICATION
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10036/2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/221,816B
;      FILING DATE:  01-APR-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Coruzzi, Laura A
;      REGISTRATION NUMBER:  30,742
;      REFERENCE/DOCKET NUMBER:  7960-030
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  27:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-221-816B-27

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1674 GAACCCTGGTG 1684
              |||||| ||||
Db         11 GAACCCAGGTG 1


RESULT 183
US-08-441-887A-338
; Sequence 338, Application US/08441887A
; Patent No. 5837832
;  GENERAL INFORMATION:
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua X.
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes on
;    TITLE OF INVENTION:  Biological Chips
;    NUMBER OF SEQUENCES:  360
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/441,887A
;      FILING DATE:  16-MAY-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/082,937
;      FILING DATE:  25-JUN-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joseph O.
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004160US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-326-2400
;      TELEFAX:  650-326-2422
;  INFORMATION FOR SEQ ID NO:  338:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (probe)
US-08-441-887A-338

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1740 CAACTCCTCCC 1750
              | |||||||||
Db          1 CGACTCCTCCC 11


RESULT 184
US-08-441-887A-339
; Sequence 339, Application US/08441887A
; Patent No. 5837832
;  GENERAL INFORMATION:
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua X.
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes on
;    TITLE OF INVENTION:  Biological Chips
;    NUMBER OF SEQUENCES:  360
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/441,887A
;      FILING DATE:  16-MAY-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/082,937
;      FILING DATE:  25-JUN-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joseph O.
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004160US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-326-2400
;      TELEFAX:  650-326-2422
;  INFORMATION FOR SEQ ID NO:  339:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (probe)
US-08-441-887A-339

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1740 CAACTCCTCCC 1750
              | |||||||||
Db          2 CGACTCCTCCC 12


RESULT 185
US-08-757-024-501
```

```
; Sequence 501, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  501:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-501

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 CGGAGATGGAG 1730
              | |||||||||
Db          2 CTGAGATGGAG 12


RESULT 186
US-08-757-024-529
; Sequence 529, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  529:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-529

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 CGGAGATGGAG 1730
              | |||||||||
Db          1 CTGAGATGGAG 11


RESULT 187
US-07-794-396-6
; Sequence 6, Application US/07794396
; Patent No. 6034233
;  GENERAL INFORMATION:
;    APPLICANT:  David Ecker et al.
;    TITLE OF INVENTION:  Modulation of HIV Gene Expression
;    TITLE OF INVENTION:  Through Interference With RNA Secondary Structure
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 6034233ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/794,396
;      FILING DATE:  19911119
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  518,929
;      FILING DATE:  May 4, 1990
;      APPLICATION NUMBER:  PCT/US91/02558
;      FILING DATE:  April 15, 1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISIS-0478
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  yes
US-07-794-396-6

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
```

```
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
              |||||:|| |
Db          2 CCAGGCUCAGA 12


RESULT 188
US-08-959-853-8/c
; Sequence 8, Application US/08959853
; Patent No. 6090553
;  GENERAL INFORMATION:
;    APPLICANT:  Robert S. Matson
;    TITLE OF INVENTION:  USE OF URACIL-DNA GLYCOSYLASE
;    TITLE OF INVENTION:  IN GENETIC ANALYSIS
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Beckman Instruments, Inc.
;      STREET:  2500 Harbor Boulevard
;      CITY:  Fullerton
;      STATE:  California
;      ZIP:  92834-3100
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  WINDOWS 95 - WORDPERFECT 7.0
;      SOFTWARE:  ASCII (DOS) TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/959,853
;      FILING DATE:  herewith
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  P.R. Harder
;      REGISTRATION NUMBER:  20,022
;      REFERENCE/DOCKET NUMBER:  45D-1566
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (714) 773-6929
;      TELEFAX:  (714) 773-7936
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-959-853-8

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1680 TGGTGTCTCCT 1690
              |||||| ||||
Db         11 TGGTGTTTCCT 1


RESULT 189
US-08-713-742-8
; Sequence 8, Application US/08713742
; Patent No. 6111085
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Manoharan
;    TITLE OF INVENTION:  Carbamate-Derivatized Nucleosides And
;    TITLE OF INVENTION:  Oligonucleosides
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 6111085ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 720 Kb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/713,742
;      FILING DATE:  17-SEP-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-2350
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-713-742-8

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
              |||||:|| |
Db          2 CCAGGCUCAGA 12


RESULT 190
US-08-211-882-5
; Sequence 5, Application US/08211882
; Patent No. 6153737
;  GENERAL INFORMATION:
;    APPLICANT:  Manoharan et al.
;    TITLE OF INVENTION:  Derivatized Oligonucleotides Having
;    TITLE OF INVENTION:  Improved Uptake And Other Properties
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 6153737ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 720 Kb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/211,882
;      FILING DATE:  22-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/782,374
;      FILING DATE:  24-OCT-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0649
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
US-08-211-882-5

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
                 |||||:|| |
Db          2 CCAGGCUCAGA 12


RESULT 191
US-08-211-882-9
; Sequence 9, Application US/08211882
; Patent No. 6153737
;  GENERAL INFORMATION:
;    APPLICANT:  Manoharan et al.
;    TITLE OF INVENTION:  Derivatized Oligonucleotides Having
;    TITLE OF INVENTION:  Improved Uptake And Other Properties
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 6153737ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 720 Kb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/211,882
;      FILING DATE:  22-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/782,374
;      FILING DATE:  24-OCT-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0649
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-211-882-9

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
                 |||||:|| |
Db          1 CCAGGCUCAGA 11


RESULT 192
US-09-372-856-8
; Sequence 8, Application US/09372856
; Patent No. 6166188
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Manoharan
;    TITLE OF INVENTION:  Carbamate-Derivatized Nucleosides And
;    TITLE OF INVENTION:  Oligonucleosides
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 6166188ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  Windows NT 4.0
;      SOFTWARE:  WordPerfect 8.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/372,856
;      FILING DATE:  12-AUG-1999
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/713,742
;      FILING DATE:  13-SEP-1996
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-4070
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-372-856-8

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
                 |||||:|| |
Db          2 CCAGGCUCAGA 12


RESULT 193
US-09-281-418-20/c
; Sequence 20, Application US/09281418
; Patent No. 6287769
; GENERAL INFORMATION:
;  APPLICANT: Inoue, Takakazu
;  TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA Fr
;  TITLE OF INVENTION: agment, Method of Assaying Microorganisms, Method of Analyzing Mic
;  TITLE OF INVENTION: nisms and Method of Assaying Contaminant
;  FILE REFERENCE: 9982-7
;  CURRENT APPLICATION NUMBER: US/09/281,418
;  CURRENT FILING DATE: 1999-03-30
;  EARLIER APPLICATION NUMBER: JP/1998/87651
;  EARLIER FILING DATE: 1998-03-31
;  EARLIER APPLICATION NUMBER: JP/1999/69694
;  EARLIER FILING DATE: 1999-03-16
;  NUMBER OF SEQ ID NOS: 216
; SEQ ID NO 20
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-281-418-20

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1748 CCCTATCCTAA 1758
                ||||||||  ||
Db         12 CCCTATCCAAA 2


RESULT 194
US-09-281-418-74/c
; Sequence 74, Application US/09281418
; Patent No. 6287769
; GENERAL INFORMATION:
;  APPLICANT: Inoue, Takakazu
;  TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F
;  TITLE OF INVENTION: agment, Method of Assaying Microorganisms, Method of Analyzing Mi
;  TITLE OF INVENTION: nisms and Method of Assaying Contaminant
;  FILE REFERENCE: 9982-7
;  CURRENT APPLICATION NUMBER: US/09/281,418
;  CURRENT FILING DATE: 1999-03-30
;  EARLIER APPLICATION NUMBER: JP/1998/87651
;  EARLIER FILING DATE: 1998-03-31
;  EARLIER APPLICATION NUMBER: JP/1999/69694
;  EARLIER FILING DATE: 1999-03-16
;  NUMBER OF SEQ ID NOS: 216
; SEQ ID NO 74
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-281-418-74

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGG 1715
                ||||||  ||||
Db         11 GTTGGGATAGG 1


RESULT 195
US-09-688-394-8
; Sequence 8, Application US/09688394
; Patent No. 6322987
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Manoharan
;    TITLE OF INVENTION:  Carbamate-Derivatized Nucleosides And
;    TITLE OF INVENTION:  Oligonucleosides
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 6322987ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  Windows NT 4.0
;      SOFTWARE:  WordPerfect 8.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/688,394
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/372,856
;      FILING DATE:  12-AUG-1999
;      APPLICATION NUMBER:  08/713,742
;      FILING DATE:  13-SEP-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-4070
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-688-394-8

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
                ||||||:||  |
Db          2 CCAGGCUCAGA 12


RESULT 196
US-09-633-659-5
; Sequence 5, Application US/09633659
; Patent No. 6395492
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Bennet, Clarence Frank
;  TITLE OF INVENTION:  Derivatized Oligonucleotides Having Improved Uptake And
;  TITLE OF INVENTION:  Other Properties
;  FILE REFERENCE:  ISIS4470
;  CURRENT APPLICATION NUMBER: US/09/633,659
;  CURRENT FILING DATE:  2000-08-07
;  PRIOR APPLICATION NUMBER:  08/211,882
;  PRIOR FILING DATE:  1994-04-22
;  PRIOR APPLICATION NUMBER:  07/782,374
;  PRIOR FILING DATE:  1991-10-24
;  NUMBER OF SEQ ID NOS:  18
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 12
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6395492el Sequence
US-09-633-659-5

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
                ||||||:||  |
Db          2 CCAGGCUCAGA 12


RESULT 197
US-09-633-659-9
; Sequence 9, Application US/09633659
; Patent No. 6395492
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Bennet, Clarence Frank
;  TITLE OF INVENTION:  Derivatized Oligonucleotides Having Improved Uptake And
;  TITLE OF INVENTION:  Other Properties
;  FILE REFERENCE:  ISIS4470
;  CURRENT APPLICATION NUMBER: US/09/633,659
;  CURRENT FILING DATE:  2000-08-07
;  PRIOR APPLICATION NUMBER:  08/211,882
;  PRIOR FILING DATE:  1994-04-22
;  PRIOR APPLICATION NUMBER:  07/782,374
;  PRIOR FILING DATE:  1991-10-24
```

```
;  NUMBER OF SEQ ID NOS:  18
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 9
;    LENGTH: 12
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
;    OTHER INFORMATION: Oligonucleotide
;    OTHER INFORMATION: Description of Artificial Sequence: No. 6395492el Sequence
US-09-633-659-9

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 88;
  Matches    9;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
              ||||||:|| |
Db          1 CCAGGCUCAGA 11


RESULT 198
US-10-112-547-27/c
; Sequence 27, Application US/10112547
; Patent No. 6579674
;   GENERAL INFORMATION:
;        APPLICANT: Miles, Vincent J.
;                   Mathews, Michael B.
;                   Katze, Michael G.
;                   Witherell, Gary
;                   Watson, Julia C.
;        TITLE OF INVENTION: METHOD FOR SELECTIVE INACTIVATION
;                            OF VIRAL REPLICATION
;        NUMBER OF SEQUENCES: 33
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Pennie & Edmonds
;             STREET: 1155 Avenue of the Americas
;             CITY: New York
;             STATE: New York
;             COUNTRY: USA
;             ZIP: 10036/2711
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: FastSEQ Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/112,547
;             FILING DATE: 28-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/221,816B
;             FILING DATE: 01-APR-1994
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Coruzzi, Laura A
;             REGISTRATION NUMBER: 30,742
;             REFERENCE/DOCKET NUMBER: 7960-030
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (212) 790-9090
;             TELEFAX: (212) 869-8864
;             TELEX: 66141 PENNIE
;   INFORMATION FOR SEQ ID NO: 27:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 12 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-10-112-547-27

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1674 GAACCCTGGTG 1684
              |||||| ||||
Db         11 GAACCCAGGTG 1


RESULT 199
5240847-3
;Patent No. 5240847
;    APPLICANT: HECKL, KONRAD;SPEVAK, WALTER;OSTERMANN, ELINBORG;
;ZOPHEL, ANDREAS;KRYSTEK, EDELTRAUD;MAURER-FOGY, INGRID;
;WICHE-CASTANON, MARIA J.;STRATOWA, CHRISTIAN;HAUPTMANN, RUDOLF
;    TITLE OF INVENTION: HUMAN MANGANESE SUPEROXIDE DISMUTASE
;(HMN-SOD)
;    NUMBER OF SEQUENCES: 34
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/167,261
;      FILING DATE: 11-MAR-1988
;SEQ ID NO:3:
;      LENGTH: 12
5240847-3

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 AAGCACCAGGC 1664
              |||||||| ||
Db          1 AAGCACCATGC 11


RESULT 200
5427911-12/c
;Patent No. 5427911
;    APPLICANT: RUANO, GUALBERTO
;    TITLE OF INVENTION: COUPLED AMPLIFICATION AND SEQUENCING
;OF DNA
;    NUMBER OF SEQUENCES: 18
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/98,748
;      FILING DATE: 28-JUL-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER: 516,499
;      FILING DATE: 01-MAY-1990
;SEQ ID NO:12:
;      LENGTH: 12
5427911-12

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 88;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1750 CTATCCTAAAG 1760
              || |||||||
Db         11 CTCTCCTAAAG 1


RESULT 201
5427911-14
;Patent No. 5427911
;    APPLICANT: RUANO, GUALBERTO
;    TITLE OF INVENTION: COUPLED AMPLIFICATION AND SEQUENCING
;OF DNA
;    NUMBER OF SEQUENCES: 18
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/98,748
;      FILING DATE: 28-JUL-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER: 516,499
;      FILING DATE: 01-MAY-1990
;SEQ ID NO:14:
;      LENGTH: 12
```

5427911-14

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 88;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1750 CTATCCTAAAG 1760
              || ||||||||
Db          2 CTCTCCTAAAG 12
```

RESULT 202
US-08-123-449A-17
; Sequence 17, Application US/08123449A
; Patent No. 5583032
; GENERAL INFORMATION:
; APPLICANT: TORRENCE, PAUL
; APPLICANT: ROBERT, SILVERMAN
; APPLICANT: RATAN, MAITRA
; APPLICANT: KRYSTYNA, LESIAK
; TITLE OF INVENTION: METHOD OF CLEAVING SPECIFIC SEQUENCES
; TITLE OF INVENTION: OF RNA
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson and Bear
; STREET: 620 Newport Center Drive
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS version
; SOFTWARE: FastSeq Version 1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/123,449A
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/10103
; FILING DATE: 10-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Fedrick, Michael F.
; REGISTRATION NUMBER: 36,799
; REFERENCE/DOCKET NUMBER: NIH034.001QPC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
; FEATURE:
; NAME/KEY: miscellaneous feature
; LOCATION: 1-4
; OTHER INFORMATION: A is linked by 2',5'-linkage
; FEATURE:
; NAME/KEY: miscellaneous feature
; LOCATION: 4
; OTHER INFORMATION: A is linked at 2' end to following
; OTHER INFORMATION: base through a linker moiety
US-08-123-449A-17

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 1e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1741 AACTCCTCCCT 1751
              |||| ||||||
Db          3 AACTACTCCCT 13
```

RESULT 203
US-08-458-050-17
; Sequence 17, Application US/08458050
; Patent No. 5677289
; GENERAL INFORMATION:
; APPLICANT: TORRENCE, PAUL
; APPLICANT: ROBERT, SILVERMAN
; APPLICANT: RATAN, MAITRA
; APPLICANT: KRYSTYNA, LESIAK
; TITLE OF INVENTION: METHOD OF CLEAVING SPECIFIC SEQUENCES
; TITLE OF INVENTION: OF RNA
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson and Bear
; STREET: 620 Newport Center Drive
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS version
; SOFTWARE: FastSeq Version 1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/458,050
; FILING DATE: 01-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/123,449
; FILING DATE: 17-SEP-1993
; APPLICATION NUMBER: PCT/US93/10103
; FILING DATE: 10-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Fedrick, Michael F.
; REGISTRATION NUMBER: 36,799
; REFERENCE/DOCKET NUMBER: NIH034.001QPC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
; FEATURE:
; NAME/KEY: miscellaneous feature
; LOCATION: 1-4
; OTHER INFORMATION: A is linked by 2',5'-linkage
; FEATURE:
; NAME/KEY: miscellaneous feature
; LOCATION: 4
; OTHER INFORMATION: A is linked at 2' end to following
; OTHER INFORMATION: base through a linker moiety
US-08-458-050-17

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 1e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1741 AACTCCTCCCT 1751

```
                    |||| ||||||
Db          3 AACTACTCCCT 13


RESULT 204
US-08-667-023-3/c
; Sequence 3, Application US/08667023
; Patent No. 5817783
;  GENERAL INFORMATION:
;    APPLICANT:  Callabreta, Bruno
;    APPLICANT:  Venturelli, Donatella
;    APPLICANT:  Martinez, Robert V.
;    TITLE OF INVENTION:  DR-nm23 AND COMPOSITIONS, METHODS OF MAKING AND
;    TITLE OF INVENTION:  METHODS OF USING THE SAME
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & No. 5817783ris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/667,023
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/000,427
;      FILING DATE:  22-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca, Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1992
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-667-023-3

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGT 1706
                ||||||||| |
Db         12 GTGGTGGAATT 2


RESULT 205
US-08-671-975A-17/c
; Sequence 17, Application US/08671975A
; Patent No. 5830656
;  GENERAL INFORMATION:
;    APPLICANT:  Milo, George
;    TITLE OF INVENTION:  CATR GENE
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CALFEE, HALTER & GRISWOLD
;      STREET:  800 SUPERIOR AVENUE, SUITE 1400
;      CITY:  CLEVELAND
;      STATE:  OHIO
;      COUNTRY:  USA
;      ZIP:  44114
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/671,975A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GOLRICK, MARY E
;      REGISTRATION NUMBER:  34,829
;      REFERENCE/DOCKET NUMBER:  22727/00134
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (216) 622-8200
;      TELEFAX:  (216) 241-0816
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-671-975A-17

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGT 1706
                ||||||||| |
Db         12 GTGGTGGAATT 2


RESULT 206
US-08-757-024-471
; Sequence 471, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  471:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
```

```
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-471

  Query Match           6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 CGGAGATGGAG 1730
              | |||||||||
Db          3 CTGAGATGGAG 13


RESULT 207
US-08-757-024-500
; Sequence 500, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  500:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-500

  Query Match           6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 CGGAGATGGAG 1730
              | |||||||||
Db          2 CTGAGATGGAG 12


RESULT 208
US-08-757-024-528
; Sequence 528, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  528:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-528

  Query Match           6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 CGGAGATGGAG 1730
              | |||||||||
Db          1 CTGAGATGGAG 11


RESULT 209
US-08-950-196-17
; Sequence 17, Application US/08950196
; Patent No. 6271369
;  GENERAL INFORMATION:
;    APPLICANT:  TORRENCE, PAUL
;    APPLICANT:  ROBERT, SILVERMAN
;    APPLICANT:  RATAN, MAITRA
;    APPLICANT:  KRYSTYNA, LESIAK
;    TITLE OF INVENTION:  METHOD OF CLEAVING SPECIFIC SEQUENCES
;    TITLE OF INVENTION:  OF RNA
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson and Bear
;      STREET:  620 Newport Center Drive
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS version '
;      SOFTWARE:  FastSeq Version 1.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/950,196
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/123,449
;      FILING DATE:
;      APPLICATION NUMBER:  PCT/US93/10103
```

```
;       FILING DATE:  10-OCT-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Fedrick, Michael F.
;       REGISTRATION NUMBER:  36,799
;       REFERENCE/DOCKET NUMBER:  NIH034.001QPC
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  714-760-0404
;       TELEFAX:  714-760-9502
;   INFORMATION FOR SEQ ID NO:  17:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
;     FRAGMENT TYPE:
;     ORIGINAL SOURCE:
;     FEATURE:
;       NAME/KEY:  miscellaneous feature
;       LOCATION:  1-4
;       OTHER INFORMATION:  A is linked by 2',5'-linkage
;     FEATURE:
;       NAME/KEY:  miscellaneous feature
;       LOCATION:  4
;       OTHER INFORMATION:  A is linked at 2' end to following
;       OTHER INFORMATION:  base through a linker moiety
US-08-950-196-17

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCT 1751
                ||||  ||||||
Db          3 AACTACTCCCT 13


RESULT 210
US-09-474-432B-120/c
; Sequence 120, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation intc oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 120
;   LENGTH: 13
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-120

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1659 CCAGGCTCACA 1669
                ||||||| ||
Db         12 CCAGGCTCCCA 2


RESULT 211
US-09-216-584-18
; Sequence 18, Application US/09216584
; Patent No. 6548657
; GENERAL INFORMATION:
;  APPLICANT: Alex, Burgin
;  APPLICANT:  Leonid, Beigelman
;  APPLICANT:  Laurent, Bellon
;  TITLE OF INVENTION: Method for Screening Nucleic Acid Catalysts
;  FILE REFERENCE: MBHB00-853-A; RPI 237/167
;  CURRENT APPLICATION NUMBER: US/09/216,584
;  CURRENT FILING DATE:  1998-12-18
;  PRIOR APPLICATION NUMBER: 09/094,381
;  PRIOR FILING DATE: 1998-06-09
;  PRIOR APPLICATION NUMBER: 60/068,212
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/049,002
;  PRIOR FILING DATE: 1997-06-09
;  NUMBER OF SEQ ID NOS: 52
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Accessible site within Kras transcript
US-09-216-584-18

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 1e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGG 1709
                ||||  ||||||
Db          2 GTGGTAGTTGG 12


RESULT 212
US-09-798-096-16
; Sequence 16, Application US/09798096
; Patent No. 6399378
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RECQL2 EXPRESSION
;  FILE REFERENCE: RTS-0207
;  CURRENT APPLICATION NUMBER: US/09/798,096
;  CURRENT FILING DATE:  2001-03-01
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonuclectide
US-09-798-096-16

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 20;
  Best Local Similarity   68.4%;  Pred. No. 2e+02;
  Matches   13;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1661 AGGCTCACAGCTGGAACCC 1679
                ||| | |||| ||  | ||
Db          2 AGGATTACAGGTGTGAGCC 20
```

```
RESULT 213
US-08-584-040-7909
; Sequence 7909, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7909:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7909

  Query Match             6.6%;  Score 9.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches    7;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCTCC 1739
              :|| | ::|||: |
Db          2 UGGCGCUUGGCUUC 15


RESULT 214
US-09-371-772B-3692
; Sequence 3692, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3692
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3692

  Query Match             6.6%;  Score 9.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches    7;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCTCC 1739
              :|| | ::|||: |
Db          2 UGGCGCUUGGCUUC 15


RESULT 215
US-09-249-155A-43/c
; Sequence 43, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
;  APPLICANT:  Heber-Katz, Ellen
;  TITLE OF INVENTION:  Compositions and Methods for Wound
;  TITLE OF INVENTION:  Healing
;  FILE REFERENCE:  00486.78503
;  CURRENT APPLICATION NUMBER: US/09/249,155A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER:  US 60/074,737
;  PRIOR FILING DATE:  1998-02-13
;  PRIOR APPLICATION NUMBER:  US 60/097,937
;  PRIOR FILING DATE:  1998-08-26
;  PRIOR APPLICATION NUMBER:  US 60/102,051
;  PRIOR FILING DATE:  1998-09-28
;  NUMBER OF SEQ ID NOS:  346
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 43
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-09-249-155A-43

  Query Match             6.5%;  Score 9;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 90;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1634 TGGGGCTTG 1642
              |||||||||
Db         11 TGGGGCTTG 3


RESULT 216
US-09-249-155A-181/c
; Sequence 181, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
;  APPLICANT:  Heber-Katz, Ellen
;  TITLE OF INVENTION:  Compositions and Methods for Wound
;  TITLE OF INVENTION:  Healing
;  FILE REFERENCE:  00486.78503
;  CURRENT APPLICATION NUMBER: US/09/249,155A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER:  US 60/074,737
;  PRIOR FILING DATE:  1998-02-13
```

```
;  PRIOR APPLICATION NUMBER:  US 60/097,937
;  PRIOR FILING DATE:  1998-08-26
;  PRIOR APPLICATION NUMBER:  US 60/102,051
;  PRIOR FILING DATE:  1998-09-28
;  NUMBER OF SEQ ID NOS:  346
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 181
;   LENGTH: 11
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-09-249-155A-181

  Query Match             6.5%;  Score 9;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 90;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1634 TGGGGCTTG 1642
              |||||||||
Db         11 TGGGGCTTG 3


RESULT 217
US-08-363-240A-249/c
; Sequence 249, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  249:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-249

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 15;
  Best Local Similarity   83.3%;  Pred. No. 1.8e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCT 1747
              ||||  ||||||
Db         13 CTCCGTACTCCT 2


RESULT 218
US-07-696-793A-7
; Sequence 7, Application US/07696793A
; Patent No. 5220004
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cetus Corporation
;      STREET:  1400 Fifty-Third Street
;      CITY:  Emeryville
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  94608
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 6.0.5
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/696,793A
;      FILING DATE:  19910507
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kevin R. Kaster
;      REGISTRATION NUMBER:  32704
;      REFERENCE/DOCKET NUMBER:  2598
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 420-3444
;      TELEFAX:  (415) 658-5239
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-07-696-793A-7

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 16;
  Best Local Similarity   73.3%;  Pred. No. 2.1e+02;
  Matches   11;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1657 CACCAGGCTCACAGC 1671
              ||||| |||  || |
Db          2 CACCAAGCTTCCACC 16


RESULT 219
US-07-977-694-7
; Sequence 7, Application US/07977694
; Patent No. 5273883
;  GENERAL INFORMATION:
;    APPLICANT:  Saiki, Randall K.
;    APPLICANT:  Nasarabadi, Shanavaz L.
;    TITLE OF INVENTION:  Methods and Reagents for G Gamma Globin
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
```

```
;       STREET:  340 Kingsland Street
;       CITY:  Nutley
;       STATE:  New Jersey
;       COUNTRY:  U.S.A.
;       ZIP:  07110-1199
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inch, 800 Kb storage
;       COMPUTER:  Apple Macintosh
;       OPERATING SYSTEM:  Macintosh 6.0.5
;       SOFTWARE:  WordPerfect
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/977,694
;       FILING DATE:  19921117
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Stacey R. Sias, Ph.D.
;       REGISTRATION NUMBER:  32,630
;       REFERENCE/DOCKET NUMBER:  8733
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (510) 814-2863
;       TELEFAX:  (510) 814-2977
;   INFORMATION FOR SEQ ID NO:  7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  Other nucleic acid
US-07-977-694-7

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 16;
  Best Local Similarity   73.3%;  Pred. No. 2.1e+02;
  Matches   11;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1657 CACCAGGCTCACAGC 1671
              ||||| |||  || |
Db          2 CACCAAGCTTCCACC 16


RESULT 220
US-08-486-962-12
; Sequence 12, Application US/08486962
; Patent No. 5763172
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    APPLICANT:  Wright, Meredith
;    APPLICANT:  Ross, Kevin L.
;    APPLICANT:  Miller, Richard A.
;    APPLICANT:  Dow, William C.
;    APPLICANT:  Kral, Vladimir A.
;    APPLICANT:  Smith, Daniel A.
;    TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94086-4521
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,962
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 774-0330
;      TELEFAX:  (408) 774-0340
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-486-962-12

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 2.2e+02;
  Matches   11;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1671 CTGGAACCCTGGTGT 1685
              ||| | || |||||
Db          1 CTGTGAGCCGGGTGT 15


RESULT 221
PCT-US94-06284-12
; Sequence 12, Application PC/TUS9406284
;  GENERAL INFORMATION:
;    APPLICANT:
;    APPLICANT:  NAME:     BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
;    APPLICANT:  SYSTEM
;    APPLICANT:  STREET:   201 West 7th Street
;    APPLICANT:  CITY:     Austin
;    APPLICANT:  STATE:    Texas
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  78701
;    APPLICANT:  TELEPHONE NO: (512)499-4462
;    APPLICANT:  TELEFAX:  (512)499-4523
;    APPLICANT:  STREET:   995 East Arques Ave.
;    APPLICANT:  CITY:     Sunnyvale
;    APPLICANT:  STATE:    California
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  94086-4593
;    APPLICANT:  TELEPHONE NO: (408)774-0330
;    APPLICANT:  TELEFAX:  (408)774-0340
;    TITLE OF INVENTION:  TEXAPHYRIN METAL COMPLEX
;    TITLE OF INVENTION:  MEDIATED ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/06284
;      FILING DATE:  CONCURRENTLY HEREWITH
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  USSN 08/075,123
;      FILING DATE:  09 JUNE 1993 (09.06.93)
;      CLASSIFICATION:
;      APPLICATION NUMBER:  USSN 08/227,370
;      FILING DATE:  14 APRIL 1994 (14.04.94)
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
```

```
;       NAME:  PARKER, DAVID L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTFB570P--
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  512/320-7200
;       TELEFAX:  713/789-2679
;       TELEX:  79-0924
;   INFORMATION FOR SEQ ID NO:  12:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
PCT-US94-06284-12

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 2.2e+02;
  Matches   11;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1671 CTGGAACCCTGGTGT 1685
              ||| | || |||||
Db          1 CTGTGAGCCGGGTGT 15


RESULT 222
US-08-486-962-15
; Sequence 15, Application US/08486962
; Patent No. 5763172
;  GENERAL INFORMATION:
;    APPLICANT:  Magda, Darren
;    APPLICANT:  Sessler, Jonathan L.
;    APPLICANT:  Wright, Meredith
;    APPLICANT:  Ross, Kevin L.
;    APPLICANT:  Miller, Richard A.
;    APPLICANT:  Dow, William C.
;    APPLICANT:  Kral, Vladimir A.
;    APPLICANT:  Smith, Daniel A.
;    TITLE OF INVENTION:  METHOD OF PHOSPHATE ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pharmacyclics, Inc.
;      STREET:  995 E. Arques Avenue
;      CITY:  Sunnyvale
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94086-4521
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,962
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Jacqueline S.
;      REGISTRATION NUMBER:  30,279
;      REFERENCE/DOCKET NUMBER:  PHAY:053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 774-0330
;      TELEFAX:  (408) 774-0340
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-486-962-15

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 18;
  Best Local Similarity   73.3%;  Pred. No. 2.3e+02;
  Matches   11;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1671 CTGGAACCCTGGTGT 1685
              ||| | || |||||
Db          2 CTGTGAGCCGGGTGT 16


RESULT 223
PCT-US94-06284-15
; Sequence 15, Application PC/TUS9406284
;  GENERAL INFORMATION:
;    APPLICANT:
;    APPLICANT:  NAME:     BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
;    APPLICANT:  SYSTEM
;    APPLICANT:  STREET:   201 West 7th Street
;    APPLICANT:  CITY:     Austin
;    APPLICANT:  STATE:    Texas
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  78701
;    APPLICANT:  TELEPHONE NO: (512)499-4462
;    APPLICANT:  TELEFAX:  (512)499-4523
;    APPLICANT:  STREET:   995 East Arques Ave.
;    APPLICANT:  CITY:     Sunnyvale
;    APPLICANT:  STATE:    California
;    APPLICANT:  COUNTRY:  United States of America
;    APPLICANT:  POSTAL CODE:  94086-4593
;    APPLICANT:  TELEPHONE NO: (408)774-0330
;    APPLICANT:  TELEFAX:  (408)774-0340
;    TITLE OF INVENTION:  TEXAPHYRIN METAL COMPLEX
;    TITLE OF INVENTION:  MEDIATED ESTER HYDROLYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/06284
;      FILING DATE:  CONCURRENTLY HEREWITH
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  USSN 08/075,123
;      FILING DATE:  09 JUNE 1993 (09.06.93)
;      CLASSIFICATION:
;      APPLICATION NUMBER:  USSN 08/227,370
;      FILING DATE:  14 APRIL 1994 (14.04.94)
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PARKER, DAVID L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTFB570P--
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/320-7200
;      TELEFAX:  713/789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US94-06284-15

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 18;
```

```
  Best Local Similarity   73.3%;  Pred. No. 2.3e+02;
  Matches   11;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1671 CTGGAACCCTGGTGT 1685
              ||| | || |||||
Db          2 CTGTGAGCCGGGTGT 16


RESULT 224
US-09-281-418-74
; Sequence 74, Application US/09281418
; Patent No. 6287769
; GENERAL INFORMATION:
;  APPLICANT: Inoue, Takakazu
;  TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F
;  TITLE OF INVENTION: agment, Method of Assaying Microorganisms, Method of Analyzing Mi
;  TITLE OF INVENTION: nisms and Method of Assaying Contaminant
;  FILE REFERENCE: 9982-7
;  CURRENT APPLICATION NUMBER: US/09/281,418
;  CURRENT FILING DATE: 1999-03-30
;  EARLIER APPLICATION NUMBER: JP/1998/87651
;  EARLIER FILING DATE: 1998-03-31
;  EARLIER APPLICATION NUMBER: JP/1999/69694
;  EARLIER FILING DATE: 1999-03-16
;  NUMBER OF SEQ ID NOS: 216
; SEQ ID NO 74
;    LENGTH: 12
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Primer
US-09-281-418-74

  Query Match             6.0%;  Score 8.4;  DB 1;  Length 12;
  Best Local Similarity   90.0%;  Pred. No. 1.4e+02;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1749 CCTATCCTAA 1758
              ||||||| ||
Db          1 CCTATCCCAA 10


RESULT 225
US-08-434-503-10
; Sequence 10, Application US/08434503
; Patent No. 5616490
;  GENERAL INFORMATION:
;    APPLICANT:  Sean M. Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  TREATMENT OF INFLAMMATORY
;    TITLE OF INVENTION:  DISEASE
;    NUMBER OF SEQUENCES:  54
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM MS-DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/434,503
;      FILING DATE:  04-MAY-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/008,895
;      FILING DATE:  19-JAN-1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  200/276
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-434-503-10

  Query Match             6.0%;  Score 8.4;  DB 1;  Length 14;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches    8;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1657 CACCAGGCTC 1666
              ||||| ||:|
Db          2 CACCACGCUC 11


Search completed: January 12, 2004, 13:54:44
Job time : 1 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: January 12, 2004, 13:51:30 ; Search time 0.001 Seconds
(without alignments)
523.474 Million cell updates/sec

Title: us-09-925-139-3
Perfect score: 139
Sequence: 1 ggatggggcttgtagcagaa.....ctatcctaaaggcccactgg 139

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 116 seqs, 1883 residues

Total number of hits satisfying chosen parameters: 232

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 120 summaries

Database : rnpb.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20	14.4	20	1	US-09-802-640-52	Sequence 52, Appl
c	2	20	14.4	20	1	US-09-925-139-5	Sequence 5, Appli
c	3	20	14.4	20	1	US-09-925-139-28	Sequence 28, Appl
c	4	20	14.4	20	1	US-09-925-139-29	Sequence 29, Appl
c	5	20	14.4	20	1	US-09-925-139-30	Sequence 30, Appl
c	6	20	14.4	20	1	US-09-925-139-47	Sequence 47, Appl
c	7	20	14.4	20	1	US-09-925-139-48	Sequence 48, Appl
c	8	20	14.4	20	1	US-09-925-139-49	Sequence 49, Appl
c	9	20	14.4	20	1	US-09-925-139-50	Sequence 50, Appl
	10	16.8	12.1	21	1	US-10-257-080-5	Sequence 5, Appli
	11	15.2	10.9	20	1	US-09-865-879-19	Sequence 19, Appl
c	12	14.8	10.6	20	1	US-10-005-956-1205	Sequence 1205, Ap
c	13	14.8	10.6	21	1	US-10-044-423-19	Sequence 19, Appl
c	14	14.4	10.4	17	1	US-09-827-395A-480	Sequence 480, App
c	15	14.4	10.4	17	1	US-09-827-395A-481	Sequence 481, App
	16	14.4	10.4	20	1	US-10-032-585-5725	Sequence 5725, Ap
	17	14.2	10.2	20	1	US-10-238-011-39	Sequence 39, Appl
c	18	14.2	10.2	20	1	US-10-001-076-147	Sequence 147, App
	19	14.2	10.2	20	1	US-10-105-004-109	Sequence 109, App
	20	14.2	10.2	20	1	US-10-007-078-60	Sequence 60, Appl
	21	13.8	9.9	17	1	US-09-877-478-302	Sequence 302, App
	22	13.8	9.9	17	1	US-09-877-478-303	Sequence 303, App
	23	13.8	9.9	17	1	US-09-877-478-1613	Sequence 1613, Ap
c	24	13.8	9.9	17	1	US-09-877-478-2360	Sequence 2360, Ap
c	25	13.4	9.6	17	1	US-09-877-478-1745	Sequence 1745, Ap
c	26	13.4	9.6	17	1	US-09-827-395A-989	Sequence 989, App
c	27	13	9.4	17	1	US-09-877-478-2361	Sequence 2361, Ap
	28	12.8	9.2	16	1	US-10-174-465-6	Sequence 6, Appli
	29	12.8	9.2	16	1	US-10-348-431-6	Sequence 6, Appli
	30	12.8	9.2	17	1	US-09-877-478-994	Sequence 994, App
	31	12.8	9.2	17	1	US-09-877-478-1614	Sequence 1614, Ap
	32	12.8	9.2	17	1	US-09-848-754A-2544	Sequence 2544, Ap
c	33	12.8	9.2	17	1	US-10-297-068-1050	Sequence 1050, Ap
c	34	12.4	8.9	17	1	US-09-818-875-3470	Sequence 3470, Ap
	35	12.4	8.9	17	1	US-09-818-875-3471	Sequence 3471, Ap
c	36	12.4	8.9	17	1	US-09-877-478-386	Sequence 386, App
c	37	12.4	8.9	17	1	US-09-827-395A-479	Sequence 479, App
c	38	12.4	8.9	17	1	US-09-827-395A-990	Sequence 990, App
c	39	12.4	8.9	17	1	US-10-209-787-3470	Sequence 3470, Ap
	40	12.4	8.9	17	1	US-10-209-787-3471	Sequence 3471, Ap
	41	12.2	8.8	17	1	US-09-866-108-527	Sequence 527, App
	42	12.2	8.8	17	1	US-09-866-108-528	Sequence 528, App
c	43	12.2	8.8	17	1	US-09-866-108-1264	Sequence 1264, Ap
	44	12.2	8.8	17	1	US-09-866-108-7831	Sequence 7831, Ap
c	45	12.2	8.8	17	1	US-09-866-108-9658	Sequence 9658, Ap
	46	12.2	8.8	17	1	US-09-416-384A-26	Sequence 26, Appl
	47	12.2	8.8	17	1	US-09-864-785-1557	Sequence 1557, Ap
c	48	12.2	8.8	17	1	US-09-864-785-2921	Sequence 2921, Ap
c	49	12.2	8.8	17	1	US-09-864-785-2922	Sequence 2922, Ap
	50	12.2	8.8	17	1	US-09-780-533A-576	Sequence 576, App
c	51	12.2	8.8	17	1	US-09-877-478-2359	Sequence 2359, Ap
	52	12.2	8.8	17	1	US-09-848-754A-1430	Sequence 1430, Ap
	53	12.2	8.8	17	1	US-09-848-754A-1500	Sequence 1500, Ap
	54	12.2	8.8	17	1	US-10-061-201-1606	Sequence 1606, Ap
	55	12.2	8.8	17	1	US-10-061-201-1608	Sequence 1608, Ap
	56	12.2	8.8	17	1	US-10-061-201-1612	Sequence 1612, Ap
c	57	12.2	8.8	17	1	US-10-061-201-1762	Sequence 1762, Ap
c	58	12.2	8.8	17	1	US-10-061-201-1763	Sequence 1763, Ap
	59	12.2	8.8	17	1	US-10-339-793-72	Sequence 72, Appl
	60	12.2	8.8	17	1	US-10-060-756A-752	Sequence 752, App
	61	12.2	8.8	17	1	US-10-163-552-471	Sequence 471, App
	62	12	8.6	16	1	US-10-232-634-5	Sequence 5, Appli
c	63	12	8.6	17	1	US-09-827-395A-755	Sequence 755, App
	64	12	8.6	17	1	US-10-061-201-945	Sequence 945, App
	65	12	8.6	17	1	US-10-061-201-946	Sequence 946, App
	66	12	8.6	17	1	US-10-061-201-947	Sequence 947, App
	67	12	8.6	17	1	US-10-061-201-948	Sequence 948, App
	68	12	8.6	17	1	US-10-061-201-949	Sequence 949, App
	69	12	8.6	17	1	US-10-061-201-950	Sequence 950, App
	70	11.8	8.5	15	1	US-09-877-478-6527	Sequence 6527, Ap
	71	11.8	8.5	15	1	US-09-943-983-5	Sequence 5, Appli
c	72	11.4	8.2	13	1	US-09-510-378-27	Sequence 27, Appl
c	73	11.4	8.2	13	1	US-09-798-260-85	Sequence 85, Appl
	74	11.4	8.2	14	1	US-09-943-983-9	Sequence 9, Appli
	75	11.4	8.2	15	1	US-09-504-231A-474	Sequence 474, App
	76	11.4	8.2	15	1	US-09-274-553D-474	Sequence 474, App
c	77	11.2	8.1	16	1	US-10-091-281-319	Sequence 319, App
c	78	11.2	8.1	16	1	US-10-043-875-261	Sequence 261, App
c	79	11.2	8.1	17	1	US-10-163-552-471	Sequence 471, App
	80	10.8	7.8	14	1	US-09-943-983-4	Sequence 4, Appli
	81	10.8	7.8	15	1	US-09-263-959-672	Sequence 672, App
	82	10.8	7.8	15	1	US-09-263-959-708	Sequence 708, App
	83	10.8	7.8	15	1	US-09-860-784-8	Sequence 8, Appli
	84	10.8	7.8	15	1	US-09-835-371-5	Sequence 5, Appli
	85	10.8	7.8	15	1	US-09-835-370-5	Sequence 5, Appli
c	86	10.8	7.8	15	1	US-09-880-313A-49	Sequence 49, Appl
	87	10.8	7.8	15	1	US-10-418-182-186	Sequence 186, App
	88	10.8	7.8	15	1	US-09-793-146-7	Sequence 7, Appli
	89	10.8	7.8	15	1	US-10-440-850-823	Sequence 823, App
c	90	10.8	7.8	15	1	US-10-010-802-130	Sequence 130, App
	91	10.6	7.6	17	1	US-09-877-478-2360	Sequence 2360, Ap
c	92	10.4	7.5	14	1	US-10-027-632-51889	Sequence 51889, A
c	93	10.4	7.5	14	1	US-10-027-632-51889	Sequence 51889, A
c	94	10.4	7.5	14	1	US-10-027-632-51894	Sequence 51894, A
c	95	10.4	7.5	14	1	US-10-027-632-51894	Sequence 51894, A
c	96	10.4	7.5	14	1	US-10-146-058-90	Sequence 90, Appl
	97	10.2	7.3	17	1	US-09-877-478-2361	Sequence 2361, Ap
c	98	10.2	7.3	17	1	US-09-848-754A-1500	Sequence 1500, Ap
c	99	10	7.2	12	1	US-09-757-049A-42	Sequence 42, Appl
c	100	10	7.2	12	1	US-10-325-403-11	Sequence 11, Appl
c	101	10	7.2	13	1	US-09-865-644-15	Sequence 15, Appl
	102	10	7.2	13	1	US-10-446-901-7	Sequence 7, Appli
c	103	9.8	7.1	13	1	US-09-510-378-19	Sequence 19, Appl
c	104	9.8	7.1	13	1	US-09-510-378-23	Sequence 23, Appl
c	105	9.8	7.1	13	1	US-09-510-378-24	Sequence 24, Appl
c	106	9.8	7.1	13	1	US-09-510-378-26	Sequence 26, Appl

c 107	9.8	7.1	13	1	US-09-510-378-28	Sequence 28, Appl
c 108	9.8	7.1	13	1	US-09-510-378-29	Sequence 29, Appl
c 109	9.8	7.1	13	1	US-09-798-260-77	Sequence 77, Appl
c 110	9.8	7.1	13	1	US-09-798-260-81	Sequence 81, Appl
c 111	9.8	7.1	13	1	US-09-798-260-84	Sequence 84, Appl
c 112	9.8	7.1	13	1	US-09-798-260-86	Sequence 86, Appl
c 113	9.8	7.1	13	1	US-09-798-260-87	Sequence 87, Appl
114	9.8	7.1	14	1	US-09-238-351-77	Sequence 77, Appl
c 115	9.8	7.1	14	1	US-09-823-847-24	Sequence 24, Appl
116	9.8	7.1	14	1	US-09-943-983-8	Sequence 8, Appli
117	9.8	7.1	14	1	US-09-848-868-6	Sequence 6, Appli
118	9.8	7.1	14	1	US-10-356-625-23	Sequence 23, Appl
c 119	9.8	7.1	14	1	US-10-091-281-372	Sequence 372, App
c 120	9.8	7.1	14	1	US-10-206-839-40	Sequence 40, Appl

ALIGNMENTS

RESULT 1
US-09-802-640-52/c
; Sequence 52, Application US/09802640
; Publication No. US20030036057A1
; GENERAL INFORMATION:
; APPLICANT: Braun, Andreas
; APPLICANT: Bonsal Aruna
; APPLICANT: Kleyn Patrick
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISEASE AND THEIR USE
; FILE REFERENCE: 24736-2048
; CURRENT APPLICATION NUMBER: US/09/802,640
; CURRENT FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-802-640-52

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1639 CTTGTAGCAGAAGGCAAGCA 1658
||||||||||||||||||||
Db 20 CTTGTAGCAGAAGGCAAGCA 1

RESULT 2
US-09-925-139-5/c
; Sequence 5, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-925-139-5

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1695 CGTGGTGGAAGTTGGGTTAG 1714
||||||||||||||||||||
Db 20 CGTGGTGGAAGTTGGGTTAG 1

RESULT 3
US-09-925-139-28/c
; Sequence 28, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-28

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1631 GGATGGGGCTTGTAGCAGAA 1650
||||||||||||||||||||
Db 20 GGATGGGGCTTGTAGCAGAA 1

RESULT 4
US-09-925-139-29/c
; Sequence 29, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-29

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1671 CTGGAACCCTGGTGTCTCCT 1690
||||||||||||||||||||
Db 20 CTGGAACCCTGGTGTCTCCT 1

RESULT 5
US-09-925-139-30/c
; Sequence 30, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-30

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1701 GGAAGTTGGGTTAGGAGTAC 1720
||||||||||||||||||||
Db 20 GGAAGTTGGGTTAGGAGTAC 1

RESULT 6
US-09-925-139-47/c
; Sequence 47, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-47

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1638 GCTTGTAGCAGAAGGCAAGC 1657
||||||||||||||||||||
Db 20 GCTTGTAGCAGAAGGCAAGC 1

RESULT 7
US-09-925-139-48/c
; Sequence 48, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESS
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-48

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1693 AGCGTGGTGGAAGTTGGGTT 1712
||||||||||||||||||||
Db 20 AGCGTGGTGGAAGTTGGGTT 1

RESULT 8
US-09-925-139-49/c
; Sequence 49, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESS
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-49

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 GGAGTACGGAGATGGAGATT 1733
||||||||||||||||||||
Db 20 GGAGTACGGAGATGGAGATT 1

RESULT 9
US-09-925-139-50/c
; Sequence 50, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESS
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-50

  Query Match 14.4%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 3.4;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1750 CTATCCTAAAGGCCCACTGG 1769
         ||||||||||||||||||||
Db 20 CTATCCTAAAGGCCCACTGG 1

RESULT 10
US-10-257-080-5
; Sequence 5, Application US/10257080
; Publication No. US20030166000A1
; GENERAL INFORMATION:
; APPLICANT: MIWA, Masanori
; APPLICANT: MATSUI, Hideki
; APPLICANT: SHINTANI, Yasushi
; TITLE OF INVENTION: No. US20030166000A1el G Protein Coupled Receptor and its DNA
; FILE REFERENCE: 2715 US0P
; CURRENT APPLICATION NUMBER: US/10/257,080
; CURRENT FILING DATE: 2002-10-08
; PRIOR APPLICATION NUMBER: PCT/JP01/03143
; PRIOR FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: JP 2000-110765
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-257-080-5

  Query Match 12.1%; Score 16.8; DB 1; Length 21;
  Best Local Similarity 90.0%; Pred. No. 14;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1732 TTGGCTCCCAACTCCTCCCT 1751
         |||||||||||| |||| |
Db 1 TTGGCTCCCAACTTCTCCTT 20

RESULT 11
US-09-865-879-19
; Sequence 19, Application US/09865879
; Publication No. US20030180707A1
; GENERAL INFORMATION:
; APPLICANT: Roninson, Igor
; APPLICANT: Dokmanovic, Milos
; APPLICANT: Chang, Bey-Dih
; TITLE OF INVENTION: REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF
; TITLE OF INVENTION: REGULATED BY RETINOIDS
; FILE REFERENCE: 99,216-H
; CURRENT APPLICATION NUMBER: US/09/865,879
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/207,535
; PRIOR FILING DATE: 2000-05-26
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Antisense primer for beta IG-H3
US-09-865-879-19

  Query Match 10.9%; Score 15.2; DB 1; Length 20;
  Best Local Similarity 85.0%; Pred. No. 23;
  Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1653 CAAGCACCAGGCTCACAGCT 1672
         || |||| ||||||||| ||
Db 1 CATGCACAAGGCTCACATCT 20

RESULT 12
US-10-005-956-1205/c
; Sequence 1205, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1205
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-005-956-1205

  Query Match 10.6%; Score 14.8; DB 1; Length 20;
  Best Local Similarity 88.9%; Pred. No. 27;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1669 AGCTGGAACCCTGGTGTC 1686
         |||||||||| |||| ||
Db 19 AGCTGGAACCTTGGTCTC 2

RESULT 13
US-10-044-423-19/c
; Sequence 19, Application US/10044423
; Publication No. US20030165862A1
; GENERAL INFORMATION:
; APPLICANT: Chou, Tze-Bin
; TITLE OF INVENTION: DROSOPHILA CLIPPED FRT (CFRT) CHROMOSOME
; TITLE OF INVENTION: INSENSITIVE TO P TRANSPOSASE, GENERATING METHOD THEREOF, AND
; TITLE OF INVENTION: APPLICATION THEREOF
; FILE REFERENCE: 529872000100
; CURRENT APPLICATION NUMBER: US/10/044,423
; CURRENT FILING DATE: 2002-09-05
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-044-423-19

  Query Match 10.6%; Score 14.8; DB 1; Length 21;
  Best Local Similarity 88.9%; Pred. No. 31;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1648 GAAGGCAAGCACCAGGCT 1665
         ||| ||||||||||||| |
Db 19 GAAAGCAAGCACCAGGAT 2

RESULT 14
US-09-827-395A-480/c
; Sequence 480, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 480
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-480

Query Match 10.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1673 GGAACCCTGGTGTCTC 1688
||||||||||||| |||
Db 17 GGAACCCTGGTGGCTC 2

RESULT 15
US-09-827-395A-481/c
; Sequence 481, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 481
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-481

Query Match 10.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1673 GGAACCCTGGTGTCTC 1688
||||||||||||| |||
Db 16 GGAACCCTGGTGGCTC 1

RESULT 16
US-10-032-585-5725
; Sequence 5725, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5725
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-5725

Query Match 10.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1737 TCCCAACTCCTCCCTA 1752
|||||||||||||| |
Db 1 TCCCAACTCCTCCCAA 16

RESULT 17
US-10-238-011-39
; Sequence 39, Application US/10238011
; Publication No. US20030091568A1
; GENERAL INFORMATION:
; APPLICANT: Frey Jurgen
; APPLICANT: Frey, Jurgen
; TITLE OF INVENTION: Inhibitors for the Formation of Soluble Human CD23
; FILE REFERENCE: 516326-2002
; CURRENT APPLICATION NUMBER: US/10/238,011
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: EP 00 107 515.9
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/827,406
; PRIOR FILING DATE: 2000-04-05
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-238-011-39

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 34;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1738 CCCAACTCCTCCCTATCCT 1756
| | |||||||||| ||||
Db 1 CTCCACTCCTCCCTTTCCT 19

RESULT 18
US-10-001-076-147/c
; Sequence 147, Application US/10001076
; Publication No. US20030096775A1
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
; FILE REFERENCE: RTS-0329
; CURRENT APPLICATION NUMBER: US/10/001,076
; CURRENT FILING DATE: 2001-10-23
; NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 147
; LENGTH: 20

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-001-076-147

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 34;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1653 CAAGCACCAGGCTCACAGC 1671
              | |||||| |||| |||||
Db         19 CCAGCACCTGGCTGACAGC 1


RESULT 19
US-10-105-004-109
; Sequence 109, Application US/10105004
; Publication No. US20030105002A1
;   GENERAL INFORMATION:
;        APPLICANT: Murray, Jeffrey
;                   Semina, Elena
;        TITLE OF INVENTION: RIEG COMPOSITIONS AND THERAPEUTIC
;                            AND DIAGNOSTIC USES THEREFOR
;        NUMBER OF SEQUENCES: 139
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: FOLEY, HOAG & ELIOT LLP
;             STREET: One Post Office Square
;             CITY: Boston
;             STATE: MA
;             COUNTRY: USA
;             ZIP: 02109-2170
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,004
;             FILING DATE: 22-Mar-2002
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/754,477
;             FILING DATE: 22-NOV-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Arnold, Beth E.
;             REGISTRATION NUMBER: 35,430
;             REFERENCE/DOCKET NUMBER: UIA-022.01
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 617-832-1000
;             TELEFAX: 617-832-7000
;   INFORMATION FOR SEQ ID NO: 109:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 109:
US-10-105-004-109

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 34;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1733 TGGCTCCCAACTCCTCCCT 1751
              || |||||||| ||||| ||
Db          2 TGTCTCCCAATTCCTCACT 20


RESULT 20
US-10-007-078-60
; Sequence 60, Application US/10007078
; Publication No. US20030105042A1
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF EIF2C1 EXPRESSION
;  FILE REFERENCE: RTS-0236
;  CURRENT APPLICATION NUMBER: US/10/007,078
;  CURRENT FILING DATE:  2001-11-08
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-007-078-60

  Query Match             10.2%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 34;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1734 GGCTCCCAACTCCTCCCTA 1752
              |||| ||| || |||||||
Db          2 GGCTGCCACCTGCTCCCTA 20


RESULT 21
US-09-877-478-302
; Sequence 302, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 302
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-302

  Query Match              9.9%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 24;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1672 TGGAACCCTGGTGTCTC 1688
              :|||||| : |:|:|:|
Db          1 UGGAACCUUUGUGUCUC 17


RESULT 22
```

```
US-09-877-478-303
; Sequence 303, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 303
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-303

  Query Match             9.9%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 24;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1673 GGAACCCTGGTGTCTCC 1689
              ||||||  :  |:|:|:||
Db          1 GGAACCUUUGUGUCUCC 17


RESULT 23
US-09-877-478-1613
; Sequence 1613, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1613
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1613

  Query Match             9.9%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 24;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1674 GAACCCTGGTGTCTCCT 1690
              |||||  :  |:|:|:||:
Db          1 GAACCUUUGUGUCUCCU 17


RESULT 24
US-09-877-478-2360/c
; Sequence 2360, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2360
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-2360

  Query Match             9.9%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 24;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCCCTATC 1754
              |||||||||||||  ||
Db         17 CCCAACTCCTCCCACTC 1


RESULT 25
US-09-877-478-1745/c
; Sequence 1745, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1745
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1745

  Query Match             9.6%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCTCCC 1750
             | ||||||||||||||
Db         16 CCCCCAACTCCTCCC 2


RESULT 26
US-09-827-395A-989/c
; Sequence 989, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE:  2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 989
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-989

  Query Match             9.6%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1673 GGAACCCTGGTGTCT 1687
             |||||||||||| ||
Db         15 GGAACCCTGGTGGCT 1


RESULT 27
US-09-877-478-2361/c
; Sequence 2361, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2361
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-2361

  Query Match             9.4%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCCC 1750
             |||||||||||||
Db         16 CCCAACTCCTCCC 4


RESULT 28
US-10-174-465-6
; Sequence 6, Application US/10174465
; Publication No. US20030232772A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 EX
;  FILE REFERENCE: PTS-0055
;  CURRENT APPLICATION NUMBER: US/10/174,465
;  CURRENT FILING DATE:  2002-06-17
;  NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 6
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-174-465-6

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 29;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1672 TGGAACCCTGGTGTCT 1687
              |||||||| || ||||
Db          1 TGGAACCCGGGCGTCT 16


RESULT 29
US-10-348-431-6
; Sequence 6, Application US/10348431
; Publication No. US20030232778A1
; GENERAL INFORMATION:
;  APPLICANT: Eric G. Marcusson
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS
;  FILE REFERENCE: ISPH-0728
;  CURRENT APPLICATION NUMBER: US/10/348,431
;  CURRENT FILING DATE:  2003-01-17
;  NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 6
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-348-431-6

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 29;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1672 TGGAACCCTGGTGTCT 1687
              |||||||| || ||||
Db          1 TGGAACCCGGGCGTCT 16


RESULT 30
US-09-877-478-994
; Sequence 994, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 994
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-994

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 35;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1672 TGGAACCCTGGTGTCT 1687
              :|||||| : |:|:|:
Db          2 UGGAACCUUUGUGUCU 17


RESULT 31
US-09-877-478-1614
; Sequence 1614, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1614
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1614

  Query Match             9.2%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 35;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1676 ACCCTGGTGTCTCCTC 1691
              ||| : |:|:|:||:|
Db          1 ACCUUUGUGUCUCCUC 16


RESULT 32
US-09-848-754A-2544
; Sequence 2544, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2544
;   LENGTH: 17
;   TYPE: RNA
```

; ORGANISM: Homo sapiens
US-09-848-754A-2544

  Query Match 9.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 81.2%; Pred. No. 35;
  Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1754 CCTAAAGGCCCACTGG 1769
         || |||||||| |:||
Db 2 CCAAAAGGCCCGCUGG 17

RESULT 33
US-10-297-068-1050/c
; Sequence 1050, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 1314OP1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1050
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1050

  Query Match 9.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 35;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1734 GGCTCCCAACTCCTCC 1749
         ||||| ||||| ||||
Db 16 GGCTCTCAACTGCTCC 1

RESULT 34
US-09-818-875-3470/c
; Sequence 3470, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3470
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3470

  Query Match 8.9%; Score 12.4; DB 1; Length 17;
  Best Local Similarity 92.9%; Pred. No. 41;
  Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTGG 1699
         ||||||||||| |||
Db 14 CTCCTCCAGCTTGG 1

RESULT 35
US-09-818-875-3471
; Sequence 3471, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3471
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3471

  Query Match 8.9%; Score 12.4; DB 1; Length 17;
  Best Local Similarity 92.9%; Pred. No. 41;
  Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTGG 1699
         ||||||||||| |||
Db 4 CTCCTCCAGCTTGG 17

RESULT 36
US-09-877-478-386/c
; Sequence 386, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24

; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 386
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-386

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 41;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1736 CTCCCAACTCCTCC 1749
| ||||||||||||
Db 14 CCCCCAACTCCTCC 1

RESULT 37
US-09-827-395A-479/c
; Sequence 479, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-479

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 41;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1675 AACCCTGGTGTCTC 1688
|||||||||| |||
Db 17 AACCCTGGTGGCTC 4

RESULT 38
US-09-827-395A-990/c
; Sequence 990, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 990
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-990

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 41;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1673 GGAACCCTGGTGTC 1686
|||||||||||| |
Db 14 GGAACCCTGGTGGC 1

RESULT 39
US-10-209-787-3470/c
; Sequence 3470, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3470
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3470

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 41;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTGG 1699
|||||||||| |||
Db 14 CTCCTCCAGCTTGG 1

RESULT 40
US-10-209-787-3471
; Sequence 3471, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30

```
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3471
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-3471

  Query Match             8.9%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 41;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1686 CTCCTCCAGCGTGG 1699
              ||||||||||  |||
Db             4 CTCCTCCAGCTTGG 17


RESULT 41
US-09-866-108-527
; Sequence 527, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 527
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-527

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1644 AGCAGAAGGCAAGCACC 1660
              ||||||  | ||||||  |
Db             1 AGCAGATGACAAGCATC 17


RESULT 42
US-09-866-108-528
; Sequence 528, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 528
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-528

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1645 GCAGAAGGCAAGCACCA 1661
              ||||| | |||||| ||
Db          1 GCAGATGACAAGCATCA 17
```

RESULT 43
US-09-866-108-1264/c
; Sequence 1264, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1264
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1264

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 44;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1729 AGATTGGCTCCCAACTC 1745
              |||| | | ||||||||
Db         17 AGATCGTCCCCCAACTC 1
```

RESULT 44
US-09-866-108-7831
; Sequence 7831, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7831
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7831

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 44;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1661 AGGCTCACAGCTGGAAC 1677
              || |||||||||| | |
Db          1 AGCCTCACAGCTGAAGC 17
```

RESULT 45
US-09-866-108-9658/c
; Sequence 9658, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

```
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9658
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-9658

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1672 TGGAACCCTGGTGTCTC 1688
              |||| ||||||  ||||
Db         17 TGGACCCCTGGCCTCTC 1


RESULT 46
US-09-416-384A-26
; Sequence 26, Application US/09416384A
; Patent No. US20020081584A1
; GENERAL INFORMATION:
;  APPLICANT:  BLUMENFELD, Marta
;  APPLICANT:  BOUGUELERET, Lydie
;  APPLICANT:  CHUMAKOV, Ilya
;  APPLICANT:  COHEN, Daniel
;  APPLICANT:  ESSIOUX, Laurent
;  TITLE OF INVENTION:  Genes, proteins and biallelic markers related to central...
;  FILE REFERENCE:  GENSET.045AUS
;  CURRENT FILING DATE:  1999-10-12
;  CURRENT APPLICATION NUMBER: US/09/416,384A
;  PRIOR APPLICATION NUMBER:  60/106,457
;  PRIOR FILING DATE:  1999-10-30
;  PRIOR APPLICATION NUMBER:  60/103,955
;  PRIOR FILING DATE:  1998-10-12
;  PRIOR APPLICATION NUMBER:  60/132,277
;  PRIOR FILING DATE:  1999-05-03
;  NUMBER OF SEQ ID NOS:  71
;  SOFTWARE:  Patent.pm
; SEQ ID NO 26
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide moCTGR1511
US-09-416-384A-26

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1685 TCTCCTCCAGCGTGGTG 1701
              | |||||  ||||||| |
Db          1 TGTCCTCGAGCGTGGGG 17


RESULT 47
US-09-864-785-1557
; Sequence 1557, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1557
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-1557

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 44;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1676 ACCCTGGTGTCTCCTCC 1692
              ||| :||:|: :||: |
Db          1 ACCAUGGUGUUUCCUUC 17


RESULT 48
US-09-864-785-2921/c
; Sequence 2921, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2921
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-2921
```

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 44;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1739 CCAACTCCTCCCTATCC 1755
              ||| |||| |||| |||
Db         17 CCAGCTCCCCCCTTTCC 1
```

RESULT 49
US-09-864-785-2922/c
; Sequence 2922, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2922
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2922

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 44;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1738 CCCAACTCCTCCCTATC 1754
              |||| |||| |||| ||
Db         17 CCCAGCTCCCCCCTTTC 1
```

RESULT 50
US-09-780-533A-576
; Sequence 576, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 576
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-576

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 44;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1704 AGTTGGGTTAGGAGTAC 1720
              ||::|| : || ||:||
Db          1 AGUUGGUUCAGAAGUAC 17
```

RESULT 51
US-09-877-478-2359/c
; Sequence 2359, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2359
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2359

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 44;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1740 CAACTCCTCCCTATCCT 1756
              |||||||||||  ||| |
Db         17 CAACTCCTCCCACTCAT 1
```

RESULT 52
US-09-848-754A-1430
; Sequence 1430, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1430
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1430

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 44;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1731 ATTGGCTCCCAACTCCT 1747
```

```
              |::|||:||||   ||:
Db          1 AUUGGCUCCCAGUACCU 17


RESULT 53
US-09-848-754A-1500
; Sequence 1500, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1500
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-1500

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 44;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1685 TCTCCTCCAGCGTGGTG 1701
              :|:||:||| | :|| |
Db          1 UCUCCUCCAUCCUGGAG 17


RESULT 54
US-10-061-201-1606
; Sequence 1606, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1606
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-1606

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1671 CTGGAACCCTGGTGTCT 1687
              | ||| ||||||| |||
Db          1 CCGGAGCCCTGGTCTCT 17


RESULT 55
US-10-061-201-1608
; Sequence 1608, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1608
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-1608

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1673 GGAACCCTGGTGTCTCC 1689
              ||| ||||||| ||| |
Db          1 GGAGCCCTGGTCTCTAC 17


RESULT 56
US-10-061-201-1612
; Sequence 1612, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1612
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-1612

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1677 CCCTGGTGTCTCCTCCA 1693
              ||||||| ||| | |||
Db             1 CCCTGGTCTCTACACCA 17


RESULT 57
US-10-061-201-1762/c
; Sequence 1762, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1762
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-1762

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1749 CCTATCCTAAAGGCCCA 1765
              || |||||||| ||||
Db         17 CTTGTCCTAAAGTCCCA 1


RESULT 58
US-10-061-201-1763/c
; Sequence 1763, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1763
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-1763

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAAGGCCC 1764
              || | |||||||| |||
Db         17 CCTTGTCCTAAAGTCCC 1


RESULT 59
US-10-339-793-72
; Sequence 72, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
;  APPLICANT: Lynx Therapeutics, Inc.
;  APPLICANT:  Shang, Jin
;  APPLICANT:  Bowen, Benjamin
;  TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
;  FILE REFERENCE: 37-000310US
;  CURRENT APPLICATION NUMBER: US/10/339,793
;  CURRENT FILING DATE:  2003-01-08
;  NUMBER OF SEQ ID NOS: 443
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 72
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-339-793-72

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1735 GCTCCCAACTCCTCCCT 1751
```

```
                | |||||||| |||| |
Db          1 GATCCCAACTGCTCCTT 17


RESULT 60
US-10-060-756A-752
; Sequence 752, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 752
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-752

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 44;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 GGCTCACAGCTGGAACC 1678
              | ||||| |||||| ||
Db          1 GACTCACTGCTGGACCC 17


RESULT 61
US-10-163-552-471
; Sequence 471, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 471
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-163-552-471

  Query Match             8.8%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 44;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1749 CCTATCCTAAAGGCCCA 1765
              ||: :||:| | |||||

Db          1 CCUCUCCUACAUGCCCA 17


RESULT 62
US-10-232-634-5
; Sequence 5, Application US/10232634
; Publication No. US20030105314A1
; GENERAL INFORMATION:
;  APPLICANT: Guida, Marco
;  APPLICANT:  Hall, Jeff
;  TITLE OF INVENTION: GENETIC TYPING OF THE HUMAN CYTOCHROME P450 2A6 GENE
;  TITLE OF INVENTION:  AND RELATED MATERIALS AND METHODS
;  FILE REFERENCE: 4389-20
;  CURRENT APPLICATION NUMBER: US/10/232,634
;  CURRENT FILING DATE:  2002-08-30
;  PRIOR APPLICATION NUMBER: US/09/586,376
;  PRIOR FILING DATE: 2000-06-02
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-232-634-5

  Query Match             8.6%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1634 TGGGGCTTGTAG 1645
              ||||||||||||
Db          1 TGGGGCTTGTAG 12


RESULT 63
US-09-827-395A-755/c
; Sequence 755, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE:  2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 755
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-755

  Query Match             8.6%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1673 GGAACCCTGGTG 1684
              ||||||||||||
Db         13 GGAACCCTGGTG 2


RESULT 64
US-10-061-201-945
; Sequence 945, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 945
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-945

  Query Match             8.6%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 GCAGAAGGCAAG 1656
             ||||||||||||
Db          6 GCAGAAGGCAAG 17


RESULT 65
US-10-061-201-946
; Sequence 946, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 946
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-946

  Query Match             8.6%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 GCAGAAGGCAAG 1656
             ||||||||||||
Db          5 GCAGAAGGCAAG 16


RESULT 66
US-10-061-201-947
; Sequence 947, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 947
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-947

  Query Match             8.6%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 GCAGAAGGCAAG 1656
             ||||||||||||
Db          4 GCAGAAGGCAAG 15


RESULT 67
US-10-061-201-948
; Sequence 948, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 948
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-948

  Query Match             8.6%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 GCAGAAGGCAAG 1656
             ||||||||||||
Db          3 GCAGAAGGCAAG 14


RESULT 68
US-10-061-201-949
; Sequence 949, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 949
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-949

  Query Match             8.6%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 GCAGAAGGCAAG 1656
             ||||||||||||
Db          2 GCAGAAGGCAAG 13


RESULT 69
US-10-061-201-950
; Sequence 950, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 950
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-950

  Query Match             8.6%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 GCAGAAGGCAAG 1656
             ||||||||||||
Db          1 GCAGAAGGCAAG 12


RESULT 70
US-09-877-478-6527
; Sequence 6527, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
```

```
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6527
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-6527

  Query Match              8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   53.3%;  Pred. No. 35;
  Matches    8;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1677 CCCTGGTGTCTCCTC 1691
              || : |:|:|:||:|
Db          1 CCUUUGUGUCUCCUC 15


RESULT 71
US-09-943-983-5
; Sequence 5, Application US/09943983
; Publication No. US20030077575A1
;   GENERAL INFORMATION:
;        APPLICANT: STUYVER, LIEVEN
;                   LOUWAGIE, JOOST
;                   ROSSAU, RUDI
;        TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
;                            MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;        NUMBER OF SEQUENCES: 164
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: ARNOLD, WHITE & DURKEE
;             STREET: P.O. BOX 4433
;             CITY: HOUSTON
;             STATE: TEXAS
;             COUNTRY: USA
;             ZIP: 77210-4433
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: Microsoft Word 6.0 / ASCII text output
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/943,983
;             FILING DATE: 31-Aug-2001
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/913,833
;             FILING DATE: 1997-09-15
;             APPLICATION NUMBER: EP 96870005.4
;             FILING DATE: 26 Jan 1996
;             APPLICATION NUMBER: EP 96870081.5
;             FILING DATE: 25 Jun 1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: KAMMERER, PATRICIA A.
;             REGISTRATION NUMBER: 29,775
;             REFERENCE/DOCKET NUMBER: INNS:008
;   INFORMATION FOR SEQ ID NO: 5:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-943-983-5

  Query Match              8.5%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 35;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 GTACGGAGATGGAGA 1731
              |||| |||||||| |
Db          1 GTACAGAGATGGAAA 15


RESULT 72
US-09-510-378-27/c
; Sequence 27, Application US/09510378
; Publication No. US20030165823A1
;   GENERAL INFORMATION:
;        APPLICANT: Cronin, Maureen T.
;                   Miyada, Charles Garrett
;                   Hubbell, Earl A.
;                   Chee, Mark
;                   Fodor, Stephen P.A.
;                   Huang, Xiaohua C.
;                   Lipshutz, Robert J.
;                   Lobban, Peter E.
;                   Morris, Macdonald S.
;                   Sheldon, Edward L.
;        TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
;                            Detecting Cystic Fibrosis
;        NUMBER OF SEQUENCES: 250
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/510,378
;             FILING DATE: 22-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/544,381
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 08/510,521
;             FILING DATE: 02-AUG-1995
;             APPLICATION NUMBER: PCT/US94/12305
;             FILING DATE: 26-OCT-1994
;             APPLICATION NUMBER: US 08/284,064
;             FILING DATE: 02-AUG-1994
;             APPLICATION NUMBER: US 08/143,312
;             FILING DATE: 26-OCT-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-004130US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-576-0200
;             TELEFAX: 415-576-0300
;   INFORMATION FOR SEQ ID NO: 27:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 13 base pairs
;             TYPE: nucleic acid
```

```
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (oligonucleotide)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-09-510-378-27

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 26;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||||||||||
Db         13 AGGGCAAGCACCA 1


RESULT 73
US-09-798-260-85/c
; Sequence 85, Application US/09798260
; Publication No. US20030165830A1
; GENERAL INFORMATION:
;  APPLICANT: Cronin, Maureen T.
;  APPLICANT:  Miyada, Charles G.
;  APPLICANT:  Hubbell, Earl A.
;  APPLICANT:  Chee, Mark
;  APPLICANT:  Fodor, Stephen P. A.
;  APPLICANT:  Huang, Xiaohua C.
;  APPLICANT:  Lipshutz, Robert J.
;  APPLICANT:  Lobban, Peter E.
;  APPLICANT:  Morris, MacDonald S.
;  APPLICANT:  Sheldon, Edward L.
;  TITLE OF INVENTION: ARRAYS OF NUCLEIC ACID PROBES FOR ANALYZING
;  TITLE OF INVENTION:  BIOTRANSFORMATION GENES
;  FILE REFERENCE: 018547-015720US
;  CURRENT APPLICATION NUMBER: US/09/798,260
;  CURRENT FILING DATE:  2002-05-01
;  PRIOR APPLICATION NUMBER: US 08/778,794
;  PRIOR FILING DATE: 1997-01-03
;  PRIOR APPLICATION NUMBER: US 08/544,381
;  PRIOR FILING DATE: 1995-10-10
;  PRIOR APPLICATION NUMBER: US 08/510,521
;  PRIOR FILING DATE: 1995-08-02
;  PRIOR APPLICATION NUMBER: WO PCT/US94/12305
;  PRIOR FILING DATE: 1994-10-26
;  PRIOR APPLICATION NUMBER: US 08/284,064
;  PRIOR FILING DATE: 1994-08-02
;  PRIOR APPLICATION NUMBER: US 08/143,312
;  PRIOR FILING DATE: 1993-10-26
;  NUMBER OF SEQ ID NOS: 156
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 85
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-798-260-85

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 26;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||||||||||
Db         13 AGGGCAAGCACCA 1


RESULT 74
US-09-943-983-9
; Sequence 9, Application US/09943983
; Publication No. US20030077575A1
;   GENERAL INFORMATION:
;        APPLICANT: STUYVER, LIEVEN
;                   LOUWAGIE, JOOST
;                   ROSSAU, RUDI
;        TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
;                            MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;        NUMBER OF SEQUENCES: 164
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: ARNOLD, WHITE & DURKEE
;             STREET: P.O. BOX 4433
;             CITY: HOUSTON
;             STATE: TEXAS
;             COUNTRY: USA
;             ZIP: 77210-4433
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: Microsoft Word 6.0 / ASCII text output
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/943,983
;             FILING DATE: 31-Aug-2001
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/913,833
;             FILING DATE: 1997-09-15
;             APPLICATION NUMBER: EP 96870005.4
;             FILING DATE: 26 Jan 1996
;             APPLICATION NUMBER: EP 96870081.5
;             FILING DATE: 25 Jun 1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: KAMMERER, PATRICIA A.
;             REGISTRATION NUMBER: 29,775
;             REFERENCE/DOCKET NUMBER: INNS:008
;    INFORMATION FOR SEQ ID NO: 9:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 14 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-943-983-9

  Query Match             8.2%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 33;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1717 GTACGGAGATGGA 1729
              |||| ||||||||
Db          1 GTACAGAGATGGA 13


RESULT 75
US-09-504-231A-474
; Sequence 474, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATEI
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/504,231A
;  CURRENT FILING DATE:  2000-02-15
;  PRIOR APPLICATION NUMBER: 09/274,553
;  PRIOR FILING DATE: 1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
```

; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 474
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-474

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 41;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTG 1698
|:||:||| ||:|
Db 3 CUCCUCCAACGUG 15

RESULT 76
US-09-274-553D-474
; Sequence 474, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: rpi 247/282
; CURRENT APPLICATION NUMBER: US/09/274,553D
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 474
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-474

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 41;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTG 1698
|:||:||| ||:|
Db 3 CUCCUCCAACGUG 15

RESULT 77
US-10-091-281-319/c
; Sequence 319, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 319
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative MYOD/E47.02 motif
US-10-091-281-319

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1663 GCTCACAGCTGGAACC 1678
||||||| ||| || |
Db 16 GCTCACACCTGTAATC 1

RESULT 78
US-10-043-875-261/c
; Sequence 261, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; TITLE OF INVENTION: Transcriptase Gene
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 261
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-261

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1690 TCCAGCGTGGTGGAAG 1705
|||| | | |||||||
Db 16 TCCATCCTTGTGGAAG 1

RESULT 79
US-10-163-552-471/c
; Sequence 471, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-471

```
  Query Match             8.1%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 63;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1636 GGGCTTGTAGCAGAAG 1651
              |||| ||||| ||| |
Db         16 GGGCATGTAGGAGAGG 1


RESULT 80
US-09-943-983-4
; Sequence 4, Application US/09943983
; Publication No. US20030077575A1
;   GENERAL INFORMATION:
;        APPLICANT: STUYVER, LIEVEN
;                   LOUWAGIE, JOOST
;                   ROSSAU, RUDI
;        TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
;                            MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;        NUMBER OF SEQUENCES: 164
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: ARNOLD, WHITE & DURKEE
;             STREET: P.O. BOX 4433
;             CITY: HOUSTON
;             STATE: TEXAS
;             COUNTRY: USA
;             ZIP: 77210-4433
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: Microsoft Word 6.0 / ASCII text output
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/943,983
;             FILING DATE: 31-Aug-2001
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/913,833
;             FILING DATE: 1997-09-15
;             APPLICATION NUMBER: EP 96870005.4
;             FILING DATE: 26 Jan 1996
;             APPLICATION NUMBER: EP 96870081.5
;             FILING DATE: 25 Jun 1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: KAMMERER, PATRICIA A.
;             REGISTRATION NUMBER: 29,775
;             REFERENCE/DOCKET NUMBER: INNS:008
;   INFORMATION FOR SEQ ID NO: 4:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 14 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-943-983-4

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 14;
  Best Local Similarity   85.7%;  Pred. No. 42;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 TACGGAGATGGAGA 1731
              ||| |||||||| |
Db          1 TACAGAGATGGAAA 14


RESULT 81
US-09-263-959-672
; Sequence 672, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  672:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-672

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATCCT 1756
              ||||||| | ||||
Db          2 CTCCTCCTTCTCCT 15


RESULT 82
US-09-263-959-708
; Sequence 708, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
```

```
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  708:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-708

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATCCT 1756
              ||||||| | ||||
Db          2 CTCCTCCTTCTCCT 15


RESULT 83
US-09-860-784-8
; Sequence 8, Application US/09860784
; Patent No. US20020151512A1
;   GENERAL INFORMATION:
;        APPLICANT: PEYMAN, Anuschirwan
;                   UHLMANN, Eugen
;        TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
;        NUMBER OF SEQUENCES: 105
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Foley & Lardner
;             STREET: 3000 K Street, N.W., Suite 500
;             CITY: Washington
;             STATE: D.C.
;             COUNTRY: USA
;             ZIP: 20007-5109
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/860,784
;             FILING DATE: 21-May-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/594,452
;             FILING DATE: 04-APR-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: SANDERCOCK, Colin G.
;             REGISTRATION NUMBER: 31,298
;             REFERENCE/DOCKET NUMBER: 18748/264/HOCE
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (202)672-5300
;             TELEFAX: (202)672-5399
;             TELEX: 904136
;   INFORMATION FOR SEQ ID NO: 8:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-860-784-8

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 84
US-09-835-371-5
; Sequence 5, Application US/09835371
; Publication No. US20020187473A1
; GENERAL INFORMATION:
;  APPLICANT: UHLMANN, Eugen
;  APPLICANT:  BREIPOHL, Gerhard
;  APPLICANT:  WILL, David W
;  TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
;  TITLE OF INVENTION:  PROCESSES FOR PREPARING THEM
;  FILE REFERENCE: 02481.1743 SEQUENCE LISTING
;  CURRENT APPLICATION NUMBER: US/09/835,371
;  CURRENT FILING DATE:  2001-04-17
;  NUMBER OF SEQ ID NOS: 53
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  base sequence
;   OTHER INFORMATION: of PNA targeting CMV
US-09-835-371-5

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 85
US-09-835-370-5
; Sequence 5, Application US/09835370
; Publication No. US20030022172A1
; GENERAL INFORMATION:
;  APPLICANT: UHLMANN, EUGEN
;  APPLICANT:  BREIPOHL, GERHARD
;  APPLICANT:  WILL, DAVID W
;  TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
;  TITLE OF INVENTION:  PROCESSES FOR PREPARING THEM
;  FILE REFERENCE: 02481.1742 SEQUENCE LISTING
;  CURRENT APPLICATION NUMBER: US/09/835,370
;  CURRENT FILING DATE:  2001-04-17
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  nucleotide
;   OTHER INFORMATION: base sequence of PNA derivatives that bind to
;   OTHER INFORMATION: viral and cellular targets
US-09-835-370-5

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 86
US-09-880-313A-49/c
; Sequence 49, Application US/09880313A
; Publication No. US20030044791A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Flemington, Erik K
;  TITLE OF INVENTION: Adaptors and Methods of Use
;  FILE REFERENCE: 9397/1000
;  CURRENT APPLICATION NUMBER: US/09/880,313A
;  CURRENT FILING DATE:  2001-06-13
;  NUMBER OF SEQ ID NOS: 276
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-09-880-313A-49

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1644 AGCAGAAGGCAAGC 1657
              ||| | ||||||||
Db         15 AGCTGCAGGCAAGC 2


RESULT 87
US-10-418-182-186
; Sequence 186, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
;  APPLICANT: Crea, Roberto
;  TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
;  FILE REFERENCE: 1551.2001-001
;  CURRENT APPLICATION NUMBER: US/10/418,182
;  CURRENT FILING DATE:  2003-04-16
;  PRIOR APPLICATION NUMBER: 60/373,558
;  PRIOR FILING DATE: 2002-04-17
;  NUMBER OF SEQ ID NOS: 423
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 186
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-10-418-182-186

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATCCT 1756
              ||||||| | ||||
Db          1 CTCCTCCTTCTCCT 14


RESULT 88
US-09-793-146-7
; Sequence 7, Application US/09793146
; Publication No. US20030203359A1
; GENERAL INFORMATION:
;  APPLICANT: UHLMANN, EUGEN
;  APPLICANT:  BREIPOHL, GERHARD
;  TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
;  TITLE OF INVENTION:  PREPARATION AND USE
;  FILE REFERENCE: 02481.1437-02
;  CURRENT APPLICATION NUMBER: US/09/793,146
;  CURRENT FILING DATE:  2001-02-27
;  PRIOR APPLICATION NUMBER: P 44 08 528.1
;  PRIOR FILING DATE: 1994-03-14
;  PRIOR APPLICATION NUMBER: 08/402,838
;  PRIOR FILING DATE: 1995-03-13
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-7

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 89
US-10-440-850-823
; Sequence 823, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revers
;  TITLE OF INVENTION:  Immune Responses
;  FILE REFERENCE: 250/130 (MBHB00-900-A)
;  CURRENT APPLICATION NUMBER: US/10/440,850
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: US/09/650,012
;  PRIOR FILING DATE: 2000-08-28
;  PRIOR APPLICATION NUMBER: US 08/585,684
;  PRIOR FILING DATE: 1996-01-12
;  PRIOR APPLICATION NUMBER: US 60/000,951
;  PRIOR FILING DATE: 1995-07-07
;  PRIOR APPLICATION NUMBER: US 09/038,073
;  PRIOR FILING DATE: 1998-03-11
;  NUMBER OF SEQ ID NOS: 2285
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 823
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-440-850-823

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   57.1%;  Pred. No. 51;
  Matches    8;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1678 CCTGGTGTCTCCTC 1691
              ||:||: :| ||:|
Db          2 CCUGGUCUCACCUC 15


RESULT 90
US-10-010-802-130/c
; Sequence 130, Application US/10010802
; Publication No. US20030078220A1
; GENERAL INFORMATION:
;  APPLICANT: Genaissance Pharmaceuticals
;  APPLICANT:  Chew, Anne
;  APPLICANT:  Denton, R. Rex
;  APPLICANT:  Duda, Amy
;  APPLICANT:  Nandabalan, Krishnan
;  APPLICANT:  Stephens, J. Claiborne
;  APPLICANT:  Windemuth, Andreas
;  TITLE OF INVENTION: Drug Target Isogenes: Polymorphisms in the Interleukin
;  TITLE OF INVENTION:  4 Receptor Alpha Gene
;  FILE REFERENCE: MWH-0002US2 IL4R alpha
;  CURRENT APPLICATION NUMBER: US/10/010,802
```

```
;  CURRENT FILING DATE:  2001-11-09
;  PRIOR APPLICATION NUMBER: PCT/US00/19094
;  PRIOR FILING DATE: 2000-07-13
;  NUMBER OF SEQ ID NOS: 413
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 130
;    LENGTH: 15
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-010-802-130

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 51;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 GAGATTGGCTCCCA 1741
              ||| ||| ||||||
Db         15 GAGCTTGCCTCCCA 2


RESULT 91
US-09-877-478-2360
; Sequence 2360, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2360
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Hepatitis B virus
US-09-877-478-2360

  Query Match             7.6%;  Score 10.6;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 77;
  Matches   10;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1694 GCGTGGTGGAAGTTGGG 1710
              | |:||  | ||::|||
Db          1 GAGUGGGAGGAGUUGGG 17


RESULT 92
US-10-027-632-51889/c
; Sequence 51889, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
;  APPLICANT: Wang, David G.
;  TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
;  TITLE OF INVENTION:  Polymorphisms in the Human Genome
;  FILE REFERENCE: 108827.129
;  CURRENT APPLICATION NUMBER: US/10/027,632
;  CURRENT FILING DATE:  2002-04-30
;  PRIOR APPLICATION NUMBER: US 60/218,006
;  PRIOR FILING DATE: 2000-07-12
;  PRIOR APPLICATION NUMBER: US 60/198,676
;  PRIOR FILING DATE: 2000-04-20
;  PRIOR APPLICATION NUMBER: US 60/193,483
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: US 60/185,218
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: US 60/167,363
;  PRIOR FILING DATE: 1999-11-23
;  PRIOR APPLICATION NUMBER: US 60/156,358
;  PRIOR FILING DATE: 1999-09-28
;  PRIOR APPLICATION NUMBER: US 60/146,002
;  PRIOR FILING DATE: 1999-08-09
;  NUMBER OF SEQ ID NOS: 325720
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 51889
;    LENGTH: 14
;    TYPE: DNA
;    ORGANISM: Human
US-10-027-632-51889

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   78.6%;  Pred. No. 48;
  Matches   11;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGATTG 1734
              :|||||| |||| |
Db         14 KGAGATGCAGATAG 1


RESULT 93
US-10-027-632-51889/c
; Sequence 51889, Application US/10027632
; GENERAL INFORMATION:
;  APPLICANT: Wang, David G.
;  TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
;  TITLE OF INVENTION:  Polymorphisms in the Human Genome
;  FILE REFERENCE: 108827.129
;  CURRENT APPLICATION NUMBER: US/10/027,632
;  CURRENT FILING DATE:  2002-04-30
;  PRIOR APPLICATION NUMBER: US 60/218,006
;  PRIOR FILING DATE: 2000-07-12
;  PRIOR APPLICATION NUMBER: US 60/198,676
;  PRIOR FILING DATE: 2000-04-20
;  PRIOR APPLICATION NUMBER: US 60/193,483
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: US 60/185,218
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: US 60/167,363
;  PRIOR FILING DATE: 1999-11-23
;  PRIOR APPLICATION NUMBER: US 60/156,358
;  PRIOR FILING DATE: 1999-09-28
;  PRIOR APPLICATION NUMBER: US 60/146,002
;  PRIOR FILING DATE: 1999-08-09
;  NUMBER OF SEQ ID NOS: 325720
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 51889
;    LENGTH: 14
;    TYPE: DNA
;    ORGANISM: Human
US-10-027-632-51889

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   78.6%;  Pred. No. 48;
  Matches . 11;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGATTG 1734
```

```
              :|||||| |||| |
Db          14 KGAGATGCAGATAG 1


RESULT 94
US-10-027-632-51894/c
; Sequence 51894, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
;  APPLICANT: Wang, David G.
;  TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
;  TITLE OF INVENTION:  Polymorphisms in the Human Genome
;  FILE REFERENCE: 108827.129
;  CURRENT APPLICATION NUMBER: US/10/027,632
;  CURRENT FILING DATE:  2002-04-30
;  PRIOR APPLICATION NUMBER: US 60/218,006
;  PRIOR FILING DATE: 2000-07-12
;  PRIOR APPLICATION NUMBER: US 60/198,676
;  PRIOR FILING DATE: 2000-04-20
;  PRIOR APPLICATION NUMBER: US 60/193,483
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: US 60/185,218
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: US 60/167,363
;  PRIOR FILING DATE: 1999-11-23
;  PRIOR APPLICATION NUMBER: US 60/156,358
;  PRIOR FILING DATE: 1999-09-28
;  PRIOR APPLICATION NUMBER: US 60/146,002
;  PRIOR FILING DATE: 1999-08-09
;  NUMBER OF SEQ ID NOS: 325720
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 51894
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Human
US-10-027-632-51894

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   78.6%;  Pred. No. 48;
  Matches   11;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGATTG 1734
              :|||||| |||| |
Db         14 KGAGATGCAGATAG 1


RESULT 95
US-10-027-632-51894/c
; Sequence 51894, Application US/10027632
; GENERAL INFORMATION:
;  APPLICANT: Wang, David G.
;  TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
;  TITLE OF INVENTION:  Polymorphisms in the Human Genome
;  FILE REFERENCE: 108827.129
;  CURRENT APPLICATION NUMBER: US/10/027,632
;  CURRENT FILING DATE:  2002-04-30
;  PRIOR APPLICATION NUMBER: US 60/218,006
;  PRIOR FILING DATE: 2000-07-12
;  PRIOR APPLICATION NUMBER: US 60/198,676
;  PRIOR FILING DATE: 2000-04-20
;  PRIOR APPLICATION NUMBER: US 60/193,483
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: US 60/185,218
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: US 60/167,363
;  PRIOR FILING DATE: 1999-11-23
;  PRIOR APPLICATION NUMBER: US 60/156,358
;  PRIOR FILING DATE: 1999-09-28
;  PRIOR APPLICATION NUMBER: US 60/146,002
;  PRIOR FILING DATE: 1999-08-09
;  NUMBER OF SEQ ID NOS: 325720
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 51894
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Human
US-10-027-632-51894

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   78.6%;  Pred. No. 48;
  Matches   11;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGATTG 1734
              :|||||| |||| |
Db         14 KGAGATGCAGATAG 1


RESULT 96
US-10-146-058-90/c
; Sequence 90, Application US/10146058
; Publication No. US20030040499A1
;  GENERAL INFORMATION:
;    APPLICANT:  Schlingensiepen, Georg-Ferdinand
;    APPLICANT:  Brysch, Wolfgang
;    APPLICANT:  Schlingensiepen, Karl-Hermann
;    APPLICANT:  Schlingensiepen, Reimar
;    APPLICANT:  Bogdahn, Ulrich
;    TITLE OF INVENTION:  Antisense-oligonucleotides for the treatment of
;    TITLE OF INVENTION:  immuno-suppressive effect of transforming-growth-factor beta (T
;    NUMBER OF SEQUENCES:  137
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman & Stern
;      STREET:  400 Seventh St. N.W.
;      CITY:  Washington D.C
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/146,058
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/535,249
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93 107 089.0
;      FILING DATE:  30-APR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93 107 849.7
;      FILING DATE:  13-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Player, William E.
;      REGISTRATION NUMBER:  31,409
;      REFERENCE/DOCKET NUMBER:  10577/P58418
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-6666
;      TELEFAX:  (202) 393-5350
;      TELEX:  RCA 248593 IDEA UR
;  INFORMATION FOR SEQ ID NO:  90:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  YES
US-10-146-058-90

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   91.7%;  Pred. No. 48;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1644 AGCAGAAGGCAA 1655
              ||||||||||  |
Db         14 AGCAGAAGGCGA 3
```

```
RESULT 97
US-09-877-478-2361
; Sequence 2361, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2361
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-2361

  Query Match             7.3%;  Score 10.2;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 88;
  Matches    9;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGTTGGG 1710
              |:||  | ||::|||
Db          2 GUGGGAGGAGUUGGG 16
```

```
RESULT 98
US-09-848-754A-1500/c
; Sequence 1500, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1500
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-1500

  Query Match             7.3%;  Score 10.2;  DB 1;  Length 17;
  Best Local Similarity   80.0%;  Pred. No. 88;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1689 CTCCAGCGTGGTGGA 1703
              ||||||  ||| |||
Db         17 CTCCAGGATGGAGGA 3
```

```
RESULT 99
US-09-757-049A-42/c
; Sequence 42, Application US/09757049A
; Patent No. US20020127702A1
; GENERAL INFORMATION:
;  APPLICANT: BERNSTEIN, Harold S.
;  APPLICANT:  COUGHLIN, Shaun R.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REGULATING CELL CYCLE
;  TITLE OF INVENTION:  PROGRESSION
;  FILE REFERENCE: UCSF-020/02US
;  CURRENT APPLICATION NUMBER: US/09/757,049A
;  CURRENT FILING DATE:  2001-01-08
;  PRIOR APPLICATION NUMBER: US 09/156,316
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: US 60/060,688
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 50
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-757-049A-42

  Query Match             7.2%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1749 CCTATCCTAA 1758
              ||||||||||
Db         12 CCTATCCTAA 3
```

```
RESULT 100
US-10-325-403-11/c
; Sequence 11, Application US/10325403
; Publication No. US20030162264A1
;   GENERAL INFORMATION:
;        APPLICANT: James D. Thompson
;                   Kenneth G. Draper
;        TITLE OF INVENTION: METHOD AND REAGENT FOR
;                            TREATMENT OF DISEASES CAUSED
;                            BY EXPRESSION OF THE c-MYC
;                            GENE
;        NUMBER OF SEQUENCES: 41
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Lyon & Lyon
;             STREET: 611 West Sixth Street
;             CITY: Los Angeles
;             STATE: California
;             COUNTRY: USA
;             ZIP: 90017
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
;             COMPUTER: IBM compatible
;             OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
;             SOFTWARE: WordPerfect (Version 5.1)
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/325,403
;             FILING DATE: 23-Dec-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/192,943
;             FILING DATE: <Unknown>
```

```
;              APPLICATION NUMBER: US/07/936,422
;              FILING DATE: <Unknown>
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Warburg, Richard J.
;              REGISTRATION NUMBER: 32,327
;              REFERENCE/DOCKET NUMBER: 197/241
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (213) 489-1600
;              TELEFAX: (213) 955-0440
;              TELEX: 67-3510
;    INFORMATION FOR SEQ ID NO: 11:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 12
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-10-325-403-11

  Query Match             7.2%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1683 TGTCTCCTCC 1692
              ||||||||||
Db         11 TGTCTCCTCC 2


RESULT 101
US-09-865-644-15/c
; Sequence 15, Application US/09865644
; Patent No. US20020045188A1
; GENERAL INFORMATION:
;  APPLICANT: Kamb et al
;  TITLE OF INVENTION: METHODS FOR VALIDATING POLYPEPTIDE TARGETS THAT CORRELATE TO
;  TITLE OF INVENTION:  CELLULAR PHENOTYPES
;  FILE REFERENCE: 29345/37561
;  CURRENT APPLICATION NUMBER: US/09/865,644
;  CURRENT FILING DATE:  2001-08-20
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Aptamer 3305
US-09-865-644-15

  Query Match             7.2%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 45;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1690 TCCAGCGTGG 1699
              ||||||||||
Db         13 TCCAGCGTGG 4


RESULT 102
US-10-446-901-7
; Sequence 7, Application US/10446901
; Publication No. US20030232781A1
; GENERAL INFORMATION:
;  APPLICANT: Wolffe, Alan P
;  TITLE OF INVENTION: MODULATION OF GENE EXPRESSION USING INSULATOR BINDING PROTEINS
;  FILE REFERENCE: SABI-015/01US  (S21-US1)
;  CURRENT APPLICATION NUMBER: US/10/446,901
;  CURRENT FILING DATE:  2003-05-27
;  PRIOR APPLICATION NUMBER: PCT/US01/44654
;  PRIOR FILING DATE: 2001-11-28
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: core sequence
US-10-446-901-7

  Query Match             7.2%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   83.3%;  Pred. No. 45;
  Matches   10;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1694 GCGTGGTGGAAG 1705
              |||:|||| ||
Db          2 GCGKGGTGGCAG 13


RESULT 103
US-09-510-378-19/c
; Sequence 19, Application US/09510378
; Publication No. US20030165823A1
;   GENERAL INFORMATION:
;        APPLICANT: Cronin, Maureen T.
;                   Miyada, Charles Garrett
;                   Hubbell, Earl A.
;                   Chee, Mark
;                   Fodor, Stephen P.A.
;                   Huang, Xiaohua C.
;                   Lipshutz, Robert J.
;                   Lobban, Peter E.
;                   Morris, Macdonald S.
;                   Sheldon, Edward L.
;        TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
;                            Detecting Cystic Fibrosis
;        NUMBER OF SEQUENCES: 250
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/510,378
;             FILING DATE: 22-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/544,381
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 08/510,521
;             FILING DATE: 02-AUG-1995
;             APPLICATION NUMBER: PCT/US94/12305
;             FILING DATE: 26-OCT-1994
;             APPLICATION NUMBER: US 08/284,064
;             FILING DATE: 02-AUG-1994
;             APPLICATION NUMBER: US 08/143,312
;             FILING DATE: 26-OCT-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-004130US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-576-0200
;             TELEFAX: 415-576-0300
;   INFORMATION FOR SEQ ID NO: 19:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 13 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (oligonucleotide)
```

```
;       SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-510-378-19

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 48;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||| |||||||
Db         13 AGGGCGAGCACCA 1

RESULT 104
US-09-510-378-23/c
; Sequence 23, Application US/09510378
; Publication No. US20030165823A1
;   GENERAL INFORMATION:
;        APPLICANT: Cronin, Maureen T.
;                   Miyada, Charles Garrett
;                   Hubbell, Earl A.
;                   Chee, Mark
;                   Fodor, Stephen P.A.
;                   Huang, Xiaohua C.
;                   Lipshutz, Robert J.
;                   Lobban, Peter E.
;                   Morris, Macdonald S.
;                   Sheldon, Edward L.
;        TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
;                            Detecting Cystic Fibrosis
;        NUMBER OF SEQUENCES: 250
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/510,378
;             FILING DATE: 22-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/544,381
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 08/510,521
;             FILING DATE: 02-AUG-1995
;             APPLICATION NUMBER: PCT/US94/12305
;             FILING DATE: 26-OCT-1994
;             APPLICATION NUMBER: US 08/284,064
;             FILING DATE: 02-AUG-1994
;             APPLICATION NUMBER: US 08/143,312
;             FILING DATE: 26-OCT-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-004130US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-576-0200
;             TELEFAX: 415-576-0300
;   INFORMATION FOR SEQ ID NO: 23:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 13 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (oligonucleotide)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-09-510-378-23

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 48;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | |||| ||||||
Db         13 AGGGCACGCACCA 1

RESULT 105
US-09-510-378-24/c
; Sequence 24, Application US/09510378
; Publication No. US20030165823A1
;   GENERAL INFORMATION:
;        APPLICANT: Cronin, Maureen T.
;                   Miyada, Charles Garrett
;                   Hubbell, Earl A.
;                   Chee, Mark
;                   Fodor, Stephen P.A.
;                   Huang, Xiaohua C.
;                   Lipshutz, Robert J.
;                   Lobban, Peter E.
;                   Morris, Macdonald S.
;                   Sheldon, Edward L.
;        TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
;                            Detecting Cystic Fibrosis
;        NUMBER OF SEQUENCES: 250
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/510,378
;             FILING DATE: 22-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/544,381
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 08/510,521
;             FILING DATE: 02-AUG-1995
;             APPLICATION NUMBER: PCT/US94/12305
;             FILING DATE: 26-OCT-1994
;             APPLICATION NUMBER: US 08/284,064
;             FILING DATE: 02-AUG-1994
;             APPLICATION NUMBER: US 08/143,312
;             FILING DATE: 26-OCT-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-004130US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-576-0200
;             TELEFAX: 415-576-0300
;   INFORMATION FOR SEQ ID NO: 24:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 13 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (oligonucleotide)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-09-510-378-24

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
```

Best Local Similarity 84.6%; Pred. No. 48;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
| ||| |||||||
Db 13 AGGGCGAGCACCA 1

RESULT 106
US-09-510-378-26/c
; Sequence 26, Application US/09510378
; Publication No. US20030165823A1
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; Miyada, Charles Garrett
; Hubbell, Earl A.
; Chee, Mark
; Fodor, Stephen P.A.
; Huang, Xiaohua C.
; Lipshutz, Robert J.
; Lobban, Peter E.
; Morris, Macdonald S.
; Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/510,378
; FILING DATE: 22-Feb-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/544,381
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004130US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-09-510-378-26

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 48;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
| ||||| |||||
Db 13 AGGGCAATCACCA 1

RESULT 107
US-09-510-378-28/c
; Sequence 28, Application US/09510378
; Publication No. US20030165823A1
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; Miyada, Charles Garrett
; Hubbell, Earl A.
; Chee, Mark
; Fodor, Stephen P.A.
; Huang, Xiaohua C.
; Lipshutz, Robert J.
; Lobban, Peter E.
; Morris, Macdonald S.
; Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/510,378
; FILING DATE: 22-Feb-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/544,381
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004130US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-510-378-28

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 48;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661

```
                    | ||||| |||||
Db          13 AGGGCAACCACCA 1


RESULT 108
US-09-510-378-29/c
; Sequence 29, Application US/09510378
; Publication No. US20030165823A1
;   GENERAL INFORMATION:
;        APPLICANT: Cronin, Maureen T.
;                   Miyada, Charles Garrett
;                   Hubbell, Earl A.
;                   Chee, Mark
;                   Fodor, Stephen P.A.
;                   Huang, Xiaohua C.
;                   Lipshutz, Robert J.
;                   Lobban, Peter E.
;                   Morris, Macdonald S.
;                   Sheldon, Edward L.
;        TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
;                            Detecting Cystic Fibrosis
;        NUMBER OF SEQUENCES: 250
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/510,378
;             FILING DATE: 22-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/544,381
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 08/510,521
;             FILING DATE: 02-AUG-1995
;             APPLICATION NUMBER: PCT/US94/12305
;             FILING DATE: 26-OCT-1994
;             APPLICATION NUMBER: US 08/284,064
;             FILING DATE: 02-AUG-1994
;             APPLICATION NUMBER: US 08/143,312
;             FILING DATE: 26-OCT-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-004130US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-576-0200
;             TELEFAX: 415-576-0300
;   INFORMATION FOR SEQ ID NO: 29:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 13 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (oligonucleotide)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-09-510-378-29

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 48;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
                | ||||| |||||
Db         13 AGGGCAAACACCA 1


RESULT 109
US-09-798-260-77/c
; Sequence 77, Application US/09798260
; Publication No. US20030165830A1
; GENERAL INFORMATION:
;  APPLICANT: Cronin, Maureen T.
;  APPLICANT:  Miyada, Charles G.
;  APPLICANT:  Hubbell, Earl A.
;  APPLICANT:  Chee, Mark
;  APPLICANT:  Fodor, Stephen P. A.
;  APPLICANT:  Huang, Xiaohua C.
;  APPLICANT:  Lipshutz, Robert J.
;  APPLICANT:  Lobban, Peter E.
;  APPLICANT:  Morris, MacDonald S.
;  APPLICANT:  Sheldon, Edward L.
;  TITLE OF INVENTION: ARRAYS OF NUCLEIC ACID PROBES FOR ANALYZING
;  TITLE OF INVENTION:  BIOTRANSFORMATION GENES
;  FILE REFERENCE: 018547-015720US
;  CURRENT APPLICATION NUMBER: US/09/798,260
;  CURRENT FILING DATE:  2002-05-01
;  PRIOR APPLICATION NUMBER: US 08/778,794
;  PRIOR FILING DATE: 1997-01-03
;  PRIOR APPLICATION NUMBER: US 08/544,381
;  PRIOR FILING DATE: 1995-10-10
;  PRIOR APPLICATION NUMBER: US 08/510,521
;  PRIOR FILING DATE: 1995-08-02
;  PRIOR APPLICATION NUMBER: WO PCT/US94/12305
;  PRIOR FILING DATE: 1994-10-26
;  PRIOR APPLICATION NUMBER: US 08/284,064
;  PRIOR FILING DATE: 1994-08-02
;  PRIOR APPLICATION NUMBER: US 08/143,312
;  PRIOR FILING DATE: 1993-10-26
;  NUMBER OF SEQ ID NOS: 156
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 77
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-798-260-77

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 48;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
                | ||| |||||||
Db         13 AGGGCGAGCACCA 1


RESULT 110
US-09-798-260-81/c
; Sequence 81, Application US/09798260
; Publication No. US20030165830A1
; GENERAL INFORMATION:
;  APPLICANT: Cronin, Maureen T.
;  APPLICANT:  Miyada, Charles G.
;  APPLICANT:  Hubbell, Earl A.
;  APPLICANT:  Chee, Mark
;  APPLICANT:  Fodor, Stephen P. A.
;  APPLICANT:  Huang, Xiaohua C.
;  APPLICANT:  Lipshutz, Robert J.
;  APPLICANT:  Lobban, Peter E.
;  APPLICANT:  Morris, MacDonald S.
;  APPLICANT:  Sheldon, Edward L.
;  TITLE OF INVENTION: ARRAYS OF NUCLEIC ACID PROBES FOR ANALYZING
;  TITLE OF INVENTION:  BIOTRANSFORMATION GENES
;  FILE REFERENCE: 018547-015720US
;  CURRENT APPLICATION NUMBER: US/09/798,260
;  CURRENT FILING DATE:  2002-05-01
```

; PRIOR APPLICATION NUMBER: US 08/778,794
; PRIOR FILING DATE: 1997-01-03
; PRIOR APPLICATION NUMBER: US 08/544,381
; PRIOR FILING DATE: 1995-10-10
; PRIOR APPLICATION NUMBER: US 08/510,521
; PRIOR FILING DATE: 1995-08-02
; PRIOR APPLICATION NUMBER: WO PCT/US94/12305
; PRIOR FILING DATE: 1994-10-26
; PRIOR APPLICATION NUMBER: US 08/284,064
; PRIOR FILING DATE: 1994-08-02
; PRIOR APPLICATION NUMBER: US 08/143,312
; PRIOR FILING DATE: 1993-10-26
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 81
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-798-260-81

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 48;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
| |||| |||||
Db 13 AGGGCACGCACCA 1

RESULT 111
US-09-798-260-84/c
; Sequence 84, Application US/09798260
; Publication No. US20030165830A1
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles G.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P. A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, MacDonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: ARRAYS OF NUCLEIC ACID PROBES FOR ANALYZING
; TITLE OF INVENTION: BIOTRANSFORMATION GENES
; FILE REFERENCE: 018547-015720US
; CURRENT APPLICATION NUMBER: US/09/798,260
; CURRENT FILING DATE: 2002-05-01
; PRIOR APPLICATION NUMBER: US 08/778,794
; PRIOR FILING DATE: 1997-01-03
; PRIOR APPLICATION NUMBER: US 08/544,381
; PRIOR FILING DATE: 1995-10-10
; PRIOR APPLICATION NUMBER: US 08/510,521
; PRIOR FILING DATE: 1995-08-02
; PRIOR APPLICATION NUMBER: WO PCT/US94/12305
; PRIOR FILING DATE: 1994-10-26
; PRIOR APPLICATION NUMBER: US 08/284,064
; PRIOR FILING DATE: 1994-08-02
; PRIOR APPLICATION NUMBER: US 08/143,312
; PRIOR FILING DATE: 1993-10-26
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 84
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-798-260-84

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 48;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
| |||| |||||
Db 13 AGGGCAATCACCA 1

RESULT 112
US-09-798-260-86/c
; Sequence 86, Application US/09798260
; Publication No. US20030165830A1
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles G.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P. A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, MacDonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: ARRAYS OF NUCLEIC ACID PROBES FOR ANALYZING
; TITLE OF INVENTION: BIOTRANSFORMATION GENES
; FILE REFERENCE: 018547-015720US
; CURRENT APPLICATION NUMBER: US/09/798,260
; CURRENT FILING DATE: 2002-05-01
; PRIOR APPLICATION NUMBER: US 08/778,794
; PRIOR FILING DATE: 1997-01-03
; PRIOR APPLICATION NUMBER: US 08/544,381
; PRIOR FILING DATE: 1995-10-10
; PRIOR APPLICATION NUMBER: US 08/510,521
; PRIOR FILING DATE: 1995-08-02
; PRIOR APPLICATION NUMBER: WO PCT/US94/12305
; PRIOR FILING DATE: 1994-10-26
; PRIOR APPLICATION NUMBER: US 08/284,064
; PRIOR FILING DATE: 1994-08-02
; PRIOR APPLICATION NUMBER: US 08/143,312
; PRIOR FILING DATE: 1993-10-26
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 86
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-798-260-86

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 48;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
| |||| |||||
Db 13 AGGGCAACCACCA 1

RESULT 113
US-09-798-260-87/c
; Sequence 87, Application US/09798260
; Publication No. US20030165830A1
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles G.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P. A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.

```
;  APPLICANT:  Morris, MacDonald S.
;  APPLICANT:  Sheldon, Edward L.
;  TITLE OF INVENTION: ARRAYS OF NUCLEIC ACID PROBES FOR ANALYZING
;  TITLE OF INVENTION:  BIOTRANSFORMATION GENES
;  FILE REFERENCE: 018547-015720US
;  CURRENT APPLICATION NUMBER: US/09/798,260
;  CURRENT FILING DATE:  2002-05-01
;  PRIOR APPLICATION NUMBER: US 08/778,794
;  PRIOR FILING DATE: 1997-01-03
;  PRIOR APPLICATION NUMBER: US 08/544,381
;  PRIOR FILING DATE: 1995-10-10
;  PRIOR APPLICATION NUMBER: US 08/510,521
;  PRIOR FILING DATE: 1995-08-02
;  PRIOR APPLICATION NUMBER: WO PCT/US94/12305
;  PRIOR FILING DATE: 1994-10-26
;  PRIOR APPLICATION NUMBER: US 08/284,064
;  PRIOR FILING DATE: 1994-08-02
;  PRIOR APPLICATION NUMBER: US 08/143,312
;  PRIOR FILING DATE: 1993-10-26
;  NUMBER OF SEQ ID NOS: 156
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 87
;    LENGTH: 13
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-798-260-87

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 48;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 AAGGCAAGCACCA 1661
              | ||||| |||||
Db         13 AGGGCAAACACCA 1


RESULT 114
US-09-238-351-77
; Sequence 77, Application US/09238351
; Patent No. US20020006643A1
; GENERAL INFORMATION:
;  APPLICANT: Kayyem, Jon Faiz
;  APPLICANT: Bamdad, Cynthia
;  TITLE OF INVENTION: Amplification of Nucleic Acids with Electronic
;  TITLE OF INVENTION: Detection
;  FILE REFERENCE: A67643/RFT/RMS
;  CURRENT APPLICATION NUMBER: US/09/238,351
;  CURRENT FILING DATE: 1999-01-27
;  EARLIER APPLICATION NUMBER: 09/014,304
;  EARLIER FILING DATE: 1998-01-27
;  EARLIER APPLICATION NUMBER: 60/073,011
;  EARLIER FILING DATE: 1998-01-29
;  EARLIER APPLICATION NUMBER: 60/084,425
;  EARLIER FILING DATE: 1998-05-06
;  EARLIER APPLICATION NUMBER: 60/084,509
;  EARLIER FILING DATE: 1998-05-06
;  EARLIER APPLICATION NUMBER: 60/078,102
;  EARLIER FILING DATE: 1998-03-16
;  NUMBER OF SEQ ID NOS: 83
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 77
;    LENGTH: 14
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  synthetic
US-09-238-351-77

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 14;
  Best Local Similarity   84.6%;  Pred. No. 60;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1658 ACCAGGCTCACAG 1670
              |||| || |||||
Db          1 ACCATGCACACAG 13


RESULT 115
US-09-823-847-24/c
; Sequence 24, Application US/09823847
; Patent No. US20020137905A1
; GENERAL INFORMATION:
;  APPLICANT: THE SCRIPPS RESEARCH INSTITUTE
;  APPLICANT:  SIMS, Peter
;  APPLICANT:  SILVERMAN, Robert
;  APPLICANT:  WIEDMER, Therese
;  TITLE OF INVENTION: PHOSPHOLIPID SCRAMBLASES AND METHODS OF USE THEREOF
;  FILE REFERENCE: SCRIP1220-1
;  CURRENT APPLICATION NUMBER: US/09/823,847
;  CURRENT FILING DATE:  2001-03-30
;  PRIOR APPLICATION NUMBER: US 60/193,939
;  PRIOR FILING DATE: 2000-03-31
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 24
;    LENGTH: 14
;    TYPE: DNA
;    ORGANISM: Artificial sequence
;    FEATURE:
;    OTHER INFORMATION: HuPLSCR1 GC box
US-09-823-847-24

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 14;
  Best Local Similarity   84.6%;  Pred. No. 60;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1735 GCTCCCAACTCCT 1747
              || |||| |||||
Db         13 GCGCCCACCTCCT 1


RESULT 116
US-09-943-983-8
; Sequence 8, Application US/09943983
; Publication No. US20030077575A1
;   GENERAL INFORMATION:
;        APPLICANT: STUYVER, LIEVEN
;                   LOUWAGIE, JOOST
;                   ROSSAU, RUDI
;        TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
;                            MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
;        NUMBER OF SEQUENCES: 164
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: ARNOLD, WHITE & DURKEE
;             STREET: P.O. BOX 4433
;             CITY: HOUSTON
;             STATE: TEXAS
;             COUNTRY: USA
;             ZIP: 77210-4433
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: Microsoft Word 6.0 / ASCII text output
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/943,983
;             FILING DATE: 31-Aug-2001
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/913,833
;             FILING DATE: 1997-09-15
;             APPLICATION NUMBER: EP 96870005.4
;             FILING DATE: 26 Jan 1996
;             APPLICATION NUMBER: EP 96870081.5
;             FILING DATE: 25 Jun 1996
```

; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-943-983-8

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 60;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1719 ACGGAGATGGAGA 1731
|| |||||||| |
Db 1 ACAGAGATGGAAA 13

RESULT 117
US-09-848-868-6
; Sequence 6, Application US/09848868
; Publication No. US20030166588A1
; GENERAL INFORMATION:
; APPLICANT: Iversen, Patrick L.
; APPLICANT: Hudziak, Robert
; TITLE OF INVENTION: Splice-Region Antisense Composition and
; TITLE OF INVENTION: Method
; FILE REFERENCE: 0450-0037.30
; CURRENT APPLICATION NUMBER: US/09/848,868
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/202,376
; PRIOR FILING DATE: 2000-05-04
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-848-868-6

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 60;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1682 GTGTCTCCTCCAG 1694
|||||| |||||
Db 2 GTGTCTTTTCCAG 14

RESULT 118
US-10-356-625-23
; Sequence 23, Application US/10356625
; Publication No. US20030186290A1
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserve, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Germaine
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; TITLE OF INVENTION: THERAPEUTIC APPLICATION
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/10/356,625
; CURRENT FILING DATE: 2003-02-03
; PRIOR APPLICATION NUMBER: US/09/230,652
; PRIOR FILING DATE: 1999-05-17
; PRIOR APPLICATION NUMBER: FR 96 09733
; PRIOR FILING DATE: 1996-08-01
; PRIOR APPLICATION NUMBER: FR 97 04680
; PRIOR FILING DATE: 1997-04-16
; PRIOR APPLICATION NUMBER: PCT/FR97/01433
; PRIOR FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-356-625-23

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 60;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1666 CACAGCTGGAACC 1678
||||| ||| |||
Db 2 CACAGGTGGGACC 14

RESULT 119
US-10-091-281-372/c
; Sequence 372, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 372
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative RREB/RREB1.01 motif
US-10-091-281-372

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 60;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGTTGGG 1710
||||| ||| |||
Db 13 GGTGGGAGTGGGG 1

RESULT 120
US-10-206-839-40/c
; Sequence 40, Application US/10206839
; Publication No. US20030099977A1
; GENERAL INFORMATION:
; APPLICANT: Guida, Marco
; APPLICANT: Kurth, Janice
; TITLE OF INVENTION: Genotyping Human Phenol Sulfotransferase
; TITLE OF INVENTION: (STP2)
; FILE REFERENCE: 4389-6 (formerly SEQ-16P)
; CURRENT APPLICATION NUMBER: US/10/206,839
; CURRENT FILING DATE: 2002-07-26
; PRIOR APPLICATION NUMBER: 09/328,174
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 40
; LENGTH: 14

; TYPE: DNA
; ORGANISM: H. sapiens
US-10-206-839-40

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 60;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1641 TGTAGCAGAAGGC 1653
              ||| |||| ||||
Db         14 TGTGGCAGCAGGC 2
```

Search completed: January 12, 2004, 13:51:31
Job time : 1 secs

```
  Best Local Similarity   83.3%;  Pred. No. 8.3e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1713 AGGAGTACGGAG 1724
              |||||  ||||
Db          4 AGGAGTCGGGAG 15


RESULT 789
ABC24272
ID   ABC24272 standard; DNA; 13 BP.
XX
AC   ABC24272;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 24289 for detecting SNP TSC0005767.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 24289; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 1 other;

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 13;
  Best Local Similarity   88.9%;  Pred. No. 6.5e+02;
  Matches    8;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1631 GGATGGGGC 1639
              |||||||:
Db          5 GGATGGGGY 13


RESULT 790
ABC24273/c
ID   ABC24273 standard; DNA; 13 BP.
XX
AC   ABC24273;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 24290 for detecting SNP TSC0005767.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 24290; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 1 other;

  Query Match             6.2%;  Score 8.6;  DB 1;  Length 13;
  Best Local Similarity   88.9%;  Pred. No. 6.5e+02;
  Matches    8;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1631 GGATGGGGC 1639
              |||||||:
Db          9 GGATGGGGY 1


Search completed: January 12, 2004, 13:48:05
Job time : 4 secs
```

```
CC   receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference
CC   sequence). Polynucleotides comprising polymorphic gene variants are
CC   useful for therapeutic purposes. For example, where a patient may benefit
CC   from expression of a particular IL4Ralpha protein isoform, an expression
CC   vector encoding the isoform may be administered to the patient. It may
CC   desirable to decrease or block expression of a particular IL4Ralpha
CC   isogene, which may be done by turning off by transforming a targeted
CC   organ, tissue or cell population with an expression vector that expresses
CC   high levels of untranslatable mRNA for the isogene. Specific therapeutics
CC   identified by these methods may be useful for allergic diseases. The
CC   present sequence is a probe for human IL4R-alpha.
XX
SQ   Sequence 15 BP; 3 A; 4 C; 6 G; 2 T; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 15;
  Best Local Similarity   83.3%;  Pred. No. 7.1e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1648 GAAGGCAAGCAC 1659
                | ||||||||| |
Db          4 GGAGGCAAGCTC 15


RESULT 787
AAA82923
ID   AAA82923 standard; DNA; 19 BP.
XX
AC   AAA82923;
XX
DT   04-DEC-2000  (first entry)
XX
DE   cdk4 ribozyme binding site #104.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
KW   restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US28772.
XX
PR   04-DEC-1998;   98US-0110954.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1  -
XX
PS   Disclosure; Page 53; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells.
CC   The ribozyme is resistant to endonuclease activity and hence is
CC   efficient in restenosis treatment.
XX
SQ   Sequence 19 BP; 5 A; 3 C; 9 G; 2 T; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.3e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1713 AGGAGTACGGAG 1724
                ||||||  ||||
Db          4 AGGAGTCGGGAG 15


RESULT 788
AAH58085
ID   AAH58085 standard; DNA; 19 BP.
XX
AC   AAH58085;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cell-cycle dependent kinase cdk4 ribozyme binding site SEQ ID NO:509.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US29500.
XX
PR   26-OCT-1999;   99US-0161532.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using
PT   ribozymes that cleave RNA encoding cytokines involved in inflammation,
PT   matrix metalloproteinases, growth factors and cell-cycle dependent
PT   kinases -
XX
PS   Example 1; Page 109; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative
CC   skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 5 A; 3 C; 9 G; 2 T; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 19;
```

```
XX
PR   23-DEC-1994;   94US-0363240.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (WARN ) WARNER LAMBERT CO.
XX
PI   Bisgaier C,  Couture L,  McSwiggen J,  Pape M,  Stinchcomb D;
XX
DR   WPI; 1996-321852/32.
XX
PT   New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA
PT   - useful for preventing or treating initial development, progression
PT   or regression of vascular diseases, esp. familial
PT   hypercholesterolaemia
XX
PS   Claim 4; Page 32; 72pp; English.
XX
CC   AAT49608-T49863 represent target sequences for the human cholesterol
CC   ester transfer protein (CETP) hammerhead (HH) ribozymes (see
CC   AAT49881-T50137). CETP is a 74 kD glycoprotein that facilitates neutral
CC   lipid transfer between plasma lipoproteins.  The numbering of the targets
CC   refers to the position of the cleavage site in full length CETP.  The
CC   ribozyme binds to 5 nucleotides either side of this site, provided the
CC   sequence UH is immediately upstream.  The ribozymes are able to cleave
CC   mRNA from the gene encoding CETP, thereby blocking synthesis and/or
CC   expression of the mRNA.  By inhibiting CETP, the reverse cholesterol
CC   transport (RCT) pathway can be inhibited (or eliminated) thereby
CC   preventing the reduction in size density of the high density lipoproteins
CC   (HDL), prolonging HDL half life, and therefore increasing HDL levels.
CC   The ribozymes can be used to treat conditions associated with abnormal
CC   levels of CETP, specifically familial hypercholesterolaemia,
CC   atherosclerosis, peripheral vascular disease, hyperbetalipoproteinaemia,
CC   hypoalphalipoproteinaemia, dyslipidaemia, vascular complications of
CC   diabetes, transplant, atherectomy and angioplastic restenosis.  By
CC   inhibiting CETP, the levels of HDL and low density lipoproteins (LDL),
CC   and the HDL:LDL ratio are favourably altered (a decrease in LDL levels,
CC   and a corresponding increase in HDL levels).  The HH ribozymes can also
CC   be used diagnostically to study genetic drift and mutations in diseased
CC   cells, and to detect CETP mRNA.  As the HH ribozymes target specific
CC   regions of the CETP gene, they have low non-specific activity.
XX
SQ   Sequence 15 BP; 5 A; 1 C; 6 G; 3 U; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 15;
  Best Local Similarity   83.3%;  Pred. No. 7.1e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCT 1747
              |||| ||||||
Db         13 CTCCGTACTCCT 2


RESULT 785
AAL45302
ID   AAL45302 standard; DNA; 15 BP.
XX
AC   AAL45302;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human KCNB1 gene allele-specific primer SEQ ID NO: 16.
XX
KW   Human; KCNB1; single nucleotide polymorphism; SNP; gene therapy;
KW   potassium voltage-gated channel; Shab-related subfamily, member 1;
KW   isogene; arrhythmia; seizures; allele-specific oligonucleotide; PCR;
KW   primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200204675-A1.
XX
PD   17-JAN-2002.
XX
PF   05-JUL-2001; 2001WO-US21307.
XX
PR   05-JUL-2000; 2000US-215885P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Chew A,  Choi JY,  Koshy B;
XX
DR   WPI; 2002-188469/24.
XX
PT   Isolated polymorphic variants of potassium voltage-gated channel,
PT   Shab-related subfamily, member 1 (KCNB1) gene useful for expressing
PT   KCNB1 protein isoform to screen drugs to treat KCNB1 activity-related
PT   disease -
XX
PS   Claim 16; Page 13; 180pp; English.
XX
CC   The present invention provides the protein, gene and cDNA sequences of
CC   the human potassium voltage-gated channel, Shab-related subfamily,
CC   member 1 (KCNB1) isogene and polymorphisms identified within these
CC   sequences. The sequences can be used to screen drugs, which involves
CC   contacting the polypeptide with a candidate agent, and to assay for
CC   binding activity as a target for drugs to treat arrhythmia and seizures.
CC   The present sequence is an allele-specific oligonucleotide primer for the
CC   gene of the invention.
XX
SQ   Sequence 15 BP; 1 A; 5 C; 7 G; 1 T; 1 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 15;
  Best Local Similarity   71.4%;  Pred. No. 7.1e+02;
  Matches   10;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              | ||||| | ||:|
Db          2 CGGCTGGGAGCCYG 15


RESULT 786
AAF69487
ID   AAF69487 standard; DNA; 15 BP.
XX
AC   AAF69487;
XX
DT   18-APR-2001  (first entry)
XX
DE   Human IL4Ralpha gene probe #127.
XX
KW   Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;
KW   allergic disease; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200104270-A1.
XX
PD   18-JAN-2001.
XX
PF   13-JUL-2000; 2000WO-US19094.
XX
PR   13-JUL-1999;   99US-0143435.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Chew A,  Denton RR,  Duda A,  Nandabalan K,  Stephens JC;
PI   Windemuth AK;
XX
DR   WPI; 2001-103078/11.
XX
PT   New isolated polynucleotide useful for the identification of
PT   therapeutics in allergic diseases is new -
XX
PS   Claim 15; Page 44; 188pp; English.
XX
CC   The present invention relates to polymorphisms of the human interleukin 4
```

```
RESULT 782
ABI69250
ID   ABI69250 standard; DNA; 12 BP.
XX
AC   ABI69250;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 369223 for detecting SNP TSC0057525.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 369223; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 12;
  Best Local Similarity   83.3%;  Pred. No. 5.4e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGG 1710
              || | |||||||
Db          1 GTAGGAGTTGGG 12


RESULT 783
ABI81529/c
ID   ABI81529 standard; DNA; 12 BP.
XX
AC   ABI81529;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 381502 for detecting SNP TSC0064394.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 381502; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 9 C; 0 G; 1 T; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 12;
  Best Local Similarity   83.3%;  Pred. No. 5.4e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGG 1710
              | || |||||||
Db         12 GGGGGAGTTGGG 1


RESULT 784
AAT49827/c
ID   AAT49827 standard; RNA; 15 BP.
XX
AC   AAT49827;
XX
DT   07-MAR-1997  (first entry)
XX
DE   Human CETP HH ribozyme target sequence #1719.
XX
KW   Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
KW   neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW   reverse cholesterol transport; high density lipoprotein; therapy; CETP;
KW   familial hypercholesterolaemia; dyslipidaemia; hypoalphalipoproteinaemia;
KW   peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW   angioplastic restenosis; low density lipoprotein; diabetes; HDL; human;
KW   LDL; ss.
XX
OS   Homo sapiens.
XX
PN   WO9620279-A1.
XX
PD   04-JUL-1996.
XX
PF   11-DEC-1995;   95WO-US16000.
```

```
XX
PT   Human brain-originated G protein-coupled receptor protein TGR5,
PT   applicable in diagnosis and developing drugs for diseases of e.g.
PT   central nervous system and digestive organs, inflammation, cancer and
PT   diabetes -
XX
PS   Example 2; Page 98; 104pp; Japanese.
XX
CC   The invention relates to a novel human G protein-coupled receptor protein
CC   TGR5 and the encoding cDNA with cerebroprotective, cardiant,
CC   immunomodulator, cytostatic, antiinflammatory and antidiabetic activity.
CC   The protein, encoded DNA and anti-TGR5 antibody are applicable in
CC   diagnosis and developing drugs for diseases of central nervous system and
CC   circulatory organs, inflammation, cancer and diabetes. The present
CC   sequence is that of a TGR5 PCR primer of the invention.
XX
SQ   Sequence 21 BP; 2 A; 9 C; 2 G; 8 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 8.1e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGG 1710
              |||||||||
Db         15 GAAGTTGGG 7


RESULT 780
ABH96992
ID   ABH96992 standard; DNA; 12 BP.
XX
AC   ABH96992;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 296985 for detecting SNP TSC0017381.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status -
XX
PS   Claim 1; SEQ ID 296985; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 8 C; 0 G; 2 T; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 12;
  Best Local Similarity   83.3%;  Pred. No. 5.4e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCC 1749
              ||||||| | ||
Db          1 CCCAACTTCCCC 12


RESULT 781
ABI69091/c
ID   ABI69091 standard; DNA; 12 BP.
XX
AC   ABI69091;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 369064 for detecting SNP TSC0057436.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status -
XX
PS   Claim 1; SEQ ID 369064; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 8 G; 2 T; 0 other;

  Query Match             6.3%;  Score 8.8;  DB 1;  Length 12;
  Best Local Similarity   83.3%;  Pred. No. 5.4e+02;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCC 1749
              ||||||| | ||
Db         12 CCCAACTTCCCC 1
```

```
XX
SQ   Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 7.4e+02;
  Matches   12;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1636 GGGCTTGTAGCAGAAGG 1652
              ||| | ||| | ||||
Db          1 GGGACTTTAGGACAAGG 17


RESULT 777
ABV73609
ID   ABV73609 standard; DNA; 20 BP.
XX
AC   ABV73609;
XX
DT   10-JAN-2003  (first entry)
XX
DE   S. albulus plasmid pNO33 related primer #1.
XX
KW   Plasmid; epsilon-polylysine; pNO33; PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   JP2002233380-A.
XX
PD   20-AUG-2002.
XX
PF   08-FEB-2001; 2001JP-0031958.
XX
PR   08-FEB-2001; 2001JP-0031958.
XX
PA   (CHCC ) CHISSO CORP.
XX
DR   WPI; 2002-736476/80.
XX
PT   A nucleic acid molecule derived from a plasmid of Streptomyces albulus
PT   -
XX
PS   Example 3; Page 4; 17pp; Japanese.
XX
CC   The invention relates to a DNA molecule which is derived from plasmid
CC   pNO33 of Streptomyces albulus. In the scope of the invention, a microbe
CC   host may be transformed by the vector. The vector is used for the
CC   preparation of epsilon-polylysine. The current sequence represents an
CC   S. albulus plasmid pNO33 related PCR primer sequence.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 20;
  Best Local Similarity   70.6%;  Pred. No. 8.1e+02;
  Matches   12;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1749 CCTATCCTAAAGGCCCA 1765
              | | | ||| | |||||
Db          2 CATCTGCTACAAGCCCA 18


RESULT 778
AAA58421/c
ID   AAA58421 standard; DNA; 20 BP.
XX
AC   AAA58421;
XX
DT   11-OCT-2000  (first entry)
XX
DE   Oct-4 transcript RT-PCR primer #2.
XX
KW   Human embryonic stem cell; oct-4 expression; development;
KW   transplantation; drug screening; drug discovery; RT-PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200027995-A1.
XX
PD   18-MAY-2000.
XX
PF   09-NOV-1999;   99WO-AU00990.
XX
PR   09-NOV-1998;   98AU-0007009.
PR   15-SEP-1999;   99AU-0002852.
XX
PA   (MONU ) UNIV MONASH.
PA   (UYSI-) UNIV SINGAPORE NAT.
PA   (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
XX
PI   Reubinoff BE,  Pera MF,  Yee FC,  Trounson AO,  Bongso A;
XX
DR   WPI; 2000-376517/32.
XX
PT   Novel undifferentiated human embryonic stem cells which are useful as a
PT   source of novel gene products  -
XX
PS   Disclosure; Page 31; 56pp; English.
XX
CC   The present sequence is a RT-PCR primer for the human oct-4 transcript.
CC   It was used to measure oct-4 expression in differentiated and
CC   undifferentiated cells. These were all derived from human embryonic stem
CC   cells. Stem cells can be used to treat inherited diseases, to study the
CC   cellular and molecular biology of early human development, in functional
CC   genomics, to identify novel growth factors and to generate differentiated
CC   cells to use in transplantation, drug screening or drug discovery in
CC   vitro.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 20;
  Best Local Similarity   70.6%;  Pred. No. 8.1e+02;
  Matches   12;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1636 GGGCTTGTAGCAGAAGG 1652
              | || ||  ||||| |
Db         17 GAGCCTGGTGCAGAAAG 1


RESULT 779
AAI99829/c
ID   AAI99829 standard; DNA; 21 BP.
XX
AC   AAI99829;
XX
DT   28-JAN-2002  (first entry)
XX
DE   Human G protein-coupled receptor protein TGR5 PCR primer SEQ ID NO 5.
XX
KW   Human; TGR5; G protein-coupled receptor protein; cerebroprotective;
KW   cardiant; immunomodulator; cytostatic; antiinflammatory; antidiabetic;
KW   cancer; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200177325-A1.
XX
PD   18-OCT-2001.
XX
PF   12-APR-2001; 2001WO-JP03143.
XX
PR   12-APR-2000; 2000JP-0110765.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
PI   Miwa M,  Matsui H,  Shintani Y;
XX
DR   WPI; 2002-010910/01.
```

```
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 5.6e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGG 1710
              |||||||||
Db          5 GAAGTTGGG 13


RESULT 775
ABF43731/c
ID   ABF43731 standard; DNA; 13 BP.
XX
AC   ABF43731;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 143728 for detecting SNP TSC0036088.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 143728; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 5.6e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGG 1710
              |||||||||
Db          9 GAAGTTGGG 1


RESULT 776
ABV91050
ID   ABV91050 standard; DNA; 17 BP.
XX
AC   ABV91050;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 1763.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-0001165.
XX
PR   30-JAN-2001; 2001WO-US00663.
PR   30-JAN-2001; 2001WO-US00664.
PR   30-JAN-2001; 2001WO-US00665.
PR   30-JAN-2001; 2001WO-US00666.
PR   30-JAN-2001; 2001WO-US00667.
PR   30-JAN-2001; 2001WO-US00668.
PR   30-JAN-2001; 2001WO-US00669.
PR   30-JAN-2001; 2001WO-US00670.
PR   23-MAY-2001; 2001US-0864761.
PR   10-OCT-2001; 2001US-0328205.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT   POSHL-1, useful for treating disorders associated with decreased
PT   expression or activity of human POSHL1 -
XX
PS   Example 2; SEQ ID NO 1763; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention.
CC   Note: The present sequence did not form part of the printed
CC   specification, but is based on sequence information supplied to Derwent
CC   by the European Patent Office.
```

```
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 111503; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 5.6e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCC 1746
              |||||||||
Db          9 CCCAACTCC 1


RESULT 773
ABF11507
ID   ABF11507 standard; DNA; 13 BP.
XX
AC   ABF11507;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111504 for detecting SNP TSC0027852.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 111504; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 5.6e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCC 1746
              |||||||||
Db          5 CCCAACTCC 13


RESULT 774
ABF43730
ID   ABF43730 standard; DNA; 13 BP.
XX
AC   ABF43730;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 143727 for detecting SNP TSC0036088.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 143727; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
```

```
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 6 C; 0 G; 4 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGG 1710
              |||||||||
Db         10 GAAGTTGGG 2


RESULT 770
ABC65198/c
ID   ABC65198 standard; DNA; 13 BP.
XX
AC   ABC65198;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 65215 for detecting SNP TSC0017166.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 65215; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 5.6e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCC 1746
              |||||||||
Db         10 CCCAACTCC 2


RESULT 771
ABC65199
ID   ABC65199 standard; DNA; 13 BP.
XX
AC   ABC65199;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 65216 for detecting SNP TSC0017166.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 65216; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 5.6e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCC 1746
              |||||||||
Db          4 CCCAACTCC 12


RESULT 772
ABF11506/c
ID   ABF11506 standard; DNA; 13 BP.
XX
AC   ABF11506;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111503 for detecting SNP TSC0027852.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
XX
PN   JP11103897-A.
XX
PD   20-APR-1999.
XX
PF   30-SEP-1997;   97JP-0282612.
XX
PR   30-SEP-1997;   97JP-0282612.
XX
PA   (SRLS-) SRL KK.
XX
DR   WPI; 1999-305860/26.
XX
PT   New primers and probes - for measurement of an Herpes B Virus (HBV)
PT   gene by a real time detecting PCR
XX
PS   Example 2; Page 8; 12pp; Japanese.
XX
CC   This invention describes a method for the measurement of an HBV gene by
CC   a real time detecting PCR. The invention also describes a method for the
CC   measurement of an HBV gene by a real time detecting PCR in which a
CC   reporter fluorescent colour and a quencher fluorescent colour are
CC   combined to an oligonucleotide, the fluorescence of said reporter
CC   fluorescent colour is controlled by fluorescence resonance energy
CC   transfer when reporter fluorescent colour is combined to the same probe
CC   as quencher fluorescent colour. The method can measure an HBV exactly in
CC   a high sensitivity.
XX
SQ   Sequence 22 BP; 5 A; 11 C; 1 G; 5 T; 0 other;

  Query Match             6.6%;  Score 9.2;  DB 1;  Length 22;
  Best Local Similarity   78.6%;  Pred. No. 7.9e+02;
  Matches   11;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTGGG 1710
                 ||| | |||||||
Db         14 TGGGAGGAGTTGGG 1


RESULT 768
ABH71789
ID   ABH71789 standard; DNA; 12 BP.
XX
AC   ABH71789;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 271766 for detecting SNP TSC0002608.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 271766; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 other;

  Query Match             6.5%;  Score 9;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCC 1746
                 |||||||||
Db          3 CCCAACTCC 11


RESULT 769
ABI06503/c
ID   ABI06503 standard; DNA; 12 BP.
XX
AC   ABI06503;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 306476 for detecting SNP TSC0022038.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 306476; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
```

```
CC   AAT08224-53 are PCR primers used for the isolation and amplification
CC   of 2 antisense DNA sequences derived from the X region of a
CC   new strain of hepatitis B. The DNA codes for a viral peptide ASXP.
CC   The ASXP peptide and antibodies recognising it are useful in the
CC   diagnosis of hepatitis caused by the virus, in the investigation
CC   of transcription activated and enhanced by the presence of the ASXP
CC   peptide, and in the development of effective antiviral and anticancer
CC   drugs for the treatment of hepatitis and hepatoma.
XX
SQ   Sequence 20 BP; 4 A; 1 C; 12 G; 3 T; 0 other;

  Query Match             6.6%;  Score 9.2;  DB 1;  Length 20;
  Best Local Similarity   78.6%;  Pred. No. 7.7e+02;
  Matches   11;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTGGG 1710
              ||| | |||||||
Db          4 TGGGAGGAGTTGGG 17


RESULT 765
AAQ81567
ID   AAQ81567 standard; DNA; 20 BP.
XX
AC   AAQ81567;
XX
DT   04-SEP-1995  (first entry)
XX
DE   Hepatitis B virus polypeptide cDNA PCR primer p142.
XX
KW   Hepatitis B virus; HBV; polypeptide; diagnosis and detection;
KW   PCR primer p142; ss.
XX
OS   Synthetic.
XX
PN   JP06321991-A.
XX
PD   22-NOV-1994.
XX
PF   14-MAY-1993;   93JP-0113136.
XX
PR   14-MAY-1993;   93JP-0113136.
XX
PA   (MITU ) MITSUBISHI KASEI CORP.
XX
DR   WPI; 1995-041293/06.
XX
PT   Polypeptide derived from type B hepatitis virus and gene to code
PT   it - used in diagnosis of type B hepatitis virus
XX
PS   Example 2; Page 5; 13pp; Japanese.
XX
CC   AAQ81567 and AAQ81568 are a pair of primers for the PCR amplfication
CC   of the cDNAs encoding the hepatitis B virus (HBV) polypeptides
CC   described in AAR68865-R68871. The polypeptides or their fragments
CC   can be used in the diagnosis and detection of HBV.
XX
SQ   Sequence 20 BP; 4 A; 1 C; 12 G; 3 T; 0 other;

  Query Match             6.6%;  Score 9.2;  DB 1;  Length 20;
  Best Local Similarity   78.6%;  Pred. No. 7.7e+02;
  Matches   11;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTGGG 1710
              ||| | |||||||
Db          4 TGGGAGGAGTTGGG 17


RESULT 766
ABT23628
ID   ABT23628 standard; DNA; 20 BP.
XX
AC   ABT23628;
XX
DT   22-MAY-2003  (first entry)
XX
DE   Stabilising reagent method related oligo SEQ ID No 80.
XX
KW   Stabilising reaction reagent; PCR; primer; RNaseH; long-term storage;
KW   specific amplification; pathogenic microorganism; chimeric;
KW   genetic engineering; clinical medicine; ss.
XX
OS   Unidentified.
XX
PN   WO2002101042-A1.
XX
PD   19-DEC-2002.
XX
PF   12-JUN-2002; 2002WO-JP05832.
XX
PR   12-JUN-2001; 2001JP-0177737.
PR   20-AUG-2001; 2001JP-0249689.
XX
PA   (TAKA-) TAKARA BIO INC.
XX
PI   Sagawa H,  Uemori T,  Mukai H,  Yamamoto J,  Tomono J,  Kobayashi E;
PI   Enoki T,  Asada K,  Kato I;
XX
DR   WPI; 2003-148805/14.
XX
PT   Method for stabilizing and storing reaction reagents for specific
PT   amplification and detection of nucleic acids particularly in e.g.
PT   identifying pathogenic microorganisms or viruses in sample  -
XX
PS   Example 15; Page 137; 177pp; Japanese.
XX
CC   The invention relates to a novel stabilising reaction reagent for use in
CC   the amplification and/or detection of a target nucleic acid comprising:
CC   preparing a reaction mixture with e.g. a nucleic acid as template, at
CC   least 1 primer and RNaseH; and incubation of the reaction mixture for a
CC   defined period of time to form a reaction product during the
CC   amplification of such target nucleic acid. The method is useful for
CC   stabilising and long-term storage of reaction reagents for highly
CC   sensitive and specific amplification and detection of nucleic acids
CC   particularly in identifying pathogenic microorganisms or viruses in a
CC   sample using chimeric oligonucleotide primers, which is useful in genetic
CC   engineering and clinical medicine. This polynucleotide sequence
CC   represents an oligo relating to the novel stabilising reaction reagent
CC   method of the invention.
XX
SQ   Sequence 20 BP; 4 A; 1 C; 12 G; 3 T; 0 other;

  Query Match             6.6%;  Score 9.2;  DB 1;  Length 20;
  Best Local Similarity   78.6%;  Pred. No. 7.7e+02;
  Matches   11;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTGGG 1710
              ||| | |||||||
Db          4 TGGGAGGAGTTGGG 17


RESULT 767
AAX37644/c
ID   AAX37644 standard; DNA; 22 BP.
XX
AC   AAX37644;
XX
DT   08-JUL-1999  (first entry)
XX
DE   HBV detecting primer 8.
XX
KW   Detection; HBV; real time; PCR; reporter; fluorescent; primer;
KW   quencher; fluorescence resonance energy transfer; ss.
XX
OS   Synthetic.
OS   Hepatitis B virus.
```

XX
OS Homo sapiens.
XX
PN WO200170982-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09559.
XX
PR 23-MAR-2000; 2000US-0536058.
XX
PA (IMMU-) IMMUSOL INC.
PA (BEGE/) BEGER C.
XX
PI Beger C, Barber J, Wong-staal F;
XX
DR WPI; 2001-611503/70.
XX
PT Novel polypeptides that are the regulators of BRCA-1, useful for
PT treating cancer and diagnosing the presence of neoplastic cells in
PT biological sample -
XX
PS Disclosure; Fig 8; 97pp; English.
XX
CC Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators,
CC ribozyme target recognition RNA sequences, DNA fragments encoding the RNA
CC and primers used in the methods of the invention. Hybridisation of
CC ribozymes to their targets results in cleavage of the RNA target. The
CC ribozymes can be used to cleave regulators of the tumour suppressor
CC BRCA-1, resulting in upregulation or downregulation of BRCA-1 in a cell.
CC The mRNA targets include those encoding the BRCA-1 regulator BR1,
CC inhibitor dominant negative 4 (ID4), breast basic conserved protein 1
CC (BBC1), CHLR2, AF6, BR2 and BR3. Regulation of BRCA-1 is useful for
CC treating and diagnosing cancer and other proliferative disorders. The
CC severity of an incidence of cancer can be lessened by regulating tumour
CC proliferation through modulation of BRCA-1 expression. The sequences of
CC the invention are useful in the development of anti-cancer drugs.
XX
SQ Sequence 16 BP; 3 A; 5 C; 3 G; 5 T; 0 other;

Query Match 6.6%; Score 9.2; DB 1; Length 16;
Best Local Similarity 78.6%; Pred. No. 6.6e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1641 TGTAGCAGAAGGCA 1654
              ||||| ||| |||
Db         15 TGTAGTAGACAGCA 2
```

RESULT 763
AAX75159
ID AAX75159 standard; RNA; 17 BP.
XX
AC AAX75159;
XX
DT 28-JUL-1999 (first entry)
XX
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #687.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US17480.
XX
PR 11-JAN-1996; 96US-0584040.
PR 26-OCT-1995; 95US-0005974.
XX
PA (CHIR) CHIRON CORP.
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT mRNA stability - useful for treating e.g. tumour angiogenesis,
PT psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS Claim 4; Page 175; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.
XX
SQ Sequence 17 BP; 0 A; 4 C; 7 G; 6 U; 0 other;

Query Match 6.6%; Score 9.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 7e+02;
Matches 7; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1726 TGGAGATTGGCTCC 1739
              :|| | ::|||: |
Db          2 UGGCGCUUGGCUUC 15
```

RESULT 764
AAT08224
ID AAT08224 standard; DNA; 20 BP.
XX
AC AAT08224;
XX
DT 23-MAY-1996 (first entry)
XX
DE p142, PCR primer used for isolation of antisense HBV strain X region.
XX
KW Hepatitis B virus; X region; antisense; antibody; vector; diagnosis;
KW hepatoma; hepatitis; antiviral; anticancer; transcription; ss.
XX
OS Synthetic.
XX
PN WO9527788-A1.
XX
PD 19-OCT-1995.
XX
PF 10-APR-1995; 95WO-JP00700.
XX
PR 11-APR-1994; 94JP-0095458.
XX
PA (DAIN-) DAINABOT CO LTD.
XX
PI Shikata T, Uchida T;
XX
DR WPI; 1995-366392/47.
XX
PT Antisense DNA sequence of X region of new hepatitis B strain,
PT related peptide(s) and antibodies - useful for diagnosis and
PT investigation of HBV infection
XX
PS Example 2; Page 22; 61pp; Japanese.
XX

```
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1..6
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   1..20
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate nucleotides; all cytidine
FT                         residues are 5-methylcytidines"
FT   modified_base   15..20
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003014306-A2.
XX
PD   20-FEB-2003.
XX
PF   05-AUG-2002; 2002WO-US24919.
XX
PR   08-AUG-2001; 2001US-0925139.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Crooke RM,  Graham MJ,  Nero PS,  Wancewicz E;
XX
DR   WPI; 2003-248014/25.
XX
PT   New antisense compound, useful for preparing a composition for treating
PT   abnormal lipid or cholesterol metabolism, atherosclerosis or
PT   cardiovascular disease  -
XX
PS   Claim 3; Page 96; 114pp; English.
XX
CC   The invention relates to new antisense compounds targeted to a nucleic
CC   acid molecule encoding human cholesteryl ester transfer protein,
CC   specifically hybridises with it and inhibits the expression of human
CC   cholesteryl ester transfer protein. The compound is useful for preparing
CC   a composition for treating abnormal lipid or cholesterol metabolism,
CC   atherosclerosis or cardiovascular disease. The present sequence
CC   represents a human cholesteryl ester transfer protein, antisense
CC   oligonucleotide of the invention.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 7 G; 2 T; 0 other;

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 20;
  Best Local Similarity   68.4%;  Pred. No. 7.4e+02;
  Matches   13;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1652 GCAAGCACCAGGCTCACAG 1670
              | |  ||||||| |  |||
Db          2 GGAGACACCAGGGTTCCAG 20


RESULT 761
AAD41746
ID   AAD41746 standard; DNA; 20 BP.
XX
AC   AAD41746;
XX
DT   30-OCT-2002  (first entry)
XX
DE   Human RECQL2 antisense oligonucleotide, ISIS #137526.
XX
KW   Antisense; RECQL2; Bloom's disorder; prophylaxis; infection; tumour;
KW   inflammation; therapy; human; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1..20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1..5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl nucleotides"
FT   modified_base   16..20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl nucleotides"
FT   modified_base   9
FT                   /*tag=  d
FT                   /mod_base= m5c
FT   modified_base   19..20
FT                   /*tag=  e
FT                   /mod_base= m5c
XX
PN   US6399378-B1.
XX
PD   04-JUN-2002.
XX
PF   01-MAR-2001; 2001US-0798096.
XX
PR   01-MAR-2001; 2001US-0798096.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ward DT,  Watt AT;
XX
DR   WPI; 2002-535979/57.
XX
PT   Antisense compounds targeted to nucleic acids encoding RECQL2
PT   associated with Bloom's disorder, for modulating RECQL2 expression and
PT   treating diseases e.g. tumors associated with expression of the RECQL2
PT   in humans  -
XX
PS   Example 15; Column 44; 86pp; English.
XX
CC   The invention relates to antisense compounds targetted to nucleic acid
CC   encoding RECQL2 (gene associated with Bloom's disorder) to inhibit the
CC   expression of RECQL2. Antisense compounds of the invention are useful
CC   for treating diseases associated with expression of RECQL2, in humans.
CC   They are useful for diagnostics, therapeutics and as research reagent,
CC   e.g. prophylactically to prevent or delay infection, inflammation or
CC   tumour formation. They are also useful in antisense therapy. The
CC   present sequence is an antisense oligonuclectide targetted to human
CC   RECQL2 DNA.
XX
SQ   Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 other;

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 20;
  Best Local Similarity   68.4%;  Pred. No. 7.4e+02;
  Matches   13;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1661 AGGCTCACAGCTGGAACCC 1679
              ||| | |||| ||  | ||
Db          2 AGGATTACAGGTGTGAGCC 20


RESULT 762
AAS56873/c
ID   AAS56873 standard; DNA; 16 BP.
XX
AC   AAS56873;
XX
DT   16-JAN-2002  (first entry)
XX
DE   Validation ribozyme DNA sequence #47.
XX
KW   Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;
KW   cytostatic; RNA cleavage; tumour suppressor; PCR primer; CHLR2; AF6; BR2;
KW   inhibitor dominant negative 4; breast basic conserved protein 1; BBC1;
KW   BR3; ID4; cancer; proliferative disorder; tumour proliferation; ss.
```

```
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 4.8e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1749 CCTATCCTAAA 1759
                 |||| ||||||
Db          3 CCTAACCTAAA 13


RESULT 758
ABF18154/c
ID   ABF18154 standard; DNA; 13 BP.
XX
AC   ABF18154;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118151 for detecting SNP TSC0029550.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 118151; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 8 G; 1 T; 0 other;

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 4.8e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCC 1746
                 ||||| |||||
Db          12 CTCCCTACTCC 2


RESULT 759
ABF18155
ID   ABF18155 standard; DNA; 13 BP.
XX
AC   ABF18155;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118152 for detecting SNP TSC0029550.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 118152; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 8 C; 0 G; 4 T; 0 other;

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 4.8e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCC 1746
                 ||||| |||||
Db          2 CTCCCTACTCC 12


RESULT 760
ABX12199
ID   ABX12199 standard; DNA; 20 BP.
XX
AC   ABX12199;
XX
DT   16-MAY-2003  (first entry)
XX
DE   Human cholesteryl ester transfer protein, antisense oligo #20.
XX
KW   Human; cholesteryl ester transfer protein; lipid metabolism;
KW   cholesterol metabolism; atherosclerosis; cardiovascular disease;
KW   antisense; probe; ss.
XX
```

```
XX
CC   The invention relates to constructing (M1) a strain of diploid fungal
CC   cells in which both alleles of a gene are modified, comprising modifying
CC   one allele by insertion or replacement by a cassette having an
CC   expressible selectable marker and modifying other allele by
CC   recombination, of a promoter replacement fragment with a heterologous
CC   promoter, so that expression of the second allele is regulated by the
CC   promoter. (M1) is useful for constructing a strain of diploid fungal
CC   cells in which both alleles of a gene are modified. The diploid fungal
CC   cells having both alleles modified are useful for identifying a gene that
CC   is essential to the survival or growth of a fungus, a gene that
CC   contributes to the virulence and/or pathogenicity of a fungus, a gene
CC   that contributes to the resistance of a diploid fungus to an antifungal
CC   agent, an antifungal agent that inhibits the growth of a diploid fungus
CC   and for identifying a therapeutic agent for treatment of a mammalian
CC   disease. (M1) is useful for identifying a compound which modulates the
CC   activity of a gene product, preferably enzymatic activity, carbon
CC   compound catabolism, biosynthetic, transporter, transcriptional,
CC   translational, signal transduction, DNA replication and cell division
CC   activity. The method is useful for identifying a compound having the
CC   ability to inhibit growth or proliferation of C. albicans cells and for
CC   treating infection by C. albicans. The present sequence is that of a PCR
CC   primer used in the method of the invention.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification but is based on sequence information supplied to Derwent by
CC   the European Patent Office.
XX
SQ   Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 other;

  Query Match             6.9%;  Score 9.6;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 7e+02;
  Matches   12;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1695 CGTGGTGGAAGTTGGG 1710
              | |||  | |||||||
Db         17 CTTGGGAGGAGTTGGG 2


RESULT 756
ABC32492/c
ID   ABC32492 standard; DNA; 13 BP.
XX
AC   ABC32492;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 32509 for detecting SNP TSC0010144.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 32509; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             6.8%;  Score 9.4;  DB 1;  Length 13;
  Best Local Similarity   90.9%;  Pred. No. 4.8e+02;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1749 CCTATCCTAAA 1759
              |||| ||||||
Db         11 CCTAACCTAAA 1


RESULT 757
ABC32493
ID   ABC32493 standard; DNA; 13 BP.
XX
AC   ABC32493;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 32510 for detecting SNP TSC0010144.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 32510; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
```

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 143818; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 1 A; 7 C; 0 G; 5 T; 0 other;

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.1e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1736 CTCCCAACTCCTC 1748
||||| ||||||| |
Db 1 CTCCTTACTCCTC 13

RESULT 754
AAQ29795
ID AAQ29795 standard; DNA; 16 BP.
XX
AC AAQ29795;
XX
DT 25-MAR-2003 (updated)
DT 19-MAR-1993 (first entry)
XX
DE A allele probe VP52.
XX
KW G-gamma globulin; GGG; polymorphism; HindIII; A allele; B; C;
KW genotype; paternity; forensic; ss.
XX
OS Synthetic.
XX
PN EP512342-A2.
XX
PD 11-NOV-1992.
XX
PF 25-APR-1992; 92EP-0107084.
XX
PR 07-MAY-1991; 91US-0696793.
XX
PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX
PI Nasarabadi SL, Saiki RK;
XX
DR WPI; 1992-374679/46.
XX
PT Determn. of an individuals genotype at the gamma-globin locus -
PT using sequence-specific oligo-nucleotide probes corresp. to 3
PT alleles
XX
PS Disclosure; Page 15; 29pp; English.
XX
CC The sequences given in AAQ29787-816 are probes which were used within
CC the method of the invention for detecting the presence of a varient
CC sequence in the G-gamma globulin (GGG) locus. The A, B and C
CC alleles can be distinguished from one another by the polymorphic
CC sequence corresponding to the HindIII site of the A allele. The
CC sequences of the three alleles are given in AAQ29842-44. The methods
CC for determining an individuals genotype at the GGG locus with
CC respect to a set of alleles improves the discriminatory power of GGG
CC typing methodology compared to previous methods using two alleles.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 16 BP; 4 A; 8 C; 1 G; 3 T; 0 other;

Query Match 6.9%; Score 9.6; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1657 CACCAGGCTCACAGCT 1672
||||| ||| || ||
Db 1 CACCAAGCTTCCACCT 16

RESULT 755
ABZ31506/c
ID ABZ31506 standard; DNA; 20 BP.
XX
AC ABZ31506;
XX
DT 30-JAN-2003 (first entry)
XX
DE Candida albicans GRACE strain PCR primer SEQ ID NO 5725.
XX
KW Fungus; yeast; tetracyclin; promoter; GRACE strain; biosynthesis;
KW signal transduction; DNA replication; cell division; growth;
KW proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX
OS Candida albicans.
XX
PN WO200253728-A2.
XX
PD 11-JUL-2002.
XX
PF 26-DEC-2001; 2001WO-US49486.
XX
PR 29-DEC-2000; 2000US-259128P.
PR 20-FEB-2001; 2001US-0792024.
PR 22-AUG-2001; 2001US-314050P.
XX
PA (ELIT-) ELITRA PHARM INC.
XX
PI Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL;
XX
DR WPI; 2002-566694/60.
XX
PT Constructing strains for identifying gene products as effective targets
PT for therapeutic intervention, by inactivating in the strain one allele
PT of a gene and placing other allele of the gene under conditional
PT expression -
XX
PS Claim 36; SEQ ID NO 5725; 167pp + Sequence Listing; English.

```
CC   topical or parenteral, especially topical or intravenous. The conjugates
CC   are especially effective under conditions where the concentration of RNA
CC   target exceeds that of available conjugate.
XX
SQ   Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 other;

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 751
AAZ88439
ID   AAZ88439 standard; DNA; 20 BP.
XX
AC   AAZ88439;
XX
DT   08-MAY-2000  (first entry)
XX
DE   Exemplary texaphyrin oligonucleotide conjugate SEQ ID NO:5.
XX
KW   Texaphyrin; metal complex; catalytic; RNA hydrolysis; virucide;
KW   antibacterial; cytostatic; antiinflammatory; antitumour;
KW   antiviral; ss.
XX
OS   Synthetic.
XX
PN   US6022959-A.
XX
PD   08-FEB-2000.
XX
PF   20-NOV-1997;   97US-0975522.
XX
PR   20-AUG-1996;   96US-0077185.
PR   20-AUG-1997;   97WO-US14682.
XX
PA   (PHAR-) PHARMACYCLICS INC.
XX
PI   Wright M,  Crofts SP,  Magda D;
XX
DR   WPI; 2000-160391/14.
XX
PT   Texaphyrin metal complex derivatized ribonucleic acids possessing
PT   hydrolytic cleavage activity against RNA are useful as e.g. antiviral,
PT   antibacterial, antitumor and antiinflammatory agents -
XX
PS   Example 4; Column 32; 30pp; English.
XX
CC   The present invention describes a conjugate with hydrolytic cleavage
CC   activity for ribonucleic acid (RNA), which comprises a texaphyrin metal
CC   complex bound to an internal linkage of an oligonucleotide or
CC   oligonucleotide analogue. AAZ88435 to AAZ88440 represent exemplary
CC   texaphyrin oligonucleotide conjugates used in the exemplification of the
CC   present invention. The novel conjugates have virucide, antibacterial,
CC   cytostatic and antiinflammatory properties, and are involved in RNA
CC   hydrolysis. The conjugates are useful for inhibiting the expression of
CC   a gene by targeted intracellular mRNA (messenger ribonucleic acid)
CC   hydrolysis. The conjugates have applications for anti-viral and
CC   anti-bacterial therapy as well as cancers and inflammatory responses
CC   caused by overexpression of certain proteins.
XX
SQ   Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 other;

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 752
ABF43820/c
ID   ABF43820 standard; DNA; 13 BP.
XX
AC   ABF43820;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 143817 for detecting SNP TSC0036107.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 143817; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 7 G; 1 T; 0 other;

  Query Match             7.1%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 4.1e+02;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCTC 1748
              ||||  |||||||
Db         13 CTCCTTACTCCTC 1


RESULT 753
ABF43821
ID   ABF43821 standard; DNA; 13 BP.
XX
AC   ABF43821;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 143818 for detecting SNP TSC0036107.
XX
```

```
XX
CC   AAQ91451-Q91457 are texaphyrin lanthanide metal DNA conjugates, which
CC   are esp. useful for the targeted intracellular hydrolysis of mRNA;
CC   inhibiting gene expression. They may also be used for the treament
CC   of liver disease, as hormone regulation agents and as hydrolysis
CC   reagents for the detoxification of alkyl phosphate esters.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 other;

  Query Match              7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 749
AAV07290
ID   AAV07290 standard; DNA; 20 BP.
XX
AC   AAV07290;
XX
DT   14-AUG-1998  (first entry)
XX
DE   Oligonucleotide #4.
XX
KW   Metallotexapyrin; dysprosium; europium; conjugate; RNase H;
KW   antisense therapy; ss.
XX
OS   Synthetic.
XX
PN   US5763172-A.
XX
PD   09-JUN-1998.
XX
PF   07-JUN-1995;   95US-0486962.
XX
PR   07-JUN-1995;   95US-0485581.
PR   21-JAN-1992;   92US-0822964.
PR   09-JUN-1993;   93US-0075123.
PR   14-APR-1994;   94US-0227370.
PR   09-JUN-1994;   94WO-US06284.
PR   26-MAY-1995;   95US-0452261.
PR   07-JUN-1995;   95US-0486962.
XX
PA   (PHAR-) PHARMACYCLICS INC.
PA   (TEXA ) UNIV TEXAS SYSTEM.
XX
PI   Dow WC,  Magda D,  Miller RA,  Sessler JL,  Wright M;
XX
DR   WPI; 1998-347306/30.
XX
PT   Enhancing therapeutic activity of oligonucleotides in cells - using
PT   conjugate comprising metallotexaphyrin, which hydrolyses phosphate
PT   ester bonds of RNA, and oligo-nucleotide, which binds to targetted
PT   RNA
XX
PS   Disclosure; Columns 37-38; 34pp; English.
XX
CC   The invention relates to a method of enhancing the therapeutic activity
CC   of oligonucleotides in cells. It comprises contacting a targeted
CC   intracellular RNA in a cell with a metallotexaphyrin-oligonucleotide
CC   conjugate. The contact is carried out under physiological conditions for
CC   a time sufficient to hydrolyse the phosphate ester bond of the targeted
CC   RNA. The metallotexaphyrin of the conjugate has catalytic activity for
CC   phosphate ester bond hydrolysis. The oligonucleotide of the conjugate
CC   has complementary binding affinity to the targeted RNA. The conjugate
CC   may be used in antisense therapies for treating, e.g. cancer, viral
CC   infections, autoimmune diseases and restenosis. The conjugate may also
CC   be used as hydrolysis reagents for the detoxification of di- and
CC   trialkyl phosphate esters, which are used in solvents, insecticides and
CC   chemical nerve gases. The metallotexaphyrin complex enhances the
CC   therapeutic activity of the oligonucleotide, not only by facilitating
CC   cellular uptake of the oligonucleotide but also by hydrolysing target
CC   RNA within the cell, independent of RNase H. Attachment to the complex
CC   may also cause the oligonucleotide to take on some of the pharmacodynamic
CC   an biodistribution properties of the texaphyrin, such as selective
CC   localisation in tumours. The present oligonucleotide is shown in the
CC   specification.
XX
SQ   Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 other;

  Query Match              7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 750
AAV07037
ID   AAV07037 standard; DNA; 20 BP.
XX
AC   AAV07037;
XX
DT   08-JUL-1998  (first entry)
XX
DE   Texaphyrin oligonucleotide conjugate.
XX
KW   Texaphyrin oligonucleotide conjugate; dysprosium; metal complex;
KW   hydrolytic cleavage activity; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /note= "A texaphyrin dysprosium metal complex, bound to
FT                          cytosine via a linking phosphate group"
XX
PN   WO9807733-A1.
XX
PD   26-FEB-1998.
XX
PF   20-AUG-1997;   97WO-US14682.
XX
PR   20-AUG-1996;   96US-0700277.
XX
PA   (PHAR-) PHARMACYCLICS INC.
XX
PI   Crofts SP,  Magda D,  Wright M;
XX
DR   WPI; 1998-179049/16.
XX
PT   New conjugates which have hydrolytic cleavage activity for RNA -
PT   comprise a texaphyrin metal complex bound to an internal linkage of
PT   an oligonucleotide
XX
PS   Example 4; Page 51; 77pp; English.
XX
CC   This sequence is shown in the specification. THe invention relates
CC   to texaphyrin oligonucleotide conjugates which have hydrolytic cleavage
CC   activity for RNA. They comprise a texaphyrin metal complex bound to an
CC   internal linkage of an oligonucleotide or oligonucleotide analogue. The
CC   conjugates may be used for the destruction of retroviral RNA, messenger
CC   RNA, ribosomal RNA, RNA cofactors, transfer RNA, small nuclear RNA and
CC   small cytoplasmic RNA. They may be used for eliminating diseased or
CC   cancerous cells or tissues, in blood purification protocols (in vivo or
CC   in vitro), in antiviral treatments, or as diagnostic probes (e.g. in
CC   determination of the nucleotide sequence of RNA or to detect
CC   polymorphisms in RNA). Administration of the conjugates is, e.g., oral,
```

```
PA   (PHAR-) PHARMACYCLICS INC.
PA   (TEXA ) UNIV TEXAS SYSTEM.
XX
PI   Dow WC,  Hemmi GW,  Iverson B,  Kral VA,  Magda D;
PI   Miller RA,  Mody T, Ross KL,  Sessler JL,  Smith DA;
PI   Wright M;
XX
DR   WPI; 1995-036382/05.
XX
PT   Texaphyrin metal complex mediated ester hydrolysis - esp. useful
PT   for targeted intracellular hydrolysis of mRNA and for inhibiting
PT   gene expression
XX
PS   Example 7; Fig 9; 125pp; English.
XX
CC   AAQ80879-Q80892 are texaphyrin lanthanide metal DNA conjugates, which
CC   are esp. useful for the targeted intracellular hydrolysis of mRNA;
CC   inhibiting gene expression. They may also be used for the treament
CC   of liver disease, as hormone regulation agents and as hydrolysis
CC   reagents for the detoxification of alkyl phosphate esters.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 other;

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 747
AAQ80880
ID   AAQ80880 standard; DNA; 20 BP.
XX
AC   AAQ80880;
XX
DT   25-MAR-2003  (updated)
DT   30-AUG-1995  (first entry)
XX
DE   Europium (III) texaphyrin (EuTx) DNA conjugate 9B.
XX
KW   Europium (III) texaphyrin (EuTx) DNA conjugate 9B; liver disease;
KW   targeted intracellular mRNA hydrolysis; gene expression inhibition;
KW   hormone regulation; hydrolysis reagents; alkyl phosphate esters;
KW   detoxification; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "EuTx-NH(CH2)6-PO4-cytosine"
XX
PN   WO9429316-A2.
XX
PD   22-DEC-1994.
XX
PF   09-JUN-1994;   94WO-US06284.
XX
PR   09-JUN-1993;   93US-0075123.
PR   14-APR-1994;   94US-0227370.
XX
PA   (PHAR-) PHARMACYCLICS INC.
PA   (TEXA ) UNIV TEXAS SYSTEM.
XX
PI   Dow WC,  Hemmi GW,  Iverson B,  Kral VA,  Magda D;
PI   Miller RA,  Mody T, Ross KL,  Sessler JL,  Smith DA;
PI   Wright M;
XX
DR   WPI; 1995-036382/05.
XX
PT   Texaphyrin metal complex mediated ester hydrolysis - esp. useful
PT   for targeted intracellular hydrolysis of mRNA and for inhibiting
PT   gene expression
XX
PS   Example 7; Fig 9; 125pp; English.
XX
CC   AAQ80879-Q80892 are texaphyrin lanthanide metal DNA conjugates, which
CC   are esp. useful for the targeted intracellular hydrolysis of mRNA;
CC   inhibiting gene expression. They may also be used for the treament
CC   of liver disease, as hormone regulation agents and as hydrolysis
CC   reagents for the detoxification of alkyl phosphate esters.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 other;

  Query Match             7.2%;  Score 10;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGGTGT 1685
              || |||  | || |||||
Db          1 CATCTGTGAGCCGGGTGT 18


RESULT 748
AAQ91455
ID   AAQ91455 standard; DNA; 20 BP.
XX
AC   AAQ91455;
XX
DT   25-MAR-2003  (updated)
DT   30-AUG-1995  (first entry)
XX
DE   Dysprosium (III) texaphyrin (DyTx) DNA conjugate.
XX
KW   Dysprosium (III) texaphyrin (DyTx) DNA conjugate; liver disease;
KW   targeted intracellular mRNA hydrolysis; gene expression inhibition;
KW   hormone regulation; hydrolysis reagents; alkyl phosphate esters;
KW   detoxification; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "DyTx-NH(CH2)6-PO4-cytosine"
XX
PN   WO9429316-A2.
XX
PD   22-DEC-1994.
XX
PF   09-JUN-1994;   94WO-US06284.
XX
PR   09-JUN-1993;   93US-0075123.
PR   14-APR-1994;   94US-0227370.
XX
PA   (PHAR-) PHARMACYCLICS INC.
PA   (TEXA ) UNIV TEXAS SYSTEM.
XX
PI   Dow WC,  Hemmi GW,  Iverson B,  Kral VA,  Magda D;
PI   Miller RA,  Mody T, Ross KL,  Sessler JL,  Smith DA;
PI   Wright M;
XX
DR   WPI; 1995-036382/05.
XX
PT   Texaphyrin metal complex mediated ester hydrolysis - esp. useful
PT   for targeted intracellular hydrolysis of mRNA and for inhibiting
PT   gene expression
XX
PS   Disclosure; Fig 21; 125pp; English.
```

```
PT   sequences, used to treat cancer  -
XX
PS   Claim 79; Page 100; 148pp; English.
XX
CC   The present invention describes nucleic acids (A) that interact stably
CC   with a target sequence and contain at least one phosphoro(di)thioate
CC   link, having endonuclease activity. (A), and more generally any
CC   catalytic nucleic acid (A') that modulates expression of the oestrogen
CC   receptor gene, are used to treat cancer (particularly of breast or
CC   endometrium), in vivo or by transforming cells ex vivo and implanting
CC   treated cells, or for other conditions associated with levels of
CC   oestrogen receptor. Because of the high selectivity for targeted RNA, (A)
CC   can also be used to correlate inhibition of gene expression with
CC   alterations in phenotype, particularly for identification of therapeutic
CC   targets, and as research reagents (for RNA, in the  same way that
CC   restriction endonucleases are used with DNA). The combination of
CC   modifications in (A) improves resistance to nucleases, binding affinity
CC   and/or activity. AAA23503 to AAA24747 represent oestrogen receptor
CC   hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their
CC   corresponding target sequences. AAA25993 to AAA26105 represent oestrogen
CC   receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent
CC   their corresponding target sequences. AAA26219 to AAA26271 represent
CC   other ribozyme sequences and antisense oligonucleotides used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 14 BP; 1 A; 8 C; 2 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   91.7%;  Pred. No. 3.6e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCC 1749
              |||| |||||||
Db          2 CCCAGCTCCTCC 13


RESULT 745
AAT49813/c
ID   AAT49813 standard; RNA; 15 BP.
XX
AC   AAT49813;
XX
DT   18-MAR-1997  (first entry)
XX
DE   Human CETP HH ribozyme target sequence #1666.
XX
KW   Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
KW   neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW   reverse cholesterol transport; high density lipoprotein; therapy; CETP;
KW   familial hypercholesterolaemia; dyslipidaemia; hypoalphalipoproteinaemia;
KW   peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW   angioplastic restenosis; low density lipoprotein; diabetes; HDL; human;
KW   LDL; ss.
XX
OS   Homo sapiens.
XX
PN   WO9620279-A1.
XX
PD   04-JUL-1996.
XX
PF   11-DEC-1995;   95WO-US16000.
XX
PR   23-DEC-1994;   94US-0363240.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (WARN ) WARNER LAMBERT CO.
XX
PI   Bisgaier C,  Couture L,  McSwiggen J,  Pape M,  Stinchcomb D;
XX
DR   WPI; 1996-321852/32.
XX
PT   New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA
PT   - useful for preventing or treating initial development, progression
PT   or regression of vascular diseases, esp. familial
PT   hypercholesterolaemia
XX
PS   Claim 4; Page 32; 72pp; English.
XX
CC   AAT49608-T49863 represent target sequences for the human cholesterol
CC   ester transfer protein (CETP) hammerhead (HH) ribozymes (see
CC   AAT49881-T50137). CETP is a 74 kD glycoprotein that facilitates neutral
CC   lipid transfer between plasma lipoproteins.  The numbering of the targets
CC   refers to the position of the cleavage site in full length CETP.  The
CC   ribozyme binds to 5 nucleotides either side of this site, provided the
CC   sequence UH is immediately upstream.  The ribozymes are able to cleave
CC   mRNA from the gene encoding CETP, thereby blocking synthesis and/or
CC   expression of the mRNA.  By inhibiting CETP, the reverse cholesterol
CC   transport (RCT) pathway can be inhibited (or eliminated) thereby
CC   preventing the reduction in size density of the high density lipoproteins
CC   (HDL), prolonging HDL half life, and therefore increasing HDL levels.
CC   The ribozymes can be used to treat conditions associated with abnormal
CC   levels of CETP, specifically familial hypercholesterolaemia,
CC   atherosclerosis, peripheral vascular disease, hyperbetalipoproteinaemia,
CC   hypoalphalipoproteinaemia, dyslipidaemia, vascular complications of
CC   diabetes, transplant, atherectomy and angioplastic restenosis.  By
CC   inhibiting CETP, the levels of HDL and low density lipoproteins (LDL),
CC   and the HDL:LDL ratio are favourably altered (a decrease in LDL levels,
CC   and a corresponding increase in HDL levels).  The HH ribozymes can also
CC   be used diagnostically to study genetic drift and mutations in diseased
CC   cells, and to detect CETP mRNA.  As the HH ribozymes target specific
CC   regions of the CETP gene, they have low non-specific activity.
XX
SQ   Sequence 15 BP; 3 A; 6 C; 4 G; 2 U; 0 other;

  Query Match             7.3%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 4.3e+02;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTGG 1682
              ||||||  | |||||
Db         15 CAGCTGTGAGCCTGG 1


RESULT 746
AAQ80879
ID   AAQ80879 standard; DNA; 20 BP.
XX
AC   AAQ80879;
XX
DT   25-MAR-2003  (updated)
DT   30-AUG-1995  (first entry)
XX
DE   Europium (III) texaphyrin (EuTx) DNA conjugate 9A.
XX
KW   Europium (III) texaphyrin (EuTx) DNA conjugate 9A; liver disease;
KW   targeted intracellular mRNA hydrolysis; gene expression inhibition;
KW   hormone regulation; hydrolysis reagents; alkyl phosphate esters;
KW   detoxification; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   7
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "EuTx-NH(CH2)6 alkylamidated thymidine"
XX
PN   WO9429316-A2.
XX
PD   22-DEC-1994.
XX
PF   09-JUN-1994;   94WO-US06284.
XX
PR   09-JUN-1993;   93US-0075123.
PR   14-APR-1994;   94US-0227370.
XX
```

PI Akhtar S, Fell P, McSwiggen JA;
XX
DR WPI; 1998-437449/37.
XX
PT Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT growth factor receptor, useful for inhibiting cell proliferation and
PT for treating cancers
XX
PS Claim 6; Page 89; 109pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules (NAMs)
CC which specifically cleave RNA derived from an epidermal growth factor
CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAMs can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell.
XX
SQ Sequence 14 BP; 2 A; 3 C; 4 G; 5 U; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred. No. 3.6e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1639 CTTGTAGCAGAA 1650
|||| |||||||
Db 13 CTTGAAGCAGAA 2

RESULT 743
AAA17659
ID AAA17659 standard; RNA; 14 BP.
XX
AC AAA17659;
XX
DT 19-JUN-2000 (first entry)
XX
DE Aryl hydrocarbon nuclear transport target site SEQ ID NO:885.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US06507.
XX
PR 27-MAR-1998; 98US-0079678.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or
PT stability of an mRNA encoding an angiogenic factors -
XX
PS Claim 53; Page 90; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with
CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3.
XX
SQ Sequence 14 BP; 3 A; 5 C; 5 G; 1 U; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 83.3%; Pred. No. 3.6e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1667 ACAGCTGGAACC 1678
||||| :|| |||
Db 3 ACAGCUGGCACC 14

RESULT 744
AAA26158
ID AAA26158 standard; DNA; 14 BP.
XX
AC AAA26158;
XX
DT 19-JUL-2000 (first entry)
XX
DE Oestrogen receptor hairpin ribozyme target sequence SEQ ID NO:2656.
XX
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
PN WO9954459-A2.
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US08547.
XX
PR 20-APR-1998; 98US-0082404.
PR 23-JUN-1998; 98US-0103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Beigelman L, McSwiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeberli P;
PI Matulic-Adamic J;
XX
DR WPI; 2000-013248/01.
XX
PT New nucleic acids that interact, and optionally cleave, target

```
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 263180; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              | ||||||||||
Db         13 GTAGATGGAGAT 2


RESULT 741
AAQ78441/c
ID   AAQ78441 standard; DNA; 14 BP.
XX
AC   AAQ78441;
XX
DT   25-MAR-2003  (updated)
DT   27-JUN-1995  (first entry)
XX
DE   TGF-beta gene phosphorothioate antisense oligonucleotide.
XX
KW   Transforming growth factor beta; TGF-beta; antisense; treatment;
KW   tumour; angiogenesis; breast tumour; neurofibroma; glioma;
KW   glioblastoma; carcinogenesis; carcinoma; oesophagus; oesophageal;
KW   gastric; gut; immunosuppression; oligonucleotide; ss.
XX
OS   Synthetic.
XX
PN   WO9425588-A2.
XX
PD   10-NOV-1994.
XX
PF   29-APR-1994;   94WO-EP01362.
XX
PR   30-APR-1993;   93EP-0107089.
PR   13-MAY-1993;   93EP-0107849.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Bogdahn U,  Brysch W,  Schlingensiepen G,  Schlingensiepen K;
PI   Schlingensiepen R;
XX
DR   WPI; 1994-358266/44.
XX
PT   New transforming growth factor beta anti:sense
PT   oligo:nucleotide(s)  - for treating immunosuppression, tumours,
PT   etc.
XX
PS   Claim 6; Page 50; 74pp; English.
XX
CC   The antisense oligonucleotides are useful in the treatment of
CC   tumours in which expression of TGF-beta is of relevance for
CC   pathogenicity and/or inhibition of pathological angiogenesis.  They
CC   are used especially for the treatment of the immunosuppressive
CC   effect of TGF-beta, augmentation of the proliferation of cytotoxic
CC   lymphocytes, treatment of endogenous hyperexpression of TGF-beta,
CC   treatment of breast tumours, neurofibromas and malignant gliomas,
CC   including glioblastomas, treatment and prophylaxis of skin
CC   carcinogenesis, and treatment of oesophageal and gastric carcinomas.
CC   See AAQ78352-Q78488.  The sequences given in GENESEQ files
CC   AAQ78352-Q78407 and AAQ78488 are antisense oligodeoxynucleotides of
CC   TGF-beta 1.  The sequences given in GENESEQ files AAQ78408-78487 are
CC   antisense oligodeoxynucleotides of TGF-beta 2 in the form of
CC   phosphorothioate analogues.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 14 BP; 1 A; 5 C; 2 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 14;
  Best Local Similarity   91.7%;  Pred. No. 3.6e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1644 AGCAGAAGGCAA 1655
              |||||||||| |
Db         14 AGCAGAAGGCGA 3


RESULT 742
AAV99069/c
ID   AAV99069 standard; RNA; 14 BP.
XX
AC   AAV99069;
XX
DT   17-MAR-1999  (first entry)
XX
DE   Human EGF-R target sequence nucleotide position 4310.
XX
KW   Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW   hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW   cancer; genetic drift; detection; mutation; ss.
XX
OS   Homo sapiens.
XX
PN   WO9833893-A2.
XX
PD   06-AUG-1998.
XX
PF   14-JAN-1998;   98WO-US00730.
XX
PR   04-DEC-1997;   97US-0985162.
PR   31-JAN-1997;   97US-0036476.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (UYAS-) UNIV ASTON.
XX
```

```
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
                || |||||||||
Db         13 TCTCTATCCTAA 2


RESULT 738
ABH61555
ID   ABH61555 standard; DNA; 13 BP.
XX
AC   ABH61555;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 261532 for detecting.SNP TSC0063469.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 261532; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
                || |||||||||
Db          1 TCTCTATCCTAA 12


RESULT 739
ABH63202
ID   ABH63202 standard; DNA; 13 BP.
XX
AC   ABH63202;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 263179 for detecting SNP TSC0063836.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 263179; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
                | ||||||||||
Db          1 GTAGATGGAGAT 12


RESULT 740
ABH63203/c
ID   ABH63203 standard; DNA; 13 BP.
XX
AC   ABH63203;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 263180 for detecting SNP TSC0063836.
```

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 250595; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1746 CTCCCTATCCTA 1757
||||||| ||||
Db 13 CTCCCTACCCTA 2

RESULT 736
ABH50619
ID ABH50619 standard; DNA; 13 BP.
XX
AC ABH50619;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 250596 for detecting SNP TSC0061192.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 250596; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1746 CTCCCTATCCTA 1757
||||||| ||||
Db 1 CTCCCTACCCTA 12

RESULT 737
ABH61554/c
ID ABH61554 standard; DNA; 13 BP.
XX
AC ABH61554;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 261531 for detecting SNP TSC0063469.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 261531; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.

```
  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              | ||||||||||
Db          1 CACTATCCTAAA 12


RESULT 733
ABH47622
ID   ABH47622 standard; DNA; 13 BP.
XX
AC   ABH47622;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 247599 for detecting SNP TSC0060506.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 247599; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||| ||||||
Db          2 GTTGGATTAGGA 13


RESULT 734
ABH47623/c
ID   ABH47623 standard; DNA; 13 BP.
XX
AC   ABH47623;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 247600 for detecting SNP TSC0060506.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 247600; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||| ||||||
Db         12 GTTGGATTAGGA 1


RESULT 735
ABH50618/c
ID   ABH50618 standard; DNA; 13 BP.
XX
AC   ABH50618;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 250595 for detecting SNP TSC0061192.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
```

XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 237480; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 4 C; 1 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1750 CTATCCTAAAGG 1761
||||||||||.|
Db 2 CTATCCTAAACG 13

RESULT 731
ABH42002/c
ID ABH42002 standard; DNA; 13 BP.
XX
AC ABH42002;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 241979 for detecting SNP TSC0059020.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 241979; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1748 CCCTATCCTAAA 1759
| ||||||||||
Db 13 CACTATCCTAAA 2

RESULT 732
ABH42003
ID ABH42003 standard; DNA; 13 BP.
XX
AC ABH42003;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 241980 for detecting SNP TSC0059020.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 241980; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 other;

```
RESULT 728
ABH36975/c
ID   ABH36975 standard; DNA; 13 BP.
XX
AC   ABH36975;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 236952 for detecting SNP TSC0057811.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 236952; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCT 1737
             ||||||||||  |
Db         12 TGGAGATTGGTT 1

RESULT 729
ABH37502/c
ID   ABH37502 standard; DNA; 13 BP.
XX
AC   ABH37502;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 237479 for detecting SNP TSC0057920.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 237479; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 1 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1750 CTATCCTAAAGG 1761
             ||||||||||  |
Db         12 CTATCCTAAACG 1

RESULT 730
ABH37503
ID   ABH37503 standard; DNA; 13 BP.
XX
AC   ABH37503;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 237480 for detecting SNP TSC0057920.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
```

```
XX
PS   Claim 1; SEQ ID 236637; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
                || |||||||||
Db         12 AAATCCTCCCTA 1


RESULT 726
ABH36661
ID   ABH36661 standard; DNA; 13 BP.
XX
AC   ABH36661;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 236638 for detecting SNP TSC0057760.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 236638; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
                || |||||||||
Db         2 AAATCCTCCCTA 13


RESULT 727
ABH36974
ID   ABH36974 standard; DNA; 13 BP.
XX
AC   ABH36974;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 236951 for detecting SNP TSC0057811.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 236951; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCT 1737
                ||||||||||  |
Db         2 TGGAGATTGGTT 13
```

XX
DE Oligonucleotide SEQ ID NO 235951 for detecting SNP TSC0005348.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 235951; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1748 CCCTATCCTAAA 1759
|| |||||||||
Db 12 CCTTATCCTAAA 1

RESULT 724
ABH35975
ID ABH35975 standard; DNA; 13 BP.
XX
AC ABH35975;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 235952 for detecting SNP TSC0005348.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 235952; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1748 CCCTATCCTAAA 1759
|| |||||||||
Db 2 CCTTATCCTAAA 13

RESULT 725
ABH36660/c
ID ABH36660 standard; DNA; 13 BP.
XX
AC ABH36660;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 236637 for detecting SNP TSC0057760.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -

```
C   central nervous system, cardiovascular and metabolic disorders. The
C   oligomers are also used for detecting cell type differentiation.
C   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
C   ABI00010-ABI82073 represent the oligomers described in the invention.
C   NOTE: The sequence data for this patent did not form part of the printed
C   specification, but was obtained in electronic format from WIPO at
C   ftp.wipo.int/pub/published_pct_sequences.
X
Q   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

 Query Match              7.5%;  Score 10.4;  DB 1;  Length 13;
 Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
 Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

y       1748 CCCTATCCTAAA 1759
             ||||||||| ||
b          2 CCCTATCCTTAA 13


ESULT 721
BH26444/c
D   ABH26444 standard; DNA; 13 BP.
X
C   ABH26444;
X
T   22-FEB-2002  (first entry)
X
E   Oligonucleotide SEQ ID NO 226421 for detecting SNP TSC0055194.
X
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB00713.
XX
PR  07-APR-2000; 2000DE-1019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A,  Piepenbrock C,  Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single nucleotide polymorphisms and cytosine
PT  methylation status  -
XX
PS  Claim 1; SEQ ID 226421; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation.
CC  ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC  ABI00010-ABI82073 represent the oligomers described in the invention.
CC  NOTE: The sequence data for this patent did not form part of the printed
CC  specification, but was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences.
XX
SQ  Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

  Query Match              7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1737 TCCCAACTCCTC 1748
             ||||||||| |||
Db        12 TCCCAACTACTC 1


RESULT 722
ABH26445
ID  ABH26445 standard; DNA; 13 BP.
XX
AC  ABH26445;
XX
DT  22-FEB-2002  (first entry)
XX
DE  Oligonucleotide SEQ ID NO 226422 for detecting SNP TSC0055194.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB00713.
XX
PR  07-APR-2000; 2000DE-1019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A,  Piepenbrock C,  Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single nucleotide polymorphisms and cytosine
PT  methylation status  -
XX
PS  Claim 1; SEQ ID 226422; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation.
CC  ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC  ABI00010-ABI82073 represent the oligomers described in the invention.
CC  NOTE: The sequence data for this patent did not form part of the printed
CC  specification, but was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences.
XX
SQ  Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match              7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1737 TCCCAACTCCTC 1748
             ||||||||| |||
Db         2 TCCCAACTACTC 13


RESULT 723
ABH35974/c
ID  ABH35974 standard; DNA; 13 BP.
XX
AC  ABH35974;
XX
DT  22-FEB-2002  (first entry)
```

```
X
N   WO200177384-A2.
X
D   18-OCT-2001.
X
F   06-APR-2001; 2001WO-IB00713.
AX
R   07-APR-2000; 2000DE-1019173.
AX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A,  Piepenbrock C,  Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single nucleotide polymorphisms and cytosine
PT  methylation status  -
XX
PS  Claim 1; SEQ ID 213536; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation.
CC  ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC  ABI00010-ABI82073 represent the oligomers described in the invention.
CC  NOTE: The sequence data for this patent did not form part of the printed
CC  specification, but was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences.
XX
SQ  Sequence 13 BP; 2 A; 7 C; 1 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              ||||||||||| |
Db          1 TCCCAACTCCGC 12


RESULT 719
ABH15230/c
ID  ABH15230 standard; DNA; 13 BP.
XX
AC  ABH15230;
XX
DT  22-FEB-2002  (first entry)
XX
DE  Oligonucleotide SEQ ID NO 215207 for detecting SNP TSC0052373.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB00713.
XX
PR  07-APR-2000; 2000DE-1019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A,  Piepenbrock C,  Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single nucleotide polymorphisms and cytosine
PT  methylation status  -
XX
PS  Claim 1; SEQ ID 215207; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation.
CC  ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC  ABI00010-ABI82073 represent the oligomers described in the invention.
CC  NOTE: The sequence data for this patent did not form part of the printed
CC  specification, but was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences.
XX
SQ  Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              ||||||||| ||
Db         12 CCCTATCCTTAA 1


RESULT 720
ABH15231
ID  ABH15231 standard; DNA; 13 BP.
XX
AC  ABH15231;
XX
DT  22-FEB-2002  (first entry)
XX
DE  Oligonucleotide SEQ ID NO 215208 for detecting SNP TSC0052373.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB00713.
XX
PR  07-APR-2000; 2000DE-1019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A,  Piepenbrock C,  Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single nucleotide polymorphisms and cytosine
PT  methylation status  -
XX
PS  Claim 1; SEQ ID 215208; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
```

```
Q   Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 other;

 Query Match              7.5%;  Score 10.4;  DB 1;  Length 13;
 Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
 Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

y       1737 TCCCAACTCCTC 1748
             ||||||||||| |
o         13 TCCCAACTCCAC 2


ESULT 716
BH13555
D   ABH13555 standard; DNA; 13 BP.
X
C   ABH13555;
X
T   22-FEB-2002  (first entry)
X
E   Oligonucleotide SEQ ID NO 213532 for detecting SNP TSC0051991.
X
W   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
W   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
W   central nervous system; gastrointestinal; respiratory; immune; metabolic.
X
S   Homo sapiens.
X
N   WO200177384-A2.
X
D   18-OCT-2001.
X
F   06-APR-2001; 2001WO-IB00713.
X
R   07-APR-2000; 2000DE-1019173.
XX
A   (EPIG-) EPIGENOMICS AG.
X
I   Olek A,  Piepenbrock C,  Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single nucleotide polymorphisms and cytosine
PT  methylation status  -
XX
PS  Claim 1; SEQ ID 213532; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation.
CC  ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC  ABI00010-ABI82073 represent the oligomers described in the invention.
CC  NOTE: The sequence data for this patent did not form part of the printed
CC  specification, but was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences.
XX
SQ  Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 other;

  Query Match              7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              ||||||||||| |
Db          1 TCCCAACTCCAC 12


RESULT 717
ABH13558/c
ID   ABH13558 standard; DNA; 13 BP.
XX
AC   ABH13558;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 213535 for detecting SNP TSC0051991.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 213535; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 1 C; 7 G; 2 T; 0 other;

  Query Match              7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              ||||||||||| |
Db          13 TCCCAACTCCGC 2


RESULT 718
ABH13559
ID   ABH13559 standard; DNA; 13 BP.
XX
AC   ABH13559;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 213536 for detecting SNP TSC0051991.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
```

```
XX
A   (EPIG-) EPIGENOMICS AG.
XX
I   Olek A,  Piepenbrock C,  Berlin K;
X
R   WPI; 2001-657177/75.
XX
T   Set of oligonucleotides, useful for diagnosis and cell typing, is
T   designed to detect single nucleotide polymorphisms and cytosine
T   methylation status  -
X
S   Claim 1; SEQ ID 212797; 29pp + Sequence Listing; German.
XX
C   This invention describes novel oligonucleotide primers or peptide nucleic
C   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
C   and cytosine methylation status in chemically pretreated genomic DNA. The
C   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
C   range of diseases including immune system, gastrointestinal, respiratory,
C   central nervous system, cardiovascular and metabolic disorders. The
C   oligomers are also used for detecting cell type differentiation.
C   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
C   ABI00010-ABI82073 represent the oligomers described in the invention.
C   NOTE: The sequence data for this patent did not form part of the printed
C   specification, but was obtained in electronic format from WIPO at
C   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ  Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              ||||||| ||||
Db          1 GAAGTTGAGTTA 12


RESULT 714
ABH12821/c
ID   ABH12821 standard; DNA; 13 BP.
XX
AC   ABH12821;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 212798 for detecting SNP TSC0051845.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 212798; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              ||||||| ||||
Db         13 GAAGTTGAGTTA 2


RESULT 715
ABH13554/c
ID   ABH13554 standard; DNA; 13 BP.
XX
AC   ABH13554;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 213531 for detecting SNP TSC0051991.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 213531; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
```

```
Db          13 GGAGACGGAGAT 2


RESULT 711
ABH00760
ID   ABH00760 standard; DNA; 13 BP.
XX
AC   ABH00760;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 200737 for detecting SNP TSC0049389.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 200737; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              |||| |||||||
Db          1 GTTGAGTTAGGA 12


RESULT 712
ABH00761/c
ID   ABH00761 standard; DNA; 13 BP.
XX
AC   ABH00761;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 200738 for detecting SNP TSC0049389.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 200738; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              |||| |||||||
Db          13 GTTGAGTTAGGA 2


RESULT 713
ABH12820
ID   ABH12820 standard; DNA; 13 BP.
XX
AC   ABH12820;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 212797 for detecting SNP TSC0051845.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
```

PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 200364; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGAT 1732
|||||| |||||
Db 13 GGAGATAGAGAT 2

RESULT 709
ABH00390
ID ABH00390 standard; DNA; 13 BP.
XX
AC ABH00390;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200367 for detecting SNP TSC0049306.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 200367; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 1 C; 7 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGAT 1732
||||| ||||||
Db 1 GGAGACGGAGAT 12

RESULT 710
ABH00391/c
ID ABH00391 standard; DNA; 13 BP.
XX
AC ABH00391;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200368 for detecting SNP TSC0049306.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 200368; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 1 A; 7 C; 1 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGAT 1732
||||| ||||||

XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 195706 for detecting SNP TSC0009428.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 195706; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 5 C; 1 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1702 GAAGTTGGGTTA 1713
||||| ||||||
Db 13 GAAGTCGGGTTA 2

RESULT 707
ABH00386
ID ABH00386 standard; DNA; 13 BP.
XX
AC ABH00386;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200363 for detecting SNP TSC0049306.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 200363; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGAT 1732
|||||| |||||
Db 1 GGAGATAGAGAT 12

RESULT 708
ABH00387/c
ID ABH00387 standard; DNA; 13 BP.
XX
AC ABH00387;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200364 for detecting SNP TSC0049306.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is

```
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              |||||| |||||
Db          1 GAAGTTAGGTTA 12


RESULT 704
ABF95707/c
ID   ABF95707 standard; DNA; 13 BP.
XX
AC   ABF95707;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 195704 for detecting SNP TSC0009428.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 195704; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              |||||| |||||
Db          13 GAAGTTAGGTTA 2


RESULT 705
ABF95708
ID   ABF95708 standard; DNA; 13 BP.
XX
AC   ABF95708;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 195705 for detecting SNP TSC0009428.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 195705; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 1 C; 5 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              ||||| ||||||
Db          1 GAAGTCGGGTTA 12


RESULT 706
ABF95709/c
ID   ABF95709 standard; DNA; 13 BP.
XX
AC   ABF95709;
```

```
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 192681; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTG 1708
                ||||||||| ||
Db          2 TGGTGGAAGGTG 13


RESULT 702
ABF92685/c
ID   ABF92685 standard; DNA; 13 BP.
XX
AC   ABF92685;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 192682 for detecting SNP TSC0047412.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 192682; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTG 1708
                ||||||||| ||
Db          12 TGGTGGAAGGTG 1


RESULT 703
ABF95706
ID   ABF95706 standard; DNA; 13 BP.
XX
AC   ABF95706;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 195703 for detecting SNP TSC0009428.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 195703; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
```

```
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
                ||||.|||||||
Db          2 CCCTTTCCTAAA 13


RESULT 699
ABF90782
ID   ABF90782 standard; DNA; 13 BP.
XX
AC   ABF90782;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 190779 for detecting SNP TSC0046907.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 190779; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
                |.||||||||||
Db          1 ATGTTGGGTTAG 12


RESULT 700
ABF90783/c
ID   ABF90783 standard; DNA; 13 BP.
XX
AC   ABF90783;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 190780 for detecting SNP TSC0046907.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 190780; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
                |.||||||||||
Db         13 ATGTTGGGTTAG 2


RESULT 701
ABF92684
ID   ABF92684 standard; DNA; 13 BP.
XX
AC   ABF92684;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 192681 for detecting SNP TSC0047412.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 182120; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
                ||||||||||  |
Db          1 TCCCTATCCTTA 12


RESULT 697
ABF87482/c
ID   ABF87482 standard; DNA; 13 BP.
XX
AC   ABF87482;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 187479 for detecting SNP TSC0046214.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 187479; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
                ||||  |||||||
Db         12 CCCTTTCCTAAA 1


RESULT 698
ABF87483
ID   ABF87483 standard; DNA; 13 BP.
XX
AC   ABF87483;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 187480 for detecting SNP TSC0046214.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 187480; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
```

```
Qy       1736 CTCCCAACTCCT 1747
              |||||||| ||
Db         12 CTCCCAACTACT 1


RESULT 694
ABF79387
ID   ABF79387 standard; DNA; 13 BP.
XX
AC   ABF79387;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 179384 for detecting SNP TSC0044413.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 179384; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCT 1747
              |||||||| ||
Db          2 CTCCCAACTACT 13


RESULT 695
ABF82122/c
ID   ABF82122 standard; DNA; 13 BP.
XX
AC   ABF82122;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 182119 for detecting SNP TSC0045020.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 182119; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
              |||||||||| |
Db         13 TCCCTATCCTTA 2


RESULT 696
ABF82123
ID   ABF82123 standard; DNA; 13 BP.
XX
AC   ABF82123;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 182120 for detecting SNP TSC0045020.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
```

```
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 174433; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 5 G; 5 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              | ||||||||||
Db          1 GTAGTTGGGTTA 12


RESULT 692
ABF74437/c
ID   ABF74437 standard; DNA; 13 BP.
XX
AC   ABF74437;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 174434 for detecting SNP TSC0043388.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 174434; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 2 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              | ||||||||||
Db          13 GTAGTTGGGTTA 2


RESULT 693
ABF79386/c
ID   ABF79386 standard; DNA; 13 BP.
XX
AC   ABF79386;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 179383 for detecting SNP TSC0044413.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 179383; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
XX
AC   ABF73144;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 173141 for detecting SNP TSC0043123.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 173141; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 1 C; 7 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 TCCTCCCTATCC 1755
             ||||||| ||||
Db         12 TCCTCCCGATCC 1


RESULT 690
ABF73145
ID   ABF73145 standard; DNA; 13 BP.
XX
AC   ABF73145;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 173142 for detecting SNP TSC0043123.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 173142; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 7 C; 1 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 TCCTCCCTATCC 1755
             ||||||| ||||
Db         2 TCCTCCCGATCC 13


RESULT 691
ABF74436
ID   ABF74436 standard; DNA; 13 BP.
XX
AC   ABF74436;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 174433 for detecting SNP TSC0043388.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
```

```
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 1 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              ||||||||| ||
Db         13 GTTAGGAGTTCG 2


RESULT 687
ABF73140/c
ID   ABF73140 standard; DNA; 13 BP.
XX
AC   ABF73140;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 173137 for detecting SNP TSC0043123.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 173137; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 TCCTCCCTATCC 1755
              ||||||| ||||
Db         12 TCCTCCCAATCC 1


RESULT 688
ABF73141
ID   ABF73141 standard; DNA; 13 BP.
XX
AC   ABF73141;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 173138 for detecting SNP TSC0043123.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 173138; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 TCCTCCCTATCC 1755
              ||||||| ||||
Db          2 TCCTCCCAATCC 13


RESULT 689
ABF73144/c
ID   ABF73144 standard; DNA; 13 BP.
```

```
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 166100; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 6 C; 1 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1693 AGCGTGGTGGAA 1704
              ||||||| |||
Db         12 AGCGTGGTAGAA 1


RESULT 685
ABF66672
ID   ABF66672 standard; DNA; 13 BP.
XX
AC   ABF66672;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 166669 for detecting SNP TSC0041743.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 166669; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 1 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              ||||||||| ||
Db          1 GTTAGGAGTTCG 12


RESULT 686
ABF66673/c
ID   ABF66673 standard; DNA; 13 BP.
XX
AC   ABF66673;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 166670 for detecting SNP TSC0041743.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 166670; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
```

```
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              |||| |||||||
Db          2 GGAAATTGGGTT 13


RESULT 682
ABF65199/c
ID   ABF65199 standard; DNA; 13 BP.
XX
AC   ABF65199;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 165196 for detecting SNP TSC0041433.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 165196; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              |||| |||||||
Db         12 GGAAATTGGGTT 1

RESULT 683
ABF66102
ID   ABF66102 standard; DNA; 13 BP.
XX
AC   ABF66102;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 166099 for detecting SNP TSC0007702.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 166099; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 1 C; 6 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1693 AGCGTGGTGGAA 1704
              |||||||| |||
Db          2 AGCGTGGTAGAA 13


RESULT 684
ABF66103/c
ID   ABF66103 standard; DNA; 13 BP.
XX
AC   ABF66103;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 166100 for detecting SNP TSC0007702.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 163797; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 0 C; 8 G; 0 U; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1745 CCTCCCTATCCT 1756
||||||| ||||
Db 12 CCTCCCTTTCCT 1

RESULT 680
ABF63801
ID ABF63801 standard; DNA; 13 BP.
XX
AC ABF63801;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 163798 for detecting SNP TSC0010383.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 163798; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1745 CCTCCCTATCCT 1756
||||||| ||||
Db 2 CCTCCCTTTCCT 13

RESULT 681
ABF65198
ID ABF65198 standard; DNA; 13 BP.
XX
AC ABF65198;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 165195 for detecting SNP TSC0041433.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 165195; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.

```
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              ||||||| ||||
Db          2 TCCCAACACCTC 13


RESULT 677
ABF61036
ID   ABF61036 standard; DNA; 13 BP.
XX
AC   ABF61036;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 161033 for detecting SNP TSC0040546.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 161033; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
              |||||||| |||
Db          1 AGATGGAGTTTG 12


RESULT 678
ABF61037/c
ID   ABF61037 standard; DNA; 13 BP.
XX
AC   ABF61037;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 161034 for detecting SNP TSC0040546.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 161034; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
              |||||||| |||
Db         13 AGATGGAGTTTG 2


RESULT 679
ABF63800/c
ID   ABF63800 standard; DNA; 13 BP.
XX
AC   ABF63800;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 163797 for detecting SNP TSC0010383.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
```

XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 155720; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1703 AAGTTGGGTTAG 1714
||||||| ||||
Db 12 AAGTTGGTTTAG 1

RESULT 675
ABF58666/c
ID ABF58666 standard; DNA; 13 BP.
XX
AC ABF58666;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 158663 for detecting SNP TSC0039936.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 158663; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1737 TCCCAACTCCTC 1748
||||||| ||||
Db 12 TCCCAACACCTC 1

RESULT 676
ABF58667
ID ABF58667 standard; DNA; 13 BP.
XX
AC ABF58667;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 158664 for detecting SNP TSC0039936.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 158664; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;

```
ABF55623/c
ID   ABF55623 standard; DNA; 13 BP.
XX
AC   ABF55623;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 155620 for detecting SNP TSC0001748.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 155620; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCT 1737
                ||||||||||  |
Db         13 TGGAGATTGGGT 2


RESULT 673
ABF55722
ID   ABF55722 standard; DNA; 13 BP.
XX
AC   ABF55722;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 155719 for detecting SNP TSC0039321.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 155719; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
                ||||||| ||||
Db          2 AAGTTGGTTTAG 13


RESULT 674
ABF55723/c
ID   ABF55723 standard; DNA; 13 BP.
XX
AC   ABF55723;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 155720 for detecting SNP TSC0039321.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
```

```
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
             | ||||||||||
Db          1 AGGTTGGGTTAG 12


RESULT 670
ABF54763/c
ID   ABF54763 standard;  DNA; 13 BP.
XX
AC   ABF54763;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 154760 for detecting SNP TSC0039120.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 154760; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
             | ||||||||||
Db          13 AGGTTGGGTTAG 2


RESULT 671
ABF55622
ID   ABF55622 standard;  DNA; 13 BP.
XX
AC   ABF55622;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 155619 for detecting SNP TSC0001748.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 155619; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCT 1737
             |||||||||| |
Db          1 TGGAGATTGGGT 12


RESULT 672
```

```
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 153251; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 2 C; 5 G; 3 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              |||||| |||||
Db          1 GTTAGGCGTACG 12


RESULT 668
ABF53255/c
ID   ABF53255 standard; DNA; 13 BP.
XX
AC   ABF53255;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 153252 for detecting SNP TSC0038744.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 153252; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 5 C; 2 G; 2 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              |||||| |||||
Db          13 GTTAGGCGTACG 2


RESULT 669
ABF54762
ID   ABF54762 standard; DNA; 13 BP.
XX
AC   ABF54762;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 154759 for detecting SNP TSC0039120.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 154759; 29pp + Sequence Listing; German.
```

```
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
              || |||||||||
Db          1 AAATCCTCCCTA 12


RESULT 665
ABF53250
ID   ABF53250 standard; DNA; 13 BP.
XX
AC   ABF53250;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 153247 for detecting SNP TSC0038744.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 153247; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 1 C; 5 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              |||||| |||||
Db          1 GTTAGGTGTACG 12


RESULT 666
ABF53251/c
ID   ABF53251 standard; DNA; 13 BP.
XX
AC   ABF53251;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 153248 for detecting SNP TSC0038744.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 153248; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 1 G; 2 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              |||||| |||||
Db         13 GTTAGGTGTACG 2


RESULT 667
ABF53254
ID   ABF53254 standard; DNA; 13 BP.
XX
AC   ABF53254;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 153251 for detecting SNP TSC0038744.
```

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 146000; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1707 TGGGTTAGGAGT 1718
||||||||| ||
Db 13 TGGGTTAGGTGT 2

RESULT 663
ABF51620/c
ID ABF51620 standard; DNA; 13 BP.
XX
AC ABF51620;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 151617 for detecting SNP TSC0038312.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 151617; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1741 AACTCCTCCCTA 1752
|| |||||||||
Db 13 AAATCCTCCCTA 2

RESULT 664
ABF51621
ID ABF51621 standard; DNA; 13 BP.
XX
AC ABF51621;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 151618 for detecting SNP TSC0038312.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 151618; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.

```
  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1713 AGGAGTACGGAG 1724
              ||||||| ||||
Db          2 AGGAGTAAGGAG 13


RESULT 660
ABF43821/c
ID   ABF43821 standard; DNA; 13 BP.
XX
AC   ABF43821;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 143818 for detecting SNP TSC0036107.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 143818; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 7 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1713 AGGAGTACGGAG 1724
              ||||||| ||||
Db         12 AGGAGTAAGGAG 1


RESULT 661
ABF46002
ID   ABF46002 standard; DNA; 13 BP.
XX
AC   ABF46002;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 145999 for detecting SNP TSC0036789.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 145999; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
              ||||||||| ||
Db          1 TGGGTTAGGTGT 12


RESULT 662
ABF46003/c
ID   ABF46003 standard; DNA; 13 BP.
XX
AC   ABF46003;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 146000 for detecting SNP TSC0036789.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
```

XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 143727; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1738 CCCAACTCCTCC 1749
||||||| ||||
Db 13 CCCAACTTCTCC 2

RESULT 658
ABF43731
ID ABF43731 standard; DNA; 13 BP.
XX
AC ABF43731;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 143728 for detecting SNP TSC0036088.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 143728; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1738 CCCAACTCCTCC 1749
||||||| ||||
Db 1 CCCAACTTCTCC 12

RESULT 659
ABF43820
ID ABF43820 standard; DNA; 13 BP.
XX
AC ABF43820;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 143817 for detecting SNP TSC0036107.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 143817; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 0 C; 7 G; 1 T; 0 other;

```
RESULT 655
ABF41114
ID   ABF41114 standard; DNA; 13 BP.
XX
AC   ABF41114;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 141111 for detecting SNP TSC0035363.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 141111; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 1 C; 8 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1694 GCGTGGTGGAAG 1705
              ||||||||| ||
Db          2 GCGTGGTGGTAG 13


RESULT 656
ABF41115/c
ID   ABF41115 standard; DNA; 13 BP.
XX
AC   ABF41115;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 141112 for detecting SNP TSC0035363.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 141112; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 8 C; 1 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1694 GCGTGGTGGAAG 1705
              ||||||||| ||
Db          2 GCGTGGTGGTAG 13


RESULT 657
ABF43730/c
ID   ABF43730 standard; DNA; 13 BP.
XX
AC   ABF43730;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 143727 for detecting SNP TSC0036088.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
```

```
XX
PS   Claim 1; SEQ ID 138482; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              | ||||||||||
Db          2 CACTATCCTAAA 13


RESULT 653
ABF39732
ID   ABF39732 standard; DNA; 13 BP.
XX
AC   ABF39732;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 139729 for detecting SNP TSC0034974.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 139729; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              || |||||||||
Db          1 GATATGGAGATT 12


RESULT 654
ABF39733/c
ID   ABF39733 standard; DNA; 13 BP.
XX
AC   ABF39733;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 139730 for detecting SNP TSC0034974.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 139730; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              || |||||||||
Db         13 GATATGGAGATT 2
```

XX
DE Oligonucleotide SEQ ID NO 134096 for detecting SNP TSC0033433.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 134096; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 1 A; 6 C; 1 G; 5 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1714 GGAGTACGGAGA 1725
||| |||||||
Db 13 GGAATACGGAGA 2

RESULT 651
ABF38484/c
ID ABF38484 standard; DNA; 13 BP.
XX
AC ABF38484;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 138481 for detecting SNP TSC0034676.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 138481; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1748 CCCTATCCTAAA 1759
| ||||||||||
Db 12 CACTATCCTAAA 1

RESULT 652
ABF38485
ID ABF38485 standard; DNA; 13 BP.
XX
AC ABF38485;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 138482 for detecting SNP TSC0034676.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -

```
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
             ||||||||| |||
Db         12 CCCTATCCCAAA 1


RESULT 648
ABF33959
ID   ABF33959 standard; DNA; 13 BP.
XX
AC   ABF33959;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 133956 for detecting SNP TSC0033403.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 133956; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
             ||||||||| |||
Db         2 CCCTATCCCAAA 13


RESULT 649
ABF34098
ID   ABF34098 standard; DNA; 13 BP.
XX
AC   ABF34098;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 134095 for detecting SNP TSC0033433.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 134095; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 1 C; 6 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1714 GGAGTACGGAGA 1725
             ||| ||||||||
Db         1 GGAATACGGAGA 12


RESULT 650
ABF34099/c
ID   ABF34099 standard; DNA; 13 BP.
XX
AC   ABF34099;
XX
DT   21-FEB-2002  (first entry)
```

XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 132773; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 3 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1701 GGAAGTTGGGTT 1712
||||||.|||||
Db 1 GGAAGTAGGGTT 12

RESULT 646
ABF32777/c
ID ABF32777 standard; DNA; 13 BP.
XX
AC ABF32777;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 132774 for detecting SNP TSC0033108.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 132774; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 3 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1701 GGAAGTTGGGTT 1712
||||||.|||||
Db 13 GGAAGTAGGGTT 2

RESULT 647
ABF33958/c
ID ABF33958 standard; DNA; 13 BP.
XX
AC ABF33958;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 133955 for detecting SNP TSC0033403.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 133955; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

```
;Q  Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 other;

 Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
 Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
 Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              ||||||||| ||
Db         12 AGTTGGGTTGGG 1


RESULT 643
ABF32774
ID   ABF32774 standard; DNA; 13 BP.
XX
AC   ABF32774;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 132771 for detecting SNP TSC0033108.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 132771; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              |||||| |||||
Db          1 GGAAGTGGGGTT 12


RESULT 644
ABF32775/c
ID   ABF32775 standard; DNA; 13 BP.
XX
AC   ABF32775;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 132772 for detecting SNP TSC0033108.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 132772; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              |||||| |||||
Db         13 GGAAGTGGGGTT 2


RESULT 645
ABF32776
ID   ABF32776 standard; DNA; 13 BP.
XX
AC   ABF32776;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 132773 for detecting SNP TSC0033108.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
```

```
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 130618; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 5 C; 0 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              ||||||||||| |
Db         13 GTTAGGAGTAAG 2


RESULT 641
ABF32046
ID   ABF32046 standard; DNA; 13 BP.
XX
AC   ABF32046;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 132043 for detecting SNP TSC0032957.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 132043; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              ||||||||| ||
Db          2 AGTTGGGTTGGG 13


RESULT 642
ABF32047/c
ID   ABF32047 standard; DNA; 13 BP.
XX
AC   ABF32047;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 132044 for detecting SNP TSC0032957.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 132044; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
```

```
Db          1 TGAGTTAGGAGT 12

RESULT 638
ABF28969/c
ID   ABF28969 standard; DNA; 13 BP.
XX
AC   ABF28969;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 128966 for detecting SNP TSC0032287.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 128966; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
              || |||||||||
Db         13 TGAGTTAGGAGT 2


RESULT 639
ABF30620
ID   ABF30620 standard; DNA; 13 BP.
XX
AC   ABF30620;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 130617 for detecting SNP TSC0032620.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 130617; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 3 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              |||||||||| |
Db          1 GTTAGGAGTAAG 12


RESULT 640
ABF30621/c
ID   ABF30621 standard; DNA; 13 BP.
XX
AC   ABF30621;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 130618 for detecting SNP TSC0032620.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
```

PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 125939; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 1 C; 5 G; 4 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1710 GTTAGGAGTACG 1721
||||||||| ||
Db 1 GTTAGGAGTTCG 12

RESULT 636
ABF25943/c
ID ABF25943 standard; DNA; 13 BP.
XX
AC ABF25943;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 125940 for detecting SNP TSC0031508.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 125940; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 5 C; 1 G; 2 T; 1 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1710 GTTAGGAGTACG 1721
||||||||| ||
Db 13 GTTAGGAGTTCG 2

RESULT 637
ABF28968
ID ABF28968 standard; DNA; 13 BP.
XX
AC ABF28968;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 128965 for detecting SNP TSC0032287.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 128965; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1707 TGGGTTAGGAGT 1718
|| |||||||||

```
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 125379 for detecting SNP TSC0031340.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 125379; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 1 C; 7 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATC 1754
              |||| |||||||
Db         13 CTCCACCCTATC 2


RESULT 634
ABF25383
ID   ABF25383 standard; DNA; 13 BP.
XX
AC   ABF25383;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 125380 for detecting SNP TSC0031340.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 125380; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 7 C; 1 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATC 1754
              |||| |||||||
Db         1 CTCCACCCTATC 12


RESULT 635
ABF25942
ID   ABF25942 standard; DNA; 13 BP.
XX
AC   ABF25942;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 125939 for detecting SNP TSC0031508.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
```

```
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 5 C; 1 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
              ||||||||||| |
Db         13 AGATGGAGATCG 2


RESULT 631
ABF25378/c
ID   ABF25378 standard; DNA; 13 BP.
XX
AC   ABF25378;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 125375 for detecting SNP TSC0031340.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 125375; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATC 1754
              |||| |||||||
Db         13 CTCCACCCTATC 2


RESULT 632
ABF25379
ID   ABF25379 standard; DNA; 13 BP.
XX
AC   ABF25379;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 125376 for detecting SNP TSC0031340.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 125376; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATC 1754
              |||| |||||||
Db          1 CTCCACCCTATC 12


RESULT 633
ABF25382/c
ID   ABF25382 standard; DNA; 13 BP.
XX
AC   ABF25382;
```

```
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 124344; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
              |||||| |||||
Db         13 AGATGGGGATTG 2


RESULT 629
ABF24348
ID   ABF24348 standard; DNA; 13 BP.
XX
AC   ABF24348;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 124345 for detecting SNP TSC0031088.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 124345; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 1 C; 5 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
              |||||||||| |
Db          1 AGATGGAGATCG 12


RESULT 630
ABF24349/c
ID   ABF24349 standard; DNA; 13 BP.
XX
AC   ABF24349;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 124346 for detecting SNP TSC0031088.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 124346; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
```

```
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
              ||||||||  |||
Db          1 TGGGTTAGTAGT 12


RESULT 626
ABF20795/c
ID   ABF20795 standard; DNA; 13 BP.
XX
AC   ABF20795;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 120792 for detecting SNP TSC0030144.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 120792; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
              ||||||||  |||
Db         13 TGGGTTAGTAGT 2


RESULT 627
ABF24346
ID   ABF24346 standard; DNA; 13 BP.
XX
AC   ABF24346;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 124343 for detecting SNP TSC0031088.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 124343; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
              ||||||  |||||
Db          1 AGATGGGGATTG 12


RESULT 628
ABF24347/c
ID   ABF24347 standard; DNA; 13 BP.
XX
AC   ABF24347;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 124344 for detecting SNP TSC0031088.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 120153; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 5 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 CTCCCTATCCTA 1757
                || |||||||||
Db         13 CTACCTATCCTA 2


RESULT 624
ABF20157
ID   ABF20157 standard; DNA; 13 BP.
XX
AC   ABF20157;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 120154 for detecting SNP TSC0029992.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 120154; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 CTCCCTATCCTA 1757
                || |||||||||
Db          1 CTACCTATCCTA 12


RESULT 625
ABF20794
ID   ABF20794 standard; DNA; 13 BP.
XX
AC   ABF20794;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 120791 for detecting SNP TSC0030144.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 120791; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
```

```
Qy       1711 TTAGGAGTACGG 1722
              ||||||||| ||
Db         12 TTAGGAGTAGGG 1


RESULT 621
ABF18154
ID   ABF18154 standard; DNA; 13 BP.
XX
AC   ABF18154;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118151 for detecting SNP TSC0029550.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 118151; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 8 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1714 GGAGTACGGAGA 1725
              |||||| |||||
Db          2 GGAGTAGGGAGA 13


RESULT 622
ABF18155/c
ID   ABF18155 standard; DNA; 13 BP.
XX
AC   ABF18155;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118152 for detecting SNP TSC0029550.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 118152; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 8 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1714 GGAGTACGGAGA 1725
              |||||| |||||
Db          2 GGAGTAGGGAGA 13


RESULT 623
ABF20156/c
ID   ABF20156 standard; DNA; 13 BP.
XX
AC   ABF20156;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 120153 for detecting SNP TSC0029992.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
```

```
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 116772; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 5 C; 1 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1711 TTAGGAGTACGG 1722
              |||| |||||||
Db         13 TTAGAAGTACGG 2


RESULT 619
ABF18044
ID   ABF18044 standard; DNA; 13 BP.
XX
AC   ABF18044;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118041 for detecting SNP TSC0029517.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 118041; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1711 TTAGGAGTACGG 1722
              |||||||||| ||
Db          2 TTAGGAGTAGGG 13


RESULT 620
ABF18045/c
ID   ABF18045 standard; DNA; 13 BP.
XX
AC   ABF18045;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118042 for detecting SNP TSC0029517.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 118042; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
XX
AC   ABF11507;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111504 for detecting SNP TSC0027852.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 111504; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              | ||||||||||
Db         13 GGAGTTGGGTTA 2


RESULT 617
ABF16774
ID   ABF16774 standard; DNA; 13 BP.
XX
AC   ABF16774;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 116771 for detecting SNP TSC0029218.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 116771; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 1 C; 5 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1711 TTAGGAGTACGG 1722
              |||| |||||||
Db          1 TTAGAAGTACGG 12


RESULT 618
ABF16775/c
ID   ABF16775 standard; DNA; 13 BP.
XX
AC   ABF16775;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 116772 for detecting SNP TSC0029218.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
```

```
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 1 C; 8 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1735 GCTCCCAACTCC 1746
              ||||||||| ||
Db         12 GCTCCCAACACC 1


RESULT 614
ABF05797
ID   ABF05797 standard; DNA; 13 BP.
XX
AC   ABF05797;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 105794 for detecting SNP TSC0026522.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 105794; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 8 C; 1 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1735 GCTCCCAACTCC 1746
              ||||||||| ||
Db          2 GCTCCCAACACC 13


RESULT 615
ABF11506
ID   ABF11506 standard; DNA; 13 BP.
XX
AC   ABF11506;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111503 for detecting SNP TSC0027852.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 111503; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              | ||||||||||
Db          1 GGAGTTGGGTTA 12


RESULT 616
ABF11507/c
ID   ABF11507 standard; DNA; 13 BP.
```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 88067; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATT 1733
||||||||| ||
Db 2 GAGATGGAGTTT 13

RESULT 612
ABC88051/c
ID ABC88051 standard; DNA; 13 BP.
XX
AC ABC88051;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 88068 for detecting SNP TSC0022140.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 88068; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATT 1733
||||||||| ||
Db 12 GAGATGGAGTTT 1

RESULT 613
ABF05796/c
ID ABF05796 standard; DNA; 13 BP.
XX
AC ABF05796;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 105793 for detecting SNP TSC0026522.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 105793; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic

```
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 CTCCCTATCCTA 1757
              ||||||| ||||
Db          2 CTCCCTACCCTA 13


RESULT 609
ABC87616
ID   ABC87616 standard; DNA; 13 BP.
XX
AC   ABC87616;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 87633 for detecting SNP TSC0022046.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 87633; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||||||| ||
Db          2 GAGATGGAGTTT 13


RESULT 610
ABC87617/c
ID   ABC87617 standard; DNA; 13 BP.
XX
AC   ABC87617;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 87634 for detecting SNP TSC0022046.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 87634; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||||||| ||
Db          12 GAGATGGAGTTT 1


RESULT 611
ABC88050
ID   ABC88050 standard; DNA; 13 BP.
XX
AC   ABC88050;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 88067 for detecting SNP TSC0022140.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 84340; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 4 C; 0 G; 5 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              |||||| |||||
Db         13 GAGATGAAGATT 2


RESULT 607
ABC84790/c
ID   ABC84790 standard; DNA; 13 BP.
XX
AC   ABC84790;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 84807 for detecting SNP TSC0021343.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 84807; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 CTCCCTATCCTA 1757
              ||||||| ||||
Db         12 CTCCCTACCCTA 1


RESULT 608
ABC84791
ID   ABC84791 standard; DNA; 13 BP.
XX
AC   ABC84791;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 84808 for detecting SNP TSC0021343.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 84808; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
```

```
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
              ||||||| ||||
Db         12 AACTCCTACCTA 1


RESULT 604
ABC82527
ID   ABC82527 standard; DNA; 13 BP.
XX
AC   ABC82527;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 82544 for detecting SNP TSC0020825.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 82544; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
              ||||||| ||||
Db          2 AACTCCTACCTA 13


RESULT 605
ABC84322
ID   ABC84322 standard; DNA; 13 BP.
XX
AC   ABC84322;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 84339 for detecting SNP TSC0021205.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 84339; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 4 G; 3 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              |||||| ||||
Db          1 GAGATGAAGATT 12


RESULT 606
ABC84323/c
ID   ABC84323 standard; DNA; 13 BP.
XX
AC   ABC84323;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 84340 for detecting SNP TSC0021205.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
```

```
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status -
XX
PS   Claim 1; SEQ ID 80357; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1742 ACTCCTCCCTAT 1753
              |||| |||||||
Db         12 ACTCTTCCCTAT 1


RESULT 602
ABC80341
ID   ABC80341 standard; DNA; 13 BP.
XX
AC   ABC80341;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 80358 for detecting SNP TSC0020399.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status -
XX
PS   Claim 1; SEQ ID 80358; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1742 ACTCCTCCCTAT 1753
              |||| |||||||
Db          2 ACTCTTCCCTAT 13


RESULT 603
ABC82526/c
ID   ABC82526 standard; DNA; 13 BP.
XX
AC   ABC82526;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 82543 for detecting SNP TSC0020825.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status -
XX
PS   Claim 1; SEQ ID 82543; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
```

```
ABC77732
ID   ABC77732 standard; DNA; 13 BP.
XX
AC   ABC77732;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 77749 for detecting SNP TSC0019796.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 77749; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGTA 1719
                |||||  ||||||
Db          1 GGGTTTGGAGTA 12


RESULT 600
ABC77733/c
ID   ABC77733 standard; DNA; 13 BP.
XX
AC   ABC77733;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 77750 for detecting SNP TSC0019796.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 77750; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGTA 1719
                |||||  ||||||
Db          13 GGGTTTGGAGTA 2


RESULT 601
ABC80340/c
ID   ABC80340 standard; DNA; 13 BP.
XX
AC   ABC80340;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 80357 for detecting SNP TSC0020399.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
```

```
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              ||||| ||||||
Db          1 CCCTAACCTAAA 12


RESULT 597
ABC77642
ID   ABC77642 standard; DNA; 13 BP.
XX
AC   ABC77642;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 77659 for detecting SNP TSC0019778.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 77659; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||||| ||||
Db          2 GAGATGGGGATT 13


RESULT 598
ABC77643/c
ID   ABC77643 standard; DNA; 13 BP.
XX
AC   ABC77643;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 77660 for detecting SNP TSC0019778.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 77660; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||||| ||||
Db         12 GAGATGGGGATT 1


RESULT 599
```

```
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 69444; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              | ||||||||||
Db         13 GAAGATGGAGAT 2


RESULT 595
ABC75934/c
ID   ABC75934 standard; DNA; 13 BP.
XX
AC   ABC75934;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 75951 for detecting SNP TSC0019457.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 75951; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              ||||| ||||||
Db         13 CCCTAACCTAAA 2


RESULT 596
ABC75935
ID   ABC75935 standard; DNA; 13 BP.
XX
AC   ABC75935;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 75952 for detecting SNP TSC0019457.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 75952; 29pp + Sequence Listing; German.
```

```
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
                ||| ||||||||
Db         13 TCCATATCCTAA 2


RESULT 592
ABC66989
ID   ABC66989 standard; DNA; 13 BP.
XX
AC   ABC66989;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 67006 for detecting SNP TSC0017552.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 67006; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
                ||| ||||||||
Db         13 TCCATATCCTAA 2


RESULT 593
ABC69426
ID   ABC69426 standard; DNA; 13 BP.
XX
AC   ABC69426;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 69443 for detecting SNP TSC0018070.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 69443; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
                | ||||||||||
Db          1 GAAGATGGAGAT 12


RESULT 594
ABC69427/c
ID   ABC69427 standard; DNA; 13 BP.
XX
AC   ABC69427;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 69444 for detecting SNP TSC0018070.
```

```
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 66465; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 5 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGTA 1719
              || |||||||||
Db          1 GGATTAGGAGTA 12


RESULT 590
ABC66449/c
ID   ABC66449 standard; DNA; 13 BP.
XX
AC   ABC66449;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 66466 for detecting SNP TSC0017468.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 66466; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGTA 1719
              || |||||||||
Db          13 GGATTAGGAGTA 2


RESULT 591
ABC66988/c
ID   ABC66988 standard; DNA; 13 BP.
XX
AC   ABC66988;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 67005 for detecting SNP TSC0017552.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 67005; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
```

```
  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| ||||||
Db         13 GAGATCGAGATT 2


RESULT 587
ABC63274
ID   ABC63274 standard; DNA; 13 BP.
XX
AC   ABC63274;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 63291 for detecting SNP TSC0016721.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 63291; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 0 C; 7 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTG 1708
              |||||| |||||
Db          1 TGGTGGGAGTTG 12


RESULT 588
ABC63275/c
ID   ABC63275 standard; DNA; 13 BP.
XX
AC   ABC63275;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 63292 for detecting SNP TSC0016721.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 63292; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 7 C; 0 G; 1 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTG 1708
              |||||| |||||
Db          13 TGGTGGGAGTTG 2


RESULT 589
ABC66448
ID   ABC66448 standard; DNA; 13 BP.
XX
AC   ABC66448;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 66465 for detecting SNP TSC0017468.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
```

```
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 57226; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| ||||||
Db         13 GAGATTGAGATT 2


RESULT 585
ABC57210
ID   ABC57210 standard; DNA; 13 BP.
XX
AC   ABC57210;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 57227 for detecting SNP TSC0015477.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 57227; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 1 C; 4 G; 3 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| ||||||
Db          1 GAGATCGAGATT 12


RESULT 586
ABC57211/c
ID   ABC57211 standard; DNA; 13 BP.
XX
AC   ABC57211;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 57228 for detecting SNP TSC0015477.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 57228; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 4 C; 1 G; 4 T; 1 other;
```

```
RESULT 582
ABC53247
ID   ABC53247 standard; DNA; 13 BP.
XX
AC   ABC53247;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 53264 for detecting SNP TSC0014711.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 53264; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              || |||||||||
Db          2 CCATATCCTAAA 13


RESULT 583
ABC57208
ID   ABC57208 standard; DNA; 13 BP.
XX
AC   ABC57208;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 57225 for detecting SNP TSC0015477.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 57225; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| ||||||
Db          1 GAGATTGAGATT 12


RESULT 584
ABC57209/c
ID   ABC57209 standard; DNA; 13 BP.
XX
AC   ABC57209;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 57226 for detecting SNP TSC0015477.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
```

```
XX
PS   Claim 1; SEQ ID 52615; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              ||||||||| |||
Db         13 TCCCAACTACTC 2


RESULT 580
ABC52599
ID   ABC52599 standard; DNA; 13 BP.
XX
AC   ABC52599;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 52616 for detecting SNP TSC0014588.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 52616; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              ||||||||| |||
Db          1 TCCCAACTACTC 12


RESULT 581
ABC53246/c
ID   ABC53246 standard; DNA; 13 BP.
XX
AC   ABC53246;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 53263 for detecting SNP TSC0014711.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 53263; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              || |||||||||
Db         12 CCATATCCTAAA 1
```

```
XX
DE   Oligonucleotide SEQ ID NO 49591 for detecting SNP TSC0014010.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 49591; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 8 G; 0 U; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 TCCTCCCTATCC 1755
              ||||||||| |||
Db         13 TCCTCCCTTTCC 2


RESULT 578
ABC49575
ID   ABC49575 standard; DNA; 13 BP.
XX
AC   ABC49575;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 49592 for detecting SNP TSC0014010.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 49592; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 TCCTCCCTATCC 1755
              ||||||||| |||
Db          1 TCCTCCCTTTCC 12


RESULT 579
ABC52598/c
ID   ABC52598 standard; DNA; 13 BP.
XX
AC   ABC52598;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 52615 for detecting SNP TSC0014588.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
```

```
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1742 ACTCCTCCCTAT 1753
              ||||||| ||||
Db          2 ACTCCTCTCTAT 13


RESULT 575
ABC47684
ID   ABC47684 standard; DNA; 13 BP.
XX
AC   ABC47684;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 47701 for detecting SNP TSC0013677.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 47701; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              | ||||||||||
Db          2 ATTTGGGTTAGG 13


RESULT 576
ABC47685/c
ID   ABC47685 standard; DNA; 13 BP.
XX
AC   ABC47685;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 47702 for detecting SNP TSC0013677.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 47702; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              | ||||||||||
Db         12 ATTTGGGTTAGG 1


RESULT 577
ABC49574/c
ID   ABC49574 standard; DNA; 13 BP.
XX
AC   ABC49574;
XX
DT   21-FEB-2002  (first entry)
```

XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 46646; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 7 C; 1 G; 3 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1740 CAACTCCTCCCT 1751
||||||| ||||
Db 1 CAACTCCGCCCT 12

RESULT 573
ABC47422/c
ID ABC47422 standard; DNA; 13 BP.
XX
AC ABC47422;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 47439 for detecting SNP TSC0013623.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 47439; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1742 ACTCCTCCCTAT 1753
||||||| ||||
Db 12 ACTCCTCTCTAT 1

RESULT 574
ABC47423
ID ABC47423 standard; DNA; 13 BP.
XX
AC ABC47423;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 47440 for detecting SNP TSC0013623.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 47440; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

```
SQ   Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1740 CAACTCCTCCCT 1751
              ||||||| ||||
Db         13 CAACTCCACCCT 2


RESULT 570
ABC46625
ID   ABC46625 standard; DNA; 13 BP.
XX
AC   ABC46625;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 46642 for detecting SNP TSC0013460.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 46642; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1740 CAACTCCTCCCT 1751
              ||||||| ||||
Db          1 CAACTCCACCCT 12


RESULT 571
ABC46628/c
ID   ABC46628 standard; DNA; 13 BP.
XX
AC   ABC46628;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 46645 for detecting SNP TSC0013460.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 46645; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 1 C; 7 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1740 CAACTCCTCCCT 1751
              ||||||| ||||
Db         13 CAACTCCGCCCT 2


RESULT 572
ABC46629
ID   ABC46629 standard; DNA; 13 BP.
XX
AC   ABC46629;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 46646 for detecting SNP TSC0013460.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
```

```
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 44261; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGG 1710
              | ||||||||||
Db          1 GAGGAAGTTGGG 12


RESULT 568
ABC44245/c
ID   ABC44245 standard; DNA; 13 BP.
XX
AC   ABC44245;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 44262 for detecting SNP TSC0013010.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 44262; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGG 1710
              | ||||||||||
Db          13 GAGGAAGTTGGG 2


RESULT 569
ABC46624/c
ID   ABC46624 standard; DNA; 13 BP.
XX
AC   ABC46624;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 46641 for detecting SNP TSC0013460.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 46641; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
```

```
Db          13 GAGATTGAGATT 2

RESULT 565
ABC40890
ID   ABC40890 standard; DNA; 13 BP.
XX
AC   ABC40890;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 40907 for detecting SNP TSC0012352.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 40907; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 1 C; 4 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
             ||||| ||||||
Db          1 GAGATCGAGATT 12


RESULT 566
ABC40891/c
ID   ABC40891 standard; DNA; 13 BP.
XX
AC   ABC40891;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 40908 for detecting SNP TSC0012352.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 40908; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 4 C; 1 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
             ||||| ||||||
Db          13 GAGATCGAGATT 2


RESULT 567
ABC44244
ID   ABC44244 standard; DNA; 13 BP.
XX
AC   ABC44244;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 44261 for detecting SNP TSC0013010.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
```

```
 T   designed to detect single nucleotide polymorphisms and cytosine
 T   methylation status  -
 X
 S   Claim 1; SEQ ID 40084; 29pp + Sequence Listing; German.
 X
 C   This invention describes novel oligonucleotide primers or peptide nucleic
 C   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 C   and cytosine methylation status in chemically pretreated genomic DNA. The
 C   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 C   range of diseases including immune system, gastrointestinal, respiratory,
 C   central nervous system, cardiovascular and metabolic disorders. The
 C   oligomers are also used for detecting cell type differentiation.
 C   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC  ABI00010-ABI82073 represent the oligomers described in the invention.
 CC  NOTE: The sequence data for this patent did not form part of the printed
 CC  specification, but was obtained in electronic format from WIPO at
 CC  ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ  Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              || |||||||||
Db         13 GTGGGGTTAGGA 2


RESULT 563
ABC40888
ID   ABC40888 standard; DNA; 13 BP.
XX
AC   ABC40888;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 40905 for detecting SNP TSC0012352.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 40905; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| ||||||
Db          1 GAGATTGAGATT 12


RESULT 564
ABC40889/c
ID   ABC40889 standard; DNA; 13 BP.
XX
AC   ABC40889;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 40906 for detecting SNP TSC0012352.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 40906; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| ||||||
```

```
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 33124 for detecting SNP TSC0010560.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 33124; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
                || |||||||||
Db          2 CCTTATCCTAAA 13


RESULT 561
ABC40066
ID   ABC40066 standard; DNA; 13 BP.
XX
AC   ABC40066;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 40083 for detecting SNP TSC0012198.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 40083; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
                || |||||||||
Db          1 GTGGGGTTAGGA 12


RESULT 562
ABC40067/c
ID   ABC40067 standard; DNA; 13 BP.
XX
AC   ABC40067;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 40084 for detecting SNP TSC0012198.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
```

```
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
              || |||||||||
Db          2 TTAGGTTAGGAG 13


RESULT 558
ABC32493/c
ID   ABC32493 standard; DNA; 13 BP.
XX
AC   ABC32493;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 32510 for detecting SNP TSC0010144.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 32510; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
              || |||||||||
Db          12 TTAGGTTAGGAG 1


RESULT 559
ABC33106/c
ID   ABC33106 standard; DNA; 13 BP.
XX
AC   ABC33106;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 33123 for detecting SNP TSC0010560.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 33123; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              || |||||||||
Db          12 CCTTATCCTAAA 1


RESULT 560
ABC33107
ID   ABC33107 standard; DNA; 13 BP.
XX
AC   ABC33107;
```

XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 31825; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 1 A; 2 C; 6 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1705 GTTGGGTTAGGA 1716
||||||| |||
Db 2 GTTGGGTTCGGA 13

RESULT 556
ABC31809/c
ID ABC31809 standard; DNA; 13 BP.
XX
AC ABC31809;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31826 for detecting SNP TSC0009913.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 31826; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 6 C; 2 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1705 GTTGGGTTAGGA 1716
||||||| |||
Db 12 GTTGGGTTCGGA 1

RESULT 557
ABC32492
ID ABC32492 standard; DNA; 13 BP.
XX
AC ABC32492;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 32509 for detecting SNP TSC0010144.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 32509; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

```
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||||||  |||
Db         12 GTTGGGTTTGGA 1


RESULT 553
ABC31800
ID   ABC31800 standard; DNA; 13 BP.
XX
AC   ABC31800;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31817 for detecting SNP TSC0009913.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31817; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||||||  |||
Db          2 GTTGGGTTCGGA 13


RESULT 554
ABC31801/c
ID   ABC31801 standard; DNA; 13 BP.
XX
AC   ABC31801;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31818 for detecting SNP TSC0009913.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31818; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||||||  |||
Db         12 GTTGGGTTCGGA 1


RESULT 555
ABC31808
ID   ABC31808 standard; DNA; 13 BP.
XX
AC   ABC31808;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31825 for detecting SNP TSC0009913.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31806; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073.represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||||||  |||
Db         12 GTTGGGTTTGGA 1


RESULT 551
ABC31792
ID   ABC31792 standard; DNA; 13 BP.
XX
AC   ABC31792;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31809 for detecting SNP TSC0009913.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31809; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||||||  |||
Db          2 GTTGGGTTTGGA 13


RESULT 552
ABC31793/c
ID   ABC31793 standard; DNA; 13 BP.
XX
AC   ABC31793;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31810 for detecting SNP TSC0009913.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31810; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
```

```
Qy       1721 GGAGATGGAGAT 1732
              ||||| ||||||
Db          2 GGAGAGGGAGAT 13


RESULT 548
ABC31005/c
ID   ABC31005 standard; DNA; 13 BP.
XX
AC   ABC31005;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31022 for detecting SNP TSC0009554.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31022; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 8 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              ||||| ||||||
Db         12 GGAGAGGGAGAT 1


RESULT 549
ABC31788
ID   ABC31788 standard; DNA; 13 BP.
XX
AC   ABC31788;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31805 for detecting SNP TSC0009913.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31805; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 GTTGGGTTAGGA 1716
              ||||||| |||
Db          2 GTTGGGTTTGGA 13


RESULT 550
ABC31789/c
ID   ABC31789 standard; DNA; 13 BP.
XX
AC   ABC31789;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31806 for detecting SNP TSC0009913.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
```

```
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31019; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 0 C; 7 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              ||||| ||||||
Db          2 GGAGAAGGAGAT 13


RESULT 546
ABC31003/c
ID   ABC31003 standard; DNA; 13 BP.
XX
AC   ABC31003;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31020 for detecting SNP TSC0009554.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31020; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 7 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              ||||| ||||||
Db          12 GGAGAAGGAGAT 1


RESULT 547
ABC31004
ID   ABC31004 standard; DNA; 13 BP.
XX
AC   ABC31004;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31021 for detecting SNP TSC0009554.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 31021; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 8 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
XX
AC   ABC24272;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 24289 for detecting SNP TSC0005767.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 24289; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              ||| ||||||||
Db         12 CCCCATCCTAAA 1


RESULT 544
ABC24273
ID   ABC24273 standard; DNA; 13 BP.
XX
AC   ABC24273;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 24290 for detecting SNP TSC0005767.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 24290; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              ||| ||||||||
Db          2 CCCCATCCTAAA 13


RESULT 545
ABC31002
ID   ABC31002 standard; DNA; 13 BP.
XX
AC   ABC31002;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31019 for detecting SNP TSC0009554.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
```

```
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
                ||||  |||||||
Db         12 GGAGGTGGAGAT 1


RESULT 541
ABC19752/c
ID   ABC19752 standard; DNA; 13 BP.
XX
AC   ABC19752;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 19769 for detecting SNP TSC0004089.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 19769; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1754 CCTAAAGGCCCA 1765
                ||||||  |||||
Db         13 CCTAAACGCCCA 2


RESULT 542
ABC19753
ID   ABC19753 standard; DNA; 13 BP.
XX
AC   ABC19753;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 19770 for detecting SNP TSC0004089.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 19770; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1754 CCTAAAGGCCCA 1765
                ||||||  |||||
Db          1 CCTAAACGCCCA 12


RESULT 543
ABC24272/c
ID   ABC24272 standard; DNA; 13 BP.
```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 14566; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 1 A; 9 C; 0 G; 3 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1736 CTCCCAACTCCT 1747
|||||| |||||
Db 2 CTCCCACCTCCT 13

RESULT 539
ABC16398
ID ABC16398 standard; DNA; 13 BP.
XX
AC ABC16398;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 16405 for detecting SNP TSC0003579.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 16405; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGAT 1732
|||| |||||||
Db 2 GGAGGTGGAGAT 13

RESULT 540
ABC16399/c
ID ABC16399 standard; DNA; 13 BP.
XX
AC ABC16399;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 16406 for detecting SNP TSC0003579.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 16406; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic

```
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              ||||||||| ||
Db          1 AGTTGGGTTTGG 12


RESULT 536
ABC11715/c
ID   ABC11715 standard; DNA; 13 BP.
XX
AC   ABC11715;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 11722 for detecting SNP TSC0002832.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 11722; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              ||||||||| ||
Db         13 AGTTGGGTTTGG 2


RESULT 537
ABC14558/c
ID   ABC14558 standard; DNA; 13 BP.
XX
AC   ABC14558;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 14565 for detecting SNP TSC0003286.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 14565; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 9 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCT 1747
              |||||| |||||
Db         12 CTCCCACCTCCT 1


RESULT 538
ABC14559
ID   ABC14559 standard; DNA; 13 BP.
XX
AC   ABC14559;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 14566 for detecting SNP TSC0003286.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 9979; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
                | ||||||||||
Db         13 ACCTCCTCCCTA 2


RESULT 534
ABC09989
ID   ABC09989 standard; DNA; 13 BP.
XX
AC   ABC09989;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 9980 for detecting SNP TSC0002575.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 9980; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
                | ||||||||||
Db         13 ACCTCCTCCCTA 2


RESULT 535
ABC11714
ID   ABC11714 standard; DNA; 13 BP.
XX
AC   ABC11714;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 11721 for detecting SNP TSC0002832.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 11721; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
```

```
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
              ||||||||||  |
Db          2 AACTCCTCCCAA 13


RESULT 531
ABC05020
ID   ABC05020 standard; DNA; 13 BP.
XX
AC   ABC05020;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 5011 for detecting SNP TSC0001740.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 5011; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 1 C; 6 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              |||||  ||||||
Db          2 GGAGACGGAGAT 13


RESULT 532
ABC05021/c
ID   ABC05021 standard; DNA; 13 BP.
XX
AC   ABC05021;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 5012 for detecting SNP TSC0001740.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 5012; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 1 A; 6 C; 1 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              |||||  ||||||
Db         12 GGAGACGGAGAT 1


RESULT 533
ABC09988/c
ID   ABC09988 standard; DNA; 13 BP.
XX
AC   ABC09988;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 9979 for detecting SNP TSC0002575.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
```

```
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 2820; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
                | ||||||||||
Db          1 CTCTATCCTAAA 12


RESULT 529
ABC04730/c
ID   ABC04730 standard; DNA; 13 BP.
XX
AC   ABC04730;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 4721 for detecting SNP TSC0001698.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 4721; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
                ||||||||||| |
Db         12 AACTCCTCCCAA 1


RESULT 530
ABC04731
ID   ABC04731 standard; DNA; 13 BP.
XX
AC   ABC04731;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 4722 for detecting SNP TSC0001698.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 4722; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
```

```
ABC00339/c
ID   ABC00339 standard; DNA; 13 BP.
XX
AC   ABC00339;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 330 for detecting SNP TSC0000062.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 330; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
                ||||||||| |
Db         13 GGAAGTTGGGAT 2


RESULT 527
ABC02828/c
ID   ABC02828 standard; DNA; 13 BP.
XX
AC   ABC02828;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 2819 for detecting SNP TSC0001100.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 2819; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
                | |||||||||
Db         13 CTCTATCCTAAA 2


RESULT 528
ABC02829
ID   ABC02829 standard; DNA; 13 BP.
XX
AC   ABC02829;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 2820 for detecting SNP TSC0001100.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
```

```
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||||||| ||
Db          1 GAGATGGAGTTT 12


RESULT 524
ABC00211/c
ID   ABC00211 standard; DNA; 13 BP.
XX
AC   ABC00211;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 202 for detecting SNP TSC0000040.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 202; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 1 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||||||| ||
Db          13 GAGATGGAGTTT 2


RESULT 525
ABC00338
ID   ABC00338 standard; DNA; 13 BP.
XX
AC   ABC00338;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 329 for detecting SNP TSC0000062.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 329; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              ||||||||| |
Db          1 GGAAGTTGGGAT 12


RESULT 526
```

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 381502; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 2 A; 9 C; 0 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1738 CCCAACTCCTCC 1749
||||||||| ||
Db 1 CCCAACTCCCCC 12

RESULT 522
AAZ93102
ID AAZ93102 standard; DNA; 13 BP.
XX
AC AAZ93102;
XX
DT 16-AUG-2000 (first entry)
XX
DE 5'UTR sequence used in cold shock expression construct.
XX
KW Expression construct; cold shock; inducible gene; gene expression;
KW downstream box; bacteria; antibiotic; ss.
XX
OS Escherichia coli.
XX
PN WO200011148-A2.
XX
PD 02-MAR-2000.
XX
PF 20-AUG-1999; 99WO-US19030.
XX
PR 20-AUG-1998; 98US-0096938.
PR 16-APR-1999; 99US-0293427.
PR 12-JUL-1999; 99US-0143380.
XX
PA (UYNE-) UNIV NEW JERSEY.
XX
PI Pang L, Jiang W, Mitta M, Inouye M, Etchegaray J;
XX
DR WPI; 2000-246559/21.
XX
PT New nucleic acid useful for regulating bacterial gene expression under
PT conditions of physiological stress that induce the cold shock response
PT of a bacterium -
XX
PS Claim 15; Page 55; 100pp; English.
XX
CC New expression constructs are described which prolong the
CC expression of cold shock inducible genes under conditions that
CC elicit the response in bacteria. The constructs comprise either a
CC downstream box, a nucleic acid that enhances the translation of cold
CC shock inducible genes under conditions that elicit the cold shock
CC response; or a cold box and at least a portion of the 5'UTR of a
CC cold shock inducible gene that represses the expression or enhances
CC the translation of the cold shock inducible gene and a downstream box
CC sequence. The overexpression of the cold shock inducible gene causes
CC a reduction in the expression of at least one endogenous protein
CC The constructs are useful as an antibiotic to kill or to stop the
CC growth of bacteria in plants and animals.
XX
SQ Sequence 13 BP; 4 A; 5 C; 4 G; 0 U; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1754 CCTAAAGGCCCA 1765
|| |||||||||
Db 2 CCGAAAGGCCCA 13

RESULT 523
ABC00210
ID ABC00210 standard; DNA; 13 BP.
XX
AC ABC00210;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 201 for detecting SNP TSC0000040.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 201; 29pp + Sequence Listing; German.

```
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 4 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
              ||||||| ||||
Db         12 AAGTTGGATTAG 1


RESULT 519
ABI80271
ID   ABI80271 standard; DNA; 12 BP.
XX
AC   ABI80271;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 380244 for detecting SNP TSC0001268.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 380244; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              |||||||| |||
Db          1 TCCCAACTACTC 12


RESULT 520
ABI81369/c
ID   ABI81369 standard; DNA; 12 BP.
XX
AC   ABI81369;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 381342 for detecting SNP TSC0064297.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 381342; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              | ||||||||||
Db         12 CTCTATCCTAAA 1


RESULT 521
ABI81529
ID   ABI81529 standard; DNA; 12 BP.
XX
AC   ABI81529;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 381502 for detecting SNP TSC0064394.
XX
```

PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 374094; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1710 GTTAGGAGTACG 1721
||||||||| ||
Db 12 GTTAGGAGTTCG 1

RESULT 517
ABI76760/c
ID ABI76760 standard; DNA; 12 BP.
XX
AC ABI76760;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 376733 for detecting SNP TSC0061961.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 376733; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 0 C; 8 G; 0 U; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1745 CCTCCCTATCCT 1756
||||||| ||||
Db 12 CCTCCCTCTCCT 1

RESULT 518
ABI79597/c
ID ABI79597 standard; DNA; 12 BP.
XX
AC ABI79597;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 379570 for detecting SNP TSC0063355.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 379570; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and

```
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              || |||||||||
Db         12 GATGTTGGGTTA 1


RESULT 514
ABI71584/c
ID   ABI71584 standard; DNA; 12 BP.
XX
AC   ABI71584;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 371557 for detecting SNP TSC0058858.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 371557; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
              ||| |||||||||
Db         12 AACCCCTCCCTA 1


RESULT 515
ABI73215
ID   ABI73215 standard; DNA; 12 BP.
XX
AC   ABI73215;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 373188 for detecting SNP TSC0059897.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 373188; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGTT 1707
              | ||||||||||
Db          1 GAGGTGGAAGTT 12


RESULT 516
ABI74121/c
ID   ABI74121 standard; DNA; 12 BP.
XX
AC   ABI74121;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 374094 for detecting SNP TSC0060488.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
```

```
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 369223; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCC 1749
                ||||||||||  |
Db         12 CCCAACTCCTAC 1


RESULT 512
ABI70995
ID   ABI70995 standard; DNA; 12 BP.
XX
AC   ABI70995;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 370968 for detecting SNP TSC0058497.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 370968; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
                | ||||||||||
Db          1 TGGGGTTAGGAG 12


RESULT 513
ABI71189/c
ID   ABI71189 standard; DNA; 12 BP.
XX
AC   ABI71189;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 371162 for detecting SNP TSC0058621.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 371162; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
```

```
RESULT 509
ABI68275
ID   ABI68275 standard; DNA; 12 BP.
XX
AC   ABI68275;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 368248 for detecting SNP TSC0056884.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 368248; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 AACTCCTCCCTA 1752
              ||||||| ||||
Db          1 AACTCCTACCTA 12


RESULT 510
ABI69091
ID   ABI69091 standard; DNA; 12 BP.
XX
AC   ABI69091;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 369064 for detecting SNP TSC0057436.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 369064; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 8 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGG 1710
              | ||||||||||
Db          1 GGGGAAGTTGGG 12


RESULT 511
ABI69250/c
ID   ABI69250 standard; DNA; 12 BP.
XX
AC   ABI69250;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 369223 for detecting SNP TSC0057525.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
```

```
PS   Claim 1; SEQ ID 366723; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 6 C; 1 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
                ||||||||| ||
Db         12 TGGGTTAGGCGT 1


RESULT 507
ABI67505/c
ID   ABI67505 standard; DNA; 12 BP.
XX
AC   ABI67505;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 367478 for detecting SNP TSC0056370.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 367478; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGTT 1707
                || |||||||||
Db         12 GTTGTGGAAGTT 1


RESULT 508
ABI68217
ID   ABI68217 standard; DNA; 12 BP.
XX
AC   ABI68217;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 368190 for detecting SNP TSC0056843.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 368190; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
                ||||||| |||
Db          1 AGATGGAGTTTG 12
```

DE Oligonucleotide primer SEQ ID NO 366395 for detecting SNP TSC0055720.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 366395; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1737 TCCCAACTCCTC 1748
||||||| |||
Db 12 TCCCAACTACTC 1

RESULT 505
ABI66749/c
ID ABI66749 standard; DNA; 12 BP.
XX
AC ABI66749;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 366722 for detecting SNP TSC0055937.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 366722; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1707 TGGGTTAGGAGT 1718
||||||||| ||
Db 12 TGGGTTAGGTGT 1

RESULT 506
ABI66750/c
ID ABI66750 standard; DNA; 12 BP.
XX
AC ABI66750;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 366723 for detecting SNP TSC0055937.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX

```
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              ||||||||||| |
Db         12 AGTTGGGTTAAG 1


RESULT 502
ABI63114
ID   ABI63114 standard; DNA; 12 BP.
XX
AC   ABI63114;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 363087 for detecting SNP TSC0053645.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 363087; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 1 C; 5 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 CGGAGATGGAGA 1731
              |||| |||||||
Db          1 CGGATATGGAGA 12


RESULT 503
ABI63218/c
ID   ABI63218 standard; DNA; 12 BP.
XX
AC   ABI63218;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 363191 for detecting SNP TSC0053712.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 363191; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
              |||||||||| |
Db         12 TCCCTATCCTCA 1


RESULT 504
ABI66422/c
ID   ABI66422 standard; DNA; 12 BP.
XX
AC   ABI66422;
XX
DT   22-FEB-2002  (first entry)
XX
```

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 355683; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1723 AGATGGAGATTG 1734
|||| |||||||
Db 1 AGATAGAGATTG 12

RESULT 500
ABI58975/c
ID ABI58975 standard; DNA; 12 BP.
XX
AC ABI58975;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 358948 for detecting SNP TSC0051393.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 358948; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 6 C; 0 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1703 AAGTTGGGTTAG 1714
| ||||||||||
Db 12 AGGTTGGGTTAG 1

RESULT 501
ABI61446/c
ID ABI61446 standard; DNA; 12 BP.
XX
AC ABI61446;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 361419 for detecting SNP TSC0052628.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 361419; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

```
  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
              ||||||||| ||
Db         12 TGGGTTAGGGGT 1


RESULT 497
ABI54852
ID   ABI54852 standard; DNA; 12 BP.
XX
AC   ABI54852;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 354825 for detecting SNP TSC0049316.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 354825; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| |||||| 
Db          1 GAGATTGAGATT 12


RESULT 498
ABI55339
ID   ABI55339 standard; DNA; 12 BP.
XX
AC   ABI55339;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 355312 for detecting SNP TSC0007163.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 355312; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1640 TTGTAGCAGAAG 1651
              |||||| |||||
Db          1 TTGTAGTAGAAG 12


RESULT 499
ABI55710
ID   ABI55710 standard; DNA; 12 BP.
XX
AC   ABI55710;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 355683 for detecting SNP TSC0004944.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
```

```
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 350010; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||||||| ||
Db         12 GAGATGGAGTTT 1

RESULT 495
ABI50660/c
ID   ABI50660 standard; DNA; 12 BP.
XX
AC   ABI50660;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 350633 for detecting SNP TSC0046789.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 350633; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGTT 1707
              |||||||| |||
Db         12 GTGGTGGATGTT 1

RESULT 496
ABI51466/c
ID   ABI51466 standard; DNA; 12 BP.
XX
AC   ABI51466;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 351439 for detecting SNP TSC0047326.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 351439; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 other;
```

```
RESULT 492
ABI46964/c
ID   ABI46964 standard; DNA; 12 BP.
XX
AC   ABI46964;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 346937 for detecting SNP TSC0044839.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 346937; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 8 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1698 GGTGGAAGTTGG 1709
              |||||| |||||
Db         12 GGTGGAGGTTGG 1


RESULT 493
ABI48545
ID   ABI48545 standard; DNA; 12 BP.
XX
AC   ABI48545;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 348518 for detecting SNP TSC0045630.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 348518; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 1 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              |||||||| ||
Db          1 GTTAGGAGTTCG 12


RESULT 494
ABI50037/c
ID   ABI50037 standard; DNA; 12 BP.
XX
AC   ABI50037;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 350010 for detecting SNP TSC0046455.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
```

```
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 345371; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 7 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 CTCCCTATCCTA 1757
             ||||||.|||||
Db         12 CTCCCTCTCCTA 1


RESULT 490
ABI45848/c
ID   ABI45848 standard; DNA; 12 BP.
XX
AC   ABI45848;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 345821 for detecting SNP TSC0044228.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 345821; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGTT 1707
             ||||| ||||||
Db         12 GTGGTTGAAGTT 1


RESULT 491
ABI46421/c
ID   ABI46421 standard; DNA; 12 BP.
XX
AC   ABI46421;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 346394 for detecting SNP TSC0044563.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 346394; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGTT 1707
             ||||||| ||||
Db         12 GTGGTGGTAGTT 1
```

```
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 342890 for detecting SNP TSC0042764.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 342890; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 CTCCCTATCCTA 1757
                ||||||||| ||
Db         12 CTCCCTATCTTA 1


RESULT 488
ABI43245
ID   ABI43245 standard; DNA; 12 BP.
XX
AC   ABI43245;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 343218 for detecting SNP TSC0042953.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 343218; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
                ||||||  |||||
Db          1 GGAAGTGGGGTT 12


RESULT 489
ABI45398/c
ID   ABI45398 standard; DNA; 12 BP.
XX
AC   ABI45398;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 345371 for detecting SNP TSC0044001.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
```

```
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
              ||||||||| ||
Db          1 TTGGGTTAGTAG 12


RESULT 485
ABI34755/c
ID   ABI34755 standard; DNA; 12 BP.
XX
AC   ABI34755;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 334728 for detecting SNP TSC0038371.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 334728; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTG 1708
              |||||| |||||
Db         12 TGGTGGTAGTTG 1


RESULT 486
ABI41618
ID   ABI41618 standard; DNA; 12 BP.
XX
AC   ABI41618;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 341591 for detecting SNP TSC0042119.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 341591; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
              |||| |||||||
Db          1 TTGGTTTAGGAG 12


RESULT 487
ABI42917/c
ID   ABI42917 standard; DNA; 12 BP.
XX
AC   ABI42917;
XX
```

OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 328971; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1704 AGTTGGGTTAGG 1715
|||||| |||||
Db 1 AGTTGGTTTAGG 12

RESULT 483
ABI30472
ID ABI30472 standard; DNA; 12 BP.
XX
AC ABI30472;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 330445 for detecting SNP TSC0035529.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 330445; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 7 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGAT 1732
|||||||||| |
Db 1 GGAGATGGAGGT 12

RESULT 484
ABI32594
ID ABI32594 standard; DNA; 12 BP.
XX
AC ABI32594;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 332567 for detecting SNP TSC0036998.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 332567; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

```
XX
SQ   Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1739 CCAACTCCTCCC 1750
              | ||||||||||
Db          1 CAAACTCCTCCC 12


RESULT 480
ABI28296
ID   ABI28296 standard; DNA; 12 BP.
XX
AC   ABI28296;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 328269 for detecting SNP TSC0034208.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 328269; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 5 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GGAGATGGAGAT 1732
              | ||||||||||
Db          1 GTAGATGGAGAT 12


RESULT 481
ABI28532/c
ID   ABI28532 standard; DNA; 12 BP.
XX
AC   ABI28532;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 328505 for detecting SNP TSC0034359.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 328505; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGGAGATTGGCT 1737
              |||||||||| |
Db         12 TGGAGATTGGTT 1


RESULT 482
ABI28998
ID   ABI28998 standard; DNA; 12 BP.
XX
AC   ABI28998;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 328971 for detecting SNP TSC0034676.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 325090; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 2 A; 1 C; 7 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1734 GGCTCCCAACTC 1745
|| |||||||||||
Db 12 GCCTCCCAACTC 1

RESULT 478
ABI25200
ID ABI25200 standard; DNA; 12 BP.
XX
AC ABI25200;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 325173 for detecting SNP TSC0032434.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 325173; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGAT 1732
|| |||||||||||
Db 1 GAAGATGGAGAT 12

RESULT 479
ABI27537
ID ABI27537 standard; DNA; 12 BP.
XX
AC ABI27537;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 327510 for detecting SNP TSC0033693.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 327510; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

```
                  || ||||||||||
Db          1 AATTCCTCCCTA 12


RESULT 475
ABI22425
ID   ABI22425 standard; DNA; 12 BP.
XX
AC   ABI22425;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 322398 for detecting SNP TSC0030840.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 322398; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1698 GGTGGAAGTTGG 1709
              | ||||||||||
Db          1 GTTGGAAGTTGG 12


RESULT 476
ABI24271/c
ID   ABI24271 standard; DNA; 12 BP.
XX
AC   ABI24271;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 324244 for detecting SNP TSC0031898.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 324244; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 5 C; 1 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1714 GGAGTACGGAGA 1725
              ||| ||||||||
Db         12 GGATTACGGAGA 1


RESULT 477
ABI25117/c
ID   ABI25117 standard; DNA; 12 BP.
XX
AC   ABI25117;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 325090 for detecting SNP TSC0032385.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 318761; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1697 TGGTGGAAGTTG 1708
|||||| ||||
Db 12 TGGTGGAGGTTG 1

RESULT 473
ABI18906/c
ID ABI18906 standard; DNA; 12 BP.
XX
AC ABI18906;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 318879 for detecting SNP TSC0028931.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 318879; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1704 AGTTGGGTTAGG 1715
||| ||||||||
Db 12 AGTGGGGTTAGG 1

RESULT 474
ABI18936
ID ABI18936 standard; DNA; 12 BP.
XX
AC ABI18936;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 318909 for detecting SNP TSC0028948.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 318909; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 5 C; 0 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1741 AACTCCTCCCTA 1752

```
AC   ABI16484;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 316457 for detecting SNP TSC0027459.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 316457; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1756 TAAAGGCCCACT 1767
              |||| |||||||
Db          1 TAAACGCCCACT 12


RESULT 471
ABI18149
ID   ABI18149 standard; DNA; 12 BP.
XX
AC   ABI18149;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 318122 for detecting SNP TSC0028456.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 318122; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 1 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 GGTTAGGAGTAC 1720
              |||||||||| |
Db          1 GGTTAGGAGTTC 12


RESULT 472
ABI18788/c
ID   ABI18788 standard; DNA; 12 BP.
XX
AC   ABI18788;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 318761 for detecting SNP TSC0028855.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
```

```
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 5 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1702 GAAGTTGGGTTA 1713
              ||||||||| ||
Db          1 GAAGTTGGGATA 12


RESULT 468
ABI16026/c
ID   ABI16026 standard; DNA; 12 BP.
XX
AC   ABI16026;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 315999 for detecting SNP TSC0027229.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 315999; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              ||||||| ||||
Db          12 GGAAGTTAGGTT 1


RESULT 469
ABI16174
ID   ABI16174 standard; DNA; 12 BP.
XX
AC   ABI16174;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 316147 for detecting SNP TSC0027307.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 316147; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 4 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
              ||||| ||||||
Db          1 AAGTTAGGTTAG 12


RESULT 470
ABI16484
ID   ABI16484 standard; DNA; 12 BP.
XX
```

```
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 313381; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              | ||||||||||
Db         12 TTCCAACTCCTC 1

RESULT 466
ABI13679
ID   ABI13679 standard; DNA; 12 BP.
XX
AC   ABI13679;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 313652 for detecting SNP TSC0025892.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 313652; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 1 C; 5 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              |||||||| |||
Db          1 GTTAGGAGAACG 12

RESULT 467
ABI13903
ID   ABI13903 standard; DNA; 12 BP.
XX
AC   ABI13903;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 313876 for detecting SNP TSC0026006.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 313876; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
```

```
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 4 C; 1 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1710 GTTAGGAGTACG 1721
              ||||||| ||||
Db         12 GTTAGGATTACG 1


RESULT 463
ABI11679/c
ID   ABI11679 standard; DNA; 12 BP.
XX
AC   ABI11679;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 311652 for detecting SNP TSC0024599.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 311652; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1632 GATGGGGCTTGT 1643
              ||||||| ||||
Db         12 GATGGGGTTTGT 1


RESULT 464
ABI13369
ID   ABI13369 standard; DNA; 12 BP.
XX
AC   ABI13369;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 313342 for detecting SNP TSC0025688.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 313342; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 AGTTGGGTTAGG 1715
              | ||||||||||
Db          1 ATTTGGGTTAGG 12


RESULT 465
ABI13408/c
ID   ABI13408 standard; DNA; 12 BP.
XX
AC   ABI13408;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 313381 for detecting SNP TSC0025710.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 307146; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 2 A; 9 C; 0 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1739 CCAACTCCTCCC 1750
||||| ||||||
Db 1 CCAACCCCTCCC 12

RESULT 461
ABI07435/c
ID ABI07435 standard; DNA; 12 BP.
XX
AC ABI07435;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 307408 for detecting SNP TSC0022484.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 307408; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1747 TCCCTATCCTAA 1758
||||| ||||||
Db 12 TCCCTTTCCTAA 1

RESULT 462
ABI08058/c
ID ABI08058 standard; DNA; 12 BP.
XX
AC ABI08058;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 308031 for detecting SNP TSC0022848.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 308031; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed

```
Qy       1706 TTGGGTTAGGAG 1717
              ||||||| ||||
Db          1 TTGGGTTGGGAG 12
```

```
RESULT 458
ABI06503
ID   ABI06503 standard; DNA; 12 BP.
XX
AC   ABI06503;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 306476 for detecting SNP TSC0022038.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 306476; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 6 C; 0 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 TCCCAACTCCTC 1748
              |||||||| |||
Db          1 TCCCAACTTCTC 12
```

```
RESULT 459
ABI06534
ID   ABI06534 standard; DNA; 12 BP.
XX
AC   ABI06534;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 306507 for detecting SNP TSC0022057.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 306507; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 6 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1698 GGTGGAAGTTGG 1709
              ||||||| ||||
Db          1 GGTGGAATTTGG 12
```

```
RESULT 460
ABI07173
ID   ABI07173 standard; DNA; 12 BP.
XX
AC   ABI07173;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 307146 for detecting SNP TSC0022360.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
```

```
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 303886; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
              ||||||||||  |
Db          1 AAGTTGGGTTTG 12


RESULT 456
ABI05053
ID   ABI05053 standard; DNA; 12 BP.
XX
AC   ABI05053;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 305026 for detecting SNP TSC0021217.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 305026; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1696 GTGGTGGAAGTT 1707
              |||||  |||||
Db          1 GTGGTTGAAGTT 12


RESULT 457
ABI05067
ID   ABI05067 standard; DNA; 12 BP.
XX
AC   ABI05067;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 305040 for detecting SNP TSC0021226.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 305040; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
ID   ABI03256 standard; DNA; 12 BP.
XX
AC   ABI03256;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 303229 for detecting SNP TSC0020398.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 303229; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 1 A; 6 C; 0 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATC 1754
             ||| |||||||||
Db          1 CTCTTCCCTATC 12


RESULT 454
ABI03600/c
ID   ABI03600 standard; DNA; 12 BP.
XX
AC   ABI03600;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 303573 for detecting SNP TSC0020536.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 303573; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
             || |||||||||
Db         12 CCTTATCCTAAA 1


RESULT 455
ABI03913
ID   ABI03913 standard; DNA; 12 BP.
XX
AC   ABI03913;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 303886 for detecting SNP TSC0020686.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
```

```
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TCCCTATCCTAA 1758
             ||||||||| ||
Db         12 TCCCTATCCAAA 1


RESULT 451
ABI00799/c
ID   ABI00799 standard; DNA; 12 BP.
XX
AC   ABI00799;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 300772 for detecting SNP TSC0019180.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 300772; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
             ||||| ||||||
Db         12 CCCTAACCTAAA 1


RESULT 452
ABI02394
ID   ABI02394 standard; DNA; 12 BP.
XX
AC   ABI02394;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 302367 for detecting SNP TSC0019966.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 302367; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1740 CAACTCCTCCCT 1751
             ||| ||||||||
Db          1 CAAATCCTCCCT 12


RESULT 453
ABI03256
```

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 298554; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 7 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1699 GTGGAAGTTGGG 1710
| ||||||||||
Db 1 GAGGAAGTTGGG 12

RESULT 449
ABH98748/c
ID ABH98748 standard; DNA; 12 BP.
XX
AC ABH98748;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 298741 for detecting SNP TSC0018259.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 298741; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1736 CTCCCAACTCCT 1747
|||||||||| ||
Db 12 CTCCCAACTACT 1

RESULT 450
ABI00532/c
ID ABI00532 standard; DNA; 12 BP.
XX
AC ABI00532;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 300505 for detecting SNP TSC0019067.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 300505; 29pp + Sequence Listing; German.
XX

```
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
              | ||||||||||
Db          1 TAGGTTAGGAGT 12


RESULT 446
ABH96180/c
ID   ABH96180 standard; DNA; 12 BP.
XX
AC   ABH96180;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 296173 for detecting SNP TSC0016943.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 296173; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 0 C; 6 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1745 CCTCCCTATCCT 1756
              |||||||||| ||
Db         12 CCTCCCTATTCT 1

RESULT 447
ABH96992/c
ID   ABH96992 standard; DNA; 12 BP.
XX
AC   ABH96992;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 296985 for detecting SNP TSC0017381.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 296985; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 8 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1699 GTGGAAGTTGGG 1710
              | ||||||||||
Db         12 GGGGAAGTTGGG 1


RESULT 448
ABH98561
ID   ABH98561 standard; DNA; 12 BP.
XX
AC   ABH98561;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 298554 for detecting SNP TSC0018170.
XX
```

```
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 293463; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;

  Query Match              7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1711 TTAGGAGTACGG 1722
              ||||||||| ||
Db         12 TTAGGAGTATGG 1


RESULT 444
ABH94245
ID   ABH94245 standard; DNA; 12 BP.
XX
AC   ABH94245;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 294238 for detecting SNP TSC0016014.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 294238; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 other;

  Query Match              7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 AGATGGAGATTG 1734
              || |||||||||
Db          1 AGTTGGAGATTG 12


RESULT 445
ABH95646
ID   ABH95646 standard; DNA; 12 BP.
XX
AC   ABH95646;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 295639 for detecting SNP TSC0016665.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 295639; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
```

```
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATC 1754
              | ||||||||||
Db         12 CCCCTCCCTATC 1


RESULT 441
ABH92917/c
ID   ABH92917 standard; DNA; 12 BP.
XX
AC   ABH92917;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 292910 for detecting SNP TSC0015404.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 292910; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1703 AAGTTGGGTTAG 1714
              |||||||||| |
Db         12 AAGTTGGGTTTG 1


RESULT 442
ABH93219/c
ID   ABH93219 standard; DNA; 12 BP.
XX
AC   ABH93219;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 293212 for detecting SNP TSC0015547.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 293212; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 0 C; 6 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 CTCCTCCCTATC 1754
              ||||| ||||||
Db         12 CTCCTTCCTATC 1


RESULT 443
ABH93470/c
ID   ABH93470 standard; DNA; 12 BP.
XX
AC   ABH93470;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 293463 for detecting SNP TSC0015629.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 291217; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 6 C; 0 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1633 ATGGGGCTTGTA 1644
||||||.|||||
Db 12 ATGGGGGTTGTA 1

RESULT 439
ABH91477
ID ABH91477 standard; DNA; 12 BP.
XX
AC ABH91477;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 291470 for detecting SNP TSC0014803.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 291470; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1716 AGTACGGAGATG 1727
||||.|||||||
Db 1 AGTAGGGAGATG 12

RESULT 440
ABH92015/c
ID ABH92015 standard; DNA; 12 BP.
XX
AC ABH92015;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 292008 for detecting SNP TSC0015047.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 292008; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 8 G; 1 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;

```
RESULT 436
ABH90089/c
ID   ABH90089 standard; DNA; 12 BP.
XX
AC   ABH90089;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 290082 for detecting SNP TSC0014210.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 290082; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 GGTTAGGAGTAC 1720
              ||||||||||  |
Db         12 GGTTAGGAGTTC 1

RESULT 437
ABH90546
ID   ABH90546 standard; DNA; 12 BP.
XX
AC   ABH90546;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 290539 for detecting SNP TSC0014397.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 290539; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCC 1749
              || |||||||||
Db          1 CCAAACTCCTCC 12

RESULT 438
ABH91224/c
ID   ABH91224 standard; DNA; 12 BP.
XX
AC   ABH91224;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 291217 for detecting SNP TSC0014696.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
```

```
PS   Claim 1; SEQ ID 285003; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 6 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 CTCCCAACTCCT 1747
              ||||||||| ||
Db          1 CTCCCAACTACT 12


RESULT 434
ABH86312/c
ID   ABH86312 standard; DNA; 12 BP.
XX
AC   ABH86312;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 286305 for detecting SNP TSC0012663.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 286305; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              || |||||||||
Db         12 GGTAGTTGGGTT 1


RESULT 435
ABH87531
ID   ABH87531 standard; DNA; 12 BP.
XX
AC   ABH87531;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 287524 for detecting SNP TSC0013129.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 287524; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 7 C; 0 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1738 CCCAACTCCTCC 1749
              |||||||||| |
Db          1 CCCAACTCCTTC 12
```

```
DE   Oligonucleotide primer SEQ ID NO 281156 for detecting SNP TSC0009500.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 281156; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
              ||||| ||||||
Db         12 TTGGGGTAGGAG 1

RESULT 432
ABH84710
ID   ABH84710 standard; DNA; 12 BP.
XX
AC   ABH84710;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 284703 for detecting SNP TSC0011953.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 284703; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1631 GGATGGGGCTTG 1642
              |||||||| |||
Db          1 GGATGGGGTTTG 12

RESULT 433
ABH85010
ID   ABH85010 standard; DNA; 12 BP.
XX
AC   ABH85010;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 285003 for detecting SNP TSC0012095.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
```

```
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 4 C; 1 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 GAGATGGAGATT 1733
              ||||| ||||||
Db         12 GAGATCGAGATT 1


RESULT 429
ABH78187/c
ID   ABH78187 standard; DNA; 12 BP.
XX
AC   ABH78187;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 278180 for detecting SNP TSC0005767.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 278180; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1634 TGGGGCTTGTAG 1645
              ||||| ||||||
Db         12 TGGGGTTTGTAG 1


RESULT 430
ABH78792/c
ID   ABH78792 standard; DNA; 12 BP.
XX
AC   ABH78792;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 278785 for detecting SNP TSC0006380.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 278785; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CCCTATCCTAAA 1759
              ||| ||||||||
Db         12 CCCAATCCTAAA 1


RESULT 431
ABH81163/c
ID   ABH81163 standard; DNA; 12 BP.
XX
AC   ABH81163;
XX
DT   22-FEB-2002  (first entry)
XX
```

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 276061; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATT 1733
||||||||| ||
Db 1 GAGATGGAGTTT 12

RESULT 427
ABH77659/c
ID ABH77659 standard; DNA; 12 BP.
XX
AC ABH77659;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 277652 for detecting SNP TSC0004662.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 277652; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 4 C; 0 G; 4 T; 0 other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATT 1733
||||| |||||
Db 12 GAGATTGAGATT 1

RESULT 428
ABH77660/c
ID ABH77660 standard; DNA; 12 BP.
XX
AC ABH77660;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 277653 for detecting SNP TSC0004662.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 277653; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

```
  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1711 TTAGGAGTACGG 1722
              |||||| |||||
Db          1 TTAGGATTACGG 12


RESULT 424
ABH74230/c
ID   ABH74230 standard; DNA; 12 BP.
XX
AC   ABH74230;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 274215 for detecting SNP TSC0003480.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 274215; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1697 TGGTGGAAGTTG 1708
              |||||||| ||
Db         12 TGGTGGAAGGTG 1


RESULT 425
ABH74324
ID   ABH74324 standard; DNA; 12 BP.
XX
AC   ABH74324;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 274309 for detecting SNP TSC0003509.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 274309; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 1 A; 1 C; 7 G; 3 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1694 GCGTGGTGGAAG 1705
              ||||||||| ||
Db          1 GCGTGGTGGTAG 12


RESULT 426
ABH76068
ID   ABH76068 standard; DNA; 12 BP.
XX
AC   ABH76068;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 276061 for detecting SNP TSC0004079.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
```

```
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 271766; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              || |||||||||
Db         12 GGGAGTTGGGTT 1

RESULT 422
ABH72659/c
ID   ABH72659 standard; DNA; 12 BP.
XX
AC   ABH72659;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 272644 for detecting SNP TSC0002888.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 272644; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
              |||| |||||||
Db         12 TTGGTTTAGGAG 1

RESULT 423
ABH73848
ID   ABH73848 standard; DNA; 12 BP.
XX
AC   ABH73848;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 273833 for detecting SNP TSC0003326.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 273833; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 other;
```

```
RESULT 419
ABH69474/c
ID   ABH69474 standard; DNA; 12 BP.
XX
AC   ABH69474;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 269451 for detecting SNP TSC0001769.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 269451; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1707 TGGGTTAGGAGT 1718
              |||||| |||||
Db         12 TGGGTTGGGAGT 1


RESULT 420
ABH71060
ID   ABH71060 standard; DNA; 12 BP.
XX
AC   ABH71060;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 271037 for detecting SNP TSC0002376.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 271037; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 TTGGGTTAGGAG 1717
              |||||||||| |
Db          1 TTGGGTTAGGTG 12


RESULT 421
ABH71789/c
ID   ABH71789 standard; DNA; 12 BP.
XX
AC   ABH71789;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 271766 for detecting SNP TSC0002608.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
```

```
PT   drug screening protocols for compounds targeting POR  -
XX
PS   Claim 14; Page 14; 141pp; English.
XX
CC   The present invention provides the protein, gene and cDNA sequences of
CC   human P450(cytochrome) oxidoreductase POR, and single nucleotide
CC   polymorphisms (SNPs) identified therein. The sequences can be used to
CC   haplotype the POR gene of an individual, and to establish whether POR is
CC   a suitable target for drugs to treat cancer and disorders associated with
CC   impaired protein synthesis in cells. The present sequence is an allele
CC   specific probe for the coding sequences of the invention.
XX
SQ   Sequence 15 BP; 3 A; 5 C; 5 G; 1 T; 1 other;

  Query Match             7.6%;  Score 10.6;  DB 1;  Length 15;
  Best Local Similarity   90.9%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1688 CCTCCAGCGTG 1698
              |||||||:|||
Db         15 CCTCCAGYGTG 5


RESULT 417
AAV28522
ID   AAV28522 standard; DNA; 12 BP.
XX
AC   AAV28522;
XX
DT   28-AUG-1998  (first entry)
XX
DE   Blackcurrant reversion virus RNA2 3' proximal fragment primer 2.
XX
KW   Blackcurrant reversion disease; BRV; RNA2; diagnosis; Ribes; PCR;
KW   primer; ss.
XX
OS   Synthetic.
OS   Blackcurrant reversion virus.
XX
PN   WO9810100-A1.
XX
PD   12-MAR-1998.
XX
PF   01-SEP-1997;   97WO-FI00507.
XX
PR   05-SEP-1996;   96FI-0003474.
XX
PA   (ABOA-) ABOATECH OY AB.
XX
PI   Latvala S,  Lehto K,  Lemmetty A,  Susi P;
XX
DR   WPI; 1998-193642/17.
XX
PT   Diagnosing blackcurrant reversion disease in plants e.g.
PT   blackcurrant - using reverse transcriptase-PCR with primers
PT   amplifying cDNA fragment complementary to fragment of new
PT   blackcurrant reversion virus
XX
PS   Claim 13; Page 29; 38pp; English.
XX
CC   Primer 2 corresponds to nucleotides 199-210 upstream of the poly-A
CC   tail of a 230 bp fraction (see AAV28520) of a blackcurrant reversion
CC   virus (BRV) nucleotide sequence, as converted to DNA.  It is used
CC   with primer 1 (see AAV28521) to amplify a cDNA fragment complementary
CC   to a 3' proximal 210 bp fragment of BRV RNA.  A claimed method for
CC   diagnosing blackcurrant reversion disease in a plant by detecting
CC   BRV involves: providing a sample from the plant to be tested;
CC   performing a reverse transcription reaction to prepare single
CC   stranded cDNA from viral RNA in the sample; amplifying the cDNA
CC   by PCR; and detecting the amplified product.  A claimed diagnostic
CC   test kit includes a primer pair designed to amplify a cDNA fragment
CC   complementary to the 3' proximal 210 bp fragment of viral RNA.  The
CC   method allows rapid, reliable diagnosis of blackcurrant reversion
CC   disease in plants, especially blackcurrant.  The viral sequence
CC   detected by primer pair 1,2 is conserved in isolates from widely
CC   different geographic locations.
XX
SQ   Sequence 12 BP; 0 A; 4 C; 4 G; 4 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1677 CCCTGGTGTCTC 1688
              | ||||||||||
Db          1 CGCTGGTGTCTC 12


RESULT 418
ABH67931
ID   ABH67931 standard; DNA; 12 BP.
XX
AC   ABH67931;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 267908 for detecting SNP TSC0000674.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB00713.
XX
PR   07-APR-2000; 2000DE-1019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single nucleotide polymorphisms and cytosine
PT   methylation status  -
XX
PS   Claim 1; SEQ ID 267908; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation.
CC   ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC   ABI00010-ABI82073 represent the oligomers described in the invention.
CC   NOTE: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 other;

  Query Match             7.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 GGAAGTTGGGTT 1712
              |||||||| |||
Db          1 GGAAGTTGTGTT 12
```

XX
OS Synthetic.
XX
PN US6107092-A.
XX
PD 22-AUG-2000.
XX
PF 29-MAR-1999; 99US-0280409.
XX
PR 29-MAR-1999; 99US-0280409.
XX
PA (ISIS-) ISIS PHARM INC.
PA (BAYU) BAYLOR COLLEGE MEDICINE.
XX
PI Cowsert LM, Bennett CF, O'Malley BW;
XX
DR WPI; 2000-586211/55.
XX
PT Antisense compounds targeted to steroid receptor RNA activator useful
PT for diagnosis, prophylaxis and treatment of diseases associated with
PT the steroid activator, such as infection, inflammation or tumor
PT formation -
XX
PS Claim 3; Column 42; 47pp; English.
XX
CC The present sequence is one of a large number of antisense
CC oligonucleotides which is directed against one of four human steroid
CC receptor RNA activator (SRA) nucleic acid sequences. Two series of
CC antisense oligonucleotides were synthesised. The first series comprised
CC 8-30 oligodeoxynucleotides with a phosphorothioate backbone. The second
CC series comprised chimeric oligonucleotides composed of a central gap
CC region, consisting of ten 2'-deoxynucleotides, which was flanked on both
CC sides by four-nucleotide wings. The wings were composed of
CC 2'-methoxyethyl (2'-MOE) nucleotides. Both series contained the same
CC nucleotide sequences. The antisense compounds are useful for research,
CC diagnosis, treatment and prophylaxis to prevent or delay infection,
CC inflammation or tumour formation. Therapeutically the oligonucleotides
CC are highly safe and are effectively administered to humans.
XX
SQ Sequence 18 BP; 3 A; 3 C; 7 G; 5 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 18;
Best Local Similarity 85.7%; Pred. No. 4.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1658 ACCAGGCTCACAGC 1671
||||||||.||||
Db 15 ACCAGGCTTCCAGC 2

RESULT 415
ABN81420/c
ID ABN81420 standard; DNA; 15 BP.
XX
AC ABN81420;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human HTATIP allele specific probe SEQ ID NO 21.
XX
KW Human; HIV-1 Tat interactive protein; HTATIP); haplotyping;
KW genotyping; transgenic; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200229089-A2.
XX
PD 11-APR-2002.
XX
PF 05-OCT-2001; 2001WO-US31593.
XX
PR 06-OCT-2000; 2000US-238655P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Armstrong B, Bentivegna SC, Choi JY, Gilson CR, Parks KE;
PI Sausker EA;
XX
DR WPI; 2002-330173/36.
XX
PT New HIV-1 tat interactive protein, 60 kDa (HTATIP) gene polymorphic
PT variants, for studying the expression and function of HTATIP and
PT screening candidate drugs for treating familial glucocorticoid
PT deficiency and cancer -
XX
PS Claim 14; Page 13; 89pp; English.
XX
CC The invention relates to novel genetic variants of the HIV-1 Tat
CC interactive protein, 60 KDa (HTATIP) gene. The polymorphic variants are
CC useful in studying the expression and function of HTATIP, in expressing
CC HTATIP protein for use in screening for candidate drugs to treat diseases
CC related to HTATIP activity, in studying the effect of the variation on
CC the biological activity of HTATIP and the binding affinity of candidate
CC drugs targeting HTATIP for the treatment of disorders. Haplotyping
CC methods are useful in validating HTATIP as a candidate target for
CC treating a specific condition or disease predicted to be associated with
CC HTATIP activity or in the design of clinical trials of candidate drugs
CC for treating a specific condition or disease associated with HTATIP
CC activity. Transgenic animals are useful for studying expression of the
CC HTATIP isogenes in vivo, for in vivo screening and testing of drugs
CC targeted against HTATIP protein and for testing the efficacy of
CC therapeutic agents and compounds for disorders. The present sequence is
CC that of a HTATIP allele specific oligonucleotide probe of the invention.
XX
SQ Sequence 15 BP; 1 A; 4 C; 5 G; 4 T; 1 other;

Query Match 7.6%; Score 10.6; DB 1; Length 15;
Best Local Similarity 90.9%; Pred. No. 3.7e+02;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCT 1665
|||:|||||||
Db 11 AGCRCCAGGCT 1

RESULT 416
ABN80551/c
ID ABN80551 standard; DNA; 15 BP.
XX
AC ABN80551;
XX
DT 19-JUL-2002 (first entry)
XX
DE Human P450(cytochrome) oxidoreductase allele specific probe #17.
XX
KW Human; P450(cytochrome) oxidoreductase; POR; cancer; haplotype; SNP;
KW single nucleotide polymorphism; flavoprotein; enzyme; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200226768-A2.
XX
PD 04-APR-2002.
XX
PF 01-OCT-2001; 2001WO-US30877.
XX
PR 29-SEP-2000; 2000US-236449P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Kazemi A, Kliem SE, Lanz EM, Messer C, Tanguay DA;
XX
DR WPI; 2002-394236/42.
XX
PT New genetic variants comprising haplotypes of the P450 (cytochrome)
PT oxidoreductase (POR) isogene, useful in improving the efficiency of

```
XX
SQ   Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 412
ABL01599
ID   ABL01599 standard; DNA; 15 BP.
XX
AC   ABL01599;
XX
DT   15-MAR-2002  (first entry)
XX
DE   c-Ha-ras targeted antisense peptide nucleic acid SEQ ID NO: 5.
XX
KW   Peptide nucleic acid; PNA; cytostatic; virucide; dermatological;
KW   antiasthmatic; overexpression; viral infection; vitiligo; antisense;
KW   pigmentation disorder; asthma; polyamide backbone; ss.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1..15
FT                    /*tag=  a
FT                    /note= "This sequence is a peptide nucleic acid, i.e. it
FT                    contains a polyamide backbone instead of a deoxyribose
FT                    backbone"
FT   modified_base    1
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "linked to one of the peptides shown in ABB04517
FT                    and ABB04518 to form a PNA-peptide conjugate"
XX
PN   WO200179216-A2.
XX
PD   25-OCT-2001.
XX
PF   07-APR-2001; 2001WO-EP04030.
XX
PR   18-APR-2000; 2000DE-1019135.
XX
PA   (AVET ) AVENTIS PHARMA DEUT GMBH.
XX
PI   Uhlmann E,  Breipohl G,  Will DW;
XX
DR   WPI; 2002-075055/10.
XX
PT   New peptide nucleic acid derivatives, useful e.g. for tumor treatment
PT   and diagnosis, contain terminal, deprotonizable phosphoryl groups for
PT   e.g. improved solubility -
XX
PS   Disclosure; Page 19; 93pp; German.
XX
CC   The present invention relates to peptide nucleic acid (PNA) derivatives
CC   having at the C-, and optionally N-, terminus one or more phosphoryl
CC   groups, at least one of which contains one or more deprotonisable groups,
CC   preferably hydroxy or mercapto. These PNAs are useful in the treatment of
CC   tumours or any disease associated with (over)expression of particular
CC   genes, including viral infections, vitiligo or other pigmentation
CC   disorders, and asthma. The present sequence is a peptide nucleic acid
CC   described in the exemplification of the invention.
XX
SQ   Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 413
ABA97499
ID   ABA97499 standard; DNA; 15 BP.
XX
AC   ABA97499;
XX
DT   16-APR-2002  (first entry)
XX
DE   c-Ha-ras targeted antisense peptide nucleic acid SEQ ID NO: 45.
XX
KW   Peptide nucleic acid; PNA; polyamide backbone; phosphoryl radical;
KW   cytostatic; virucide; dermatological; antiasthmatic; cancer; antisense;
KW   viral infection; vitiligo; pigmentation disorder; asthma; ss.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO200179249-A2.
XX
PD   25-OCT-2001.
XX
PF   07-APR-2001; 2001WO-EP04027.
XX
PR   18-APR-2000; 2000DE-1019136.
XX
PA   (AVET ) AVENTIS PHARMA DEUT GMBH.
XX
PI   Uhlmann E,  Breipohl G,  Will DW;
XX
DR   WPI; 2002-089643/12.
XX
PT   New peptide nucleic acid derivatives, useful e.g. for treating tumors
PT   and diagnosis, have N-terminal phosphoryl residue for improving e.g.
PT   solubility in water -
XX
PS   Disclosure; Page 90; 96pp; German.
XX
CC   The present invention relates to peptide nucleic acid (PNA) derivatives.
CC   These can be used in the treatment of cancer, viral infections, vitiligo
CC   or other pigmentation disorders, and asthma. The present sequence is an
CC   oligonucleotide fragment of a PNA described in the exemplification of the
CC   invention.
XX
SQ   Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 414
AAA92609/c
ID   AAA92609 standard; DNA; 18 BP.
XX
AC   AAA92609;
XX
DT   04-JAN-2001  (first entry)
XX
DE   Antisense oligonucleotide ISIS# 30428.
XX
KW   Human; SRA; steroid receptor RNA activator; cytostatic; antiinflammatory;
KW   SRA inhibitor; cancer; infection; antisense oligonucleotide; ss.
```

```
DE   Human epoxide hydroxylase 2 PCR primer #11.
XX
KW   Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
KW   cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW   adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW   aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW   cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW   epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW   glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW   HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW   NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile;
KW   STM; UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW   UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW   multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW   multidrug resistance associated protein 3; cancer; prostate;
KW   acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW   altered drug metabolism; cardiovascular function; colorectal tumour;
KW   central nervous system; pulmonary; immunological.
XX
OS   Homo sapiens.
XX
PN   WO200257410-A2.
XX
PD   25-JUL-2002.
XX
PF   28-NOV-2001; 2001WO-US44838.
XX
PR   28-NOV-2000; 2000US-0724389.
XX
PA   (DNAS-) DNA SCI LAB INC.
XX
PI   Guida M,  Hall J;
XX
DR   WPI; 2002-698522/75.
XX
PT   Isolated nucleic acid molecules having polymorphisms in known human
PT   genes e.g. cytochrome p450 and cathepsin S useful as genetic linkage
PT   markers for locating, identifying and characterizing the genes
PT   responsible for disorder-related traits  -
XX
PS   Example 10; Page 116; 714pp; English.
XX
CC   This invention relates to the sequence of an isolated nucleic acid
CC   molecule comprising at least one base variation from that of a known
CC   human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC   cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC   aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC   (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
CC   inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase
CC   activating protein (FLAP), glutathione-S-transferase 12 (GST12),
CC   histamine-N-methyl transferase (HNMT), (kallikrein 2) KLK2, nicotinamide
CC   -N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC   sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC   (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC   transferase  (UGT2B15), urokinase receptor (uPA), multidrug resistance
CC   1 (MDR1), lactotransferrin (LTF), multidrug resistance associated
CC   protein 3 (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine
CC   muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or
CC   CHMR5) sequence. The polymorphisms in the human genes cited in the
CC   invention are useful as genetic linkage markers for locating and
CC   characterising the genes that are responsible for specific traits within
CC   the genome and eventually identifying the genes responsible for a
CC   variety of disorder-related traits as a result of their e.g.,
CC   overexpression, constitutive expression, mutation or underexpression,
CC   which may be used in diagnosing and/or treating the disorders. The
CC   nucleic acid molecules comprising the polymorphic sequences contained
CC   in CYP4501A1, CYPP4501A2, CYP4502E1, ARNT, EPHX2, GST12, NNMT, NQO2,
CC   NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful
CC   for screening individuals for altered drug metabolism. The polymorphic
CC   sequences contained in CYP4501A1, CYPP4501A2, AHR, MDR1 and/or MDR3 may
CC   also be used to screen individuals for susceptibility to cancer.
CC   Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered
CC   cardiovascular function, in COX2 for altered susceptibility to
CC   colorectal tumours, in DBI or CHMR1 for altered central nervous system
CC   function, in FLAP and HNMT for altered pulmonary, immunological or
CC   haematological function, in KLK2 for altered serine protease activity in
CC   the prostate, in LTF for altered immunological or haematological
CC   function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral
CC   nervous system function. The present sequence represents a PCR
CC   primer used to amplify the sequences of the invention.
XX
SQ   Sequence 15 BP; 3 A; 1 C; 9 G; 2 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GATGGAGATTGGCT 1737
              || |||||| ||||
Db          1 GAGGGAGATGGGCT 14


RESULT 411
AAL46735
ID   AAL46735 standard; DNA; 15 BP.
XX
AC   AAL46735;
XX
DT   08-AUG-2002  (first entry)
XX
DE   c-Ha-ras antisense oligonucleotide #1.
XX
KW   Modified antisense oligonucleotide; antisense; cancer; infection;
KW   cytostatic; virucide; anti-HIV; hepatotropic; antiinflammatory; c-Ha-ras;
KW   phosphorothioate backbone; integrin; cell-cell adhesion receptor; ss.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1..7
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "optionally phosphorothioate backbone"
FT   modified_base   10..14
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "optionally phosphorothioate backbone"
XX
PN   EP1182206-A2.
XX
PD   27-FEB-2002.
XX
PF   07-NOV-1994; 2001EP-0124078.
XX
PR   12-NOV-1993;   93DE-4338704.
PR   07-NOV-1994;   94EP-0117513.
XX
PA   (FARH ) HOECHST AG.
XX
PI   Peymann A,  Uhlmann E,  Mag M,  Kretschmar G,  Helsberg M,  Winkler I;
XX
DR   WPI; 2002-353922/39.
XX
PT   New nuclease-resistant oligonucleotides having modified non-terminal
PT   pyrimidine nucleoside(s), useful e.g. for treating cancer or viral
PT   diseases or as diagnostic reagents  -
XX
PS   Disclosure; Page 9; 19pp; German.
XX
CC   The present invention relates to oligonucleotides having at least one
CC   non-terminal pyrimidine nucleoside modified and additionally having the
CC   5'- and/or 3'-terminal modified. These can be used in the treatment of
CC   viral infections, such as HIV, HSV-1, HSV-2, influenza virus, VSV,
CC   hepatitis B and papilloma viruses, cancer and diseases involving
CC   integrins and cell-cell adhesion receptors. The present sequence is an
CC   antisense oligonucleotide of the invention.
```

KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 86; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1724 GATGGAGATTGGCT 1737
|||||| |||||
Db 1 GATGGAGCCTGGCT 14

RESULT 409
AAH49214
ID AAH49214 standard; DNA; 15 BP.
XX
AC AAH49214;
XX
DT 26-NOV-2001 (first entry)
XX
DE Anti-c-Ha-ras oligonucleotide VIII.
XX
KW Polyamide-oligonucleotide derivative; anticancer; antiproliferative;
KW antiviral; hepatotropic; vasotropic; antisense inhibition; ribozyme;
KW integrin; cell-cell adhesion; cancer; restenosis; stability; PNA;
KW peptide nucleic acid; ss.
XX
OS Synthetic.
XX
PN EP1113021-A2.
XX
PD 04-JUL-2001.
XX
PF 08-MAR-1995; 2001EP-0104012.
XX
PR 14-MAR-1994; 94DE-4408528.
PR 08-MAR-1995; 95EP-0103332.
XX
PA (AVET) AVENTIS PHARMA DEUT GMBH.
XX
PI Uhlmann E, Breipohl G;
XX
DR WPI; 2001-591267/67.
XX
PT New DNA-peptide nucleic acid chimeras, useful e.g. as antisense agents
PT for treating e.g. cancer, also as diagnostic probes and primers -
XX
PS Disclosure; Page 22; 54pp; German.
XX
CC This invention describes novel polyamide-oligonucleotide derivatives (I)
CC and their physiologically acceptable salts of formula
CC F((DNA)-Li)_q(PNA-Li)_r(DNA-Li)_s(PNA)_t)_xF' where q, r, s, t = 0 or 1,
CC with the sum of two or more adjacent letters at least 2; x = 1-20; DNA
CC = nucleic acid (such as DNA or RNA or their known derivatives); Li =
CC covalent linkage between DNA and PNA, i.e. a bond or a residue containing
CC at least one atom of carbon, nitrogen, oxygen or sulfur; PNA = polyamide
CC structure containing at least one nucleobase different from thymine; and
CC F, F' = end groups and/or are connected through a covalent bond. The
CC products of the invention have anticancer, antiproliferative, antiviral,
CC hepatotropic and vasotropic activity and can be used for the inhibition
CC of gene expression by antisense, ribozyme, sense, or triple-helix
CC methods, or by binding to proteins (aptamers). (I) are used for treating
CC diseases caused by viruses (human immune deficiency, herpes simplex,
CC influenza, vesicular stomatitis, hepatitis B or papilloma), or mediated
CC by integrins or cell-cell adhesion reactions, for treating cancer, or
CC for inhibiting restenosis, particularly as antisense reagents. They are
CC also useful in heterogeneous or homogeneous assays, as primers or probes,
CC particularly where the target is amplified before being detected by
CC hybridization, for diagnosis of genetic, malignant or pathogen-related
CC diseases. (I) retain the increased affinity for complementary strands and
CC better stability in serum, associated with conventional peptide nucleic
CC acids (PNA), but lack the disadvantages, i.e. have improved cellular
CC uptake, do not aggregate in aqueous solution, and have reduced affinity
CC for purification materials, reduced cytotoxicity, better sequence
CC specificity. They are more active than either DNA or PNA oligomers. When
CC used as probes, (I) show different responses to base-pair mismatches in
CC the DNA and PNA segments, allowing better discrimination between
CC pathogenic and non-pathogenic conditions such as the transition from
CC proto-oncogene to oncogene, also, when used as primers, with the PNA
CC segment at the 5'-end, they produce amplicons resistant to
CC 5'-exonuclease, allowing this enzyme to be used to eliminate RNA or DNA
CC primers. The DNA component allows additional reactions not possible with
CC PNA alone, e.g. 3'-tailing and (I) may be incorporated into a gene.
CC AAH49208-AAH49264 represent oligonucleotides used to illustrate the
CC method of the invention.
XX
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCTG 1681
|||||| ||||| |
Db 1 CAGCTGCAACCCAG 14

RESULT 410
ABS97484
ID ABS97484 standard; DNA; 15 BP.
XX
AC ABS97484;
XX
DT 23-DEC-2002 (first entry)
XX

DE IGF-I oligonucleotide #2559.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 77; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1732 TTGGCTCCCAACTC 1745
              ||||||||||  ||
Db         14 TTGGCTCCCAGGTC 1
```

RESULT 407
AAF52888
ID AAF52888 standard; DNA; 15 BP.
XX
AC AAF52888;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3848.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 86; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 4 A; 2 C; 7 G; 2 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1721 GGAGATGGAGATTG 1734
              ||||||||||  ||
Db          2 GGAGATGGAGCCTG 15
```

RESULT 408
AAF52892
ID AAF52892 standard; DNA; 15 BP.
XX
AC AAF52892;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3852.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

```
RESULT 404
AAF51502
ID   AAF51502 standard; DNA; 15 BP.
XX
AC   AAF51502;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #2462.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU00693.
XX
PR   21-JUN-1999;   99US-0140345.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by
PT   administering UV (ultra-violet) treatment (optional) and an antisense
PT   nucleic acid that inhibits or reduces growth factor mediated cell
PT   proliferation and/or inflammation -
XX
PS   Example 8; Page 77; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects
CC   of skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and
CC   AAF45153-F45161). The method is useful for ameliorating the effects of
CC   psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC   keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC   skin, a hyperneovascular condition such as a neovascular condition of the
CC   retina, brain or skin, growth factor-mediated malignancies, other
CC   sclerotic disease, kidney disease, hyperproliferation of the inside of
CC   blood vessels or any other hyperplasia.
XX
SQ   Sequence 15 BP; 4 A; 5 C; 5 G; 1 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1652 GCAAGCACCAGGCT 1665
             |||| ||| |||||
Db          1 GCAACCACGAGGCT 14


RESULT 405
AAF51598/c
ID   AAF51598 standard; DNA; 15 BP.
XX
AC   AAF51598;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #2558.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU00693.
XX
PR   21-JUN-1999;   99US-0140345.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by
PT   administering UV (ultra-violet) treatment (optional) and an antisense
PT   nucleic acid that inhibits or reduces growth factor mediated cell
PT   proliferation and/or inflammation -
XX
PS   Example 8; Page 77; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects
CC   of skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and
CC   AAF45153-F45161). The method is useful for ameliorating the effects of
CC   psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC   keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC   skin, a hyperneovascular condition such as a neovascular condition of the
CC   retina, brain or skin, growth factor-mediated malignancies, other
CC   sclerotic disease, kidney disease, hyperproliferation of the inside of
CC   blood vessels or any other hyperplasia.
XX
SQ   Sequence 15 BP; 4 A; 4 C; 5 G; 2 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1732 TTGGCTCCCAACTC 1745
              |||||||||  ||
Db         15 TTGGCTCCCAGGTC 2


RESULT 406
AAF51599/c
ID   AAF51599 standard; DNA; 15 BP.
XX
AC   AAF51599;
XX
DT   30-MAR-2001  (first entry)
XX
```

Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1717 GTACGGAGATGGAG 1730
              | ||| |||||||
Db         15 GCACGAAGATGGAG 2
```

RESULT 402
AAF51269/c
ID AAF51269 standard; DNA; 15 BP.
XX
AC AAF51269;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2229.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 75; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 1 A; 7 C; 2 G; 5 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1717 GTACGGAGATGGAG 1730
              | ||| |||||||
Db         14 GCACGAAGATGGAG 1
```

RESULT 403
AAF51501
ID AAF51501 standard; DNA; 15 BP.
XX
AC AAF51501;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2461.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 77; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1652 GCAAGCACCAGGCT 1665
              |||| ||| ||||
Db          2 GCAACCACGAGGCT 15
```

CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 3 A; 6 C; 1 G; 5 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1719 ACGGAGATGGAGAT 1732
||| |||||||| |
Db 15 ACGAAGATGGAGTT 2

RESULT 400
AAF51267/c
ID AAF51267 standard; DNA; 15 BP.
XX
AC AAF51267;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2227.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 75; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 3 A; 5 C; 2 G; 5 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1719 ACGGAGATGGAGAT 1732
||| |||||||| |
Db 14 ACGAAGATGGAGTT 1

RESULT 401
AAF51268/c
ID AAF51268 standard; DNA; 15 BP.
XX
AC AAF51268;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2228.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 75; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 2 A; 6 C; 2 G; 5 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;

CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 4 A; 6 C; 2 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1699 GTGGAAGTTGGGTT 1712
||||||||||||| |
Db 15 GTGGAACTTGGGAT 2

RESULT 398
AAF47177/c
ID AAF47177 standard; DNA; 15 BP.
XX
AC AAF47177;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #597.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 7; Page 48; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 3 A; 9 C; 1 G; 2 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1696 GTGGTGGAAGTTGG 1709
|| ||||||| ||||
Db 14 GGGGTGGAACTTGG 1

RESULT 399
AAF51266/c
ID AAF51266 standard; DNA; 15 BP.
XX
AC AAF51266;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2226.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 75; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the

PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 6; Page 39; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1726 TGGAGATTGGCTCC 1739
||||||| |||||
Db 15 TGGAGATCCGCTCC 2

RESULT 396
AAF45992/c
ID AAF45992 standard; DNA; 15 BP.
XX
AC AAF45992;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #831.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 6; Page 39; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 3 A; 5 C; 5 G; 2 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1726 TGGAGATTGGCTCC 1739
||||||| |||||
Db 14 TGGAGATCCGCTCC 1

RESULT 397
AAF47173/c
ID AAF47173 standard; DNA; 15 BP.
XX
AC AAF47173;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #593.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 7; Page 48; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1

XX
KW Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;
KW allergic disease; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200104270-A1.
XX
PD 18-JAN-2001.
XX
PF 13-JUL-2000; 2000WO-US19094.
XX
PR 13-JUL-1999; 99US-0143435.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
PI Windemuth AK;
XX
DR WPI; 2001-103078/11.
XX
PT New isolated polynucleotide useful for the identification of
PT therapeutics in allergic diseases is new -
XX
PS Claim 15; Page 44; 188pp; English.
XX
CC The present invention relates to polymorphisms of the human interleukin 4
CC receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference
CC sequence). Polynucleotides comprising polymorphic gene variants are
CC useful for therapeutic purposes. For example, where a patient may benefit
CC from expression of a particular IL4Ralpha protein isoform, an expression
CC vector encoding the isoform may be administered to the patient. It may
CC desirable to decrease or block expression of a particular IL4Ralpha
CC isogene, which may be done by turning off by transforming a targeted
CC organ, tissue or cell population with an expression vector that expresses
CC high levels of untranslatable mRNA for the isogene. Specific therapeutics
CC identified by these methods may be useful for allergic diseases. The
CC present sequence is a probe for human IL4R-alpha.
XX
SQ Sequence 15 BP; 3 A; 4 C; 6 G; 2 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1728 GAGATTGGCTCCCA 1741
||| ||| ||||||
Db 15 GAGCTTGCCTCCCA 2

RESULT 394
AAF69956
ID AAF69956 standard; DNA; 15 BP.
XX
AC AAF69956;
XX
DT 18-APR-2001 (first entry)
XX
DE Human TNFRSF11B gene ASO probe, SEQ ID NO: 12.
XX
KW Human; TNFRSF11B; osteoclastogenesis inhibitory factor;
KW single nucleotide polymorphism; SNP; osteoclast recruitment;
KW osteoclast function; osteoporosis; metastatic bone disease;
KW Paget's disease; rheumatoid arthritis; periodontal bone disease;
KW ASO; allele-specific oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200104137-A1.
XX
PD 18-JAN-2001.
XX
PF 10-JUL-2000; 2000WO-US18803.
XX
PR 09-JUL-1999; 99US-0143020.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
XX
DR WPI; 2001-147175/15.
XX
PT Human Osteoclastogenesis Inhibitory Factor nucleotides, comprising
PT single nucleotide polymorphisms, useful for studying e.g. osteoporosis,
PT Paget's disease and rheumatoid arthritis -
XX
PS Claim 15; Page 21; 114pp; English.
XX
CC The present sequence is a probe used to detect polymorphisms in the human
CC osteoclastogenesis inhibitory factor (TNFRSF11B). Polynucleotides
CC comprising one or more of twenty four novel single nucleotide
CC polymorphisms in the TNFRSF11B gene have been identified. TNFRSF11B
CC regulate osteoclast recruitment and function. An understanding of
CC variations in the gene should thus be useful in developing new therapies
CC for metabolic disorders caused by abnormal osteoclast recruitment and
CC function such as osteoporosis, metastatic bone disease, Paget's disease,
CC rheumatoid arthritis and periodontal bone disease.
XX
SQ Sequence 15 BP; 1 A; 5 C; 4 G; 5 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1677 CCCTGGTGTCTCCT 1690
|||||||| ||||
Db 2 CCCTGGTGGATCCT 15

RESULT 395
AAF45991/c
ID AAF45991 standard; DNA; 15 BP.
XX
AC AAF45991;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #830.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense

PN WO200125245-A2.
XX
PD 12-APR-2001.
XX
PF 05-OCT-2000; 2000WO-US27487.
XX
PR 06-OCT-1999; 99US-0157909.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX
DR WPI; 2001-308220/32.
XX
PT New human death-associated protein 6 (DAXX) gene variants comprising 19
PT polymorphic sites useful in studying the effect of variation on the
PT biological activity of DAXX and in developing drugs targeting the
PT protein -
XX
PS Claim 15; Page 19; 97pp; English.
XX
CC Sequences AAS04338-AAS04413 represent oligonucleotide primers specific
CC for a DNA encoding human death-associated protein 6 (DAXX). This DNA may
CC comprise one or more polymorphisms at specific nucleotide positions to
CC form one of nineteen possible polymorphic variants. Associations between
CC a trait and a genotype or a haplotype of the DAXX gene can be identified
CC by comparing the frequency of the genotype or haplotype in a population
CC exhibiting the trait with that of a reference population. A higher
CC frequency in the trait population indicates an association. Methods
CC involving genotyping or haplotyping of the DAXX gene of an individual can
CC lead to prediction of haplotype pairs for the DAXX gene of related
CC individuals, and may be useful in studying the expression and biological
CC function of DAXX, as well as in developing drugs targeting this protein.
CC Polymorphic variants of DAXX are useful in studying the effect of the
CC variation on the biological activity of DAXX as well as on the binding
CC affinity of candidate drugs targeting DAXX for the treatment of
CC autoimmune diseases and other immune disorders. Polymorphism is also
CC useful for studying population diversity, anthropological lineage,
CC paternity testing, forensic applications, and for identifying
CC associations between the DAXX genetic variation and a trait such as level
CC of drug response or susceptibility to disease. DAXX proteins may be used
CC to measure binding affinities of one or more candidate drugs targeting
CC the DAXX protein.
XX
SQ Sequence 15 BP; 4 A; 9 C; 1 G; 1 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1632 GATGGGGCTTGTAG 1645
|| |||||||||| ||
Db 15 GTTGGGGCTTGGAG 2

RESULT 392
AAF60907
ID AAF60907 standard; DNA; 15 BP.
XX
AC AAF60907;
XX
DT 15-MAY-2001 (first entry)
XX
DE Anti-c-Ha-ras oligonucleotide SEQ ID 16.
XX
KW Transport; membrane; cytostatic; virucide; vasotropic; dermatological;
KW antipsoriatic; antiasthmatic; gene therapy; tumor cell; antisense;
KW tumor therapy; drug; ss.
XX
OS Unidentified.
XX
PN DE19935302-A1.
XX
PD 08-FEB-2001.
XX
PF 28-JUL-1999; 99DE-1035302.
XX
PR 28-JUL-1999; 99DE-1035302.
XX
PA (AVET) AVENTIS PHARMA DEUT GMBH.
XX
PI Uhlmann E, Greiner B, Unger E, Gothe G, Schwerdel M;
XX
DR WPI; 2001-203679/21.
XX
PT New substituted aryl conjugates of parent molecules, especially
PT oligonucleotides, having improved transmembrane and intracellular
PT transport properties, useful as medicaments or diagnostic agents -
XX
PS Disclosure; Page 6; 28pp; German.
XX
CC This invention describes a novel conjugate (I) which consists of (A) a
CC molecule to be transported and (B) at least one aryl residue of formula
CC -Ar-(X-C(Y)-R_1)_n (II). Ar = group containing at least one aromatic
CC ring; X = O or N (sic); Y = O, S or NH-R_2 (sic); R_1 = optionally
CC substituted 1-23C alkyl (optionally containing double and/or triple
CC bonds); R_2 = optionally substituted 1-18C alkyl (optionally containing
CC double and/or triple bonds); n = integer of 1 or more. (A) is bonded to
CC (B) directly or via a chemical group, provided that the chemical group is
CC other than CH_2-S if the bond is via a phosphodiester linkage of (A). The
CC invention also describes (i) the preparation of a conjugate (I') of (A')
CC a molecule to be transported and (B') at least one aryl residue (not
CC restricted to (II)), by preparing (A') containing a reactive function at
CC the position at which (B') is to be bonded, preparing (B') and reacting
CC (A') and (B'); and (ii) the use of aryl groups (II) (optionally bonded
CC via a chemical group) for transporting (A) across biological membranes.
CC The products of the invention have cytostatic, virucide, vasotropic,
CC dermatological, antipsoriatic and antiasthmatic activity and can be used
CC for gene therapy. Conjugation of (A) with (B) is useful for transporting
CC (A) across biological membranes or into eukaryotic or prokaryotic cells
CC (specifically bacterial, yeast or mammalian cells, including human cells,
CC particularly tumor cells). Medicaments, diagnostic agents and test kits
CC containing (I) are also claimed. Typically (I) are antisense
CC oligonucleotide derivatives for tumor therapy; oligonucleotide drugs for
CC treating viral infections or diseases associated with integrins or
CC cell-cell interactions (e.g. restenosis, vitiligo, psoriasis or asthma);
CC or labeled oligonucleotides for in vivo diagnostic use, e.g. by in situ
CC hybridization. Conjugation with (B) markedly improves the cellular uptake
CC of (A), e.g. in tumor cells. (B) include fluorescein derivative residues,
CC in which case the conjugates (I) are fluorescently labeled, allowing
CC microscopic monitoring of cellular uptake etc. The cellular uptake of (I)
CC is superior to that obtained using other conjugated groups related to
CC (II); e.g. oligonucleotides conjugated with fluorescein diacetate (within
CC the scope of (B)) have superior uptake to corresponding fluorescein
CC conjugates.
XX
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCTG 1681
|||||| ||||| |
Db 1 CAGCTGCAACCCAG 14

RESULT 393
AAF69487/c
ID AAF69487 standard; DNA; 15 BP.
XX
AC AAF69487;
XX
DT 18-APR-2001 (first entry)
XX
DE Human IL4Ralpha gene probe #127.

KW hyperproliferative disease; fat deposition; obesity; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5952011-A.
XX
PD 14-SEP-1999.
XX
PF 30-MAY-1995; 95US-0452800.
XX
PR 30-DEC-1992; 92US-0998973.
PR 31-DEC-1991; 91US-0816284.
PR 30-MAY-1995; 95US-0452800.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Grant FJ, O'Hara PJ, Sheppard PO;
XX
DR WPI; 1999-539175/45.
XX
PT New human placental transglutaminase useful for promoting healing of
PT wounds
XX
PS Example 1; Column 33; 19pp; English.
XX
CC PCR primers AAZ10279-80 were used to amplify a 468 bp fragment of Human
CC placental transglutaminase cDNA for use as a probe to isolate the full
CC length sequence. The specification also describes Human placental
CC transglutaminase, which catalyses calcium ion-dependent crosslinking of
CC protein-bound glutamine and lysine residues, i.e. stabilizes basement
CC membrane structures. Compositions comprising Human placental
CC transglutaminase can be used to facilitate wound repair in a patient.
CC The protein can also be used in adhesives to promote wound healing,
CC e.g. ulcers or skin grafts, in preparation of foods e.g. cheese or
CC pastes, to prevent deterioration of dried fish caused by protozoans,
CC for enzymatic labeling of proteins or cell membranes, to introduce
CC cleavable crosslinks, and in solid-phase reversible removal of specific
CC proteins from biological systems. Expression of Human placental
CC transglutaminase is also a marker for identification of antagonists and
CC agonists of cell apoptosis which are potentially useful for treating
CC Alzheimer's or Parkinson's diseases, to inhibit apoptosis in patients
CC undergoing chemotherapy and to increase their blood cell counts or for
CC control of hyperproliferative disease or as a marker to identify agents
CC that control fat deposition in some forms of obesity.
XX
SQ Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1663 GCTCACAGCTGGAA 1676
              || | |||||||||
Db          1 GCGCTCAGCTGGAA 14
```

RESULT 390
AAS04346/c
ID AAS04346 standard; DNA; 15 BP.
XX
AC AAS04346;
XX
DT 07-SEP-2001 (first entry)
XX
DE Human DAXX DNA allele-specific oligonucleotide primer #9.
XX
KW Death-associated protein 6; DAXX; polymorphism; haplotype pair; human;
KW immune disorder; autoimmune disease; population diversity; ss;
KW paternity testing; anthropological lineage; forensic application;
KW oligonucleotide primer.
XX
OS Homo sapiens.
XX
PN WO200125245-A2.
XX
PD 12-APR-2001.
XX
PF 05-OCT-2000; 2000WO-US27487.
XX
PR 06-OCT-1999; 99US-0157909.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX
DR WPI; 2001-308220/32.
XX
PT New human death-associated protein 6 (DAXX) gene variants comprising 19
PT polymorphic sites useful in studying the effect of variation on the
PT biological activity of DAXX and in developing drugs targeting the
PT protein -
XX
PS Claim 15; Page 19; 97pp; English.
XX
CC Sequences AAS04338-AAS04413 represent oligonucleotide primers specific
CC for a DNA encoding human death-associated protein 6 (DAXX). This DNA may
CC comprise one or more polymorphisms at specific nucleotide positions to
CC form one of nineteen possible polymorphic variants. Associations between
CC a trait and a genotype or a haplotype of the DAXX gene can be identified
CC by comparing the frequency of the genotype or haplotype in a population
CC exhibiting the trait with that of a reference population. A higher
CC frequency in the trait population indicates an association. Methods
CC involving genotyping or haplotyping of the DAXX gene of an individual can
CC lead to prediction of haplotype pairs for the DAXX gene of related
CC individuals, and may be useful in studying the expression and biological
CC function of DAXX, as well as in developing drugs targeting this protein.
CC Polymorphic variants of DAXX are useful in studying the effect of the
CC variation on the biological activity of DAXX as well as on the binding
CC affinity of candidate drugs targeting DAXX for the treatment of
CC autoimmune diseases and other immune disorders. Polymorphism is also
CC useful for studying population diversity, anthropological lineage,
CC paternity testing, forensic applications, and for identifying
CC associations between the DAXX genetic variation and a trait such as level
CC of drug response or susceptibility to disease. DAXX proteins may be used
CC to measure binding affinities of one or more candidate drugs targeting
CC the DAXX protein.
XX
SQ Sequence 15 BP; 3 A; 10 C; 1 G; 1 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1632 GATGGGGCTTGTAG 1645
              | |||||||||  ||
Db         15 GGTGGGGCTTGGAG 2
```

RESULT 391
AAS04348/c
ID AAS04348 standard; DNA; 15 BP.
XX
AC AAS04348;
XX
DT 07-SEP-2001 (first entry)
XX
DE Human DAXX DNA allele-specific oligonucleotide primer #11.
XX
KW Death-associated protein 6; DAXX; polymorphism; haplotype pair; human;
KW immune disorder; autoimmune disease; population diversity; ss;
KW paternity testing; anthropological lineage; forensic application;
KW oligonucleotide primer.
XX
OS Homo sapiens.
XX

ID AAT14843 standard; DNA; 15 BP.
XX
AC AAT14843;
XX
DT 25-MAR-2003 (updated)
DT 14-NOV-1996 (first entry)
XX
DE Human prostatic transglutaminase primer ZC4048.
XX
KW Human; prostatic; prostate; placental; transglutaminase; primer;
KW calcium dependent crosslinking; tissue adhesive; wound repair; PCR;
KW skin graft; food; protozoan deterioration; dried fish; meat texture;
KW cleavable crosslink; apoptosis; degenerative nerve disease; amplify;
KW hyperproliferation; factor XIII; blood; immunogenicity; stability;
KW half life; ss.
XX
OS Synthetic.
XX
PN US5514579-A.
XX
PD 07-MAY-1996.
XX
PF 30-DEC-1992; 92US-0998973.
XX
PR 30-DEC-1992; 92US-0998973.
PR 31-DEC-1991; 91US-0816284.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Grant FJ, O'Hara PJ, Sheppard PO;
XX
DR WPI; 1996-238771/24.
XX
PT DNA encoding human prostatic and placental trans:glutaminase - used
PT e.g. as tissue adhesive, food stabiliser or to screen cpds. that
PT modulate apoptosis
XX
PS Example 1; Column 33; 19pp; English.
XX
CC The sequences given in AAT14838-45 are primers which were used in the
CC amplification and cloning of the full length DNA which encodes human
CC prostatic transglutaminase. See also AAT14825. These primers are
CC based on the unique clone PTG561/2 which was isolated using the primer
CC sequences given in AAT14827-36. The primers are based on regions of
CC conserved amino acid sequences identified from a multiple alignment
CC of known transglutaminase sequences, human erythrocyte membrane protein
CC band 4.2 and the rat dorsal protein-1. One region of homology chosen
CC for primer design corresponds to the active site of factor XIII, and
CC two other regions were chosen which seemed to have structural importance
CC based on the presence of hydrophobic residues and Pro residues.
CC (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1663 GCTCACAGCTGGAA 1676
|| | |||||||||
Db 1 GCGCTCAGCTGGAA 14

RESULT 388
AAV48892/c
ID AAV48892 standard; DNA; 15 BP.
XX
AC AAV48892;
XX
DT 15-OCT-1998 (first entry)
XX
DE c-fos gene antisense oligonucleotide c-fos-6.
XX
KW c-fos; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN EP856579-A1.
XX
PD 05-AUG-1998.
XX
PF 31-JAN-1997; 97EP-0101531.
XX
PR 31-JAN-1997; 97EP-0101531.
XX
PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI Brysch W, Schlingensiepen K;
XX
DR WPI; 1998-400910/35.
XX
PT Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratic of
PT residues able to form two or three hydrogen bonds, have greater
PT activity and reduced toxicity, used therapeutically or to modulate
PT growth of cells in culture
XX
PS Claim 10; Fig 7; 286pp; English.
XX
CC AAV48887-929 represent antisense oligonucleotides directed against the
CC c-fos gene. Of these, only oligonucleotides AAV48887-917 resulted
CC in significant redcution in c-fos protein expression, while
CC oligonucleotides AAV48918-29 had little effect. The oligonucleotides
CC exemplify the invention. The specification describes oligonucleotides
CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC can each form three hydrogen bonds to cytosine; do not contain four
CC consecutive nucleotides able to form three H-bonds each to four
CC consecutive cytosines; do not contain two sequences of three consecutive
CC nucleotides each able to form three H-bonds to three consecutive
CC cytosines, and the ratio between residues able to form two H-bonds each
CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC oligonucleotides are used to modulate expression of genes, particularly
CC the genes for p53, ErB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC oligonucleotides can also be used to analyse function of proteins (by
CC altering their expression or activity) and therapeutically, e.g. in
CC cases of cancer or (targeting TGF) for stimulating the immune system.
XX
SQ Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTGG 1699
|| ||||||| |||
Db 14 CTTCTCCAGCATGG 1

RESULT 389
AAZ10279
ID AAZ10279 standard; DNA; 15 BP.
XX
AC AAZ10279;
XX
DT 09-NOV-1999 (first entry)
XX
DE Primer ZC4048 used to amplify human prostatic transglutaminase cDNA.
XX
KW Human placental transglutaminase; calcium ion-dependent crosslinking;
KW basement membrane structure; wound repair; adhesive; wound healing;
KW ulcer; skin graft; food preparation; cheese; prostatic transglutaminase;
KW enzymatic labeling; cell apoptosis; Alzheimer's disease; dried fish;
KW Parkinson's disease; chemotherapy; blood cell count;

KW Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW reverse cholesterol transport; high density lipoprotein; therapy; CETP;
KW familial hypercholesterolaemia; dyslipidaemia; hypoalphalipoproteinaemia;
KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
KW LDL; ss.
XX
OS Oryctolagus cuniculus.
XX
PN WO9620279-A1.
XX
PD 04-JUL-1996.
XX
PF 11-DEC-1995; 95WO-US16000.
XX
PR 23-DEC-1994; 94US-0363240.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (WARN) WARNER LAMBERT CO.
XX
PI Bisgaier C, Couture L, McSwiggen J, Pape M, Stinchcomb D;
XX
DR WPI; 1996-321852/32.
XX
PT New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA
PT - useful for preventing or treating initial development, progression
PT or regression of vascular diseases, esp. familial
PT hypercholesterolaemia
XX
PS Claim 4; Page 41; 72pp; English.
XX
CC AAT50138-T50359 represent target sequences for the rabbit cholesterol
CC ester transfer protein (CETP) hammerhead (HH) ribozymes (see
CC AAT50360-T50546). CETP is a 74 kD glycoprotein that facilitates neutral
CC lipid transfer between plasma lipoproteins. The numbering of the targets
CC refers to the position of the cleavage site in full length CETP. The
CC ribozyme then binds to 5 nucleotides either side of this site. The
CC ribozymes are able to cleave mRNA from the gene encoding CETP, thereby
CC blocking synthesis and/or expression of the mRNA. By inhibiting CETP,
CC the reverse cholesterol transport (RCT) pathway can be inhibited (or
CC eliminated) thereby preventing the reduction in size density of the high
CC density lipoproteins (HDL), prolonging HDL half life, and therefore
CC increasing HDL levels. The ribozymes can be used to treat conditions
CC associated with abnormal levels of CETP, specifically atherosclerosis,
CC familial hypercholesterolaemia, peripheral vascular disease,
CC dyslipidaemia, hyperbetalipoproteinaemia, hypoalphalipoproteinaemia,
CC vascular complications of diabetes, transplant, atherectomy and
CC angioplastic restenosis. By inhibiting CETP, the levels of HDL and low
CC density lipoproteins (LDL), and the HDL:LDL ratio are favourably altered
CC (a decrease in LDL levels, and a corresponding increase in HDL levels).
CC The HH ribozymes can also be used diagnostically to study genetic drift
CC and mutations in diseased cells, and to detect CETP mRNA. As the HH
CC ribozymes target specific regions of the CETP gene, they have low
CC non-specific activity.
XX
SQ Sequence 15 BP; 5 A; 6 C; 0 G; 4 U; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGATTG 1734
||||||| || |||
Db 15 GGAGATGAAGTTTG 2

RESULT 386
AAT50231/c
ID AAT50231 standard; RNA; 15 BP.
XX
AC AAT50231;
XX

DT 07-MAR-1997 (first entry)
XX
DE Rabbit CETP HH ribozyme target sequence #513.
XX
KW Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW reverse cholesterol transport; high density lipoprotein; therapy; CETP;
KW familial hypercholesterolaemia; dyslipidaemia; hypoalphalipoproteinaemia;
KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
KW LDL; ss.
XX
OS Oryctolagus cuniculus.
XX
PN WO9620279-A1.
XX
PD 04-JUL-1996.
XX
PF 11-DEC-1995; 95WO-US16000.
XX
PR 23-DEC-1994; 94US-0363240.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (WARN) WARNER LAMBERT CO.
XX
PI Bisgaier C, Couture L, McSwiggen J, Pape M, Stinchcomb D;
XX
DR WPI; 1996-321852/32.
XX
PT New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA
PT - useful for preventing or treating initial development, progression
PT or regression of vascular diseases, esp. familial
PT hypercholesterolaemia
XX
PS Claim 4; Page 41; 72pp; English.
XX
CC AAT50138-T50359 represent target sequences for the rabbit cholesterol
CC ester transfer protein (CETP) hammerhead (HH) ribozymes (see
CC AAT50360-T50546). CETP is a 74 kD glycoprotein that facilitates neutral
CC lipid transfer between plasma lipoproteins. The numbering of the targets
CC refers to the position of the cleavage site in full length CETP. The
CC ribozyme then binds to 5 nucleotides either side of this site. The
CC ribozymes are able to cleave mRNA from the gene encoding CETP, thereby
CC blocking synthesis and/or expression of the mRNA. By inhibiting CETP,
CC the reverse cholesterol transport (RCT) pathway can be inhibited (or
CC eliminated) thereby preventing the reduction in size density of the high
CC density lipoproteins (HDL), prolonging HDL half life, and therefore
CC increasing HDL levels. The ribozymes can be used to treat conditions
CC associated with abnormal levels of CETP, specifically atherosclerosis,
CC familial hypercholesterolaemia, peripheral vascular disease,
CC dyslipidaemia, hyperbetalipoproteinaemia, hypoalphalipoproteinaemia,
CC vascular complications of diabetes, transplant, atherectomy and
CC angioplastic restenosis. By inhibiting CETP, the levels of HDL and low
CC density lipoproteins (LDL), and the HDL:LDL ratio are favourably altered
CC (a decrease in LDL levels, and a corresponding increase in HDL levels).
CC The HH ribozymes can also be used diagnostically to study genetic drift
CC and mutations in diseased cells, and to detect CETP mRNA. As the HH
CC ribozymes target specific regions of the CETP gene, they have low
CC non-specific activity.
XX
SQ Sequence 15 BP; 4 A; 6 C; 0 G; 5 U; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGATTG 1734
||||||| || |||
Db 14 GGAGATGAAGTTTG 1

RESULT 387
AAT14843

```
CC   analogues which act as inhibitors of gene expression (as sense/antisense,
CC   ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e.
CC   probes for detecting nucleic acid) or for treatment of diseases caused
CC   by viruses, influenced by integrins or cell-cell adhesion receptors,
CC   induced by factors such as TNF-alpha, or cancer or restenosis. The
CC   products of the invention satisfy the requirements of good in-vivo
CC   stability; ability to cross cellular and nuclear membranes, and specific
CC   binding to target nucleic acid better than known oligonucleotides.
XX
SQ   Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 383
AAX33907
ID   AAX33907 standard; DNA; 15 BP.
XX
AC   AAX33907;
XX
DT   30-JUN-1999  (first entry)
XX
DE   c-Ha-ras expression inhibitor.
XX
KW   Gene expression inhibitor; probe; nucleic acid detection; growth factor;
KW   viral infection; therapy; HSV-1; cancer; restenosis; integrin;
KW   cell-cell adhesion receptor; c-Ha-ras; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   AU9648028-A.
XX
PD   26-SEP-1996.
XX
PF   12-MAR-1996;   96AU-0048028.
XX
PR   24-NOV-1995;   95DE-1043865.
PR   13-MAR-1995;   95DE-1008923.
XX
PA   (FARH ) HOECHST AG.
XX
PI   Breipohl G,  Peyman A,  Uhlmann E,  Wallmeier H;
XX
DR   WPI; 1996-455932/46.
XX
PT   New phosphono:mono:ester oligo:nucleotide analogues - inhibitors of
PT   gene expression for treating viral infections, cancer, restenosis,
PT   etc.
XX
PS   Disclosure; Page 41; 129pp; English.
XX
CC   This sequence represents an inhibitor of c-Ha-ras expression, and is an
CC   example of an oligonucleotide analogue of the invention. The
CC   oligonucleotide analogues of the invention are used as inhibitors of gene
CC   expression (antisense oligonucleotides, ribozymes, sense oligonucleotides
CC   and triplex-forming oligonucleotides), as probes for the detection of
CC   nucleic acids, and as auxiliaries in molecular biology. As gene
CC   expression inhibitors they may be used for treating viral infections
CC   (especially where the virus is HSV-1, HSV-2, an influenza virus, VSV,
CC   hepatitis B or papilloma virus), cancer, restenosis, medical conditions
CC   mediated by integrins or cell-cell adhesion receptors, and medical
CC   conditions induced by growth factors (especially TNF-alpha).
XX
SQ   Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 384
AAT44237
ID   AAT44237 standard; DNA; 15 BP.
XX
AC   AAT44237;
XX
DT   22-JUL-1997  (first entry)
XX
DE   c-Ha-ras antisense component of capped oligonucleotide.
XX
KW   Antisense therapy; cellular ras oncogene; c-Ha-ras;
KW   guanosine; nuclease resistance; stability; ss.
XX
OS   Synthetic.
XX
PN   DE19502912-A1.
XX
PD   01-AUG-1996.
XX
PF   31-JAN-1995;   95DE-1002912.
XX
PR   31-JAN-1995;   95DE-1002912.
XX
PA   (FARH ) HOECHST AG.
XX
PI   Peyman A,  Uhlmann E;
XX
DR   WPI; 1996-355223/36.
XX
PT   Oligo:nucleotide(s) with series of G residues at at least one end
PT   have increased stability against nuclease and cell penetration -
PT   are partic. anti:sense sequences for treating and diagnosing cancer,
PT   viral diseases etc.
XX
PS   Claim 3; Page 13; 15pp; German.
XX
CC   Ten- to 40-mer oligonucleotides which have a cap of 1-10 (esp. 4)
CC   G residues on at least one end are provided; if caps are present at
CC   both ends, they can be of the same or different lengths. A cap
CC   sequence increases nuclease resistance of the oligonucleotide and
CC   also increases cell penetration. The present sequence is that of a
CC   preferred oligonucleotide, directed against c-Ha-ras sequences, which
CC   can be capped for use in anticancer therapy.
XX
SQ   Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 385
AAT50229/c
ID   AAT50229 standard; RNA; 15 BP.
XX
AC   AAT50229;
XX
DT   07-MAR-1997  (first entry)
XX
DE   Rabbit CETP HH ribozyme target sequence #512.
XX
```

```
XX
CC   The antisense oligonucleotide (ON) shown is a derivative of an
CC   equivalent wild type Human c-Ha-ras ON, in which at least
CC   one, esp. 2-10, non-terminal pyrimidine nucleotide(s) is/are modified.
CC   The modification may be: (a) replacement of a phosphodiester linkage by:
CC   a phosphoro-thioate (PS), -dithioate, -aramidate; borano-, alkyl-,
CC   aralkyl-phosphate; 2,2,2-trichloro-1,1dimethyl-, alkyl- or aryl-
CC   phosphonate linkage; or (3'-thio)formacetal, methylhydroxylamine, oxime,
CC   methylenedimethylhdrazo, dimethylene sulphone or silyl linkage; (b)
CC   replacement of a sugar phosphate backbone by a 'morphholinonucleoside'
CC   oligomer; (c) replacement of beta-D-2-deoxyribose by another sugar or
CC   carbocyclic, open-chain or bicyclic sugar analogue; or (c) replacement
CC   of the natural nucleoside base by an analogue, e.g.
CC   5-hydroxymethyl-uridine.  The 5' and/or 3' terminus may also be modified
CC   with a lipophilic gp., eg. a farnesyl. The modifications increase
CC   nuclease resistance and thus improve stability and activity.
XX
SQ   Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

  Query Match              7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CAGCTGGAACCCTG 1681
              |||||| ||||| |
Db          1 CAGCTGCAACCCAG 14


RESULT 381
AAX66553
ID   AAX66553 standard; RNA; 15 BP.
XX
AC   AAX66553;
XX
DT   20-JUL-1999  (first entry)
XX
DE   Human CD40 hammerhead ribozyme target SEQ ID NO:3185.
XX
KW   Arthritic condition; graft tolerance; immune response; target; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW   stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW   rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9618736-A2.
XX
PD   20-JUN-1996.
XX
PF   22-NOV-1995;   95WO-US15516.
XX
PR   05-OCT-1995;   95US-0541365.
PR   13-DEC-1994;   94US-0354920.
PR   23-DEC-1994;   94US-0363253.
PR   23-DEC-1994;   94US-0363254.
PR   17-FEB-1995;   95US-0390850.
PR   20-APR-1995;   95US-0426124.
PR   02-MAY-1995;   95US-0432874.
PR   04-MAY-1995;   95US-0434509.
PR   07-JUL-1995;   95US-0000951.
PR   07-JUL-1995;   95US-0000974.
PR   07-AUG-1995;   95US-0512861.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Draper K,  Gustofson J,  McSwiggen J,  Pavco P,  Stinchcomb DT;
PI   Beigelman L,  Karpeisky A,  Modak A,  Usman N,  Burgin A;
PI   Matulic-Adamic J,  Jarvis T,  Thompson JD,  Wincott F;
XX
DR   WPI; 1996-300653/30.
XX
PT   Enzymatic nucleic acid molecules having a hammer-head motif - used
PT   for the treatment of arthritis, induction of graft tolerance or
PT   treatment of auto-immune diseases
XX
PS   Claim 10; Page 204; 307pp; English.
XX
CC   The present invention describes a novel enzymatic nucleic acid (ENA)
CC   having a hammerhead motif (HM) comprising: (i) at least 5 ribose
CC   residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
CC   at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
CC   The ENA's can inhibit collagenase and stromelysin production in the
CC   synovial membrane of joints for the treatment or prevention of arthritis,
CC   particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC   be used to treat antigen presenting cells of a donor to induce tolerance
CC   in a recipient to an alloantigen of a donor. They can also be used for
CC   enhancing graft tolerance or for treating autoimmune disease, and for
CC   treating allergies and other inflammatory conditions. The ENA's can also
CC   be used in diagnosis. Ribozyme therapy impacts on the expression of
CC   stromelysin without introducing the non-specific effects upon gene
CC   expression which accompany treatment with retinoids and dexamethasone.
CC   The concentration of ribozyme required to affect a therapeutic treatment
CC   is lower than that required of antisense molecules, and is highly
CC   specific. The present sequence is used in the exemplification of the
CC   present invention.
XX
SQ   Sequence 15 BP; 1 A; 7 C; 3 G; 4 U; 0 other;

  Query Match              7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   57.1%;  Pred. No. 3.4e+02;
  Matches    8;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1678 CCTGGTGTCTCCTC 1691
              ||:||: :| ||:|
Db          2 CCUGGUCUCACCUC 15


RESULT 382
AAX24191
ID   AAX24191 standard; DNA; 15 BP.
XX
AC   AAX24191;
XX
DT   01-JUL-1999  (first entry)
XX
DE   Phosphonomonoester oligonucleotide analogue 8.
XX
KW   Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;
KW   ribozyme; diagnostic agent; detection; treatment; disease; virus;
KW   integrin; cell-cell adhesion receptor; TNF-alpha; ss.
XX
OS   Synthetic.
XX
PN   DE19508923-A1.
XX
PD   19-SEP-1996.
XX
PF   13-MAR-1995;   95DE-1008923.
XX
PR   13-MAR-1995;   95DE-1008923.
PR   24-NOV-1995;   95DE-1043865.
XX
PA   (FARH ) HOECHST AG.
XX
PI   Anuschirwan P,  Breipohl G,  Uhlmann E,  Wallmeier H;
XX
DR   WPI; 1996-425893/43.
XX
PT   New oligo:nucleotide analogues contg. phospho:mono:ester bridges -
PT   for therapeutic inhibition of gene expression, e.g. in cancer or
PT   viral infection, with good specificity and in vivo stability
XX
PS   Disclosure; Page 22; 36pp; German.
XX
CC   This invention describes novel phosphonomonoester oligonucleotide
```

KW 8-azapurine; modification; stronger complex; inhibition; ss.
XX
OS Synthetic.
XX
PN EP680969-A2.
XX
PD 08-NOV-1995.
XX
PF 26-APR-1995; 95EP-0106230.
XX
PR 02-MAY-1994; 94DE-4415370.
XX
PA (FARH) HOECHST AG.
XX
PI Lampe S, Seela F;
XX
DR WPI; 1995-375165/49.
XX
PT New oligo:nucleotide(s) contg. 8-aza:purine base - useful as
PT therapeutic and diagnostic agents with more stable hybridisation to
PT target nucleic acid
XX
PS Disclosure; Page 37; 51pp; German.
XX
CC AAT44425-54 are antisense oligonucleotides which have at least one
CC 8-azapurine base. The presence of an 8-azapurine base results in
CC significantly stronger complexing when hybridising to target nucleic
CC acids. The present sequence is against c-Ha-ras.
XX
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCTG 1681
||||||.|||||.|
Db 1 CAGCTGCAACCCAG 14

RESULT 379
AAQ97685
ID AAQ97685 standard; DNA; 15 BP.
XX
AC AAQ97685;
XX
DT 22-MAR-1996 (first entry)
XX
DE Biotinylated antisense oligonucleotide against c-Ha-ras.
XX
KW antisense; c-ras; antigen; monoclonal antibody; avidin; biotinylation;
KW non-viral vector; complex; Lewis Y antigen; bladder carcinoma; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1
FT /*tag= a
FT /mod_base= 5'-biotin-C
XX
PN WO9521195-A1.
XX
PD 10-AUG-1995.
XX
PF 06-FEB-1995; 95WO-US01161.
XX
PR 07-FEB-1994; 94US-0192655.
XX
PA (RERE-) RES DEV FOUND.
XX
PI Donato NJ, Rosenblum MG;
XX
DR WPI; 1995-283733/37.
XX
PT A non-viral vector having a cell binding component - used to
PT introduce genetic material into, or to deliver a cytotoxic moiety to
PT a specific cell.
XX
PS Example 14; Page 18; 35pp; English.
XX
CC A non-viral vector comprising a cell binding component having a biotin-
CC binding element (eg. avidin or streptavidin) conjugated to a
CC biotinylated moiety is claimed. The cell binding element is a monoclonal
CC antibody (MAb) or a ligand which binds a cell surface receptor or a
CC nucleic acid, pref. a triplex forming oligonucleotide or an antisense
CC oligonucleotide. A MAb (BR96) which specifically binds Lewis Y antigen on
CC several human carcinomas was chemically conjugated to avidin. AAQ97685 is
CC complementary to the c-Ha-ras 5' flanking mRNA sequence and was
CC synthesised with a biotinylated cytosine at the 5' terminal position. The
CC biotinylated oligonucleotide was incubated with the BR96-Avidin and
CC complexes of BR96-avidin:antisense c-Ha-ras were purified. The complexes
CC were incubated with T24 bladder carcinoma cells which express Lewis Y
CC antigen and also contain the c-Ha-ras oncogene. After incubation the
CC product of the ras oncogene, p21, was monitored by western blotting. Cell
CC growth was also monitored. Neutralisation of the effects of ras oncogene
CC by intracellular delivery of antisense molecules through internalisation
CC of the Lewis Y antigen was demonstrated.
XX
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCTG 1681
||||||.|||||.|
Db 1 CAGCTGCAACCCAG 14

RESULT 380
AAQ88720
ID AAQ88720 standard; DNA; 15 BP.
XX
AC AAQ88720;
XX
DT 27-FEB-1996 (first entry)
XX
DE c-Ha-ras modified antisense oligonucleotide.
XX
KW antisense; analogue; non-terminal pyrimidine; phosphorothioate;
KW backbone; treatment; HIV; human immunodeficiency virus; HSV;
KW herpes simplex virus; cancer; integrin; cell adhesion receptor;
KW infection; diagnosis; nuclease resistance; ss.
XX
OS Homo sapiens.
XX
PN EP653439-A2.
XX
PD 17-MAY-1995.
XX
PF 07-NOV-1994; 94EP-0117513.
XX
PR 12-NOV-1993; 93DE-4338704.
XX
PA (FARH) HOECHST AG.
XX
PI Helsberg M, Kretzschmar G, Mag M, Peyman A, Uhlmann E;
PI Winkler I;
XX
DR WPI; 1995-180677/24.
XX
PT New anti:sense oligo:nucleotide analogues - with modified
PT non-terminal pyrimidine nuclectide units, useful for treating viral
PT infections, cancer, etc.
XX
PS Claim 1; Page 23; 36pp; German.

```
XX
PD   08-JUL-1993.
XX
PF   30-DEC-1992;   92WO-US11353.
XX
PR   31-DEC-1991;   91US-0816284.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Grant FJ,  O'Hara PJ,  Sheppard PO;
XX
DR   WPI; 1993-227323/28.
XX
PT   Isolated polynucleotide molecule, for stabilising good prepn. -
PT   utilised for coding human prostatic or placental trans glutaminase(s)
PT   and DNA, for repairing wounds, ulcerated lesions, skin grafts, and
PT   cellular markers
XX
PS   Example; Page 43; 48pp; English.
XX
CC   The sequence is that of oligonucleotide ZC4048 which was used in a
CC   PCR to confirm the presence of additional 5' sequences, as part of
CC   the generation of a full-length human prostate transglutaminase
CC   cDNA clone. It was designed to hybridise to the antisense lambda
CC   sequences near the EcoRI site of the lambda-gt11 vector.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1663 GCTCACAGCTGGAA 1676
              || | |||||||||
Db          1 GCGCTCAGCTGGAA 14


RESULT 377
AAT56203/c
ID   AAT56203 standard; RNA; 15 BP.
XX
AC   AAT56203;
XX
DT   25-MAR-2003  (updated)
DT   14-MAY-1997  (first entry)
XX
DE   Mouse TNF-a hammerhead ribozyme target sequence (nt position 615).
XX
KW   Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW   gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW   intercellular adhesion molecule; rel A; tumour necrosis factor;
KW   TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW   translocation; chronic myelogenous leukaemia; CML; cancer;
KW   Philadelphia chromosome; inflammation; autoimmune disease;
KW   atherosclerosis; myocardial infarction; stroke; restenosis;
KW   transplant rejection; rheumatoid arthritis; psoriasis;
KW   myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW   human immunodeficiency virus; acquired immune deficiency syndrome;
KW   AIDS; ss.
XX
OS   Mus musculus.
XX
PN   WO9523225-A2.
XX
PD   31-AUG-1995.
XX
PF   23-FEB-1995;   95WO-IB00156.
XX
PR   30-JAN-1995;   95US-0380734.
PR   23-FEB-1994;   94US-0201109.
PR   29-MAR-1994;   94US-0218934.
PR   04-APR-1994;   94US-0222795.
PR   07-APR-1994;   94US-0224483.
PR   15-APR-1994;   94US-0227958.
PR   15-APR-1994;   94US-0228041.
PR   18-MAY-1994;   94US-0245736.
PR   06-JUL-1994;   94US-0271280.
PR   15-AUG-1994;   94US-0291932.
PR   16-AUG-1994;   94US-0291433.
PR   17-AUG-1994;   94US-0292620.
PR   19-AUG-1994;   94US-0293520.
PR   02-SEP-1994;   94US-0300000.
PR   08-SEP-1994;   94US-0303039.
PR   23-SEP-1994;   94US-0311486.
PR   23-SEP-1994;   94US-0311749.
PR   28-SEP-1994;   94US-0314397.
PR   03-OCT-1994;   94US-0316771.
PR   07-OCT-1994;   94US-0319492.
PR   11-OCT-1994;   94US-0321993.
PR   04-NOV-1994;   94US-0334847.
PR   10-NOV-1994;   94US-0337608.
PR   28-NOV-1994;   94US-0345516.
PR   16-DEC-1994;   94US-0357577.
PR   23-DEC-1994;   94US-0363233.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Chowrira B,  Direnzo A,  Draper KG,  Dudycz LW;
PI   Grimm S,  Karpeisky A,  Kisich K,  Matulic-adamic J,  Mcswiggen JA;
PI   Modak A,  Pavco P,  Beigleman L,  Sullivan SM,  Sweedler D;
PI   Thompson JD,  Tracz D,  Usman N,  Wincott FE,  Woolf T;
XX
DR   WPI; 1995-351090/45.
XX
PT   Ribozymes having modified bases and methods for producing them  -
PT   for use in inhibiting disease related genes
XX
PS   Claim 2; Page 250; 407pp; English.
XX
CC   The present sequence represents a preferred target sequence for an
CC   enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNF-alpha
CC   mRNA at the nucleotide base position indicated in the DE line.
CC   Regions of the mRNA that do not form secondary folding
CC   structures and that contain potential hammerhead and hairpin
CC   ribozyme cleavage sites were identified by computer analysis.
CC   Ribozymes directed against these mRNA sequences were designed and
CC   synthesised with modifications that improve their nuclease
CC   resistance. The ribozymes are designed to cleave the target
CC   sequences and thereby inhibit TNF-alpha expression, making them
CC   potentially useful for treating rheumatoid arthritis, septic shock
CC   and other inflammatory disorders including psoriasis, as well as
CC   for treatment of AIDS.
CC   (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ   Sequence 15 BP; 2 A; 8 C; 2 G; 3 U; 0 other;

  Query Match             7.8%;  Score 10.8;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1708 GGGTTAGGAGTACG 1721
              |||| ||||| |||
Db         15 GGGTGAGGAGCACG 2


RESULT 378
AAT44432
ID   AAT44432 standard; DNA; 15 BP.
XX
AC   AAT44432;
XX
DT   27-JAN-1997  (first entry)
XX
DE   Antisense oligonucleotide VIII against c-Ha-ras.
XX
```

XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US17712.
XX
PR 03-AUG-1998; 98US-0095212.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers -
XX
PS Disclosure; Page 557; 1343pp; English.
XX
CC The present invention describes a new composition comprising an
CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
CC asthma, impeded respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasise to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of
CC the ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 1680
CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
CC invention. N.B. Sequences given in the disclosure of the present
CC invention do not match up with their corresponding SEQ ID NO: sequences
CC given in the sequence listing.
XX
SQ Sequence 14 BP; 0 A; 9 C; 2 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1733 TGGCTCCCAACTCC 1746
||||||| |||| |
Db 1 TGGCTCCCCCCTCC 14

RESULT 375
AAQ22446/c
ID AAQ22446 standard; DNA; 15 BP.
XX
AC AAQ22446;
XX
DT 05-AUG-1992 (first entry)
XX
DE Probe (6) for DNA fingerprint analysis.
XX
KW M13; consensus; hypervariable region; HVR; ss.
XX
OS Synthetic.
XX
PN US5097024-A.
XX
PD 17-MAR-1992.
XX
PF 25-SEP-1989; 89US-0411823.
XX
PR 25-SEP-1989; 89US-0411823.
XX
PA (HODE/) HODES M E.
XX
PI Hodes ME, Norris FH, Hodes MZ;
XX
DR WPI; 1992-113708/14.
XX
PT New DNA sequences as DNA probes - for use in paternity and
PT maternity testing, analysis of tumour cells, animal or plant
PT breeding, etc.
XX
PS Claim 1; Page 13; 13pp; English.
XX
CC The DNA probes represented in AAQ22441-76 are 15 nucleotide sequences
CC wherein 8 nucleotides of each sequence are G, 3 are T, 1 is C, 1 is
CC A and 2 are N, except that the nucleotide sequence is not the M13
CC consensus sequence GAGGGTGGNGGNTCT. The probes can detect hyper-
CC variable regions (HVRs) in genomic DNA with such precision as to
CC enable individuals to be identified or fingerprinted by reference
CC to variations in their DNA in these regions. The DNA probes can be
CC used in paternity and maternity testing, zygosity testing in twins,
CC cell chimerism studies, e.g. detection of donor versus recipient
CC cells after bone marrow transplantation, forensic medicine, family
CC gp. verification, tests for inbreeding, pedigree analysis,
CC identification of loci or genetic diseases, animal or plant
CC breeding and pedigree analysis authentication, quality control of
CC cell lines and analysis.
CC Preparation: The M13 sequence was initially randomised manually by
CC the method of random sampling without replacement to produce
CC random sequences. Later a computer programme was written
CC that implemented an algorithm that produced a random sequence by
CC sampling without replacement. Several of the random sequences that
CC were obtd. were synthesised, labelled and used as DNA probes.
XX
SQ Sequence 15 BP; 2 A; 1 C; 9 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1736 CTCCCAACTCCTCC 1749
| | |||||||||||
Db 15 CCCACAACTCCTCC 2

RESULT 376
AAQ45774
ID AAQ45774 standard; DNA; 15 BP.
XX
AC AAQ45774;
XX
DT 25-MAR-2003 (updated)
DT 08-DEC-1993 (first entry)
XX
DE Human prostate transglutaminase gene PCR primer ZC4048.
XX
KW Degenerate; polymerase chain reaction; enzyme; inter alia;
KW therapeutic wound repair; skin graft closure; food prepn.;
KW preparation; stabilising; marker; identifying agent; agonists;
KW antagonists; cellular apoptosis; ss.
XX
OS Synthetic.
XX
PN WO9313207-A2.

PS Claim 14; Page 625; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention.
XX
SQ Sequence 14 BP; 0 A; 9 C; 2 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1733 TGGCTCCCAACTCC 1746
||||||| ||||
Db 1 TGGCTCCCCCCTCC 14

RESULT 373
AAF21471
ID AAF21471 standard; DNA; 14 BP.
XX
AC AAF21471;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human multiple target antisense (MTA) oligonucleotide #3038.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US08020.
XX
PR 06-APR-1999; 99US-0127958.
XX
PA (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX
PS Disclosure; Page 297; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention.
XX
SQ Sequence 14 BP; 0 A; 9 C; 2 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1733 TGGCTCCCAACTCC 1746
||||||| ||||
Db 1 TGGCTCCCCCCTCC 14

RESULT 374
AAA34646
ID AAA34646 standard; DNA; 14 BP.
XX
AC AAA34646;
XX
DT 28-JUL-2000 (first entry)
XX
DE Human adenosine receptor related polynucleotide SEQ ID NO:2335.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 1999-229400/19.
XX
PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT vasoconstriction
XX
PS Disclosure; Page 74; 120pp; English.
XX
CC The specification describes antisense oligonucleotides (AAX52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene
CC initiation codons, genomic flanking regions, intron-exon borders, the
CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
CC regions and all segments of RNAs encoding proteins associated with one
CC or more diseases, conditions or mixtures. The antisense oligonucleotides
CC may be derived from sequences AAX55272-74. These multiple target
CC oligonucleotides (specifically AAX55180-271) can be used for the
CC antisense treatment of diseases and conditions. Typical diseases and
CC conditions are those associated with impaired respiration and
CC inflammation, including lung diseases, pulmonary vasoconstriction,
CC inflammation, allergic rhinitis, acute asthma, allergies, asthma, impeded
CC respiration, respiratory distress syndrome, pain, cystic fibrosis,
CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
CC obstructive pulmonary disease (COPD), and cancers such as leukemias,
CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
CC hepatic metastases, as well as all types of cancers which may metastasize
CC or have metastasized to the lungs, including breast and prostate cancer.
XX
SQ Sequence 14 BP; 0 A; 9 C; 2 G; 3 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1733 TGGCTCCCAACTCC 1746
              ||||||||  ||||
Db          1 TGGCTCCCCCCTCC 14
```

RESULT 371
AAX14792
ID AAX14792 standard; DNA; 14 BP.
XX
AC AAX14792;
XX
DT 24-MAR-1999 (first entry)
XX
DE Triple helix forming nucleotides 727-740 of Hepatitis B virus.
XX
KW Triple-helix forming region; Triplex formation; DNA detection;
KW identification; bacteria; oncogene; virus; ds.
XX
OS Hepatitis B virus.
XX
PN US5861244-A.
XX
PD 19-JAN-1999.
XX
PF 22-DEC-1993; 93US-0173489.
XX
PR 22-DEC-1993; 93US-0173489.
PR 29-OCT-1992; 92US-0968436.
XX
PA (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
PI Hepburn AG, Wang C;
XX
DR WPI; 1999-130384/11.
XX
PT Assay of genetic sequences based on triplex formation from double
PT stranded analyte - and hybrid of anchor and reporter sequences, with
PT reporter released if triplex formation occurs, used e.g. to identify
PT bacteria
XX
PS Disclosure; Columns 19-20; 168pp; English.
XX
CC The present sequence represents a potential triple-helix forming region.
CC It can be used to demonstrate the assay of the invention. The assay
CC comprises adding a sample containing double-stranded DNA test sequences,
CC e.g. containing the present sequence, to an aqueous medium containing at
CC least one complex of anchor DNA, attached to a solid support, and
CC reporter DNA, where either a part of the anchor DNA or reporter DNA is
CC designed to form a triple-strand structure with part of the test
CC sequence. Triplex formation results in displacement of the reporter DNA
CC which is detected as an indication of the presence of the DNA test
CC sequence. The method is used to detect DNA sequences, particularly for
CC identification of bacteria (by detecting genes for ribosomal RNA) in
CC clinical samples, but also detection of oncogenes and Hepatitis B virus.
XX
SQ Sequence 14 BP; 0 A; 7 C; 0 G; 7 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1743 CTCCTCCCTATCCT 1756
              |||||  |||  ||||
Db          1 CTCCTTCCTTTCCT 14
```

RESULT 372
AAF20768
ID AAF20768 standard; DNA; 14 BP.
XX
AC AAF20768;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human multiple target antisense (MTA) oligonucleotide #2335.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US08020.
XX
PR 06-APR-1999; 99US-0127958.
XX
PA (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX

KW arthritis; angiogenesis inhibitor; tumours; cancer; ss.
XX
OS Synthetic.
XX
PN WO9516032-A1.
XX
PD 15-JUN-1995.
XX
PF 09-DEC-1993; 93WO-EP03461.
XX
PR 09-DEC-1993; 93WO-EP03461.
XX
PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI Brysch W, Schlingensiepen GF, Schlingensiepen K;
PI Schlingensiepen R;
XX
DR WPI; 1995-224318/29.
XX
PT New antisense cpds. for treating diseases associated with growth
PT factors - esp. neoplasia, autoimmune diseases and pathological
PT angiogenesis
XX
PS Claim 3; Page 12; 30pp; English.
XX
CC AAQ74119-Q74124 are platelet derived growth factor (PDGF-A) antisense
CC oligonucleotides (DNA or RNA). They can be used to treat diseases
CC associated with growth factors, e.g. breast or pancreatic carcinoma,
CC glioma or melanoma, and rheumatoid arthritis. They can also be used
CC to inhibit angiogenesis, e.g. in tumours.
XX
SQ Sequence 14 BP; 3 A; 4 C; 3 G; 4 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1726 TGGAGATTGGCTCC 1739
              ||||||| | ||||
Db         14 TGGAGATAGACTCC 1
```

RESULT 369
AAT98896
ID AAT98896 standard; DNA; 14 BP.
XX
AC AAT98896;
XX
DT 23-MAR-1998 (first entry)
XX
DE Probe 41w18 for HIV RT gene wild type E40M41.
XX
KW Reverse transcriptase gene; HIV; RT gene; antiviral drug susceptibility;
KW virus susceptibility; antiviral drug resistant viral strain; retrovirus;
KW Hepadnaviridae; HIV RT genotyping; probe; ss.
XX
OS Synthetic.
OS Human immunodeficiency virus type 1.
XX
PN WO9727332-A1.
XX
PD 31-JUL-1997.
XX
PF 17-JAN-1997; 97WO-EP00211.
XX
PR 25-JUN-1996; 96EP-0870081.
PR 26-JAN-1996; 96EP-0870005.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Louwagie J, Rossau R, Stuyver L;
XX
DR WPI; 1997-393716/36.
XX
PT Determining susceptibility to antiviral drugs of reverse
PT transcriptase containing viruses - useful for genotyping HIV RT and
PT detecting antiviral resistant HIV
XX
PS Claim 13; Page 36; 59pp; English.
XX
CC This sequence represents a probe for a wild type HIV reverse
CC transcriptase (RT) gene fragment. This sequence can be used in the method
CC of the invention for determining the susceptibility to antiviral drugs of
CC viruses which contain RT genes and are present in a biological sample. It
CC comprises: (1) releasing, isolating or concentrating the polynucleic
CC acids present in a sample; (2) amplifying the relevant part of the RT
CC genes present with at least one suitable primer pair; (3) hybridising the
CC polynucleic acids of step (1) or (2) with at least two RT gene probes,
CC the probes being applied to known locations on a solid support, and are
CC capable of simultaneously hybridising to their respective target regions
CC under appropriate hybridisation and wash condition allowing the detection
CC of homologous targets, or with the probes hybridising specifically with a
CC sequence complementary to any of the target sequences; (4) detecting the
CC hybrids formed in step (3); and (4) inferring the nucleotide sequence at
CC the codons of interest (codons 38-44, 47-53, 65-72, 73-77, 148-154,
CC 180-187, 212-216, and 217-220), and/or the amino acids of the codons of
CC interest and/or antiviral drug resistance spectrum, and possible the type
CC of viral isolates involved from the differential hybridisation signals
CC obtained in step (4). The method is specifically used to detect antiviral
CC drug resistant strains of viruses containing RT genes, especially HIV
CC retroviruses and Hepadnaviridae. The method can also be used for
CC genotyping HIV RT.
XX
SQ Sequence 14 BP; 7 A; 1 C; 4 G; 2 T; 0 other;

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1718 TACGGAGATGGAGA 1731
              ||| |||||||| |
Db          1 TACAGAGATGGAAA 14
```

RESULT 370
AAX55199
ID AAX55199 standard; DNA; 14 BP.
XX
AC AAX55199;
XX
DT 05-JUL-1999 (first entry)
XX
DE Multiple antisense oligonucleotide 20.
XX
KW Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW prostate cancer; ss.
XX
OS Synthetic.
XX
PN WO9913886-A1.
XX
PD 25-MAR-1999.
XX
PF 17-SEP-1998; 98WO-US19419.
XX
PR 09-JUN-1998; 98US-0093972.
PR 17-SEP-1997; 97US-0059160.
XX